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ABSTRACT 
 
The metabolic syndrome (MetS) is a collection of various metabolic, hormonal and 
immunological risk factors that cluster together, closely related to poorly understood 
phenomena such a hyperinsulinaemia (insulin resistance), hyperleptinaemia (leptin 
resistance), a low grade, systemic and chronic inflammation and, in males, 
hypogonadism. Infertility is increasing globally, and male factor infertility accounts for 
a large percentage of couples who are not able to conceive. The relationship 
between components of MetS and male reproductive health is not clear, and 
requires further investigation, as does the impact of MetS on male reproductive 
health in a case controlled study. The impact of hyperinsulinaemia, hyperleptinaemia 
and inflammatory cytokines on the male reproductive tract also requires 
investigation. Furthermore, it is hypothesised that these phenomena negatively 
impact steroidogenesis cascades. In order to investigate this, a case controlled study 
and TM3 Leydig cell culture experiments were designed.  
 
Participants were recruited from public advertisements, and screened for strict 
exclusion criteria, including acute or chronic inflammation, hormonal treatments, 
vasectomy and leukocytospermia (> 106/ml). Following clinical diagnostics, 78 males 
were either placed into a control group (CG) or the MetS group, with numerous 
parameters compared between them. Serum was assayed for routine risk markers 
including HDL cholesterol, triglycerides, glucose and C-reactive protein (CRP). 
Saliva was assayed for free testosterone and progesterone. Semen samples 
underwent semen analysis for ejaculation volume, sperm concentration and motility, 
vitality, morphology and leukocyte concentration, in addition to mitochondrial 
membrane potential (MMP) and DNA fragmentation (DF). Both serum and seminal 
fluid were further assayed for insulin, leptin, tumour necrosis factor-alpha (TNFα) and 
interleukins 1-beta (IL1β), 6 (IL6) and 8 (IL8). Glucose was also assayed in seminal 
fluid. Separately, hCG stimulated TM3 Leydig cells were exposed to varying 
concentrations of insulin (0.01, 0.1, 1 & 10 pg/ml), TNFα, IL1β, IL6 and IL8 (0.1, 1, 
10 & 100 pg/ml) for 48 hours at optimal cell culture conditions. TM3 cell viability, 
protein concentration and testosterone and progesterone concentrations were 
assessed.  
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Results indicated that males in the MetS group (n=34) had significantly increased 
body mass index, waist circumference, blood pressure, triglycerides, glucose, and C-
reactive protein (CRP) with decreased HDL cholesterol, as compared to the CG. 
Furthermore, ejaculation volume, sperm concentration, total sperm count, 
progressive and total motility were significantly decreased in the MetS group, and 
sperm with abnormal MMP and DF were increased in this group. No difference was 
found for morphology. Serum and seminal insulin, leptin, TNFα, IL1β, IL6 and IL8 
were all significantly increased in the MetS group. Both testosterone and 
progesterone were also significantly decreased in the MetS group. Insulin increased 
testosterone and decreased progesterone in the TM3 cells. TNFα, IL1β and IL6 all 
decreased testosterone and progesterone concentrations and TM3 cell viability. IL8 
increased TM3 cell viability and decreased progesterone, will no effect on 
testosterone.  
 
These results suggest MetS is associated with decreased fertility potential in males. 
Furthermore, a significant increase in seminal insulin, leptin, TNFα, IL1β, IL6 and IL8 
suggests local reproductive tract inflammation in the absence of leukocytospermia. 
Strong correlations between serum and seminal insulin, leptin, TNFα, IL1β, IL6 and 
IL8, as well as serum CRP, imply that these systemic phenomenons are related to 
the reproductive tract changes observed. Therefore, the underlying pathophysiology 
of MetS negatively affects male reproduction, in addition to general health and well-
being. A decrease in progesterone and testosterone suggests a collapse in 
steroidogenesis cascades. Additionally, inflammation, increased leptin and insulin 
resistance likely contribute to this collapse in steroidogenesis based on TM3 cell 
culture experiments. These results provide novel avenues for further investigations.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Metabolic syndrome 
 
The metabolic syndrome (MetS) is considered to be a collection of various metabolic 
risk factors that tend to cluster together, resulting in an increased risk for 
cardiovascular disease (CVD), type-2 diabetes mellitus (T2DM) and various cancers 
(Grundy et al., 2004; Huang, 2009). Although the exact aetiology and 
pathophysiology of MetS is still a matter of contention (Taslim & Tai, 2009), the 
syndrome comprises of various poorly understood pathophysiological phenomena, 
associated with complex metabolic, hormonal and immune dysfunctions. The 
common features that cluster together include central (abdominal) obesity, 
hypertension, dyslipidaemia (particularly low HDL-cholelsterol) and glucose 
intolerance, as illustrated in Figure 1 (Eckel et al., 2005; Kasturi et al., 2008; Huang, 
2009). These appear to be linked together by insulin resistance (IR) and a low grade 
proinflammatory state (Kasturi et al., 2008; Monteiro & Azevedo, 2010). In males, a 
state of hypogonadism is also well defined (Kasturi et al., 2008; Saad & Gooren, 
2011). These are all well documented risks for CVD and T2DM (Eckel et al., 2005; 
Kasturi et al., 2008; Huang, 2009). It is not clear in the scientific literature which 
components are considered as aetiological phenomena or as a consequence of the 
syndrome.  
 
Complications of obesity have been known for centuries, with Hippocrates observing 
that ‘sudden death is more common in those that are naturally fat than lean’ 
(Chadwick & Mann, 1950). Obesity was linked to lipid abnormalities and 
hypertension in the 17th century by Nicholas Tulp (Tulp syndrome) (Erkelens et al., 
1993). In the 18th century, Giovanni Battista Morgagni associated visceral adiposity 
with hypertension, dyslipidaemia, hyperuricaemia, CVD and sleep apnoea (Enzi et 
al., 2003). The Swedish physician Kylin reported the clustering of hypertension, 
hyperglycaemia, dyslipidaemia and hyperuricaemia (gout) within certain patients in 
the 1920’s (Nilsson, 2001) followed by the association of the ‘android’ obesity 
phenotype with CVD and T2DM in the 1940’s (Vague, 1947). The term ‘metabolic 
syndrome’ appears to be first coined in 1977 by Haller, in which he described a 
collection of obesity, diabetes, hyperlipidaemia, hyperuricaemia and hepatic 
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steatosis in the German population that predisposed them to developing ischaemic 
heart disease (Haller, 1977). The concept was later described by Reaven in 1988, 
with hyperinsulinaemia and IR identified as a common underlying thread linking 
these associations together (Reaven, 1988). MetS has been described using various 
terminologies in the past, such as ‘syndrome X’, ‘insulin resistance syndrome’ and 
even the ‘deadly quartet’ (Reaven, 1988; Kaplan, 1989; DeFronzo & Ferrannini, 
1991). The more modern terminology and descriptions was formalised in 1998 by the 
World Health Organisation (WHO) (Alberti & Zimmit, 1998).  
 
 
Metabolic 
Syndrome
Abdominal
obesity
Increased 
blood 
pressure
Reduced 
HDL 
cholesterol
Increased 
triglyceride
Increased 
glucose
 
 
Figure 1: The five central features in the definition and current diagnostic criteria for 
metabolic syndrome as described by Alberti et al. (2009). This definition is based on 
the syndrome being a clustering of various risk factors for cardiovascular disease 
and type 2 diabetes mellitus. 
cHDL = High Densitiy Lipoprotein Cholesterol 
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Significant controversies continue to be associated with MetS. Critics argue that this 
collection of risk factors should not be considered a syndrome at all, as it lacks a 
clear aetiology and the pathophysiology is not well defined, in addition to continuing 
arguments over the evidence that has led to the currently accepted cut off values for 
diagnostics (Kahn, 2006; Gale, 2008; Alberti et al., 2009; Kuk & Ardern, 2009). The 
clinical relevance of the syndrome is also questioned, with arguments that MetS 
adds little to no additional predictive value for CVD over the traditional Framingham 
risk factors, and that the risks associated with MetS are not greater than the some of 
its parts (Gale, 2008; Schweiger et al., 2008). It is further argued by some authors 
that there is no real change in clinical management of patients as compared to the 
individual components of MetS (Kahn, 2006; Gale, 2008; Kuk & Ardern, 2009). 
However, studies indicating that up to 40% of obese individuals may be metabolically 
normal, and therefore have reduced risk of complications associated with MetS and 
obesity in general. Conversely, there are also lean patients who are diagnosed with 
MetS, and this can provide important clinical information (Brochu et al., 2001; 
Grundy, 2006; Stephan et al., 2008; Kuk & Ardern, 2009). 
  
1.1.1. Prevalence and epidemiology  
 
There has been a dramatic global increase in the incidence of MetS over the past 20 
years, closely associated with the global epidemic of obesity and T2DM, making the 
syndrome a global epidemic in its own right (Zimmet et al., 2001; Potenza & 
Meckanick, 2009). In fact, the global epidemics of obesity, CVD and T2DM have 
drawn attention to this cluster of metabolic and fat derangements as common and 
interrelated underlying pathophysiologies (Potenza & Meckanick, 2009). Although 
numerous studies have assessed prevalence and epidemiological factors, they 
generally differ widely in design and diagnostic criteria that are used (Cameron et al., 
2004; Potenza & Meckanick, 2009).  
 
Epidemiologic studies have demonstrated wide variations and differences in 
prevalence by age, gender, and ethnicity. The prevalence in adults varies from as 
low as 8% in India to as high as 24% in America for men, and as low as 7% in 
France to as high as 43% in Iran for Woman. Overall, prevalence in America is 
approximately 34.4%, approximately 24.6% - 30.9% in Europe, with significantly 
 
 
 
 
4 
 
lower rates in Japan of approximately 8.1% - 9.9% (Cameron et al., 2004; Pais et al., 
2009; Potenza & Meckanick, 2009; Razzouk & Muntner, 2009). The association with 
age is a generally constant variable, indicating MetS is highly age dependent. 
However, there is an increase in incidence of MetS in younger people, too (Sinha et 
al., 2002; Wei et al., 2003; Weiss et al., 2004; Ervin, 2009; Potenza & Meckanick, 
2009). This is again parallel with an increase in obesity, T2DM and CVD in younger 
adults and even children (Sinha et al., 2002; Wei et al., 2003; Weiss et al., 2004). 
 
1.1.1.1. Prevalence in South Africa 
 
The prevalence of MetS in the South African population is not well defined. Ker and 
colleagues (2007) reported that 31% of a group of 1410 corporate executives that 
belonged to a specialist health and fitness company in South Africa had MetS. An 
additional 33% had two criteria of MetS, thus considered borderline. Similar findings 
were reported in a smaller subset of black executives assessed.  In a study of 500 
black and 254 white diabetic patients in South Africa, 46.5% and 74.1% of the cohort 
were found to have MetS, respectively (Kalk & Joffe, 2008). Similar prevalence was 
found in a corresponding female cohort. This was slightly higher in women (25%) 
than in men (10.5%). A more recent publication by George and colleagues (2013) 
indicates a 29% and 46% prevalence of MetS in 374 African and 350 Asian Indian 
adults, respectively. A study assessing children aged 10 – 16 years old in South 
African schools identified MetS prevalence rates of 8.9% (n=158), 6.4% (n=281) and 
14% (n=57) in black, coloured and Caucasians males respectively, and 5.2% 
(n=288), 5.7% (n=415) and 6.8% (n=73) in black, coloured and Caucasian females. 
The overall rate of MetS in this study was 6.5% (Matsha et al., 2009). Generally, 
based on scanty data available, it appears that MetS is highly prevalent in the urban 
setting across numerous socio-economic and racial backgrounds.  
 
1.1.2. Definitions, diagnosis and classification  
 
MetS can be described as a master in disguise, as it can present in various ways 
according to different components that are being expressed in each individual (Eckel 
et al., 2005). It has proven difficult, and even controversial, to define and diagnose 
(Alberti et al., 2009). Since the formulation of criteria by the World Health 
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Organisation (WHO) in 1998 (Alberti & Zimmit, 1998), numerous criteria have been 
published (Alberti et al., 2009).  Although the diagnostic criteria proposed by the 
organisations had various similarities, key differences are found. These differences 
were particularly evident in the inclusion of obesity and the role of insulin resistance 
as diagnostic criteria (Alberti et al., 2009). 
 
The WHO criteria were the first to tie together the key components of insulin 
resistance, obesity, dyslipidaemia and hypertension (Alberti & Zimmit, 1998). 
However, the definition mandates that insulin resistance be present in order to 
achieve the diagnosis (Alberti & Zimmit, 1998). Furthermore, the use of the 
euglycaemic clamp for assessment of insulin resistance is not easily applied in the 
clinical setting. The WHO criteria also included the presence of microalbuminaemia 
as a possible diagnostic criterion, absent in all other definitions (Alberti & Zimmit, 
1998; Grundy et al., 2004; Alberti et al., 2009; Taslim & Tai, 2009).  
 
In 1999, the European Group for the Study of Insulin Resistance (EGIR) published a 
set of criteria (Balkau & Charles, 1999). Similar to the WHO, this also requires insulin 
resistance to be mandatory in order to achieve a diagnosis of MetS (Alberti et al., 
2009). The definition of insulin resistance is based on a fasting serum insulin 
measurement. This is easier to achieve in a clinical setting, but risks the exclusion of 
patients with T2DM in the diagnosis (Huang, 2009; Taslim & Tai, 2009).  
 
The Adult Treatment Panel III (ATPIII) guidelines (National Cholesterol Education 
Programme, 2002), although criticised for not including insulin resistance (Cheal et 
al., 2004; Liao et al., 2004), tended to be the most widely used in medical research 
for the definition of MetS for both clinical and research purposes as it is considered 
to be the most easily applied in the clinical setting (Grundy et al., 2004; Alberti et al., 
2009; Huang 2009; Taslim & Tai, 2009). The ATPIII was developed in 2001 by the 
National Cholesterol Education Programme, and requires that any three of five set 
criteria must be met for a diagnosis of MetS. These include increased waist 
circumference, hypertension, hypertriglyceridaemia, reduced high density lipoprotein 
(HDL) cholesterol and increased fasting glucose (National Cholesterol Education 
Programme, 2002).  
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The criteria set by the American Association of Clinical Endocrinology (AACE) in 
2003 are essentially a combination of the WHO and ATPIII definitions except that no 
specific defined number of risk factors are specified. This leaves the diagnosis to 
clinical judgement, and thus more subjective (Grundy et al., 2004; Taslim & Tai, 
2009).  
 
In 2005, the International Diabetes Foundation (IDF) published criteria for MetS that 
required obesity, and not insulin resistance, as a central and mandatory criterion 
(Zimmet et al., 2005). This was an important development, recognising the 
relationship between different abdominal fat risk associations with different 
populations. The criticism with these criteria is the fact that obesity is the emphasis, 
and not insulin resistance (Alberti et al., 2009; Huang, 2009; Taslim & Tai, 2009).  
 
In 2009, a joint scientific statement was published following meetings between the 
International Diabetes Federation Task Force on Epidemiology and Prevention, the 
National Heart, Lung and Blood Institute, the American Heart Association, the World 
Heart Federation, the International Atherosclerosis Society, and the International 
Association for the Study of Obesity (Alberti et al., 2009). This was an attempt to 
unify the various criteria, to ‘harmonise’ the variations of definitions and diagnostic 
criteria for MetS. It was agreed that there should not be an obligatory component, 
and that waist measurement would be a very useful screening tool (and not other 
assessments of obesity such as the body mass index). Five central criteria are set, 
and any three would qualify for the diagnosis of MetS. A single set of cut off points 
are suggested for all variables except waist circumference, which has variations 
based on ethnic backgrounds. There are, however, differences for male and female 
cut off values in waist circumference and HDL-cholesterol measurements (Alberti et 
al., 2009). The key components of this criterion are outlines in Table 1. Based on the 
purposes for this thesis, these cut off values are components for males only and are 
used to define MetS in this study.  
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Table 1:  A summary of the current criteria for the clinical diagnosis of metabolic 
syndrome in Asian, Caucasian and Sub-Saharan African males. A minimum of three 
criteria need to fulfilled to obtain a clinical diagnosis. Categorical cut of values for 
waist circumference vary based on ethnic background (Alberti et al., 2009).  
Criteria Categorical Cut Off Points 
Waist Circumference 
Sub-Saharan African  ≥ 94 cm;  
Caucasian ≥ 94 cm;  
Asian  ≥ 90cm;  
Blood pressure (or relevant medication) Systolic ≥ 130 mmHg and/or diastolic ≥ 
85 mmHg  
Fasting triglycerides (or relevant 
medication) > 1.70 mmol/L 
HDL Cholesterol (or relevant 
medication) < 1.00 mmol/L 
Fasting glucose (or relevant 
medication) > 5.5 mmol/L  
 
 
1.1.3. Complications and clinical consequences  
 
Almost by definition, MetS is closely associated with a risk for CVD and T2DM. The 
syndrome is further associated with a general risk of morbidity and mortality, with 
numerous other co-morbidities being associated with the syndrome. These include, 
but are not limited to, various cancers (particularly colorectal, breast, endometrial, 
prostate, hepatic, renal and pancreatic) (Calle et al., 2003; Pais et al., 2009; 
Gallagher et al., 2010; Braun et al., 2011; Esposito et al., 2013a; Esposito et al., 
2013b), polycystic ovarian syndrome, non-alcoholic hepatic steatosis and/or steatitis, 
cholelithiasis, obstructive sleep apnoea, gout and hyperuricaemia (Eckel et al., 2005; 
Huang, 2009) and Alzheimer’s disease (De Felice, 2013). Many of these phenomena 
are also closely related to the development of IR in numerous studies, again 
highlighting the important central role of IR in MetS (Cheal et al., 2004).  
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A meta-analysis of prospective studies indicates that MetS is associated with an 
increased relative risk (RR) of developing T2DM of 2.99, alongside a RR of 
developing CVD of 1.65 and a RR of all causes of mortality of 1.27 (Ford, 2005). 
Furthermore, mortality from any cause in those diagnosed with MetS has been 
suggested to increase 2.26 fold in males and 2.78 fold in females after adjustments 
for age, BMI, cholesterol levels, exercise, alcohol consumption and smoking 
(Potenza & Meckanick, 2009).  
 
1.2. Pathophysiology of metabolic syndrome 
 
As with an adequate and generally well accepted definition and set of diagnostic 
criteria for MetS, the exact aetiology and pathophysiology is also a matter of 
contention. A simplification of the pathophysiology as discussed below is 
represented in Figure 2 below.  
 
1.2.1. Aetiology and risk factors 
 
Although there is a clear genetic predisposition, and an unfavourable genotype is 
indeed an important risk, environmental factors are considered more influential in the 
development of the syndrome. Well defined risk factors that contribute to the MetS 
epidemic include a sedentary lifestyle, increased caloric intake and poor dietary 
choices (Eckel et al., 2005; Huang 2009). 
 
Genetic predisposition is highly complex, and involves multiple genes and numerous 
single nucleotide polymorphisms. Support is offered in numerous studies that 
associate heritability with components of MetS, including obesity, insulin resistance, 
hypertension, HDL-cholesterol levels and triglycerides, as well as the consequences, 
such as CVD and T2DM. Genes encoding leptin and the leptin receptor have also 
been found to be important in the predisposition of obesity and MetS, as are genes 
encoding lipolysis and β2- and β3-adrenoreceptors, peroxisome-proliferator 
activated receptor-γ (PPARγ) (Groop, 2000; Hegele, 2003; Dallongeville et al., 2003; 
Fumeron et al., 2004).  
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Figure 2: The simplified schematic summarising the complex interactions associated 
with the pathophysiology of metabolic syndrome in males.  This includes phenomena 
such as insulin resistance, leptin resistance, chronic inflammation and 
hypogonadism.  
 
 
In a modern ‘Westernised’ society, the abundance of an excess supply of calories is 
associated with an obesity epidemic, MetS and the various clinical associations. An 
increase in the prevalence of obesity is associated with rising levels of hypertension, 
dyslipidaemia, insulin resistance, CVD and T2DM, which are interrelated, 
culminating in the MetS (Huang, 2009; Zeelie et al., 2010). In addition to abundance 
of calories, the food quality is of importance (Eckel et al., 2005). Lack of dietary fibre, 
fruit and vegetables and even a lack of moderate alcohol consumption, has been 
associated with MetS (Potenza & Meckanick, 2009). A lack of adequate exercise, the 
so called ‘sedentary lifestyle’ is also strongly associated with an increased risk for 
obesity and MetS (Eckel et al., 2005). 
 
Associations between total fat intake, insulin resistance, MetS and coronary heart 
disease are primarily mediated through the saturated and unsaturated fatty acid 
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components (Hodson et al., 2001). Saturated fatty acids have long been associated 
with obesity, and have been related to a corresponding risk of the metabolic 
syndrome (insulin resistance), T2DM and CVD. Unsaturated fatty acids are widely 
considered to have a more beneficial biological effect in humans, with many arguing 
in favour of replacing saturated fats with unsaturated fats, rather than carbohydrates, 
to cause a favourable change in serum lipid profiles. This is associated with the so-
called Mediterranean diet, considered protective against MetS (Hodson et al., 2001; 
Riccardi et al., 2004; Potenza & Meckanick, 2009). 
 
Chronic psychosocial and work stress is also considered an important factor in the 
development of MetS. The mechanisms and pathways for this association is 
complex, mediating specific imbalances with the hypothalamic-pituitary-adrenal 
system and an activation of the sympathetic nervous system (Björntorp, 2001; 
Tsigos & Chrousos, 2002; Vitaliano et al., 2002; Chandola et al., 2006; Tentorlouris 
et al., 2006). 
 
1.2.2. Obesity and the role of adipose tissue 
 
In adults, predominant white adipose tissue (WAT) can be classified into two braod 
types, namely subcutaneous and visceral, with distinct gene expressions 
(phenotypes) associated with obesity. Subcutaneous adipose tissue is generally 
considered to be protective against features associated with obesity and MetS 
(Kwon & Pessin, 2013). The inability to convert excess carbohydrates to lipids for 
storage in subcutaneous tissue is thought to be a prominent mechanism in the 
development of MetS and associated complications (Bastard et al., 2006; Kwon & 
Pessin, 2013).  
 
The global obesity pandemic is a prominent driving force behind the increased 
incidence of MetS. There is indeed a close relationship between obesity, particularly 
visceral obesity assessed by a waist circumference measurement, and MetS. 
However, the manner of inclusion and the definition of obesity has generated much 
discussion and controversy (Alberti et al., 2009; Huang, 2009; Taslim & Tai, 2009). 
To illustrate the importance of BMI as a predictor of MetS, being overweight, with 
 
 
 
 
11 
 
high triglycerides, low HDL or hypertension, more often resulted in a diagnosis of 
MetS the identification of IR (Cheal et al., 2004). 
 
Waist circumferences (WC) or the waist-to-hip ratio (WHR) is included and favoured 
above BMI for several definitions of MetS (Grundy et al., 2004; Alberti et al., 2009; 
Huang, 2009; Taslim & Tai, 2009). WC correlates with IR and has a stronger 
association with the development of CVD and T2DM than BMI alone (Alberti et al., 
2009; Gallagher et al., 2010). It is important to be certain that an increased WC is 
due to intra-abdominal (visceral) fat deposits and not subcutaneous fat, which is only 
possible with MRI technology (Eckel et al., 2005). A further area of controversy is the 
observed variation of the role of visceral obesity in different sexes, and especially in 
those with different ethnic backgrounds (Taslim & Tai, 2009). South Asian 
populations have greater amounts of visceral adiposity for given WC measurements 
compared to European populations (Alberti et al., 2005; Lear et al., 2007; Alberti et 
al., 2009; Gallagher et al., 2010). As an example, those in Singapore have a greater 
amount of adiposity compared to Caucasions with the same BMI (Deurenberg et al., 
2002), indicating that those with different ethnic backgrounds carry different amounts 
of intra-abdominal fat and therefore risk of MetS (Araneta & Barrett-Connor, 2005; 
Kadowaki et al., 2006; Lear et al., 2007).   
 
Normal weight individuals can also be diagnosed with MetS (Ruderman, 1998; Eckel 
et al., 2009), as obesity is just one of five components according to the criteria 
suggested by Alberti and colleagues (2009). Conversely, there are patients with 
increased WC and BMI that do not exhibit other features of MetS, and are also 
associated with a lower risk for CVD and T2DM compared to others in similar weight 
categories with MetS features (Huang, 2009). However, with literature indicating that 
weight loss can lead to improvements of multiple features of MetS simultaneously, 
visceral obesity appears to be a core central feature involved in the pathophysiology 
(Huang, 2009). 
 
Adipose tissue comprises of adipocytes (containing a single, large fat droplet), 
preadipocytes, macrophages and lymphocytes. Traditionally, this tissue was thought 
to act predominantly as a major storage site for energy and insulator. However, 
adipose tissue further secretes various proteins termed adipokines (general term 
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used to denote any protein synthesised and secreted by adipocytes) amongst 
numerous other metabolically active molecules (Trayhurn & Wood, 2004; Wozniak et 
al., 2009). These proteins circulate in the body acting predominantly as hormones, 
communicating with tissues such as the brain, liver, muscle, the immune system and 
adipose tissue itself (Kwon & Pessin, 2013). Examples of these molecules include 
leptin, resistin, retinol binding protein-4, chemerin, CC-chemokine ligand 2, CC-
chemokine receptor type 5, angiopoitin-like protein, adiponectin, omentin-1 apelin 
and traditional cytokines such as tumour necrosis factor-alpha (TNFα), interleukin 1β 
(IL1β) and interleukin 6 (IL6) (Bastard et al., 2006; Kwon & Pessin, 2013).  Adipose 
tissue is therefore considered to be an important hormonally active organ and a 
prominent controller of energy homeostasis, metabolic function, immune activity and 
reproduction (Trayhurn & Beattie, 2001; Nawrocki & Scherer, 2004; Juge-Aubry et 
al., 2005; Wang et al., 2008; Wozniak et al., 2009).  Via the activity of adipokines, 
adipose tissue has been shown to actively modulate and participate in various 
metabolic and inflammatory processes. (Trayhurn & Beattie, 2001; Nawrocki & 
Scherer, 2004; Juge-Aubry et al., 2005; Wang et al., 2008). 
 
1.2.3. Insulin and insulin resistance 
 
Insulin is a polypeptide based hormone produced predominantly in the Islets of 
Langerhans of the endocrine pancreas by β-cells and is well described as the key 
hormone involved in the regulation of glucose and free fatty acid uptake by tissue 
cells uptake, with roles in the promotion and regulation of growth, differentiation and 
metabolism. This action is mediated mostly through action on liver, adipose and 
skeletal muscle tissue, although many other tissues have receptors for the action of 
insulin. Insulin is essentially a 51 amino acid dimer of two chains (A and B), each 
containing three α-helices linked together by disulfide bonds (Brange & Langkjoer, 
1993; Menting et al., 2013).  
 
Insulin stimulates the uptake and use of glucose differently in various tissues, 
mediated predominantly via hepatocytes, adipocytes and skeletal muscle. In an 
insulin sensitive individual, increased blood glucose stimulates the β-cells of the 
pancreas to synthesis and release insulin. Acting via the insulin responsive glucose 
transporter 4 (GLUT4) receptor, glucose is taken up by these tissues (Kim et al., 
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2006a). Via this mechanism, insulin stimulates glycogen synthesis from glucose for 
storage, and suppresses hepatic gluconeogensis (Kim et al., 2006a; Karnieli & 
Armoni, 2008). Insulin sensitivity correlates positively with cellular expression of 
GLUT4 (Karnieli & Armoni, 2008). The net effect of these predominant functions of 
insulin is to reduce glucose concentration in the blood stream via an increase in 
GLUT4 mediated cellular uptake. Glucose is then stored primarily as glycogen, with 
excess glucose being stored as fat (Kim et al., 2006a; Huang, 2009).  
 
Insulin mediates metabolic and mitogenic effects through binding to cell surface 
insulin receptors, leading to activation of two pathways: the phosphoinositide 3-
kinase (PI3K) and the mitogen-activated protein kinase (MAPK) pathways (Huang, 
2009; Gallagher et al., 2010). PI3K results in activation of 3-phosphoinositide-
dependent protein kinase 1 (PDK1) and Akt kinase (Huang, 2009). This PI3K-Akt 
pathway is responsible for most downstream metabolic effects of insulin function, 
which includes activation of endothelial nitric oxide synthase (eNOS) and 
translocation of GLUT4 in skeletal muscle and adipocytes (via increased PPARγ 
gene expression and actin mediated mobilisation) (Taniguchi et al., 2006).  
 
The activation of the MAPK pathway generally mediates transcription of factors 
involved with cell growth (Gallagher et al., 2010). Effects of metabolites in this 
pathway result in vasoconstriction, increased expression of vascular cell adhesion 
molecules and growth and mitogenesis of vascular smooth muscle cells (Kim et al., 
2006a; Huang, 2009; Gallagher et al., 2010). In brief, under normal function, insulin 
promotes cellular glucose uptake, inhibits gluconeogenesis, decreases adipose 
tissue lipolysis and hepatic very low density lipoprotein synthesis, in addition to 
decreasing appetite in the brain (Gallagher et al., 2010). It further mediates 
endothelial and vascular smooth muscle function (Huang, 2009).  
 
1.2.3.1. Insulin resistance 
 
Impaired insulin signalling is central to development of the metabolic syndrome and 
can promote cardiovascular disease indirectly through development of abnormal 
glucose and lipid metabolism, hypertension, and a proinflammatory state (Rask-
Madsen & Kahn, 2012). Changes in insulin function are illustrated in Figure 3.  
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Figure 3: Insulin signalling in metabolic syndrome. Insulin actions which are insulin 
resistant in metabolic syndrome are labeled ‘R’, whereas insulin actions which 
remain insulin sensitive in metabolic syndrome are labeled ‘S’.  
Adapted from Rask-Madsen & Kahn (2012). 
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The basic concept of insulin resistance (IR) describes the phenomenon whereby 
adipose, hepatic or muscle cells do not respond to receptor mediated action of 
insulin, exacerbated by a dysregulation in various feedback mechanisms (Huang, 
2009). IR can be described as a defect in the activity and action of insulin associated 
with fasting and even postprandial hyperinsulinaemia in order to maintain 
euglycaemia (Eckel et al., 2005). Insulin's action directly on vascular endothelium, 
atherosclerotic plaque macrophages, and in the heart, kidney, and retina has now 
been described, and impaired insulin signalling in these locations can alter 
progression of cardiovascular disease in the metabolic syndrome and affect 
development of microvascular complications of diabetes mellitus (Rask-Madsen & 
Kahn, 2012). This metabolic phenomenon is closely associated with 
hyperinsulinaemia and hyperglycaemia, and IR is therefore a powerful predictor of 
T2DM (Huang, 2009).  
 
As a result of these associations, IR is generally the most accepted and unifying 
hypothesis to describe the underlying pathophysiology of MetS (Eckel et al., 2005; 
Gallagher et al., 2010). However, Cheal and colleagues (2004) also highlighted that 
although IR and/or hyperinsulinaemia is closely correlated with the diagnosis of 
MetS, their results indicated a sensitivity and positive predictive value of IR for MetS 
to be 46% and 76%, respectively. Obesity and increased WC is a predominant risk 
factor for the development of insulin IR, and appears to play a central role in the 
pathogenesis of atherosclerosis and T2DM (Liao et al., 2004; Zeyda & Stulnig, 
2009). Although some obese patients do express the metabolic phenotype 
associated with CVD and T2DM, increasing IR is closely associated with MetS 
derangements such as higher blood pressure, triglyceride levels, low HDL 
cholesterol and glucose deregulation (Gallagher et al., 2010).  
 
In IR, the PI3K-Akt pathway is affected, whereas MAP kinase pathway is not. This 
leads to a mismatch between these functions, and the balance between these 
pathways is affected (Huang, 2009). Inhibition of PI3K-Akt leads to reduced eNOS 
and thereby reduced nitric oxide (NO), resulting in endothelial dysfunction. It is also 
associated with reduced GLUT4 translocation, leading to reduced uptake of glucose 
by adipocytes and skeletal muscle (Huang, 2009). This pathway is also associated 
with a negative influence on the hypothalamic-pituatary –testis (HPT) axis (Acosta-
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Martínez, 2012) (illustrated in Figure 4) and spermatozoa function post ejaculation 
(Andò & Aquila, 2005).  
 
By contrast, the MAP-kinase pathway is overly active, leading to increased 
vasoconstriction, over expression of vascular cell adhesion molecules (which 
increases leukocyte interaction with blood vessel wall) and increases smooth muscle 
cell growth in blood vessels (Huang, 2009). IR thus leads to various vascular 
abnormalities that are closely associated with atherosclerosis (and hence CVD) and 
hyperglycaemia (and hence T2DM) (Eckel et al., 2005).  
 
 
 
Figure 4: P13K pathway alterations in insulin and leptin resistance and effects on 
the hypothalamic-pituitary-testis axis during chronic metabolic disturbances.  
Alterations in the levels and sensitivity to peripheral hormones and metabolic signals, 
including insulin and leptin, play a major role in the dysfunction of the PI3K in this 
figure, altered PI3K signalling is linked to the negative effects that metabolic 
imbalance has on the HPG axis.  
IRS: Insulin Receptor Substrate; PI3K: Phosphoinositide 3-kinase; PIP2: 
Phosphatidylinositol-diphosphate; PIP3: Phosphatidylinositol-triphosphate; IGF-1: 
Insulin-Like Growth Factor 1; ERα: Oestrogen Receptor alpha.  
Adapted from Acosta-Martínez (2012).  
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Various metabolic factors play a role in the development of IR. This includes, but not 
limited to free fatty acids, inflammatory cytokines, adipokines, ROS, and 
mitochondrial dysfunction (Eckel et al., 2005; Huang, 2009; Gallagher et al., 2010). 
However, factors that can induce IR are also generally worsened by IR. This 
includes obesity itself, dyslipidaemia (such as increased triglycerides and VLDL and 
reduced HDL), glucose intolerance and inflammation (Eckel et al., 2005; Huang, 
2009; Gallagher et al., 2010). 
 
Various methods are used to estimate the sensitivity of cells to the action of insulin. 
The gold standard is considered the Euglycaemic Hyperinsulinaemic Clamp (EHC), 
as it directly measures the action of insulin on glucose metabolism in steady state 
conditions. However, this method is not suitable for clinical assessment (Rabasa-
Lhoret et al., 2003). The Quantitative Insulin Sensitivity Check Index (QUICKI), 
proposed by Katz and colleagues (2000), is calculated from fasting blood glucose 
and insulin concentrations, with a decreased score indicative of decreased insulin 
sensitivity (increased insulin resistance) (Rabasa-Lhoret et al., 2003). Evidence 
indicates that the QUICKI is a useful assessment of insulin sensitivity, and that this 
score correlates closely with EHC across a wide range of glucose concentrations 
(i.e. is better correlated to EHC  than other fasting-based index of insulin sensitivity 
in different insulin resistant states) (Hrebicek et al., 2002; Rabasa-Lhoret et al., 2003; 
Yokoyama et al., 2004).  
 
1.2.4. Leptin 
 
Work with genetically obese mouse models (ob/ob) lead to the identification of the ob 
gene and its protein product, leptin (from leptos, meaning thin) in 1994. The ob/ob 
mouse was found to lack this hormone. Leptin has been associated with reducing 
appetite and food consumption resulting in reduced body mass and body fat percent, 
with the maintenance of lean tissues. Injecting leptin into rodents is associated with 
increased energy expenditure, improvement in glycaemic control and even 
reproductive function (Bastard et al., 2006; Kwon & Pessin, 2009; Galic et al., 2010). 
Leptin is almost exclusively expressed by adipocytes, specifically visceral adipose 
tissues (Bastard et al., 2006). Serum leptin concentrations are correlated with 
several features of metabolic syndrome, and highly correlated with BMI and visceral 
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obesity, although the association with MetS and insulin resistance appears to be 
independent of rising BMI. This relationship is significantly mediated through the 
effects of central obesity (Esteghamati et al., 2009). 
 
The protein structure of leptin is very similar to that of other pro-inflammatory 
cytokines, including interleukin-2 and IL6 (Ahima & Flier, 2000). Leptin receptors also 
belong to the class 1 receptor family, with also the indication that inflammation is 
raised in hyperleptinaemia without obesity (Loffreda et al., 1998; van Dielen et al., 
2001). Therefore, although typically known for action on the central nervous system 
to regulate food intake and energy expenditure (Bastard et al., 2006), leptin can also 
mediate inflammation via receptor interactions (LepRb) (Kwon & Pessin, 2009; 
Procaccini et al., 2012). It also activates monocytes to synthesise and secrete IL6 
and TNFα, amongst other cytokines, in addition to Th1 cell stimulation (Kwon & 
Pessin, 2009; Procaccini et al., 2012).  Almost all tissues exhibit leptin receptors, 
indicating a significant role in for leptin in overall physiology (Kwon & Pessin, 2009; 
Procaccini et al., 2012).  
 
Leptin interacts with six types of receptors (Ob-Ra–Ob-Rf, or LepRa-LepRf), that in 
turn are encoded by a single gene, LEPR (Wang et al., 1996).  Ob-Rb is the only 
receptor isoform that can signal intracellularly via the JAK2/STAT3 and MAPK signal 
transduction pathways (Malendowicz et al., 2006).  As with insulin, biological effects 
of leptin are mediated via activation of the PI3K intracellular pathway (Figure 4) 
(Donato et al., 2010; Acosta-Martínez, 2012). As a breakdown in this pathway is 
central to the concept of insulin resistance (Huang, 2009), this too leads to a 
phenomenon associated with MetS termed leptin resistance (Acosta-Martínez, 
2012).  
 
1.2.5. Inflammation and inflammatory cytokines 
 
MetS is closely associated with a low grade, asymptomatic, systemic and chronic 
inflammatory state (Monteiro & Azevedo, 2010; Fuentes et al., 2013). This is 
demonstrated by a subtle and detrimental increase in serum C-reactive protein 
(CRP), a biochemical marker of inflammation that can be easily assessed in 
laboratory investigations (Haffner, 2003; Tamakoshi et al., 2003; Monteiro & 
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Azevedo, 2010; Brooks et al., 2010). Synthesised in the liver, CRP production is up-
regulated by the pro-inflammatory cytokines tumour necrosis factor alpha (TNFα) 
and interleukin-6 (IL6), with both cytokines raised in the serum of obese patients and 
those with MetS (Tamakoshi et al., 2003; Khaodhiar et al., 2004; Monteiro & 
Azevedo, 2010; Brooks et al., 2010). A chronic and subtly raised CRP concentration 
in serum, the so-called highly sensitive CRP (hs-CRP) (Brooks et al., 2010), is 
considered a non-specific inflammatory marker and predictor of T2DM, sub-clinical 
atherosclerosis, CVD and even some cancers (Pradhan et al., 2001; Malik et al., 
2005; Reaven 2005; Haffner, 2006; Yuan et al., 2006; Hsing et al., 2007; Nakano et 
al., 2010).  
 
Increased visceral obesity results in an altered secretion pattern of adipokines 
(Nawrocki & Scherer, 2004; Juge-Aubry et al., 2005; Kintscher et al., 2008; 
Nishimura et al., 2009; Fuentes et al., 2013). These adipokines, which originate 
adipocytes themselves as well as from adipose tissue-associated macrophages, 
have been found to play a significant role in multiple metabolic and inflammatory 
responses in human physiology and pathology, with a corresponding enhanced 
basal inflammatory tone (Nawrocki & Scherer, 2004; Juge-Aubry et al., 2005; 
Kintscher et al., 2008; Nishimura et al., 2009; Fuentes et al., 2013). This increased 
inflammatory setting is closely associated with the phenomenon of IR, which is 
considered by many researchers to be an underlying and central feature of the MetS 
(Nawrocki & Scherer, 2004; Kasturi et al., 2008, Kintscher et al., 2008; Phillips & 
Prins, 2008). Furthermore, all the parameters included in the definition and diagnosis 
of MetS are associated with a low-grade inflammatory state (Esposito & Giugliano, 
2004), typically identified via a significant correlation with CRP (Pradhan et al., 2001; 
Malik et al., 2005; Haffner, 2006; Yuan et al., 2006; Nakano et al., 2010). As this pro-
inflammatory state is directly linked with obesity, insulin resistance, diabetes and 
endothelial dysfunction (Esposito & Giugliano, 2004; Phillips & Prins, 2008), it is 
even suggested that MetS may be an adipose tissue disease different from obesity, 
and would thus be characterised by systemic inflammatory markers (Camera et al., 
2008; Oda, 2008). This relationship is illustrated in Figure 5. 
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Figure 5: Leukocytes and adipose tissue inflammation associated with MetS. 
Macrophage and lymphocyte infiltration in adipose tissue may greatly contribute to 
obesity-related metabolic dysfunction and chronic inflammation, as well as 
adipocytes.  
CVD: cardiovascular diseases.  
Adapted from Fuentes et al. (2013).  
 
 
Immune cells are known to increasingly infiltrate adipose tissue in direct correlation 
to increased adipose tissue. Initial T-lymphocyte accumulation (Kintscher et al., 
2008; Nishimura et al., 2009) is followed by macrophages (Lumeng et al., 2012), 
which increasingly secrete proinflammatory cytokines such as TNFα, IL6 and 
interleukin 1-beta (IL1β) which contributes significantly to the induction of IR 
(Nawrocki & Scherer, 2004; Juge-Aubry et al., 2005; Bastard et al., 2006; Kintscher 
et al., 2008; Nishimura et al., 2009). 
 
1.2.5.1. Tumour necrosis factor-alpha (TNFα) 
 
TNFα was originally discovered as a protein that mediates tumour necrosis with a 
role in cancer cachexia, induced via endotoxin activity on macrophages (Kwon & 
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Pessin, 2009). It is a 26kDa transmembrane protein that is converted to a 17kDa 
soluble molecule via metalloproteinase. Although produced by a variety of cell types, 
it is mostly associated with macrophages and lymphocytes. Although adipocytes are 
capable of synthesising and secreting TNFα, this activity is weak in humans, and it is 
now thought that increased secretion associated with obesity is from M1-
macrophages that infiltrate the adipose tissue (Bastard et al., 2006; Galic et al., 
2010).  TNFα has a wide range of inflammatory functions, with a variety of factors 
that can induce its production, and is thought to contribute to obesity associated 
complications (Wozniac et al., 2009).  
 
TNFα has been well studied in the development of IR and MetS. However, the 
precise role and even origin of the protein requires further investigation. Numerous 
studies have shown that TNFα can impair insulin signalling in hepatocytes, adipose 
tissue and skeletal muscle (Galic et al., 2010). This is mediated via phosphorylation 
of insulin receptor substrate-1 (IRS-1), likely preventing the interaction of this protein 
with insulin receptor beta subunit and inhibiting this pathway (Bastard et al., 2006). In 
both cell culture and rodent models, TNFα administration induces IR, and 
neutralisation of TNFα improves insulin sensitivity (Kwon & Pessin, 2009) and 
improves insulin senstivity in high fat diet induced IR in rodent models (Uysal et al., 
1997). Long term TNFα-antagonist administration to obese patients with rheumatoid 
arthritis also improves insulin sensitivity (Kwon & Pessin, 2009).  In obese patients 
with T2DM, this treatment does not improve hyperglycaemia or insulin sensitivity, but 
it does improve insulin sensitivity in obese patients without T2DM. However, this 
treatment in humans is highly controversial (Kwon & Pessin, 2009; Galic et al., 
2010). 
 
1.2.5.2. Interleukin 1-beta (IL1β) 
 
Interleukin 1-beta (IL1β), also known as catabolin, is a member of the IL1 cytokine 
family. This cytokine is produced via cleavage of pro-IL1β by NLRP3-caspase-1, 
which in turn is activated by a multiprotein complex called the inflammasome and 
mediates inflammatory activities including cell proliferation, differentiation and 
apoptosis (Mills & Dunne, 2009; Tack et al., 2012). Various lines of research suggest 
that IL1β plays an important role in obesity associated inflammation and insulin 
 
 
 
 
22 
 
resistance (Tack et al., 2012). In NLRP3-caspase-1 deleted animal models, or 
inhibition of caspase 1, there is some protection offered against IR development 
induced by obesity (Stienstra  et al., 2010; Vandanmagsar et al., 2011). In the IL1 
receptor I (IL1RI) deficient mice fed a high fat diet, typically associated with the 
production of obesity and IR, the lack of IL1β binding is also associated with IR 
protection and a reduced adipose tissue inflammatory response (McGillicuddy et al., 
2012).  IL1β is also known to promote the inflammatory response, typically inducing 
production of other proinflammatory cytokines (Tanaka et al., 1999; Jager et al., 
2007). 
  
1.2.5.3. Interleukin 6 (IL6) 
 
Interleukin 6 (IL6) is produced by many cell types, including monocytes and 
macrophages, fibroblasts and endothelial cells (Bastard et al., 2006). It is estimated 
that 15-30% of circulating IL6 is derived from adipose tissue in the absence of 
inflammation (Mohamed-Ali et al., 1997), with increased secretion associated with 
visceral adipose tissue rather than subcutaneous depots (Fain et al., 2004). In both 
non-obese and obese individuals, IL6 has a very close correlation with CRP levels, 
and IL6 is a predominant stimulator for hepatic CRP synthesis (Fain et al., 2004).   
IL6 circulates at high plasma concentrations in MetS, and may represent a hormonal 
factor that induces muscle insulin resistance (Fernandez-Real et al., 2001; Esposito 
& Giugliano, 2004). As mentioned above, IL6 is typically secreted from activated 
macrophages and lymphocytes, but adipose tissue may be the source in non-acute 
inflammatory conditions such as MetS (Mohamed-Ali et al. 1997).  IL6 levels 
correlate positively with BMI, hyperinsulinaemia (Fried et al., 1998), insulin sensitivity 
(Pradhan et al., 2001) and T2DM – although serum concentrations remain within 
normal limits (Fernandez-Real & Ricart, 2003). IL6 also appears to play a very 
prominent role in the link between obesity, MetS and coronary heart disease (Yudkin 
et al., 2000). TNFα is also a strong inducer of IL6 from adipocytes themselves 
(Rotter et al., 2003). 
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1.2.5.4. Interleukin 8 (IL8) 
 
IL8, also known as neutrophil chemotactic factor, is a member of the CXC 
chemokine family, is produced predominantly by macrophages, but can be produced 
by any cell with toll like receptors (Baggiolini & Clark-Lewis, 1992). It is produced in 
response to activation of the innate immune system. IL8 predominantly has 
chemotactic (for granulocytes) and angiogenic properties, actively functioning in both 
acute inflammation and endothelial cell proliferation, and can also induce 
phagocytosis by granulocytes (Baggiolini & Clark-Lewis, 1992).  
 
IL8 are secreted by adipocytes, and circulating concentrations are positively 
correlated with BMI, WC and IR, suggesting roles in obesity related phenomenon 
such as MetS (Kim et al., 2006b). TNFα has been shown to increase IL8 release in 
visceral adipose tissue (Bruun et al., 2001), with further studies indicating increased 
IL8 associated with increased waist-to-hip ratio and fat mass (Straczkowski et al., 
2002). 
  
1.2.6. Hormonal changes and hypogonadism in males 
 
Hormonal changes that are associated with MetS in males include reduced serum 
total testosterone, free testosterone and sex hormone binding globulin (SHBG), 
increased serum oestrogen, insulin (insulin resistance), leptin, FSH, LH and prolactin 
(Kasturi et al., 2008; Hofny et al., 2010). As described below, these hormones are 
also involved in male reproductive function, and therefore these changes are of 
interest in studies related to male infertility.  
 
In adult males, MetS correlates with reduced serum testosterone concentrations and 
raised gonadotrophins, thus reflecting a state of primary hypogonadism (Pasquali, 
2006; Guay, 2009; Saad & Gooren, 2009). As a more recent and very important 
development, it is emerging in the scientific literature that reduced serum 
testosterone in non-obese men, including those with asymptomatic androgen 
deficiency, increases the risk of developing MetS (Boyanov et al., 2003; Kupelian et 
al., 2006; Traish et al., 2009). This is further associated with further lines of evidence 
suggesting that the clinical administration of testosterone can improve many of the 
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characteristics associated with the syndrome, as well as T2DM, in male patients 
(Saad & Gooren, 2009).  
 
Reduced testosterone associated with obesity and MetS is partly explained by 
increased activity of the aromatase cytochrome P450 enzyme which is over 
expressed in visceral adipose tissue associated with obesity. This results in 
increased peripheral conversion of testosterone into oestrogens (Roth et al., 2008). 
This is further associated with reduced LH and FSH production by the pituitary, 
leading to reduced testosterone synthesis (hypogonadotropic hypogonadism) and 
reduced spermatogenesis (Cabler et al., 2010).   
 
1.3. Male reproduction and infertility  
 
Infertility is defined by the World Health Organisation (WHO) as ‘the inability of a 
couple to achieve conception or bring a pregnancy to term after 12 months or more 
of regular (at least three times per week), unprotected sexual intercourse’ (WHO, 
2010). It affects 15% (approximately one in seven) of couples trying to conceive 
(Kefer et al., 2009). Of these cases, 25-50% can be attributed partially or solely to 
the male partner (Lampiao & du Plessis, 2008a; Hamada et al., 2012a), with up to 
7% of men affected by infertility during their reproductive lifetime (Behre & Nieschlag, 
2000). Interestingly, it appears that sperm dysfunction is the single most common 
cause of infertility among couples of reproductive age (Barratt et al., 2011).  
 
An assessment of sperm quality, based on WHO guidelines (2010), is normally used 
to estimate the fertilisation potential of the male partner. A decrease in sperm quality 
is considered a major reflection of the decreased ability of the male partner to 
contribute to fertilisation (Hamada et al., 2012a). As the incidence is increasing, male 
infertility represents a challenging and important area of laboratory and clinical 
science investigation, with a need to further improve diagnostics, mechanisms and 
possible treatments (Hamada et al., 2012a).  
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1.3.1.  Causes and risks of male infertility 
 
Male infertility arises from a variety of health problems, including genetic causes, 
organic pathology and lifestyle or environmental factors that can negatively influence 
the male fertility potential (Esteves et al., 2012).  
 
Well defined genetic causes of infertility include Klinefelter syndrome, Kallmann 
syndrome and cryptorchidism (± 2.7% cases) (Dada et al., 2011; Hamada et al., 
2011). The known acquired causes of male factor infertility include varicoceles  
(± 25% cases), urogenital infections (± 10% cases), immunogenic causes (such as 
antisperm antibodies), impotence or sexual/ejaculation inadequacy (±0.7% cases), 
testicular failure (± 1.1% cases), other acquired urogenital abnormalities (e.g. 
structural complication following infections or inflammation, such as mumps orchitis), 
and various endocrine disorders (± 1.5% cases) (Dohle et al., 2005; Hamada et al., 
2011; Esteves et al., 2012; Hamada et al., 2012a). Although numerous aetiologies 
and risks are associated with male infertility, approximately 20 - 50% of these cases 
have no known aetiology, termed ‘idiopathic’ (Hamada et al., 2012a), which is also 
termed idiopathic oligoasthenoteratozoospermia (iOAT) (Jungwirth et al., 2012). This 
term denotes unexplained abnormalities in sperm parameters that include low sperm 
concentration, reduced sperm motility and abnormal sperm morphology (Jungwirth et 
al., 2012). 
 
Various environmental and lifestyle factors are increasingly associated with changes 
in male reproductive function, affecting fertilisation ability. Risks associated with male 
factor sub- or infertility include consumption of alcohol and tobacco, recreational drug 
use (such as marijuana and cocaine), exposure to excessive testicular heat (i.e. 
welders; bakers), prolonged urban driving and sitting (related to testicular heat), 
exposure to oestrogens and androgens, various environmental toxins known as 
endocrine disruptors (e.g. pesticides; phthalates), exposure to heavy metals (e.g. 
lead; cadmium), stress (both physiological and psychological), ionising radiation and 
even exposure to cell phone radiation (Dohle et al., 2005; Agarwal et al., 2008; 
Makker et al., 2009; Mendiola et al., 2009; Esteves et al., 2012). As discussed in 
more detail below, obesity (and conceivably MetS) is also associated with male 
infertility. Semen is therefore considered a sensitive indicator of environmental, 
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occupational and lifestyle exposures that can exert direct toxic effects and hormonal 
disruption (Mendiola et al., 2009). 
 
1.3.2. Male fertility assessment 
 
Male fertility and infertility should be investigated with a complete and detailed 
medical history and a thorough systemic and genital examination (Hamada et al., 
2011; Esteves et al., 2012; Hamada et al., 2012a). Typically, a standard semen 
analysis is done (detailed below) in order to investigate sperm function (Aitken, 2006; 
Lewis, 2007; Hamada et al., 2012a). However, the predictive value of a normal 
semen test is approximately 60% (van der Steeg et al., 2010). In addition, hormonal 
analysis can be done, including testosterone, FSH, LH, oestrogen, prolactin and 
thyroid function (Hamada et al., 2012a). Additional analysis includes visual 
investigations such as ultrasounds, especially of the testes, vas deferens, seminal 
vescicles and prostate (Hamada et al., 2012a). Genetic testing is also required in 
many cases (Dada et al., 2011; Hamada et al., 2011; Esteves et al., 2012). In some 
cases, particularly cases that appear to be idiopathic (otherwise normal history, 
clinical and visual examinations, semen analysis and hormonal assessments), more 
elaborate analyses can be offered. This includes antisperm antibody determination, 
postcoital (sperm cervical fluid penetration) test, sperm DNA fragmentation and 
chromotin tests, sperm mitochondrial membrane potential, ROS assessment in 
seminal fluid and acrosome reaction tests (Aitken, 2006; Lewis, 2007; Dada et al., 
2011; Hamada et al., 2011; Esteves et al., 2012). A more detailed flow diagram for 
male fertility assessment, as recommended by Hamada et al. (2011) is illustrated in 
Figure 6 below.  
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Figure 6: A detailed protocol for the clinical diagnostic approach to male fertility 
assessments as recommended by Hamada et al. (2011).  
 
1.3.3. The semen analysis 
 
Human semen, and particularly spermatozoa, is produced via complex and 
sophisticated biological processes, produced by specialised cells and tissues. 
Spermatozoa are produced over a 72 day cycle by germinal epithelium, and are very 
sensitive to changes in the regulatory mechanisms (Mendiola et al., 2009). These 
mechanisms include (but not limited to) hormonal factors such as testosterone,  
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insulin and leptin,  and various cytokines (Dohle et al., 2003; Martinez et al., 2007; 
Lampiao et al., 2009).  Damage or disruption of this cycle can occur at any stage, 
and may be either reversible or permanent (Mendiola et al., 2009). During 
ejaculation, semen is produced from a concentrated suspension of spermatozoa, 
stored in the paired epididymides, diluted and mixed by fluid secretions from the 
accessory sex organs, mostly the prostate and seminal vesicles (WHO, 2010). 
Semen therefore has two key factors, namely the number of spermatozoa (reflecting 
sperm production by the testes) and the total fluid volume (WHO, 2010).   
 
The standard for male fertility assessment is outlined in the Laboratory Manual for 
the Examination and Processing of Human Semen 5th Edition (WHO, 2010). Notably, 
this latest edition lowers most normal values for male sperm parameters compared 
to the previous additions of the WHO guideline manuals (Esteves et al., 2012; 
Hamada et al., 2012a). Various spermatozoa parameters, such as motility, vitality 
and morphology, are important fertility markers, as is the quality and composition of 
the seminal fluid, such as volume, liquefaction, viscosity, pH and leukocyte 
concentration (WHO, 2010).  Normal sperm parameter cut off values is listed in 
Table 2.  
 
In must be noted, however, that although the semen analysis remains a standard 
test in male fertility assessments, its clinical value is limited as 5% of fertile men and 
16% of infertile men display poor semen analyses (Lewis, 2007). There are also 
large variations between males from different geographical locations and countries, 
individuals within the same regions and even different samples from the same 
individuals (Lewis, 2007). In addition to the number of spermatozoa, the functional 
capacity of sperm is considered a more sensitive determinant of fertility potential 
(Aitkin, 2006). However, two factors are clear: firstly, samples with values below cut 
off values increases the risk of subfertility; secondly, values higher than cut off points 
do not provide any diagnostic information (Barratt et al., 2009).  
 
 
 
 
 
 
 
 
29 
 
Table 2: Cut off values for normal results associated with the standard semen 
analysis.  
Parameter Normal finding Reference 
Semen volume > 1.5ml WHO, 2010 
Total sperm count > 39 x 106/ejaculate WHO, 2010 
Sperm concentration > 15 x 106/ml WHO, 2010 
Progressive Motility > 32% WHO, 2010 
Total Motility > 40% WHO, 2010 
Vitality > 58%  WHO, 2010 
Morphology > 4% normal forms WHO, 2010 
Leukocytes < 1 x 106 leukocytes/ml WHO, 2010 
 
 
1.3.3.1. Sperm concentration and total sperm count 
 
Sperm concentration, represented as number of spermatozoa per ml of seminal fluid 
(WHO 2010), is a predictor of conception and is closely related to time of pregnancy. 
Sperm concentration is not a direct measure of testicular sperm output, however, 
total sperm count is (Ng et al., 2004). Total sperm count is not synonymous with 
sperm concentration, but defined as the total number of spermatozoa in the entire 
ejaculate (product of sperm concentration and ejaculate volume) (WHO, 2010). 
However, both sperm concentration and total sperm count reflect testicular sperm 
productivity (Hamada et al., 2012a). 
 
1.3.3.2. Sperm motility 
 
The ability of sperm to move, the motility, is an important factor in fertilisation 
(Hamada et al., 2012a). Motility can be classified by WHO (2010) into three 
categories: namely progressive, non-progressive and immotile. Progressive motility 
(PM) is defined as spermatozoa moving actively, either linearly or in a large circle, 
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regardless of speed. Non-progressive motility (NP) is considered all other patterns of 
motility. Immobility is defined as spermatozoa with no movement (WHO, 2010). Total 
sperm motility is considered the sum of PM and NP (WHO, 2010). As with sperm 
concentration and total sperm count, the percentage of motile sperm, particularly 
PM, is closely related to male fertility potential and pregnancy rates (Hamada et al., 
2012a). 
   
1.3.3.3. Sperm vitality 
 
Sperm vitality is simply a measure of the percenage of alive (viable) and dead 
spermatozoa in a sample, and expressed as a percentage of viable cells (WHO, 
2010). Although often a routine parameter, it is especially important in the 
assessment of samples with less than 40% sperm motility (WHO, 2010). It is 
clinically important to know if immotile cells are dead or alive, and interpretation of 
vitality needs to be considered in light of motility (i.e. the percentage of viable cells 
should exceed that of total sperm motility) (WHO, 2010). Typically, the motility and 
vitality correlate with each other (Paoli et al., 2011). A large proportion of vital yet 
immotile cells is associated with flagellum defects (Chemes & Rawe, 2003), while 
immotile and non-viable cells (necrozoospermia) may indicate epididymal pathology 
(Correa-Pérez et al., 2004). 
  
1.3.3.4. Morphology 
 
Human spermatozoa morphology is highly variable, and it has proven difficult to 
identify and describe the normal shape of cells with fertilisation potential. With the 
application of strict criteria (Kruger et al., 1986; Menkveld et al., 1990), increased 
percentage of normal forms of morphology is associated with increased fertilisation 
ability, and parameters have been established that are important markers in 
prognosis of fertility (Menkveld et al., 1990; Eggert-Kruse et al., 1995; Obara et al., 
2001). In a review by Coetzee and colleagues (1998), a large proportion of studies 
included indicated that normal sperm morphology and acrosome mophology is an 
important factor in male fertility potential. Application of the strict criteria is a reliable 
estimation of fertilization ability of human spermatozoa (Obara et al., 2001). 
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Normal spermatozoa consist of a smooth and regularly contoured oval shaped head 
with well defined acrosomal regions, a slender and regular midpiece (about the same 
length as the sperm head), a principle piece uniform in calibre and an endpiece. This 
can be simplified into a head (including neck) and tail (midpiece and principle piece), 
with both pieces needing to be normal (Mortimer & Menkveld, 2001). Head defects 
can include being too large or small, tapered, pyriform, round, amorphous, 
vacuolated, changes in the acrosomal area, double heads, or any combination of 
these. Neck and midpiece defects can include asymmetrical insertion of the 
midpiece into the head, thick or irregular, sharply bent, abnormally thin, or any 
combination of these. Principal piece defects include being short, multiple, broken, 
smooth hairpin bends, sharply angulated bends, of irregular width, coiled, or any 
combination of these (Kruger, 1993).  
 
1.3.3.5. Leukocytes 
 
Leukocytes, predominantly polymorphonuclear (PMN) leukocytes in the form of 
granulocytes, are present in ejaculated semen (Wolff, 1995; Martinez et al., 2007). It 
is important to differentiate these from spermatozoa on microscopy and especially 
with morphology staining techniques and assessments (Johanisson et al., 2000). 
Although visual differences between spermatozoa and leukocytes can be identified 
on microscopy, peroxidise reaction assays are frequently used as most PMN cells in 
semen are peroxidise positive granulocytes (Endtz et al., 1974; Politch et al., 1993, 
Wolff, 1995).  
 
The total number of leukocytes in the ejaculate is correlated with the severity of the 
inflammation or infection (Wolff, 1995). The prevalence of leukocytospermia among 
male infertility patients is approximately 10% to 20%, with much controversy on the 
significance of leukocytes in semen (Wolff, 1995; Henkel, 2005). Reports of cut off 
values for peroxidise-positive leukocytes in fertile men range from 0.5 – 1 x 106 per 
ml of seminal fluid, with the WHO defining leukocytospermia as > 106/ml in previous 
editions of the manual (WHO, 2010). This has been found by some to be too high, 
and others to be too low (Henkel, 2005). However, increasing numbers of leukocytes 
in the ejaculate is associated with infection, inflammation and poor semen quality 
and fertility endpoints (Henkel & Schill, 1998; Sanocka-Maciejewska et al., 2005). 
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Increased leukocytes and leukocyte activity associated with infections or 
inflammation are associated with reduced seminal volume and  sperm cell count, 
impaired sperm motility and DNA integrity of spermatozoa (Kohn et al., 1998; 
Henkel, 2011a). 
 
1.3.3.6. DNA fragmentation  
 
Although the semen analysis remains the laboratory cornerstone in the assessment 
of male fertility potential, additional investigations have more recently been employed 
(Aitken, 2006). The inclusion of DNA damage in sperm can provide a more 
comprehensive analysis, as damaged sperm DNA is associated with numerous 
fertility checkpoints (Henkel et al., 2010; Schulte et al., 2009). This includes impaired 
fertilisation, reduced rate of early embryo development, reduced implantation, 
increased risk of spontaneous abortions and even birth defects (Lewis & Simon, 
2010). Determination of DNA integrity in spermatozoa may be a primary predictor of 
the future health of the offspring, in addition to a predictor of semen function (such as 
morphology and motility), fertilisation, pregnancy complication risks, live birth rates 
and vitro fertilisation (IVF) outcomes (Henkel et al., 2004; Sergerie et al., 2005; 
Henkel et al., 2010; Sharma et al., 2013; Simon et al., 2013). Assessment of sperm 
DNA damage can also be useful in diagnostics associated with idiopathic cases of 
male infertility, with up to 80% of these cases displaying spermatozoa  DNA 
fragmentation (> 25% of sample) (Simon et al., 2013).  
 
Causes to damages in spermatozoa DNA are numerous, and importantly include 
oxidative stress due to ROS (Henkel, 2005; Sergerie et al., 2005; Henkel, 2011a). 
Apart from intrinsic production of ROS associated with mitochondrial energy 
production, increased ROS is associated with various factors, such as leukocyte 
activities, infections and inflammation, environmental pollutants and toxins, smoking 
and alcohol use, psychological and physiological stressors, nutritional deficiencies 
and advanced age, amongst other sources. Other causes of DNA fragmentation 
include aberrant spermatozoa maturation, apoptosis and radiation (Henkel, 2005; 
Sergerie et al., 2005; Henkel, 2011a; Sharma et al., 2013).  
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There are numerous methods to assess DNA integrity. TUNEL and COMET (in 
neutral conditions) assess molecular DNA strand breaks, whereby SCSA (sperm 
chromatic structure assay) and COMET (in alkaline conditions) assess susceptibility 
of DNA to damage, rather than damage itself (Sharma et al., 2013).  
 
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end 
labeling (TUNEL) is considered an important technique used in the assessment of 
sperm DNA damage.  The TUNEL staining technique is able to detect the 
percentage of spermatozoa in a given sample with either single or double-stranded 
DNA breaks (Henkel, 2005; Sharma et al., 2010; Sharma et al., 2013). There is a 
good correlation between percentages of sperm with DNA damaged found using 
optical microscopy versus flow cytometry, although actual percentages may be 
different (Domínguez-Fandos et al., 2007). 
 
1.3.3.7. Mitochondrial membrane potential 
 
Inner mitochondrial membrane potential (MMP) is considered an indicator of the 
mitochondrial energetic state in cells, as is considered the factor which most closely 
represents spermatozoal mitochondrial function (Paoli et al., 2011). In spermatozoa 
particularly, MMP is closely associated with motility (Paoli et al., 2011; Marchetti et 
al., 2012). In addition, sperm with high MMP are morphologically normal (MMP may 
be reduced in sperm with abnormal morphology), and can be a general indicator of 
sperm function overall (Marchetti et al., 2012). Increased percentage of sperm with 
abnormal MMP is associated with reduced fertility outcome, and particularly 
associated with reduced in vitro fertilisation (IVF) rates and embryo quality (Gallon et 
al., 2006; Marchetti et al., 2012). Marchetti and colleagues have published numerous 
articles related to MMP and IVF outcomes. In couples with >36% spermatozoa with 
reduced MMP, there was no chance of a pregnancy outcome (Marchetti et al., 2012). 
 
1.3.4. Treatments for male infertility 
 
Counselling and education for infertile men, including their partners, is an important 
approach to treatment. This can include various lifestyle modifications based on the 
detailed patient history (Esteves et al., 2012). Unfortunately, few male fertility 
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disorders have a pharmacological option as first line therapy. Although some known 
causes have targeted and effective options, other causes and iOAT are associated 
with non-specific and empirical therapeutic options with unknown efficacy (Hamada 
et al., 2012b). Therefore, treatments of male infertility can be divided into specific 
medical therapy (for known and clinically identified causes) and non-
specific/empirical medical therapy (for idiopathic cases).  
 
Specific medical treatments are aimed at well defined causes such as urogenetial 
infections (e.g. antibiotics; non steroidal anti-inflammatory drugs; corticosteroids), 
primary hypogonadism (e.g. testosterone); secondary (hypogonadotropic) 
hypogonadism (e.g. gonadotropin releasing hormone), hyperpolactinaemia (e.g 
dopamine agonists) and erectile dysfunction (e.g. phosphodiesterase-5 inhibitors). 
However, these therapies are estimated to be effective in approximately 20% of 
cases only (Hamada et al., 2012b).  
 
Idiopathic cases remain a greater challenge in clinical practice, with many options 
having little effect. Treatments include various hormonal treatments (e.g. aromatase 
inhibitors; 5α-reductase inhibitors; testosterone - although testosterone therapy is 
contraindicated in idiopathic infertility), anti-inflammatory medications and various 
antioxidants (e.g. vitamin C; vitamin E; carotenes; carnitine; selenium; zinc) (Snowell 
et al., 2011; Hamada et al., 2012b; Esteves et al., 2012). Anti-oxidant therapy in 
idiopathic infertility reportedly offers modest benefit, increased live birth rates with 
few side effects (Hamada et al., 2012b), although further studies are required.  
 
1.4. Steroid hormones in male reproductive function 
 
Lipophilic steroid hormones are produced via an enzymatic cascade in a process 
termed steroidogenesis. This can occur in various tissues, and most prominently in 
the gonads (testes or ovaries), adrenal medula and adipose tissues (Sherbet et al., 
2003; Midzak et al., 2009; Ye et al., 2011). Testosterone synthesis in males is most 
prominent in the Leydig cells within the testes (Midzak et al., 2009; Miller & Auchus 
2011). The basic overview discussed below is illustrated in Figure 7. 
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Figure 7: Steroidogenesis cascades in the synthesis of testosterone by the Leydig 
cell. Mediated by LH stimulation and intracellular cAMP activation, cholesterol is 
transport across the mitochondrial membrane by StAR and converted to 
pregnenolone. Pregnenolone is transported to the endoplasmic reticulum, where 
enzymatic activity produces various steroid based hormones. This figure illustrates 
the ∆4-steroid pathway.  
StAR: steroidogenic acute regulatory protein; P450scc: cholesterol side chain 
cleavage; 17α-OH-lase: 17α-hydroxylase; C17-20-lyase: 17,20 lyase; 3β-HSD: 3β-
hydroxysteroid dehydrogenase; 17KSR: 17β-hydroxysteroid dehydrogenase;  
Adapted from Zirkin & Chen (2000). 
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Steroid based hormones are all produced from cholesterol. Adult Leydig cell 
testosterone synthesis depends on pulsations of LH by the anterior pituitary gland 
(Midzak et al., 2009). On binding of LH to the Leydig cell membrane receptors, a 
cascade of intracellular events occurs. This includes LH receptor and G-protein 
coupling, activation of adenylate cyclase, increased intracellular cAMP followed by 
cAMP dependent phosphorylation of proteins through protein kinase A (Midzak et al., 
2009). 
 
Following LH stimulation, cholesterol is transported into the inner mitochondrial 
membrane. As cholesterol does not diffuse freely across this membrane, numerous 
enzymes are involved in this transport. The most prominent of these is the 
steroidogenic acute regulatory protein (StAR) (Midzak et al., 2009; Miller & Auchus 
2011; Ye et al., 2011). Here, cholesterol is metabolised into pregnenolone via the 
cytochrome P450 cholesterol side chain cleavage (P450scc/CYP11A1) enzyme 
(Midzak et al., 2009; Miller & Auchus 2011).  
 
Pregnenolone is then transported to the endoplasmic reticulum for further 
metabolism (Midzak et al., 2009; Miller & Auchus 2011).  Pregnenolone can either be 
metabolised into progesterone via the 3β-hydroxysteroid dehydrogenase (3β-HSD) 
or 17α-OH-pregnenolone via cytochrome P450 17α-hydroxylase (CYP17) (Sherbet 
et al., 2003; Midzak et al., 2009; Miller & Auchus 2011; Ye et al., 2011). 
Progesterone is hydrolysed into 17α-hydroxyprogesterone (17α-OH-P) also via the 
enzyme CYP17, and then into androstenedione via cytochrome P450 17,20-lyase 
action (Sherbet et al., 2003; Midzak et al., 2009; Miller & Auchus 2011; Ye et al., 
2011). Androstenedione is then the immediate precursor to testosterone, a 
conversion catalysed by 17β-hydroxysteroid dehydrogenase (17β-HSD) (Midzak et 
al., 2009; Miller & Auchus 2011). This enzyme mediated cascade in testosterone 
synthesis is termed the ∆4-steroid pathway, in which progesterone is the entry 
(Sherbet et al., 2003). Mineralocorticoids and corticosteroids are also derived from 
progesterone via alternative pathways and the cytochrome P450 21-hydroxylase (Ye 
et al., 2011).  
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Alternatively, 17α-OH-pregnenolone can be metabolised into dehyroepiandrosterone 
(DHEA) (via 17,20-lyase), then to androstenedione (via 3β-HSD) and testosterone 
via the via the ∆5-steroid pathway (Sherbet et al., 2003; Midzak et al., 2009; Miller & 
Auchus 2011).  
 
Testosterone can be further metabolised into 17β oestradiol via cytochrome P450 
aromatase, or into dihydrotestosterone (DHT) via 5α-reductase (Payne &, 
Youngblood, 1995; Miller & Auchus 2011; Ye et al., 2011). 
 
1.4.1. Testosterone 
 
Testosterone is a steroid hormone that is a major part of the androgen group, 
consisting of a 19 carbon chain (C-19). In males, testosterone is primarily produced 
by Leydig cells in the interstitial space of the testes (Dohle et al., 2003). The role of 
androgens, particularly testosterone, in male fertility is well defined, particularly via 
action on Sertoli cells to promote steroidogenesis (Singh et al., 1995). Androgens 
play a key role in the development of male reproductive organs, and are essential for 
male puberty and sexual function (Dohle et al., 2003). Testosterone levels are also 
25 – 125 times higher in the testes (intratesticular) compared to the serum, for 
unknown yet essential purposes in spermatogenesis. In the absence of testosterone 
(or functional androgen receptors), males are infertile (Dohle et al., 2003; Walker, 
2011). Although detailed mechanisms of the role of testosterone in spermatogenesis 
require further investigation, the major target for testosterone function are the Sertoli 
cells, where activation of androgen receptors directly changes gene expression 
(classical pathway), or tesosterone activates kinases that regulate key processes in 
the maintenance of spermatogenesis (Walker, 2011). Additional roles for 
testosterone include muscle formation, body compositions and fat regulation, bone 
mineralisation and cognitive functions (Dohle et al., 2003).  
 
Testosterone deficiency, known as hypogonadism (in males), can be a relatively 
common finding in the assessment of male infertility cases (Dohle et al., 2003). 
There are numerous potential causes of this, which can be classed as testicular 
failure (primary) or of hypothalamic or pituitary origin (secondary; hypogonadotropic) 
(Dohle et al., 2003). As discussed above, hypogonadotropic hypogonadism is well 
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established in obesity and MetS, both as a risk factor and a consequence (Kasturi, et 
al., 2008; Cabler et al., 2010). In ageing males, testosterone levels gradually decline 
up to 50% by age 60, closely associated with hypospermatogenesis on testicular 
biopsy (Dohle et al., 2003). 
 
1.4.2. Progesterone 
 
Progesterone is a 21 carbon (C-21) steroid hormone (Sherbet et al., 2003), the major 
naturally occurring hormone of a class known as progestogens, with well defined 
roles in the female menstrual cycle (particularly the luteal phase), pregnancy, 
fertilisation and embryogenesis (Andersen & Tufik, 2006; Pluchino et al., 2006). 
Although the role of progesterone in female reproduction physiology and pathology 
has been extensively elicited, and progesterone is even defined in textbooks as a 
‘female’ hormone, there is minimal literature on progesterone in male reproductive 
function (Oettel & Mukhopadhyay, 2004; Andersen & Tufik, 2006). This is despite the 
fact that there is no great difference in serum progesterone concentrations between 
men and woman, except during the luteal phase of the menstrual cycle and during 
pregnancy (Oettel & Mukhopadhyay, 2004). Traditionally, progesterone in males has 
been viewed as an unimportant precursor hormone in male physiology, and has only 
recently begun to be recognised as an important modulator of male endocrine 
function (Sherbet et al., 2003; Oettel & Mukhopadhyay, 2004). Progesterone in men 
is produced by steroidgenesis in the adrenal glands and the testes, and is an 
essential precursor for all steroid hormones, including testosterone. Progesterone 
also regulates the hypothalamus and pituitary gland in the synthesis of gonadotropin 
releasing hormone (GnRH) and gonadotropins (LH & FSH), respectively. There is 
evidence that the hormone regulates sexual behaviour centrally (Oettel & 
Mukhopadhyay, 2004; Andersen & Tufik, 2006). Evidence also suggests that 
progesterone has various modulating functions in the central nervous system, and 
therefore affects mood, behaviour and cognitive functions (Oettel & Mukhopadhyay, 
2004; Pluchino et al., 2006). 
 
In the field of male contraception, a stronger focus on progesterone in the male 
reproductive system has been studied, with progestins suppressing gonadotropin 
releasing hormone (GnRH) and gonadotropin (LH; FSH) secretion by the 
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hypothalamus and the pituitary gland respectively. The addition of progestins with 
testosterone administration improves the rate of suppression of spermatogenesis in 
male hormonal contraception methods (McLachlan et al., 2004). Some progestins 
have been found to influence male sexual behaviour, and have even been reported 
to reduce a variety of deviant male sexual acts (such as paedophilia and rape) and 
hypersexuality in general, although these reports are highly contentious. However, 
this is partly why the role of testosterone in the determination of male libido seems to 
be overstated (Andersen & Tufik, 2006).  
 
Progesterone action in seminal fluid has been well established, and is an essential 
requirement for numerous molecular processes leading to successful fertilisation 
after ejaculation of spermatozoa (Oettel & Mukhopadhyay, 2004). These functions 
include capacitation (Foresta et al., 1992), acrosome reaction (Meizel & Turner, 
1991), increasing intracellular calcium concentration (Thomas & Meizel, 1989) and 
the stimulation of phospholipase activity and tyrosine phosphorolation of sperm 
proteins (Baldi et al., 2002). In addition, it is suggested that progesterone exerts a 
lipolytic action on spermatozoa, and increased glucose-6-phosphate activity, 
indicating a role in glucose metabolism via progesterone receptors (De Amicis et al., 
2011). In sperm obtained from patients with varicocele, progesterone did not induce 
energy consumption, most likely through a decreased expression of these receptors 
on spermatozoa membranes (De Amicis et al., 2011).  
 
Progesterone has also been found to influence various metabolic parameters in 
males. In 1986, Chen et al. reported that pharmacological doses of progesterone 
significantly reduced plasma concentrations of cholesterol, triglycerides, LDL-
cholesterol and apolipopritein B in men. More recently, Ma et al. (2009) found a 
negative association between serum progesterone and carotid artery 
atherosclerosis, determined via carotid intima-media thickness, in Chinese men over 
60 years of age. This association remained after correcting for traditional 
atherosclerosis risk factors such as age, BMI, waist-to-hip ratio cholesterol and LDL 
levels, triglyceride levels, high-sensitive C-reactive protein and blood pressure. 
Incidentally, no such association was found in woman. Furthermore, these authors 
that progesterone negatively correlated with triglyceride concentrations, with no 
correlation with the other parameters listed above.  
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Ageing males have been shown to have increased progesterone concentrations in 
testicular tissues and the spermatic cord vein, associated with a reduction in 
testosterone concentrations (Pirke et al., 1980). Further indications from rat Leydig 
cell cultures imply that progesterone may inhibit testosterone production in ageing 
males, and hence may have a detrimental effect on Leydig cell function (Gruenewald 
et al., 1992) 
 
Blanchette and colleagues (2006) reported a negative correlation between body 
weight, BMI and waist circumference with serum progesterone concentrations (as 
well as 17-hydroxyprogesterone, dehydroepiandrosterone sulphate, testosterone 
and dihydrotestosterone). Progesterone has therefore not been fully investigated in 
men who are obese or been diagnosed with MetS or T2DM. 
 
1.4.3. Saliva measurement of steroid hormone 
 
The accurate measurement of steroid hormones remains a challenge, and it is stated 
that inaccurate measurements are obtained by routine immunoassays (Goncharoc et 
al., 2005; Goncharov et al., 2006). It is also remains unresolved which parameter is 
best suited for assessment of activity, the total, bioavailable or free concentrations 
(e.g. total testosterone, bioavailable testosterone or free testosterone) (Goncharov et 
al., 2006).  As steroid hormones are protein bound in serum, particularly sex 
hormone binding globulin (SHBG) and to a lesser degree albumin, the accurate 
assessment of the fraction of the free hormone is difficult to assess (Goncharov et 
al., 2006). Saliva is considered a source of steroid hormones, including progesterone 
and testosterone that is unbound to SHBG or albumin (Goncharov et al., 2006). 
Saliva levels of steroid hormones have been reported to correlate well with serum 
levels that represent an accurate measure of free hormone in peripheral tissues. In 
addition, it offers a non-invasive collection method that can be readily obtained over 
any time period (Brown et al., 2008).  
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1.5. Obesity, metabolic syndrome and male reproductive function 
 
Although the effect of excess body fat on reproduction has been more extensively 
studied in females, there has been a recent increase in literature assessing the 
relationship between obesity and semen characteristics, male endocrine changes, 
male sexual function and male factor infertility. In a chapter entitled ‘The health 
disadvantages of excessive weight’ in his Canon of Medicine, Avicenna wrote ‘this 
[obese] human [man] has a cold temperament; this is why he is infertile, unable to 
impregnate [woman] and has low semen’ (Avicenna, 1593).  
 
Obesity, as a cardinal feature of MetS, is closely associated with an increased 
incidence of male factor infertility, with several patho-physiological mechanisms 
being implicated (Giagulli et al., 1994; Hammoud et al., 2008a; Kasturi et al., 2008; 
Hofny et al., 2009). Numerous studies have found an inverse correlation between 
increased obesity and semen quality that negatively affects male fertility, with an 
increased chance of subfertility among couples in which the male partner is obese. 
Hormonal changes that positively correlate with obesity include reduced serum total 
testosterone, free testosterone and sex hormone binding globulin (SHBG), and 
increased serum oestrogen (raised oestrogen:testosterone ratio), insulin (insulin 
resistance), leptin, FSH, LH and prolactin (Kasturi et al., 2008; Hofny et al., 2009; 
Cabler et al., 2010). Some physical mechanisms that have been implicated in 
obesity linked male infertility include erectile dysfunction (Cheng et al., 2007; Pauli et 
al., 2008), increased scrotal temperature (Hjollund et al., 2000) and sleep apnoea 
(Luboshitzky et al., 2005). Thus, the relationship between obesity and male infertility 
is multifactorial and complex (Hammoud et al., 2008b), and calls  for a better 
understanding of the underlying mechanisms that result in abnormal sperm function 
in obese men (Fejes et al., 2005; Aggerholm et al. 2008; du Plessis et al., 2010; 
Hammoud et al., 2008a;  Chavarro et al., 2010; Hofny et al., 2009).  
 
Any negative effect of obesity on sperm parameters as determined by the WHO 
(2010) has not been conclusively resolved. Studies are not consistent, nor has there 
been a clear dose-response mechanism elicited (Hammoud et al., 2008a). Various 
studies have shown a reduction in sperm count and concentration, motility, vitality, 
morphology, and DNA integrity associated with obesity (Fejes et al., 2005, 2006; 
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Kort et al., 2006; Aggerholm et al., 2008; Hammoud et al., 2008b; Pauli et al., 2008; 
Chavarro et al., 2010; Hofny et al., 2009; Håkonsen et al., 2011; Rybar et al., 2011). 
In contrast, other researchers have not found similar relationships (Aggerholm et al., 
2008; Chavarro et al., 2010; Rybar et al., 2011). A limited meta-analytical review by 
MacDonald et al. (2010) investigated the association of BMI with hormonal and 
semen paramaters, and found no negative association between increased body 
weight and reduced semen parameters strong evidence for reduced testosterone 
with increased body mass index. In contrast, a more recent meta-analysis by 
Sermondade et al. (2013) found that obesity is associated with an increased risk for 
oligozoospermia or azoospermia. Although there is no clear evidence to show 
reduced sperm parameters in obese men, a disproportionately large number of men 
seeking infertility treatment are obese (du Plessis et al., 2010). Due to lack of 
research in this area, it is suggested that more controlled studies should be 
undertaken with increased focused on potential underlying mechanisms, in addition 
to increased focus on obesity as an aetiology of male infertility in the clinic (Cabler et 
al., 2010).  
 
Further lines of a causal relationship between obesity and male reproductive 
dysfunction are suggested by a group of studies indicating that diet and/or exercise 
induced weight loss can improve various parameters, such as increasing 
testosterone and SHBG levels, decreasing insulin and leptin and improving semen 
parameters in obese men (Isidori et al., 1999; Kaukua et al., 2003; Niskanen et al., 
2004; Kasturi et al., 2008; Chavarro et al., 2010), in addition to a reduction in 
peripheral inflammatory cytokine concentrations (Ziccardi et al., 2002; Sharman & 
Volek, 2004). 
 
The effect of other parameters associated with MetS, such as dyslipidaemia, 
hypertension and hyperglycaemia, have only had limited scientific investigation 
(Kasturi et al., 2008). Ramírez-Torres et al. (2000), found no correlation between 
sperm abnormalities and hypertension, glucose intolerance and diabetes mellitus. 
However, the authors did indicate a relationship between dyslipidaemia and sperm 
abnormalities. Shalaby et al. (2004) reported a potential role for dyslipidaemia in the 
development of infertility in male rates fed a high cholesterol diet. Several studies 
have found an inverse relationship between blood pressure and total serum 
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testosterone concentrations, which may result in impaired reproductive potential 
(Kasturi et al., 2008). Palmer et al. (2012a) reported a positive correlation between 
glycaemia and sperm DNA fragmentation, with a negative correlation to normal 
morphological sperm, regardless of adiposity, in mice fed a high fat diet.  
 
T2DM, a known consequence of MetS, has increasingly been associated with male 
factor infertility in recent years, with complex and multifactoral factors involved. Poor 
semen quality, such as reduced sperm concentration and motility, abnormal 
morphology, mitochondrial DNA damage, nuclear DNA damage and increased 
seminal plasma abnormalities have been reported (La Vignera et al., 2012a). 
 
Mallidis and colleagues (2011) published a study in which animals fed a high fat diet 
induced metabolic changes characteristic of MetS, indicated that these changes may 
be associated with poor sperm quality and decreased spermatogenesis, although 
this was minimal. They hypothesised that this effect was primarily due to increased 
blood glucose as opposed to hypogonadism. In a recently published human cohort 
study, consisting of male partners of infertile couples, Lotti and colleagues (2013a) 
published results indicating that MetS is associated with poor sperm morphology and 
testes ultrasound inhomogeneity, in addition to hypogonadism, ED and depression, 
and hence declines sexual and overall health.  
 
Hormonal changes that are associated with MetS and negatively affect various 
parameters of male fertility include reduced serum total testosterone (TT), free 
testosterone (FT) and sex hormone binding globulin (SHBG), increased serum 
oestrogen, insulin (insulin resistance), leptin, FSH, LH and prolactin, (Eckel et al., 
2005). Conversely, the role of progesterone has not been extensively studied in 
males who are obese or diagnosed with MetS. Blanchette and colleagues (2006) 
reported a negative correlation between body weight, BMI and waist circumference 
with serum progesterone concentrations (as well as 17-hydroxyprogesterone, 
dehydroepiandrosterone sulphate, TT and dihydrotestosterone). Furthermore, the 
role of progesterone in male fertility has not been fully investigated, despite the fact 
that there is no great difference in serum progesterone concentrations between men 
and woman, except during the luteal phase of the menstrual cycle and during 
pregnancy (Oettel & Mukhopadhyay, 2004). 
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1.5.1. Insulin and male reproductive function  
 
Insulin is considered a central regulator of gonadal function and spermatogenesis, 
although the role of insulin on the male reproductive system has not been fully 
elicited (Aquila et al., 2005a; Lampiao & du Plessis, 2008a; Lampiao et al., 2009). 
Furthermore, this well established metabolic hormone has been identified in human 
ejaculate, and human spermatozoa have been shown to synthesis and secrete 
insulin in an autocrine fashion in the ejaculate (Aquila et al., 2005a). Insulin also 
increased motility, nitric oxide concentrations and increases the acrosome reaction in 
vitro (Aquila et al., 2005a; Lampiao & du Plessis, 2008a). However, both increased 
and decreased serum levels of insulin have been shown to correlate negatively with 
male fertility (as do increased and decreased levels of leptin) (Lampiao et al., 2009). 
Ando and Aquila (2005) have suggested that the PI3K/Akt pathway is activated 
following insulin receptor stimulation by insulin, as illustrated in Figure 4.  
 
Insulin has been reported as an important regulator of male reproduction via actions 
on the hypothalamus-pituitary-testes (HPT) axis, with modulating actions on 
gonadotropic releasing hormone (GnRH), LH and FSH centrally, and Leydig and 
Sertoli cell function locally (Lampiao et al., 2009). Pitteloud et al. (2005a) published 
in vivo evidence that insulin resistance is associated with decreased testosterone 
secretion from Leydig cells in males. However, the role of insulin in male (in)fertility 
has not been well elicited and remains poorly understood, especially in the context of 
insulin resistance.  
 
1.5.2. Leptin and male reproductive function 
 
Leptin, a well known central (hypothalamic) regulator of food intake and energy 
expenditure (Bastard et al., 2006), is also associated with metabolic and endocrine 
effects and a role in normal reproduction and sexual maturation (Wauters et al., 
2000). This hormone also appears to have an important role in the puberty process, 
with mutations in the leptin (ob) gene associated with hypogonadism and no pubertal 
development in humans (Strobel et al., 1998).  
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The mechanisms by which leptin modulates reproductive potential is not clear, 
although evidence indicates effects through interaction with the hypothalamus and 
effects on GnRH production (Wauters et al., 2000; Lampiao et al., 2009). Reduced or 
absent leptin is associated with reduced GnRH, with effects on LH/FSH and 
testosterone levels, thereby influencing the HPG axis (Wauters et al., 2000; Lampiao 
et al., 2009). Higher serum leptin levels has also been associated with reduced 
motility and straight line velocity of sperm (Glander et al., 2002). However, the exact 
role of leptin in male and female reproduction requires further clarification (Lampiao 
et al., 2009).  
 
Leptin is found in human seminal fluid, and leptin receptors are expressed on 
spermatozoa in addition to soluble receptors in seminal fluid (Jope et al., 2003). 
Interestingly, leptin (as well as insulin) appears to be synthesised and secreted by 
ejaculated spermatozoa, particularly mediating motility (Aquila et al., 2005b; Andò & 
Aquila, 2005). In uncapacitated samples, leptin is found within intracellular granules 
in the midpiece predominantly, and decreases significantly at capacitation, indicating 
a role alongside insulin in capacitation (Andò & Aquila, 2005). However, the source 
of is not well defined. Ando and Aquila (2005) have suggested that the PI3K/Akt 
pathway is activated following leptin receptor stimulation by leptin, similarly to insulin. 
Similarities and differences for both insulin and leptin action on intracellular 
mediators in spermatozoa is illustrated and summarised in Figure 8.  
 
Leptin has been identified in the ejaculate (Aquila et al., 2005b), although the role of 
leptin levels on semen function has remained controversial and conflicting (Lampiao 
& du Plessis, 2008a). Some evidence indicates that leptin may modulate sperm 
motility, morphology, acrosome reaction and nitric oxide production, as well as 
sperm capacitation (Aquila et al., 2005b; Lampiao & du Plessis, 2008a) 
 
Based on a series of experiments and literature reviews, Lampiao and colleagues 
(2009) hypothesised that leptin and insulin can mediate effects synergistically on 
post-ejaculated spermatozoa. The stimulation of respective receptors converge on 
the PI3K intracelleular signalling pathway, leading to protein kinase B (PKB/Akt) 
phosphorylation, causing the translocation of GLUT8 and insertion into the cell 
membrane. This would then allow spermatozoa uptake of glucose for metabolism 
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and motility (Aiston & Agius, 1999; Lampiao et al., 2009). This pathway can also 
diverge and stimulate endothelial nitric oxide synthase (eNOS) of spermatozoa to 
increase NO production and influence acrosome reaction (Aiston & Agius, 1999; 
Lampiao et al., 2009).   
 
Figure 8: Hypothetic model of functional interaction between insulin and leptin in 
human ejaculated spermatozoa. Both hormones signalling converge on the PI3K/Akt 
pathway as observed in somatic cells. In sperm insulin and leptin show a similar 
positive action on GSA and G6PDH activities, however they sound to diverge in the 
β-fatty acid metabolism. As evidenced, insulin inhibits α-oxidation and makes easier 
lypogenesis while leptin antagonizes both actions and provides additional metabolic 
fuel through stimulation of FFA α-oxidation.  
ϕ: blocked; TAG: triacylglycerol; FFA: free fatty acid; DAG: diacylglycerol; PPP: 
pentose phosphate pathway; CPT1: carnitine palmitoyl transferase 1; UCPs: 
uncoupling proteins; IRS-1: Insulin Receptor Substrate 1; Predicted signaling 
pathways depicted by broken arrows are as yet unknown.  
Adapted from Ando & Aquila (2005). 
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1.5.3. Cytokines and male reproduction 
 
The seminal plasma contains significant levels of various cytokines normally present 
in the male genital tract (Huleihel et al., 1996; Dousset et al., 1997; Martinez et al., 
2007; Politch et al., 2007). It is generally thought that these proteins in the seminal 
plasma originate from Leydig cells, Sertoli cells, the epididymis and the prostate, with 
expressions modulated during the seminiferous epithelium cycle, but these origins 
are still a matter of scientific contention (Huleihel et al., 1999; Martinez et al., 2007).  
 
Although several proinflammatory cytokines, such as TNFα, IL6 and IL8, may 
promote sperm membrane lipid perioxidation beneficial for fertilisation, increased 
concentrations in seminal fluid may negatively affect sperm fertility capability (Basu 
et al., 2004; Martinez et al., 2007). Studies have shown that increased inflammation 
in the male reproductive tract associated with leukospermia results in a negative 
effect on spermatogenesis and function of spermatozoa (Koçak et al., 2002; Basu et 
al.,2004; Eggert-Kruse et al., 2007; Martinez et al., 2007; Gallegos et al., 2008; La 
Vignera et al., 2012c). As with leptin and insulin presence in semen, several pro-
inflammatory cytokines at physiological concentrations may have beneficial effects 
on male genital function. This is evident with increased lipid perioxidation of sperm 
membranes (mediated by cytokines) being important in the sperm fecundation 
process (Martinez et al., 2007), cytokine modulation of pro- and anti-oxidant systems 
(Sanocka et al., 2003) and the indication that some cytokines play a role in testicular 
function and modulation of steroid release from the testes (Eggert-Kruse et al., 
2001). However, with increased cytokine concentration in the setting of 
inflammation/infection, these polypeptides appear to have a detrimental effect on 
male fertility (Gruschwitz et al., 1996; Eggert-Kruse et al., 2001). The potential 
negative effects of inflammatory cytokines on spermatozoa is no clear, however, 
numerous studies have indicated that an increase in seminal cytokines is associated 
with a reduction in sperm count, motility and reduced male fertility potential 
(Gruschwitz et al., 1996; Dousset et al., 1997; Koçak et al., 2002; Basu et al., 2004; 
Lampiao & du Plessis, 2008b; Tronchon et al., 2008).  
 
Several lines of evidence indicate that various cytokines are involved in male fertility 
(Dousset et al., 1997). Elevated seminal plasma concentrations of several cytokines, 
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including IL6 and TNFα, have been associated with poor semen quality and male 
infertility (Naz & Kaplan, 1994; Gruschwitz et al., 1996; Dousset et al., 1997; Camejo 
et al., 2001; Eggert-Kruse et al., 2001). Many of the cytokines and immune factors 
present in semen of fertile men are involved in normal male reproductive biology, but 
an inflammation and/or infectious related rise in these immunological mediators is 
associated with an increased risk of male factor infertility (Hales et al., 1999; Hedger 
& Meinhardt, 2003). In vitro, cytokines have been shown to affect human sperm 
motility, increase the production of ROS by human spermatozoa, and reduce the ova 
penetrating ability of spermatozoa (Dousset et al., 1997). It is also suggested that an 
increase in cytokine expression may lead to an increased absorption onto sperm 
cells and a subsequent rise in regulatory activity (Dousset et al., 1997). Seshadri et 
al. (2009) showed significant higher concentrations of IL6 in mild and severe 
oligozoospermic men, higher concentrations of IL8 and IL10 in asthenozoospermic 
men, and higher concentrations of IL6, IL10 and TNFα in obstructed azoospermic 
men. The study also showed that concentrations of IL10 correlated closely with 
numerous other cytokines in both the obstructed azoospermic group and the 
asthenospermic group, indicating that the origin of these cytokines is outside of the 
testis. A study conducted by Poltich et al. (2007) indicated the presence of various 
cytokines and other immunological factors in the semen of healthy men. High 
concentrations of IL8 were present in all samples, with IL6, IL10 and TNFα among 
the cytokines detected in low concentrations. Furthermore, the study showed that 
polymorphonucleocyte (PMN) counts correlated significantly with IL6 and TNFα 
concentrations (amongst other cytokines). There is, however, controversy in the 
relationship between semen quality and elevated cytokine levels, with various 
studies supporting both sides of the argument (Kokab et al., 2010). More recently, 
Bialas and colleagues (2009) have shown that changes in testicular cytokine activity 
are related to male infertility. It is also suggested that increased cytokines associated 
with excessive white adipose tissue can exert toxic effects on spermatozoa via ROS 
(Fraczek & Kurpisz, 2007).  
 
Male genital tract inflammation has been cited as a cause, or at least a contributing 
factor, of male infertility. However, there is difficulty in diagnosis due to the 
asymptomatic nature of the disease and the precise definition of male genital tract 
inflammation, which does not differentiate between infection as a cause and non-
 
 
 
 
49 
 
infectious inflammation (Kopa et al., 2005).  According to the World Health 
Organisation (WHO), leukocytospermia (more than 1 million leukocytes per ml of 
seminal fluid) is the most significant diagnostic indicator, and is assessed with the 
culture of pathogenic bacteria, increased seminal viscosity and/or abnormal 
biochemistry (WHO, 2010). Leukocytospermia significantly correlates with increased 
IL6, IL8, and TNFα in male semen, with IL8 and TNFα associated with simultaneous 
presence of leukocytes and IL6 more associated with presence of leukocytes 
(Martínez-Prado et al., 2010), and has been associated with decreased sperm 
numbers and impaired sperm motility (Wolff, 1995; Sanocka et al., 2003; Henkel et 
al., 2005). 
  
1.6. Hypothesis of this thesis 
 
On searching the scientific literature, it is apparent that the effect of MetS on male 
reproductive function and fertility potential has not been sufficiently investigated. 
With various components of MetS tentatively linked to a reduced fertility potential in 
males, it is hypothesised that male fertility may be compromised in the setting of this 
pathophysiological disorder. As both MetS and male infertility are dramatically on the 
increase globally, and that male hypogonadism appears to be a central risk for CVD 
and T2DM in males, this demands investigation into possible relationships between 
these various phenomenons. Although any negative relationship between MetS and 
male infertility is likely to be multifactorial and complex, a clear association first 
needs to be suggested by case controlled investigations. Prior to the onset of this 
study, there has not been as case controlled investigation into any possible impact of 
MetS on male fertility parameters.  
 
It is conceivable that an additional source of increased inflammatory cytokines in the 
male reproductive tract may be related to the systemic pro-inflammatory changes 
associated with MetS. Increased serum concentrations may potentially cross into the 
testicular tissue via the blood testes barrier, and/or gain access to seminal fluid 
through secretions of the seminal vesicles and prostate during ejaculation, potentially 
reducing sperm concentration, motility and fertilisating capabilities. This would 
provide a novel explanation for reduced fertility potential in obese, MetS and T2DM 
males. It is hypothesised that MetS will have a negative influence on seminal 
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parameters as compared to healthy males in a case controlled study. In addition, it is 
hypothesised that seminal concentrations of insulin, leptin, TNFα, IL1β, IL6 and IL8 
will be increased and positively correlate to well establish serum changes.  
 
It is well known that testosterone is reduced in MetS males, so it is predicted that this 
will hold true in this study. In addition, it is hypothesised that progesterone 
concentrations will also be reduced indicating a compromised steroidogenesis 
cascade. Although hypogonadism has been well established in obese and MetS 
males, these studies have all been done on serum total free concentrations. There 
are no studies in the literature assessing salivary testosterone or progesterone in 
MetS males.  
 
As insulin and cytokines are known to regulate steroidogenesis in Leydig cells, it is 
predicted that insulin, leptin, TNFα, IL1β, IL6 and IL8 will affect both progesterone 
and testosterone production in these cells, as well as cell viability.  
 
1.7. Aims of the study 
 
a. Investigate an association between metabolic syndrome and seminal 
parameters in males, including sperm concentration, motility, vitality, 
morphology, mitochondrial membrane potential and DNA fragmentation; 
 
b. Investigate changes in seminal fluid insulin, leptin, TNFα, IL1β, IL6 and IL8 in 
metabolic syndrome males, and compare with serum changes; 
 
c. Investigate changes in free progesterone in males with metabolic syndrome in 
light of free testosterone concentrations obtained from saliva; 
 
d. Investigate effects of insulin, TNFα, IL1β, IL6 and IL8 on cell viability, protein 
production and testosterone and progesterone concentrations in an hCG 
(human chorionic gonadotropin) stimulated TM3 cell line. 
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CHAPTER 2 - MATERIALS AND METHODS 
 
2.1. Study design overview 
 
The study consists of two arms: a case controlled investigation that included 
volunteer participants and a TM3 Leydig cell culture model exposed to various 
concentrations of insulin and inflammatory cytokines.  
 
The case control study assessed male patients with metabolic syndrome (MetS) 
against a control group (CG) of males. Various parameters were assessed, which 
can be divided into clinical, biochemical and seminal. Clinical and biochemical 
assessments were used to define and diagnose participants in terms of MetS and 
insulin resistance (IR). Further biochemical assays assessed serum cytokine 
concentrations and leptin. Biochemical analysis of saliva was used to assess free 
testosterone (FT) and free progesterone (FP) concentrations. Standard semen 
analysis according to the World Health Organisation (WHO, 2010) was carried out, in 
addition to the determination of abnormal mitochondrial membrane potential (MMP) 
and DNA fragmentation (DF) of spermatozoa. Furthermore, seminal fluid was 
assayed for cytokines, insulin and leptin concentrations. Comparisons were made 
between the groups for the various variables, and correlations were made of the 
entire cohort to investigate associations between variables. 
 
The cell culture model essentially exposed the TM3 Leydig cell line to various 
concentrations of insulin and cytokines for 48 hours, all co-cultured with 25 mIU/ml 
human Chorianic gonadotropin (hCG). Cell viability and protein was determined, and 
supernant was assayed for testosterone and progesterone concentrations. 
 
2.2. Recruitment of participants 
 
This clinical case controlled study was approved by the Ethics Committee of the 
University of the Western Cape, Bellville, South Africa. Participants were recruited 
randomly via word of mouth and advertisements distributed by hand, electronically 
and in local community newspapers, between October 2010 and February 2013.  
Therefore, the cohort represents those confined to the Western Cape region of 
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South Africa, with multiple ethnic and cultural backgrounds. Accepted participants 
attended one consultation and were individually counselled on the study background 
and design, and all participants signed an informed consent form in order to undergo 
a full medical consultation and clinical examination, and allow for sample collection 
and relevant biochemical testing. All participants received detailed feedback on the 
results via email, telephone or a follow up consultation, with detailed report of clinical 
results for their records. They were further advised appropriately on the 
recommended treatments or further investigations that may be required. All 
participants had direct access to the clinician during the study period.  
 
Subjects were expected to be fasting for a minimum of 8 hours before blood 
collection, and abstain from sexual activity for a minimum of three and maximum of 
five days before collection of a semen sample. Further instructions related to sample 
collections included was not consume caffeine or tobacco, chew gum or brush teeth 
1 hour prior to the consultation. All samples were collected in the morning between 
7h00 and 10h00. All of the relevant biological samples were collected at the 
consultation, specifically blood (via venous puncture), passive saliva (via ‘drooling) 
and semen (via masturbation into a sterile container). A total of 78 participants were 
included in the study for data analysis, divided into a MetS group (n=34) and control 
group (n=44) based on the MetS diagnostic criteria outlined by Alberti et al. (2009) 
(Table 1). 
 
2.2.1. Inclusion and exclusion factors 
 
Eligibility criteria included being an adult male of between 18 and 70 years of age. 
On pre-clinical screening via telephonic or electronic communication, interested 
participants with a vasectomy, diagnosed with any disorder of the prostate, 
reproductive system or systemic pathology, or on any hormonal therapy (e.g. 
testosterone or insulin) in the last six months were excluded from entering the study. 
In order to reduce possible selection bias, all other interested participants were 
accepted to enter the study. The details of this clinical interview and sample 
collections are described below.  
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Following clinical investigation and sample assays, participants with clinically 
apparent reproductive disorders (e.g. varicocele), leukocytospermia (conservatively 
defined for this study as >0.5 x 106/ml) or with a known or clinically detected acute or 
chronic inflammatory condition were excluded from study. Further exclusion factors 
based on medical history and examination included a surgery or hospital admission 
for any reason within the last 6 months. Participants with unexplained (idiopathic) 
azoospermia (n=4; 2 participants from each group) had semen parameters removed 
from the study, but clinical, biochemical and hormonal parameters were included for 
data analysis. Participants with a history of unexplained infertility between the male 
and female partner were included in the study. Participants on medication related to 
MetS, smokers, and those diagnosed with T2DM were included in the study. A 
summary of specific and general exclusion criteria is tabulated in Table 3 below: 
 
Table 3: Specific and general exclusion criteria for the study. 
Specific Exclusion Criteria General Exclusion Criteria 
Vasectomy. Surgery or hospitalisation in the last six 
months. 
Leukocytospermia (> 0.5 x 106/ml). Inability to supply a semen sample by 
masturbation at the consultation in 
which serum and saliva samples were 
collected. 
Existing diagnosis of any testicular, 
prostate or other reproductive tract 
pathology. 
Existing diagnosis of a known local or 
chronic systemic inflammatory disease. 
Clinical or laboratory indication of any 
testicular, prostate or other 
reproductive tract pathology. 
Clinical or laboratory detection of a 
known local or chronic systemic 
inflammatory disease. 
Insulin, testosterone or thyroid 
medications in the last six months. 
Recreational illicit drug use in the last 
six months. 
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2.2.2. Clinical interview and sample collection 
 
All participants accepted for participation following initial screening attended a clinical 
history, medical examination and sample collection at specified clinics at the Bellville 
Campus of the University of the Western Cape (Natural Medicine Clinic) or in 
Stellenbosch (Natural Health Centre). The medical history was recorded by a trained 
clinician following a medical history template. The outline of the history is Table 4 
below. 
 
Following an intensive medical history, the participants underwent a full clinical 
examination, including genital examinations. The examination aspects recorded 
included are tabulated below in Table 5. The genital examination did not routinely 
include a rectal and prostate exam (digital rectal examination), except where 
clinically indicated based on recommended screening guideline, medical history 
and/or physical examinations.  
 
Following medical history and physical examination, biological samples were 
collected. Saliva samples were collected via drooling. Serum samples were collected 
via appropriate venopuncture techniques on arm (antecubital fossa) or hand veins 
(when arm veins not able to be located). Semen samples were collected via 
masturbation into a sterile container. All samples were collected within a maximum 
window of 30 minutes. Further details are provided where relevant below.  
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Table 4: Medical history guideline for clinical case taking.  
Category Specific Details 
General - personal information and demographics 
Main or current 
medical complaints 
- detailed history were applicable 
Medical and surgical 
history 
- previous hospitalisation and/or surgery 
- known allergies 
Current medications - prescribed medicines 
- nutritional supplements 
Family history - heart disease and diabetes 
- cancer 
- general 
Psycho-social 
history 
- smoking and tobacco consumption 
- caffeine use 
- alcohol use 
- recreational drug use 
Fertility history - number of children biologically fathered 
- year of birth of youngest child (if applicable) 
- personal or couple related fertility complaints 
Systems review - head, neck and ENT (ear, nose and throat) 
- chest (including cardiovascular and respiratory 
systems) 
- abdomen (including gastrointestinal system 
- genito-urinary system 
- musculoskeletal system 
- skin 
- endocrine system 
- neurological and psychiatric system 
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Table 5: Clinical examination used for patient consultations.  
Category Specific Details 
General 
assessment 
- overview of patient’s demeanour and appearance 
Vital signs  - height & weight (body mass index) 
- waist circumference 
- temperature 
- pulse and respiration rate and rhythm 
- blood pressure 
Lymphadenopathy - cervical, axilla and inguinal 
Systems 
examination 
- head, neck, orophyryngeal and ENT  
- chest (including cardiovascular and respiratory 
systems) 
- abdomen (including gastrointestinal system 
- genito-urinary system 
- musculoskeletal system 
- skin 
- endocrine system 
- neurological and psychiatric system 
 
2.3. Clinical data collection 
 
Relevant clinical data collected by a trained clinician included age, body mass index 
(BMI), waist circumference (WC) and blood pressure. Height was recorded by a 
standardised wall chart, and weight was recorded on a digital scale to the nearest 
decimal point. BMI was calculated by body weight (kilograms to nearest decimal 
point) divided by height (meters) squared (kg/m2). The WC was measured in 
centimetres around the abdomen at the midpoint between the lowest point of the 
costal margin and the highest point of the iliac crest with the patient standing and 
relaxed. Blood pressure was measured on the dominant arm after a rest period of at 
least 15 minutes, and recorded as systolic (SBP) and diastolic (DBP). All 
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measurements above were taken twice, with the mean between the two samples 
taken as the recorded parameter.  
 
The fasting blood samples were analysed for high density lipoprotein (HDL) 
cholesterol, triglycerides, glucose, insulin, leptin and inflammatory cytokines (TNFα; 
IL1β; IL6; IL8). Saliva underwent analysis for FT and FP concentrations. Semen was 
analysed for ejaculate volume, sperm concentration, total sperm count, progressive 
motility, total motility, vitality, abnormal mitochondrial membrane potential, DNA 
fragmentation and seminal leukocyte concentration. Seminal fluid further underwent 
investigation for glucose, insulin and inflammatory cytokines (TNFα; IL1β; IL6; IL8). 
Each participant was provided a unique alpha numeric code in which all samples 
were labelled.  
 
All laboratory assays were conducted by an adequately trained technician. Samples 
sent to outside laboratories for analysis were blinded to clinical data and 
identification of the patients. Standard semen analysis done at the UWC laboratory 
were not blinded to clinical data and history of the participant, but was blinded to 
further biochemical data. Samples frozen or fixed to slides and assayed in batched 
analysis at future dates allowed blinding to clinical, biochemical and other seminal 
parameters previously recorded via sample codes. Selection bias was limited as no 
participants who met the criteria were excluded from data analysis. Participants with 
idiopathic azoospermia (n=4; 2 participants in each group) had data removed from 
the seminal analysis for statistical analysis. Further potential confounding variables 
not included in detail by the data collection process and analysis includes lifestyle 
factors (diet, physical activity and alcohol use), educational status, and 
socioeconomic background. 
 
Based on the clinical and laboratory data, participants were assessed for MetS 
according to the diagnostic criteria outlined in Table 1 (Alberti et al., 2009). Various 
parameters were compared between the groups. 
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2.3.1. Serum lipogram, triglycerides, insulin and glucose 
 
Blood was collected in sodium fluoride and serum separating tubule (SST) 
vacutainers® (BD Biosciences, Franklin Lakes, New Jersey, USA), and transported 
immediately to PathCare Laboratories (Pathcare Park, Goodwood, South Africa) for 
analysis. PathCare Laboratories are a private commercial pathology laboratory 
servicing clinical practice and research sectors in South Africa. HDL, triglycerides 
(lipogram) and glucose were assayed using the timed endpoint method. Highly 
sensitive C-reactive Protein (CRP) was done using the Beckman Coulter LX system 
(Brea, California, USA).  
 
2.3.2. Saliva hormones: testosterone and progesterone  
 
Saliva samples were collected by passive drooling into a sterile Eppendorf container 
and immediately stored at -20ºC until sampling. After thawing, samples were 
centrifuged at 2500xg prior to analysis. Testosterone and progesterone assays were 
performed using commercial ELISA kits (IBL International GMBH, Hamburg, 
Germany). A minimum of 1.5 ml of saliva fluid was required for appropriate assays. 
Participants who were not able to produce adequate saliva sample were permitted in 
the study (n=10; 6 in the control group and 4 in the MetS group), and had these 
parameters removed from data analysis. All available samples were assayed in 
duplicate, with a mean value recorded for data analysis. These assays were 
conducted at Synexa Life Sciences (Milnerton, Cape Town, South Africa).  
 
The Testosterone Saliva ELISA (IBL International GMBH, Hamburg, Germany) is an 
enzyme immunoassay for in-vitro diagnostic quantitative determination of free 
testosterone in human saliva. The reportable range is 2–760 pg/ml with intra- and 
inter-assay coefficients of variation (CV) of 4.2–15.1% and 5.5–6% respectively. The 
Progesterone Saliva ELISA (IBL International GMBH, Hamburg, Germany) is an 
enzyme immunoassay for the in-vitro diagnostic quantitative determination of free 
progesterone in human saliva.  The reportable range is 3.8–5000 pg/ml with CV of 
4.7–7.6% and 5.3–7.7% respectively. Samples were assayed on an ELISA reader 
obtained from Biotek (Winooski, VT, USA). 
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2.4. Semen analysis 
 
Semen was collected via masturbation into sterile wide-mouthed containers and 
transferred to a 37ºC incubator within 30 minutes of collection. Seminal fluid was left 
for 60 minutes to liquefy (combination of room temperature and incubator). 
Participants with samples that did not liquefy appropriately would be excluded from 
the study. Participants with excess viscosity for adequate analysis (n=3; 2 in the 
control group and 1 in the MetS group) had minute (spatula tip) amounts of α-
chymotrypsin (Sigma-Aldrich, St. Louis, MO, USA) added to seminal fluid for 
analysis.  
 
2.4.1. Medium used in semen analysis 
 
Phosphate Buffered Saline (PBS) was used as a standard buffer and dilutant were 
applicable in seminal analysis and cell culture experiments. Concentrated PBS 
tablets were acquired from Oxoid Microbiology Products (Basingstoke, United 
Kingdom). Tablets were dissolved in distilled water as instructed by the manufacture 
for use in laboratory assays.  
 
Human tubal fluid medium (HTFM) was prepared according to the method outlined 
by Quinn and colleagues (1985) and adjusted to an osmolarity of 280 mOsmol/Kg. 
Before use, 10 mg/ml Human Serum Albumin (HSA) (Sigma-Aldrich, St. Louis, MO, 
USA) was added. Aliquots were prepared and frozen at -20C̊ for future use. HTFM 
use throughout the thesis refers to the final solution used in laboratory procedures.  
 
2.4.2. Seminal volume and total sperm count  
 
Seminal volume was assessed by the transfer of the sample into a measuring 
cylinder with a wide mouth. The volume was visually read directly after liquefaction 
with an accuracy of 0.1 ml. Total sperm count was assessed by the multiplication of 
seminal volume with the sperm concentration (WHO, 2010). 
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2.4.3. Sperm concentration and motility (CASA system) 
 
Sperm count and motility was assessed using the Motility/Concentration module of 
the Sperm Class Analyzer® (SCA) CASA system version 4.1.0.1 (Microptic S.L., 
Barcelona, Spain).  
 
For analysis, a Nikon Eclipse 50i microscope (IMP, Cape Town, South Africa) 
equipped with phase contrast optics and a heated stage was used. Assays were 
conducted within 30 minutes of liquefaction, kept at 37ºC as outlined by WHO 
(2010). Sperm concentrations of >50 x 106/ml were diluted with HTFH to below this 
threshold for accurate motility assessments.  
 
Appropriate disposable counting chambers were used with software specifications 
recommended by the manufacturer. Between a minimum of 5 and maximum of 10 
representative fields were examined and a minimum of 200 spermatozoa included in 
the assessment.  An example of a representative field from one participant (placed in 
the control group) is shown in Figure 9.  
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Figure 9: Typical determination of sperm concentration and motility by means of the 
Sperm Class Analyzer® (SCA) CASA system version 4.1.0.1 (Microptic S.L., 
Barcelona, Spain). This figure specifically indicates motility, with red and green 
comprised of progressively motile sperm, blue representing non-progressively motile 
sperm and yellow representing immotile sperm.  
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2.4.4. Sperm vitality 
 
Sperm vitality was assessed using the eosin-nigrosin staining technique within  
30 minutes following liquefaction as outlined by WHO (2010). Eosin-nigrosin stain 
was prepared by dissolving 0.67 g eosin Y (Sigma-Aldrich, St. Louis, MO, USA) and 
0.9 g sodium choride in 100 ml purified water.  
 
Following this, 10 g of nigrosin (Sigma-Aldrich, St. Louis, MO, USA) was added to 
the solution, boiled, and left to cool to room temperature. The stain was filtered and 
stored in a sealed dark glass container at room temperature for use in the assays. 
After mixing the semen sample, 20 µl was removed and mixed with 20 µl eosin–
nigrosin suspension in an Eppendorf vial. After 30 seconds, a smear of the 
suspension was made on a glass slide and allowed to air dry at room temperature. 
This was done in duplicate.  
 
Immediately after drying, each slide with examined with bright field optics at ×1000 
magnification. A minimum of 100 (those with poor sperm count) and maximum of 
200 spermatozoa were counted on each slide, recorded as stained (dead) vs 
unstained (alive) cells, and an average between both slides determined when the 
difference between the two slides was considered acceptable (WHO, 2010).  
 
The vitality is represented as percentage of vital (unstained) cells. .  An example of a 
representative field from one participant (placed in the control group) is shown in 
Figure 10.    
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Figure 10: Typical determination of sperm vitality by means the eosin-nigrosin 
staining technique. The unstained (alive) cells are depicted by white arrows pointing 
to the right. The stained cells (dead) are depicted by red arrows pointing to the left. 
 
2.4.5. Morphology 
 
Morphology was assessed by the preparation of a smear and the application of the 
Papanicoloaou staining method as outlined by WHO (2010). A smear of semen on 
frosted slides was made after mixing sample. To do this, 10µl semen was place on 
the non-frosted end of the slide. A slide cover slip was used to pull the semen 
sample along the surface of the slide. The slides were allowed to air dry and stored 
in a cool dark cupboard for later staining and counting. They were transported in 
dark slide holding containers to be evaluated by Professor R. Menkveld (Department 
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of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Academic 
Hospital, Tygerberg), according to strict criteria (Menkveld et al., 1990).  
 
2.4.6. Leukocytes 
 
Leukocytes concentration was determined using the peroxidase staining technique 
as described by Politch and colleagues (Politch et al., 1993; Politch et al., 2007). An 
amount of 125 mg Benzidine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
50 ml distilled water and 50 ml 96% (v/v) ethanol, mixed and prepared in aliquots of 
4 ml each. These were stored in the dark at 4ºC for a maximum of 6 months, and 
labelled ‘stock solution’. In order to conduct the assay, a fresh ‘working solution’ was 
made by adding 5 µl 30% hydrogen peroxidise (H2O2-) to the stock solution at room 
temperature. After liquefaction, 20 µl of ejaculate was mixed with 20 µl working 
solution and incubated for 5 minutes at room temperature. Following this, 160 µl 
phosphate buffer solution (PBS) was then added. Counting was done using a 
Neubar chamber at 400x magnification with a dilution factor of 1:10 considered. 
Clearly stained brown cells were considered peroxidise positive. For every 1 
peroxidase positive cell counted, a score of 100 000 leukocytes per ml semen 
(0.1x106/ml) was recorded. 
 
2.4.7. Mitochondrial membrane potential (MMP) 
 
MMP was assessed as described previously (Henkel et al., 2011b) using a Zeiss 
fluorescence microscope (Oberkochen, Germany) for analysis after staining sperm 
with DePsipher staining kit (R&D Systems Inc., Minneapolis, MN, USA). DePsipher 
is a lipophilic cation (5, 5´, 6, 6´-tetrachloro-1, 1´, 3, 3´-tetraethylbenzimidazolyl 
carbocyanin iodide) used as a mitochondrial marker.  
 
A sample of liquefied semen was diluted 1:5 ratio with HTFM and centrifuged for  
10 minutes at 500xg. The supernant was discarded, the pellet re-suspended in 
DePsipher staining solution and incubated for 20 minutes at 37ºC in the dark. The 
DePsipher sperm suspension was then centrifuged at 500xg, the supernatant was 
discarded, and the pellet re-suspended in 100µl pre-warmed 1X reaction buffer. The 
cells were observed immediately with fluorescence microscopy at 1000-times 
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magnification. Sperm exhibiting a green fluorescence within their mid pieces were 
regarded as having disturbed MMP, while those sperm showing red fluorescence 
were regarded as having intact MMP (as shown in Figure 11). A minimum of 100 
(those with poor sperm count) and maximum of 200 spermatozoa were counted on 
each slide. The percentage of sperm with disturbed (abnormal) MMP was calculated 
and recorded. 
 
 
 
Figure 11: Typical determination of mitochondrial membrane potential (MMP) in 
spermatozoa stained with the DePsipher staining solution and observed under 
fluorescent microscopy. Sperm showing red fluorescence, indicated by the red arrow 
pointing to the left, was regarded as having intact MMP. Sperm exhibiting a green 
fluorescence within their mid pieces, indicated by the green arrow pointing to the 
right, were regarded as having disturbed MMP.  
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2.4.8. DNA fragmentation 
 
DNA fragmentation was assessed by the terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) assay according to Henkel et al. (2004). The 
DeadEndTM Colorimetric TUNEL System (Promega Corp., Madison, WI, USA) end 
labels the fragmented DNA of apoptotic cells using a modified TUNEL assay.  
 
A sample of liquefied semen was diluted in a 1:5 ratio with HTFM and centrifuged for 
10 minutes at 500xg. The pellet was re-suspended in PBS (Oxoid, Basingstoke, 
Hampshire, UK). A smear on a Superfrost® slide (Mentzel, Braunschweig, Germany) 
was made and allowed to air dry and accumulated for future analysis. All slides were 
analysed within 6 weeks of preparation. 
 
Prepared slides were fixed in 4% methanol-free formaldehyde (Sigma-Aldrich, St. 
Louis, MO, USA) in PBS for 25 minutes at 4ºC. Slides were washed in fresh PBS for 
5 minutes at room temperature, then sperm cells permeabilized in 0.2% Triton X-100 
(Sigma-Aldrich, St. Louis, MO, USA) in PBS for 5 minutes. After adequate rinsing of 
slides in fresh PBS, cells were allowed to equilibrate using the equilibration buffer 
(100µl added to each slide) for 10 minutes. Based on number of samples requiring 
assessment, the TdT incubation buffer was prepared in the dark according to 
manufacturer instruction. Slides were blotted around the equlibrilated areas and 20 
µl TdT incubation buffer was added to an area of 5 cm2 and covered with plastic 
slips. This was incubated in the dark at 37ºC for 60 minutes and terminated using 
SSC diluted appropriately with deionised water for 15 minutes. The slides were 
washed in fresh PBS at room temperature 5 times of 5 minutes each, before draining 
excess water. Immediately following washing, DNA fragmentation was assessed by 
manual counting done using a Zeiss fluorescence microscope (Oberkochen, 
Germany). A minimum of 100 (those with poor sperm count) and maximum of 200 
spermatozoa were counted on each slide and the results expressed as a percentage 
of cells showing green flouresence indicating fragmented DNA (TUNEL-positive 
cells). An example is of a field is shown in figure 12.  
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Figure 12: Typical determination of TUNEL positive cells using flourescence 
microscopy techniques. The cells showing bright green flourescence ‘glow’, as 
highlighted by the green arrows, was considered to have damaged DNA content.  
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2.5. Serum and seminal fluid cytokines 
 
Cytokines in serum and seminal fluid investigated included TNFα, IL1β), IL6 and IL8. 
Blood was collected in serum separating tubule vacutainers® (BD Biosciences, 
Franklin Lakes, New Jersey, USA) and centrifuged at 5000xg for 10 minutes. Serum 
was transferred to a sterile Eppendorf container and stored at -20ºC until sampling. 
These assays were conducted at Synexa Life Sciences (Milnerton, Cape Town, 
South Africa).  
 
Both serum and seminal fluid were assessed using the BDTM Cytometric Bead Array 
(CBA) Human Inflammatory Cytokines Kit (BD Biosciences, Franklin Lakes, New 
Jersey, USA), which is a multiplexed assay using the sensitivity of amplified 
flourescence detection by flow cytometry to detect soluble analytes in a particle 
based immunoassay. The reportable range for cytokines assessed has an upper 
quantifiable limit of 5000 pg/ml. The lower quantifiable limits are variable; TNFα = 3.7 
pg/ml, IL1β = 7.2 pg/ml, IL6 = 2.5 pg/ml and IL8 = 3.6 pg/ml. Intra-assay CV are 6–
10% for TNFα, 4–7% for IL1β, 5–8% for IL6 and 2–5% for IL8. Inter-assay CV is 8–
15% for TNFα, 4.9–13% for IL1β, 9–10% for IL6 and 4–7% for IL8. All samples were 
assayed in duplicate, with a mean value recorded for data analysis. Samples were 
assayed on an flow cytometry reader obtained from BD Biosciences (Franklin Lakes, 
New Jersey, USA). 
 
2.6. Seminal fluid insulin 
 
Seminal insulin was assayed using the Human Insulin ELISA Kit (RayBiotech, Inc., 
Norcross, Georgia, USA). This is an in-vitro ELISA based assay for the quantitative 
measurement of insulin. Following liquefaction and seminal analysis, remaining 
semen was centrifuged at 5000xg for 10 minutes. Seminal fluid was transferred to 
Eppendorf containers and frozen at -20ºC until sampling. All reagents and samples 
were thawed and brought to room temperature for analysis. The lower quantitative 
limit is 4 µIU/ml, with an intra- and inter-assay CV of <10% and <12% respectively.  
These assays were conducted at Synexa Life Sciences (Milnerton, Cape Town, 
South Africa). All samples were assayed in duplicate, with the mean value recorded 
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for data analysis. Samples were assayed on an ELISA reader obtained from BioTek 
(Winooski, VT, USA). 
 
2.7. Serum and seminal fluid leptin 
 
Serum and seminal leptin was assayed using the Human Leptin ELISA Kit 
(RayBiotech, Inc., Norcross, Georgia, USA). This is an in-vitro ELISA based assay 
for the quantitative measurement of leptin. Blood was collected serum separating 
tubule vacutainers® (BD Biosciences, Franklin Lakes, New Jersey, USA), centrifuged 
at 5000xg for 10 minutes, with serum transported Eppendorf containers and frozen 
at -20ºC until sampling. Following liquefaction and seminal analysis, remaining 
semen was centrifuged at 5000xg for 10 minutes. Seminal fluid was transferred to 
Eppendorf containers and frozen at -20ºC until sampling. All reagents and samples 
were thawed and brought to room temperature for analysis. The lower quantitative 
limit is 2 pg/ml, with an intra- and inter-assay CV of <10% and <12% respectively.  
These assays were conducted at Synexa Life Sciences (Milnerton, Cape Town, 
South Africa). All samples were assayed in duplicate, with the mean value recorded 
for data analysis. Samples were assayed on an ELISA reader obtained from BioTek 
(Winooski, VT, USA). 
 
2.8. Seminal fluid glucose 
 
Seminal glucose was assayed using the Glucose (HK) Assay Kit (Sigma-Aldrich, St. 
Louis, MO, USA). This is an in-vitro ELISA based assay for the quantitative 
measurement of leptin. Following liquefaction and seminal analysis, remaining 
semen was centrifuged at 5000xg for 10 minutes. Seminal fluid was transferred to 
Eppendorf containers and frozen at -20ºC until sampling. All reagents and samples 
were thawed and brought to room temperature for analysis. The CV of the kit based 
on correspondence with the supplier is 2.0%. If the duplicate samples are within 2% 
of each other, these were considered accurate and the mean value recorded for data 
analysis. These assays were conducted at Synexa Life Sciences (Milnerton, Cape 
Town, South Africa). All samples were assayed in duplicate, with the mean value 
recorded for data analysis. Samples were assayed on an ELISA reader obtained 
from BioTek (Winooski, VT, USA). 
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2.9. TM3-Leydig cell culture experiments 
 
A hCG stimulated TM3-Leydig cell culture model was used in order to investigate the 
effect of insulin and cytokines on cell viability, protein concentration and steroid 
hormone (testosterone and progesterone) production. The TM3 immortalised mouse 
(Mus muscularis) Leydig cells (ATCC, Middlesex, United Kingdom) are obtained 
from testicular tissues of 11- 13 day old mice, with epithelial morphology and 
adherent culture properties (ATCC CRL-1714). Passages between 19 and 24 were 
used for the expiriments. Cells were cultured in optimal conditions described below. 
For each experiment, approximately 25 000 cells were seeded in a sterile 96-well 
plate for 48 hours. Medium was then removed, and cells were further cultured with 
experimental medium at varying concentrations for a further 48 hours, with 25 
mIU/ml hCG co-culture for stimulation of steroidogenesis. After termination of the 
experiment, the following parameters were assessed: cell viability (XTT assay), 
protein concentration, testosterone concentration and progesterone concentration. 
All experiments were done in triplicate, and repeated six times. 
 
2.9.1. Cell culture conditions 
 
TM3-Leydig cells were cultured using standard sterile cell culture techniques. Cell 
culture medium used was Dulbecco’s Modified Eagle Medium F-12 (DMEM/F-12) 
(Gibco, Johannesburg, South Africa) with 5% Horse Serum (Gibco, Johannesburg, 
South Africa), 2.5% Fetal Bovine Serum (Gibco, Johannesburg, South Africa) and 
1% Penicillin-Streptomyosin (Sigma-Aldrich, St. Louis, MO, USA). Cells were 
cultured in 75 ml culture flasks and incubated at 37ºC with 5% CO2.  When confluent, 
and for experimental preparations, cultured cells were detached using 0.25% 
Trypsin/EDTA (Gibco, Johannesburg, South Africa).  
 
2.9.2. Preparation of cells for experiments 
 
Cultured cells were allowed to reach confluence in 75 ml cell culture flasks for 
experiments. Medium was removed and flask washed with sterile PBS briefly. An 
amount of 2 ml 0.25% Trypsin/EDTA was added for 10 seconds before removal. The 
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flask was then allowed to sit flat for 2-3 minutes before 2 ml medium was added and 
briefly swirled. The cell rich medium was removed and placed in a sterile test tube. 
The medium was centrifuged at 2500xg and the pellet resuspended in 2 ml culture 
medium.  
 
TM3 cells in suspension were counted using Trypan Blue stain (Sigma-Aldrich, St. 
Louis, MO, USA) under light microscopy on a haematocytometer at 20x 
magnification. Based on the cell count, approximately 25 000 cells were seeded 
under optimal and sterile conditions in 96-well plates with 300 µl of medium and 
incubated for 48 hours in preparation for the experiments. 
 
2.9.3. Cell culture experiments 
 
After 48 hours of preparation, the cells were co-cultured for a further 48 hours with 
25 µl/ml hCG (hCG stimulated cells) and 4 concentrations of a specific hormone or 
cytokine being investigated. Experiments included a positive (25 µl/ml hCG) and a 
negative (hCG negative) control. In preparation of each experiment, hCG medium 
was prepared fresh using aliquots of 5000 mIU/ml hCG (Sigma-Aldrich, St. Louis, 
MO, USA) frozen at -20ºC. Frozen aliquots of 5 µl were allowed to thaw in a water 
bath at 37ºC. As 995 µl medium added to 5 µl determined a concentration of 25 
mIU/L (dilution factor of 1:200), appropriate dilutions was determined for the 
preparation of adequate amount of medium required for the experiment. All 
experiments had a positive (hCG 25 mIU/ml) and a negative (medium) control.   
 
2.9.3.1. Insulin 
 
Recombinant insulin appropriate for mouse cell culture experiments was obtained 
from Sigma-Aldrich (St. Louis, MO, USA) as a lyophilised powder. As per 
manufacturer instructions, 25 mg insulin was reconstituted by adding 1250 µl 0.01M 
hydrochloric acid (HCl) solution to achieve 20 mg/ml concentration. This solution was 
further diluted at 1:1000 with culture medium in order to achieve 20 pg/ml insulin 
stock solution. Aliquots of this stock solution were frozen at -20ºC until required for 
experiments.  
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For each experiment, four concentrations of insulin were used:  
 
• 10 ng/ml 
• 1 ng/ml 
• 0.1 ng/ml 
• 0.01 ng/ml 
 
From 20 pg/ml stock solution, a dilution of 1:1000 was made with prepared 25 mIU/L 
hCG medium to achieve 20 ng/ml. This was again diluted at 1:2 to achieve 10 ng/ml. 
Serial dilutions of 1:10 with hCG medium was done to achieve 1, 0.1 and 0.01 ng/ml 
concentrations.  
 
After preparation of various insulin concentrations in hCG medium, prepared cell 
culture experimental plates were visually inspected. Medium was removed in sterile 
conditions, and the four concentrations were added at 300 µl to each well as 
appropriate, in addition to 300 µl of positive and negative controls. An exposure of  
48 hours was allowed before termination of the experiment.  
 
2.9.3.2. Tumour necrosis factor-alpha (TNFα) 
 
Recombinant TNFα appropriate for mouse cell culture experiments was obtained 
from Sigma-Aldrich (St. Louis, MO, USA) as a lyophilised powder. As per 
manufacturer instructions, 10 µg TNFα was reconstituted by adding 100 µl distilled 
and sterilised water to achieve 100 µg/ml solution. This solution was further diluted at 
1:10 with culture medium in order to achieve 10 µg/ml TNFα stock solution. Aliquots 
of this stock solution were frozen at -20ºC until required for experiments.  
 
For each experiment, four concentrations of TNFα were used:  
 
• 100 ng/ml 
• 10 ng/ml 
• 1 ng/ml 
• 0.1 ng/ml 
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From 10 µg/ml stock solution, a dilution of 1:10 was made with prepared 25 mIU/L 
hCG medium to achieve 1000 ng/ml. Further serial dilutions of 1:10 with hCG 
medium was done to achieve 100, 10, 1 and 0.1 ng/ml concentrations for the 
experiments.  
 
After preparation of various TNFα concentrations in hCG medium, prepared cell 
culture experimental plates were visually inspected. Medium was removed in sterile 
conditions, and the four concentrations were added at 300 µl to each well as 
appropriate, in addition to 300 µl of positive and negative controls. An exposure of  
48 hours was allowed before termination of the experiment.  
 
2.9.3.3. Interleukin 1-beta (IL1β) 
 
Recombinant IL1β appropriate for mouse cell culture experiments was obtained from 
Sigma-Aldrich (St. Louis, MO, USA) as a lyophilised powder. As per manufacturer 
instructions, 5 µg IL1β was reconstituted by adding 50 µl distilled and sterilised water 
to achieve 100 µg/ml solution. This solution was further diluted at 1:10 with culture 
medium in order to achieve 10 µg/ml IL1β stock solution. Aliquots of this stock 
solution were frozen at -20ºC until required for experiments.  
 
For each experiment, four concentrations of IL1β were used:  
 
• 100 ng/ml 
• 10 ng/ml 
• 1 ng/ml 
• 0.1 ng/ml 
 
From 10 µg/ml stock solution, a dilution of 1:10 was made with prepared 25 mIU/L 
hCG medium to achieve 1000 ng/ml. Further serial dilutions of 1:10 with hCG 
medium was done to achieve 100, 10, 1 and 0.1 ng/ml concentrations for the 
experiments.  
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After preparation of various IL1β concentrations in hCG medium, prepared cell 
culture experimental plates were visually inspected. Medium was removed in sterile 
conditions, and the four concentrations were added at 300 µl to each well as 
appropriate, in addition to 300 µl of positive and negative controls. An exposure of  
48 hours was allowed before termination of the experiment.  
 
2.9.3.4. Interleukin 6 (IL-6) 
 
Recombinant IL6 appropriate for mouse cell culture experiments was obtained from 
Sigma-Aldrich (St. Louis, MO, USA) as a lyophilised powder. As per manufacturer 
instructions, 5 µg IL6 was reconstituted by adding 50 µl distilled and sterilised water 
to achieve a 100 µg/ml solution. This solution was further diluted at 1:10 with culture 
medium in order to achieve a 10 µg/ml IL6 stock solution. Aliquots of this stock 
solution were frozen at -20ºC until required for experiments.  
 
For each experiment, four concentrations of IL6 were used:  
 
• 100 ng/ml 
• 10 ng/ml 
• 1 ng/ml 
• 0.1 ng/ml 
 
From 10 µg/ml stock solution, a dilution of 1:10 was made with prepared 25 mIU/L 
hCG medium to achieve 1000 ng/ml. Further serial dilutions of 1:10 with hCG 
medium was done to achieve 100, 10, 1 and 0.1 ng/ml concentrations for the 
experiments.  
 
After preparation of various IL6 concentrations in hCG medium, prepared cell culture 
experimental plates were visually inspected. Medium was removed in sterile 
conditions, and the four concentrations were added at 300 µl to each well as 
appropriate, in addition to 300 µl of positive and negative controls. An exposure of  
48 hours was allowed before termination of the experiment.  
 
 
 
 
 
75 
 
2.9.3.5. Interleukin 8 (IL-8) 
 
Recombinant IL8 appropriate for mouse cell culture experiments was obtained from 
Sigma-Aldrich (St. Louis, MO, USA) as a lyophilised powder. As per manufacturer 
instructions, 10 µg IL8 was reconstituted by adding 100 µl distilled and sterilised 
water to achieve a 100 µg/ml solution. This solution was further diluted at 1:10 with 
culture medium in order to achieve a 10 µg/ml IL8 stock solution. Aliquots of this 
stock solution were frozen at -20ºC until required for experiments.  
 
For each experiment, four concentrations of IL8 were used:  
 
• 100 ng/ml 
• 10 ng/ml 
• 1 ng/ml 
• 0.1 ng/ml 
 
From 10 µg/ml stock solution, a dilution of 1:10 was made with prepared 25 mIU/L 
hCG medium to achieve 1000 ng/ml. Further serial dilutions of 1:10 with hCG 
medium was done to achieve 100, 10, 1 and 0.1 ng/ml concentrations for the 
experiments.  
 
After preparation of various IL8 concentrations in hCG medium, prepared cell culture 
experimental plates were visually inspected. Medium was removed in sterile 
conditions, and the four concentrations were added at 300 µl to each well as 
appropriate, in addition to 300 µl of positive and negative controls. An exposure of  
48 hours was allowed before termination of the experiment.  
 
2.9.4. Experimental assays 
 
After 48 hours exposure to experimental concentrations, experiments were 
terminated. Cell viability, protein concentration and steroid hormone (testosterone 
and progesterone) concentrations were assayed for statistical analysis.  
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2.9.4.1. Cell viability and proliferation determination 
 
Cell viability was assessed using the Cell Proliferation Kit II (XTT) (Roche, Illovo, 
Johannesburg, South Africa). XTT (sodium 3 -́[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid hydrate)) is cleaved by 
living viable cells from a yellow tetrazolium salt to an orange formazan dye, which 
can be quantified using standard ELISA readers.  
 
In order to conduct the assay, under sterile conditions, XTT labelling reagent and the 
electron coupling reagent were thawed at 37ºC and each mixed thoroughly, and 1 µl 
electron coupling reagent was added to 50 µl XTT labelling reagent (or in required 
amounts based on this ratio). A total of 200 µl of experimental culture medium was 
removed and stored in Eppendorf containers at -20ºC for future analysis if required. 
50 µl XTT labelling mixture was added to the remaining 100 µl experimental cell 
culture fluid to achieve a final XTT concentration of 0.3 mg/ml. This was incubated 
for 5-6 hours in the dark at 37ºC in the cell culture incubator. Following incubation, 
the plate was read with an ELISA reader (Labtech, East Sussex, UK) at a 
wavelength of 450 nm and recorded. Cell viability was expressed as a percentage of 
XTT binding as compared to the hCG control group.  
 
2.9.4.2. Protein concentration determination 
 
Protein concentration was determined using the Bio-Rad Protein Assay Dye Reagent 
Concentrate, a colormetric assay. The assay is based on the reaction of proteins 
with an alkaline copper tartrate solution and Folin reagent. Materials used for the 
assay includes Protein Assay Reagent A (Bio-Rad, Hercules, California, USA) and 
Protein Assay Reagent B (Bio-Rad, Hercules, California, USA).    
 
In order to perform the assay, a lysis solution was prepared by adding  
250 mg sodium dodecyle sulphate (SDS) (Sigma-Aldrich, St. Louis, MO, USA) and 
10 mg sodium hydroxide pellets (NaOH) with 250 ml distilled water and thoroughly 
dissolved. Following this, 300 µl of supernant was removed from cell culture plate 
wells and transferred to an Eppendorf container to be stored at -20ºC to be used for 
steroid hormone determination. The plate was hit on dry paper to remove all excess 
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fluid. An amount of 200 µl lysis solution was added to each well and incubated at 
room temperature for 30 minutes. After this, 20 µl was transferred in duplicate to 
another 96-well plate, along with standard dilutions of Bovine Serum Albumin (BSA) 
(Sigma-Aldrich, St. Louis, MO, USA) diluted with lysis solution (1400 µg/ml; 1000 
µg/ml; 600 µg/ml; 200 µg/ml and pure lysis solution as 0 µg/ml). An amount of 200µl 
Reagent B and 25 µl Reagent A was added to each well and incubated at room 
temperature for a further 30 minutes. This was then read at 690 nm on a standard 
ELISA reader (Labtech, East Sussex, UK). Protein concentration was quantified 
based on the standard curve determined by BSA concentrations, an example of 
which is illustrated in Figure 13.  
 
 
 
 
 
Figure 13: A standard curve based on Bovine Serum Albumin (BSA) concentrations 
with a correlation coefficient (r2) of 0.9821. The regression equation used for 
conversion of light wave to protein concentrations of samples was  
y=-197.8895+4347.3318x. 
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2.9.4.3. Testosterone 
 
Testosterone concentrations were determined from experimental cell culture 
supernant stored in Eppendorf containers from the wells used for protein 
determination. Supernant was stored at -20ºC until being assayed. The testosterone 
ELISA kits (DRG International, Inc., Springfield, New Jersey, USA), an enzyme 
based immunoassay for quantitative in vitro assays, was used to determine 
testosterone concentrations.  The sensitivity of the assay is 0.083-16 ng/ml with an 
intra- and inter-assay CV of 3.28-4.16% and 4.73-9.94% respectively. All assays 
were carried out in duplicate, with the mean value recorded as the testosterone 
concentration. Testosterone concentration was quantified based on the standard 
curve determined by supplied testosterone concentrations, an example of which is 
illustrated in Figure 14.  
 
 
 
Figure 14: A standard curve based on testosterone standard dilutions supplied with 
the ELISA kit. The correlation coefficient (r2) of this example was 0.9551, and the 
formula used for conversion of light wave to testosterone concentrations of samples 
was y=17.2287+-8.3024x.  
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2.9.4.4. Progesterone 
 
Progesterone concentrations were determined from experimental cell culture 
supernant stored in Eppendorf containers from the wells used for protein 
determination. Supernant was stored at -20ºC until being assayed. The progesterone 
ELISA kits (DRG International, Inc., Springfield, New Jersey, USA), an enzyme 
based immunoassay for quantitative in vitro assays, was used to determine 
progesterone concentrations.  The sensitivity of the assay is 0-40 ng/ml with an intra- 
and inter-assay CV of 5.4-6.99% and 4.34-9.96% respectively. All assays were done 
in duplicate, with the mean value recorded as the progesterone concentration. 
Progesterone concentration was quantified based on the standard curve determined 
by supplied progesterone concentrations, an example of which is illustrated in Figure 
15. 
 
 
Figure 15: A standard curve based on progesterone standard dilutions supplied with 
the ELISA kit. The correlation coeffecient (r2) of this example was 0.9549, and the 
formula used for conversion of light wave to progesterone concentrations of samples 
was y=40.4473+-22.9516x. 
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2.10. Statistical analysis 
 
Statistical analysis was performed using the MedCalc software (Version 12.0; 
Mariakerke, Belgium). After testing for normal distribution using the Kolmogorov-
Smirnov test, appropriate statistical tests, either parametric (Pearson correlation, 
independent samples t-test) or non-parametric (Spearman Rank correlation, Mann-
Whitney test) were performed. A P-value of <0.05 was considered as significant. 
Correlations were determined using Rank correlation coefficients, with P<0.05 
considered significant and the correlation coefficient expressed as r2.  
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CHAPTER 3 – RESULTS 
 
3.1. Case controlled study cohort 
 
A total number of 78 participants have been included in the study after supplying the 
appropriate biological samples and not reaching any of the exclusion criteria 
determined prior to onset of the study Table 3. Although a total of 85 participants 
requested to take part in the study, seven participants were excluded based on these 
criteria. The majority were excluded at the electronic or telephonic communication 
phase, with three participants due to reported hormonal therapy (insulin or 
testosterone treatments) and three due to a vasectomy history. One participant was 
excluded after supplying samples due to leukocytospermia (he was subsequently 
referred to an appropriate practitioner for further evaluation and treatment, with full 
disclosure of all clinical and biochemical results obtained). An additional three 
participants were originally excluded based on a recent history of inflammatory 
pathology (n=2) or surgery (n=1), but allowed to enter the study after a period of six 
months following full recovery.  Selection bias was limited as no participants who met 
the criteria were excluded from data analysis, nor were participants invited to the 
study. Based on the diagnostic criteria for metabolic syndrome as outlined in Table 1 
(Alberti et al., 2009), 44 participants were placed in the control group (CG), and 34 
participants were placed in the metabolic syndrome group (MetS).  
 
3.1.1. Potential confounding factors 
 
Numerous potential confounding variables were identified in the study. These 
included participant age, body mass index (BMI), demographics, number of MetS 
components, specific MetS components in phenotypic expression, underlying MetS 
components (e.g. insulin resistance/hyperinsulinaemia; T2DM), medications related 
to MetS and smoking. Details of these factors present in the cohort are in Table 6 
and Table 7. Further factors recorded included recent fertility history (where 
applicable) and semen analysis characteristics (Table 8).  P-value differences 
between the groups were calculated using Fisher’s Exact Test. As there is no 
statistical difference between the groups for most of these factors, statistical 
correction of data using regressional analysis was not conducted.  
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Although many of these factors were asked in a clinical history, not all potential 
confounding factors were recorded in detail for statistical analysis. These include 
additional lifestyle factors (such as frequency and/or type of exercise, nutrition, 
nutritional and herbal supplements and alcohol use), education, socio-economic 
status, occupation, potential exposure to toxins and endocrine disruptors, exposure 
to excessive testicular heat or irradiation (e.g. cell phones) and sexual (dys)function 
(e.g. poor libido; erectile dysfunction; premature ejaculation). 
 
 
Table 6: Details of potential confounders such as age, BMI, demographics and 
smoking in the full cohort, with comparisons between the control and MetS groups. 
Variables are represented as percentages rounded to the nearest decimal point.  
P-value was determined using Fisher’s Exact Test. 
Variable 
Cohort 
(n=78) 
Control 
(n=44) 
MetS 
(n=34) P-value 
Age (years) 
   18-29 
   30-39 
   40-49 
   50-59 
   60-70 
 
11.5% 
46.2% 
26.9% 
12.8% 
2.6% 
 
11.4% 
54.5% 
22.7% 
9.1% 
2.3% 
 
11.8% 
35.1% 
32.4% 
17.8% 
2.9% 
 
1.000 
0.315 
0.622 
0.502 
1.000 
BMI  
   18-24.9 (normal weight) 
   25-29.9 (over-weight) 
   30-34.9 (obese) 
   >35 (morbidly obese) 
 
25.6% 
34.6% 
19.2% 
20.6% 
 
40.9% 
50.0% 
9.1% 
0% 
 
5.8% 
14.7% 
32.4% 
47.1% 
 
0.008 
0.022 
0.048 
<0.001 
Demographics 
   Caucasian 
   Coloured 
   Black 
   Asian 
 
66.7% 
25.6% 
7.7% 
- 
 
72.7% 
15.9% 
11.4% 
- 
 
58.8% 
38.3% 
2.9% 
- 
 
0.590 
0.131 
0.393 
- 
Smokers 15.4% 11.4% 20.5% 0.369 
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Table 7: Potential confounding parameters such as the metabolic syndrome 
diagnostic criteria, individual metabolic syndrome components, associated metabolic 
features and related medications in the full cohort, with comparisons between the 
control and MetS groups. Variables are represented as percentages rounded to the 
nearest decimal point. P-value was determined using Fisher’s Exact Test. Insulin 
resistance is based on a QUICKI cut off value of <0.357. Low grade inflammation is 
based on an hs-CRP value of >1.00mmol/L. 
Variable 
Cohort 
(n=78) 
Control 
(n=44) 
MetS 
(n=34) P-value 
MetS diagnostic criteria  
   0 criterion 
   1 criterion 
   2 criterions 
   3 criterions 
   4 criterions 
   5 criterions 
 
17.9% 
28.2% 
10.3% 
29.5% 
10.2% 
3.8% 
 
31.8% 
50.0% 
18.2% 
- 
- 
- 
 
- 
- 
- 
67.7% 
23.5% 
8.8% 
 
- 
- 
- 
- 
- 
- 
MetS components: 
   Increased WC 
   Hypertension 
   Reduced HDL cholesterol 
   Hypertriglyceridaemia 
   Increased serum glucose 
 
56.4% 
41.0% 
42.3% 
19.2% 
15.4% 
 
36.7% 
18.2% 
20.5% 
4.6% 
2.3% 
 
82.4% 
70.6% 
70.6% 
38.2% 
32.4% 
 
0.039 
0.003 
0.006 
0.004 
0.004 
Insulin resistance (QUICKI) 47.4% 18.2% 85.3% <0.001 
T2DM 3.8% - 8.8% 0.091 
Low grade inflammation     
(hs-CRP) 66.6% 43.2% 97.1% 0.032 
MetS medications 
   Hypertension  
   Cholesterol  
   Triglycerides 
   Glucose  
Other medications 
   COX inhibitors 
21.8% 
17.9% 
10.3% 
- 
3.8% 
 
3.8% 
2.3% 
2.3% 
- 
- 
- 
 
0% 
47.1% 
38.2% 
23.5% 
- 
8.8% 
 
8.8% 
<0.001 
<0.001 
0.002 
- 
0.091 
 
0.091 
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Table 8: Details of recent fertility history (where applicable) and semen analysis 
characteristics in the study cohort and comparisons between the control and 
metabolic syndrome groups. Variables are represented as percentages rounded to 
the nearest decimal point. P-value was determined using Fisher’s Exact Test. 
Recent history of couple infertility was defined as an inability to achieve a conception 
with regular sexual intercourse over last 12 months. Proven fertility was defined as a 
live birth within the last 2 years of the consultation date. The following definitions 
were used: hypospermia = < 1.5ml ejaculate; azoospermia = no sperm in the 
ejaculate; oligozoospermia = < 15x106 spermatozoa per ml ejaculate; 
normozoospermia = > 15x106 spermatozoa per ml ejaculate; asthenozoospermia = 
progressive motility < 32% and/or total motility < 40% spermatozoa; 
necrozoospermia = < 58% viable spermatozoa; teratozoospermia = < 4% normal 
form (morphology) spermatozoa; leukospermia = > 0.5 x 106 leukocytes per ml 
ejaculate;    Percentage of sperm with fragmented DNA (DF) = > 25% spermatozoa 
damaged; Percentage of spermatozoa with damaged mitochondria (MMP) = > 36% 
spermatozoa (WHO, 2010; Marchetti et al., 2012; Simon et al., 2013).   
Variable 
Cohort 
(n=78) 
Control 
(n=44) 
MetS 
(n=34) P-value 
Recent history of couple 
infertility 
15.4% 9.1% 35.3% 0.028 
Recent history of proven 
fertility 
15.4% 25.0% 2.9% 0.024 
Sperm parameters: 
   Hypospermia 
   Azoorspermia 
   Oligozoospermia 
   Normospermia 
   Asthenozoospermia 
   Necrozoospermia 
   Teratospermia 
   Leukocytosis 
   DF  
   MMP 
 
14.1% 
5.1% 
16.7% 
78.2% 
58.9% 
23.1% 
58.9% 
- 
21.8% 
52.5% 
 
6.8% 
4.5% 
6.8% 
88.7% 
47.8% 
22.7% 
52.3% 
- 
6.8% 
38.6% 
 
23.5% 
5.8% 
29.4% 
64.8% 
73.5% 
52.9% 
67.6% 
- 
41.2% 
70.6% 
 
0.106 
1.000 
0.035 
0.389 
0.268 
0.078 
0.576 
- 
0.006 
0.128 
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3.1.1.1. Cohort age and age distributions  
 
Mean ages (years) between the groups did not significantly differ (CG = 37.8 ± 8.8; 
MetS = 40.7 ± 9.8), with a range of 24 – 67 years for the entire cohort Table 9. Age 
groups were based on decades as outlined in Table 6. The majority of participants 
were in the 30 – 39 years old age group for the whole cohort and each specific group 
(a common age group for fathering a child). No statistical difference was observed 
between the groups for any of the age group subsets. Therefore, the impact of age 
on the results and statistical analysis is limited.  
 
3.1.1.2. Cohort body mass index (BMI) distribution 
 
Mean BMI was significantly higher (P<0.0001) in the MetS group (25.7 ± 3.0) 
compared to the control group (33.8 ± 5.2) (Table 9). BMI categories assessed are 
normal weight (BMI = 18 – 24.9), over-weight (BMI 25 – 29.9), obese (BMI = 30 – 
34.9) and morbidly obese (BMI > 35) (Kort et al., 2006; Ervin, 2009). Participants in 
each BMI category are detailed in Table 6. The majority of participants in the study 
were either normal weight (25.6%) or over-weight (34.6%), with fewer participants 
obese (19.2%) or morbidly obese (20.6%). Generally, more participants in the MetS 
group were obese or morbidly obese. Significantly more CG participants were 
normal weight (P=0.008) or over-weight (P=0.022) compared to MetS participants. 
Conversely, more MetS participants were obese (P=0.048) or morbidly obese 
(P<0.001) compared to CG participants.  
 
3.1.1.3. Cohort demographic distribution 
 
The majority of participants in the study were Caucasians (66.7%), with coloured 
(25.6%) and black (7.7%) participants less represented. No Asians or other 
demographic backgrounds were in the study cohort. There was no difference 
between CG and MetS group participants for any of these demographics. Details are 
tabulated in Table 6. 
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Table 9: Clinical and biochemical parameters compared between the control group 
(n=44) and metabolic syndrome group (n=34). All statistical analysis using the 
Student‘s t-test, and values expressed as mean±SD (range), except * = Mann-
Whitney tests expressed as median (interquartile range). MMP = mitochondrial 
membrane potential.BMI = body mass index; HDL = high density lipoprotein; QUICKI 
= quantitave insulin sensitivity check index.  
Parameter Control MetS 
P-
value 
Age (years) 37.8 ± 8.8 (24 – 67) 
40.7 ± 9.8 
(26 – 63) 0.1702 
BMI (kg/m2) 25.7 ± 3.0 (18.6 – 31.5) 
33.8 ± 5.2 
(22.3 – 44.0) 
<0.000
1 
Waist circumference 
(cm) 
92.3 ± 9.1 
(73 – 108) 
116.6 ± 12.1 
(89 – 142) 
<0.000
1 
Systolic BP (mmHg)* 120.0 (110.0 – 125.0) 
135.0 
(130.0 – 140.0) 
<0.000
1 
Diastolic BP (mmHg)* 80.0 (72.5 – 80.0) 
90.0 
(85.0 – 90.0) 
<0.000
1 
Serum HDL 
Cholesterol (mmol/L) 
1.24 ± 0.33 
(0.57 – 2.24) 
0.95 ± 0.26 
(0.58 – 2.04) 0.0001 
Serum Triglycerides 
(mmol/L) 
0.96 ± 0.39 
(0.42 – 2.7) 
1.69 ± 0.98 
(0.47 – 5.33) 0.0002 
Serum Glucose 
(mmol/L) 
5.03 ± 0.59 
(3.8 – 7.0) 
5.79 ± 1.70 
(4.4 – 9.7) 0.0018 
Serum Insulin (mIU/ml) 5.73 ± 2.27 (2.4 – 14.3) 
12.77 ± 5.45 
(3.8 – 32.0) 
<0.000
1 
QUICKI Index (Insulin 
Resistance) 
0.373 ± 0.024 
(0.319 – 0.436) 
0.327 ± 0.025 
(0.276 – 0.391) 
<0.000
1 
hs-CRP (mmol/L) 1.04 ± 0.64 (0.2 – 2.96) 
2.55 ± 0.7 
(1.0 – 3.64) 
<0.000
1 
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3.1.1.4. Smokers in the cohort 
 
Smokers were allowed to enter the study (Table 6). A total of 12 smokers (15.4%) 
were in the cohort. Of these, 5 were in the CG (11.4% of the CG) and 7 in the MetS 
group (20.5% of the MetS group). This difference was not statistically significant 
(P=0.369).  
 
3.1.1.5. Metabolic syndrome criteria, components, medications and 
related metabolic disorders in the cohort 
 
The cohort (n=78) consisted of 44 (56.4%) participants in the CG and 34 (43.6%) 
participants in the MetS group. Based on the Fishers Exact test, this was not a 
significant difference (P=0.406). The number of diagnostic criteria in the MetS is 
related to the severity of the syndrome and an increasing risk of complications and 
chronic disease. Of participants representing the full cohort, 17.9% did not fulfill any 
criterion, 28.2% fulfilled 1 criterion and 10.3% fulfilled 2 criterions. MetS is defined in 
the study as 3 or more of the criterion outlined in Table 1. A proportion of 29.5% of 
the cohort fulfilled 3 criterions, with 10.2% fulfilling 4 criterions and 3.8% fulfilling of 
all 5 criterion. The majority of participants in the CG group (50%) fulfilled 2 diagnostic 
criterions, with the majority of participants in the MetS group (67.7%) fulfilling 3 
diagnostic criterions. It is not possible to determine the difference between the 
groups. Details are summarised in Table 7.  
 
In terms of individual components of MetS (Table 1), the majority of the cohort 
(56.4%) had an increased waist circumference (WC). This is followed by reduced 
HDL cholesterol (42.3%), hypertension (41%), hypertriglyceridaemia (19.2%) and 
increased serum glucose (15.4%). As mentioned above, 17.9% of the cohort did not 
full any of these criterions, and numerous participants had more than one 
component. After group comparisons, the MetS group had significantly increased 
proportion of participants with each of these components compared to the CG. The 
details are summarised in Table 7. It is important to note that medications related to 
MetS are also part of the diagnostic criteria.  
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Participants on any medication related to the metabolic syndrome are significantly 
increased in the MetS group (p<0.001). Hypertensive, cholesterol (statins) and 
triglyceride (fibrate) medications were found to be significantly higher in the MetS 
group (P<0.001, P<0.001 & P=0.002, respectively). Glucose regulating medication 
use was increased in the MetS group, but this was not significant (P=0.091). 
Although not addressing the MetS criterion, non-steroidal anti-inflammatory drugs 
(COX-inhibitors) were used by 3.8% of the cohort; all of them in the MetS group. 
However, this difference did not reach statistical significance. No other medications 
were used by participants in the study. It is not known if these medications have a 
positive or negative impact on fertility and hormonal parameters in males. The details 
are summarised in Table 7. 
 
Insulin resistance (IR) is closely related to obesity, MetS and T2DM, and can be 
accurately determined based on the QUICKI (Katz et al., 2000). Using a QUICKI 
ratio of < 0.357 as a marker of IR supplied by PathCare Laboratories (Pathcare Park, 
Goodwood, South Africa), 47.4% of the cohort was diagnosed with IR. This was 
distributed between the groups with 18.2% of the CG and 85.3% of the MetS group 
having IR. This increased number of participants with IR in the MetS group was 
statistically significant (P<0.001). Low grade inflammation is also a feature of MetS 
(Monteiro & Azevedo, 2010), with hs-CRP concentrations of > 1.00 mmol/L as a 
marker of low grade inflammation (PathCare Laboratories, Pathcare Park, 
Goodwood, South Africa).  
 
Based on this definition, 66.6% of the cohort displayed low grade systemic 
inflammation. The MetS group had a significantly increased (P=0.032) number of 
participants with inflammation (97.1%) compared to those in the control group 
(43.2%). Participants with T2DM not on insulin were included in the study. Although 
it is well established that T2DM has a negative association with male fertility (La 
Vignera et al., 2012), patients with diabetes do fulfil the MetS diagnostic criteria and 
have been included for analysis. A total of 3 participants (3.8%) were included in the 
study, all of them in the MetS group (8.8%). However, the number of participants 
with T2DM included in the study did not differ significantly from the control group 
(p=0.091). The details are summarised in Table 7. 
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3.1.1.6. Reproductive potential of the cohort  
 
Recent history of couple infertility was defined as an inability to achieve a conception 
with regular sexual intercourse over last 12 months without any form of contraception 
(WHO, 2010). Although 15.4% of the cohort fulfilled this definition, not all participants 
were currently attempting to have children. Furthermore, there was no analysis of the 
female partner in this assessment. However, within the study, there was a 
statistically significant (P=0.028) increased number in the MetS group (35.3%) 
compared to the CG (9.1%) with a recent history of infertility. For purposes of this 
study, proven fertility was defined as a live birth within the last 2 years of the 
consultation date. In the cohort, 15.4% had recently had children, with statistically 
significant (P=0.024) increased numbers in the control group (25%) compared to the 
MetS group (2.9%). These are summarised in Table 8. 
 
3.1.1.7. Semen analysis and abnormalities in the cohort 
 
Abnormality semen analysis definitions are outlined in Table 2 based on WHO 
(2010). DNA fragmentation and MMP values are based on Simon and colleagues 
(2013) and Marchetti and colleagues (2012), respectively.  
 
Assessing the cohort for ejaculate volume, 14.1% had hypospermia (<1.5ml). 
Although 23.5% in the MetS group had hypospermia compared to 6.8% in the CG, 
this difference was not significant (P=0.106). In each group, 2 participants had 
azoospermia (5.1% of the total cohort). This was not significantly different between 
the groups. Within the total cohort, 78.2% had normozoospermia (> 15 x 106 
spermatozoa per ml), with 16.8% participants with oligozoospermia (< 15 x 106 
spermatozoa per ml). Although the CG had an increased percentage of participants 
considered normozoospermia (88.7%) compared to the MetS group (64.8%), this 
was not significant (P=0.389). However, the percentage of participants with 
oligozoospermia in the MetS group (29.4%) compared to the CG (6.8%) was 
significantly increased (P=0.035). Within the total cohort, asthenozoospermia 
(progressive motility < 32% and/or total motility < 40% spermatozoa) was identified 
in 58.9% of participants, necrozoospermia (< 58% viable spermatozoa) was 
identified in 23.1% of participants, teratozoospermia (< 4% normal form 
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(morphology) spermatozoa) was identified in 58.9% of participants, DNA 
fragmentations (> 25% spermatozoa damaged) identified in 21.8% of participants 
and abnormal MMP (> 36% spermatozoa) identified in 52.5% of participants. 
Although all these parameters were generally more frequent in the MetS group 
compared to CG, only DNA fragmentations was significantly different (P=0.006). 
These are summarised in Table 8.  
 
3.2. Clinical and biochemical parameter results 
 
Predictable differences are found between the groups of all parameters. MetS 
patients had significantly increased body mass index (P<0.0001), waist 
circumference (P<0.0001), systolic blood pressure (P<0.0001), diastolic blood 
pressure (P<0.0001), triglycerides (P=0.0002) and glucose (P=0.0018), with 
decreased HDL-cholesterol (P=0.0001). Serum insulin concentrations were 
significantly increased in MetS (P<0.0001), with the QUICKI significantly decreased 
(P<0.0001). hs-CRP was significantly increased (P<0.0001) in MetS. Details of 
mean, standard deviation and range are summarised in Table 9.  
 
3.3. Semen analysis and sperm function results 
 
A total of 4 participants in the cohort were diagnosed with idiopathic azoospermia 
(Table 8). As they did not meet any other exclusion criteria, they were entered into 
the study. This included 2 participants from the CG group, and 2 participants in the 
MetS group. This difference was not statistically significant based on the Fisher’s 
Exact Test (P=1.0). However, these participants had all semen parameters reported 
in this section removed from analysis, with all other parameters in the study included 
(including other seminal fluid assays for insulin, leptin and inflammatory cytokines). 
Therefore, 74 participants had data entered for semen analysis, with 42 in the CG 
and 32 the MetS group. In addition, not all samples were assayed for DNA 
fragmentation (DF) or abnormal mitochondrial membrane potential (MMP), with a 
total number of samples assayed being 55 and 67, respectively. This was due to 
inadequate sampling, low ejaculate volume and/or low sperm counts. For DF, 28 
samples from CG and 27 samples from MetS group were obtained. For MMP, 36 
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samples from CG and 31 samples from MetS group were obtained. Results for 
semen analysis are summarised in Table 10. 
 
Ejaculation volume was significantly (P=0.008) decreased in the MetS group, with 
sperm concentration also significantly decreased (P=0.0005) in the MetS group 
compared to the CG. As the product of volume and concentration, total sperm count 
was also significantly (P=0.0002) decreased in the MetS group. Sperm functions 
were significantly decreased in MetS group, including progressive motility 
(P=0.0225), total motility (P=0.0033) and vitality (P=0.0006). Although there was a 
decreased percentage of sperm with abnormal morphology in the MetS group  
(2.72 ± 2.38%) compared to the CG (3.9 ± 3.17%), this was not statistically 
significant (P=0.0817).  Percentage of sperm with abnormal MMP (P=0.0007) and 
DF (p=0.004) were significantly increased in MetS patients. The results are 
summarised in Table 10.  
 
Although most parameters were significantly different between the groups, the mean 
or median values for most parameters in both groups were above the WHO (2010) 
(Table 2) recommended thresholds for a normal semen analysis, except for vitality 
(50.0 ± 23.2%) and progressive motility (20.0 ±17.1%) in the MetS group. Although 
there is no statistical difference in morphology between the groups, the mean values 
in both groups are below the WHO (2010) recommended thresholds (CG: 3.9 ± 
3.17%; MetS: 2.72 ± 2.38%). Based on a threshold for abnormal MMP 
recommended by Marchetti et al. (2012), both the CG and MetS group means are 
above this value (42.1 ± 25.8% & 63.1 ± 22.2%). Based on the threshold for DF 
recommended by Simon et al. (2013), only the MetS group was above this threshold 
(26.9 ± 19.7%). 
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Table 10: Seminal parameters compared between the control group (n=42) and 
participants diagnosed with the metabolic syndrome (n=32), except MMP (n=36 and 
n=31 respectively) and DNA fragmentation (n=28 and n=27 respectively). All 
statistical analysis using the Student‘s t-test, and values expressed as mean±SD 
(range), except * = Mann-Whitney tests expressed as median (interquartile range). 
MMP = mitochondrial membrane potential.  
Parameter Control MetS P-value 
Ejaculation Volume 
(ml)* 
2.55 
(1.95 – 3.5) 
2.0 
(1.2 – 2.5) 0.0080 
Sperm Concentration 
(million/ml) 
43.7 ± 24.6 
(6.4 – 110.8) 
26.7 ± 15.8 
(3.2 – 58.7) 0.0005 
Total Sperm Count 
(million)* 
103.6 
(65.6 – 139.5) 
48.1 
(25.5 – 65.8) 0.0002 
Sperm Vitality 
(% sperm alive) 
67.3 ± 15.4 
(29 – 92) 
50.0 ± 23.2 
(6 – 88) 0.0006 
Progressive Motility   
(% motile) 
29.4 ± 17.2 
(0.0 – 59.5) 
20.0 ±17.1 
(0.0 – 70.1) 0.0225 
Total Motility 
(% motile) 
57.5 ± 20.8 
(18.5 – 90.1) 
42.9 ± 19.9 
(1.1 – 78.4) 0.0033 
Morphology (% 
normal) 
3.9 ± 3.17 
(1 – 14) 
2.72 ± 2.38 
(0 – 12) 0.0817 
MMP (% abnormal) 42.1 ± 25.8 (3 – 95) 
63.1 ± 22.2 
(21 – 100) 0.0007 
DNA Fragmentation  
(% abnormal) 
13.9 ± 9.8 
(3 – 45) 
26.9 ± 19.7 
(4 – 83) 0.0040 
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3.4. Saliva steroid hormone concentrations 
 
All 78 participants supplied saliva samples for analysis. However, a total of 10 
samples were not assayed (6 in the CG & 4 in the MetS group). This was due to 
either an inadequate sample size (5 in the CG and 1 in the MetS group) or values 
below the lower limit of quantification (LLOQ) (1 in the CG and 3 in the MetS group). 
Therefore, samples included in data analysis represented 38 participants in the CG 
and 30 participants in the MetS group.  
 
Free testosterone (P=0.0001) and free progesterone (P=0.0011) concentrations 
were significantly reduced in participants with MetS compared to controls. Results 
are summarised in Table 11.  
 
Table 11: Saliva hormone parameters compared between the control group (n=38) 
and participants diagnosed with the metabolic syndrome (n=30). All statistical 
analysis using the Student‘s t-test, and values expressed as mean±SD (range).  
Parameter Control MetS P-value 
Free Testosterone 
(pg/ml) 
272.5 ± 162.4 
(74.0 – 744.2) 
144.7 ± 87.4 
(32.5 – 415.8) 0.0001 
Free Progesterone 
(pg/ml) 
95.2 ± 45.3 
(29.4 – 212.8) 
65.4 ± 24.9 
(24.6 – 122.7) 0.0011 
 
 
3.5. Serum and seminal glucose and insulin concentrations 
 
Serum glucose (P=0.0018) and insulin (P<0.0001) concentrations were increased in 
participants with MetS compared to the control group, as illustrated in Table 9.  
 
Of 78 semen samples received, 61 samples were assayed accuratly for seminal 
glucose concentrations, with 37 in the CG and 24 in the MetS group. In the CG, 2 
samples did not yield adequate seminal fluid for analysis, and 5 samples were 
recorded as below the lowest level of quantification (LLOQ) .  
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Of the MetS group, 7 samples did not yield adequate seminal fluid for analysis, and 3 
samples were recorded as LLOQ. Seminal glucose concentrations showed a trend to 
be decreased in the MetS group, however, this did not reach statistical significance 
(P=0.0531).  
 
A total of 42 semen samples were assayed for insulin concentrations, with with 20 in 
the CG and 22 in the MetS group.  This was based on the first 42 participants who 
supplied samples and did not reach any exclusions. Seminal insulin concentrations 
are significantly higher in the MetS group (P<0.0001). In addition, seminal insulin is 
highly concentrated as compared to serum concentrations. Results are summarised 
alongside serum insulin and glucose concentrations in Table 12.  
 
Table 12: Seminal  concentrations for glucose and insulin compared between the 
control group (n=37 & n=20 Respectively) and participants diagnosed with the 
metabolic syndrome (n=24 & n=22 respectively). Serum glucose and insulin (CG: 
n=44; MetS n=34) have been included for comparitive purposes. All statistical 
analysis using the Student‘s t-test, and values expressed as mean±SD (range), 
except * = Mann-Whitney tests expressed as median (interquartile range).  
Parameter Control MetS P-value 
Serum Glucose 
(mmol/L) 
5.03 ± 0.59 
(3.8 – 7.0) 
5.79 ± 1.70 
(4.4 – 9.7) 0.0018 
Seminal Glucose 
(µg/ml) 
472.1 ± 245.3 
(48.1 – 990.0) 
357.1 ± 207.1 
 (90.6 – 781.7) 0.0531 
Serum Insulin (mIU/ml) 5.73 ± 2.27 (2.4 – 14.3) 
12.77 ± 5.45 
(3.8 – 32.0) <0.0001 
Seminal Insulin (mIU/ml) 164.7 ± 75.6 (128.7 – 368.0) 
539.8 ± 245.7 
(175.6 – 1059.9) <0.0001 
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3.6. Serum and seminal inflammatory cytokine concentrations 
 
Of the 78 serum and semen samples received, all were assayed for cytokine 
concentrations. However, some results were below the lowest level of quantification 
(LLOQ), and other results were not considered reliable for data analysis. Results are 
summarised in Table 13.   
 
Serum tumor necrosis factor-alpha (TNFα) had results for 36 samples from the CG, 
and 29 samples from the MetS group analysed.  Within the CG, 8 samples were 
LLOQ. Within the MetS group, 5 samples were LLOQ. Seminal TNFα had 33 
samples from the CG, and 26 samples from the MetS group.  Within the CG, 5 
samples were LLOQ, and 6 removed due to unreliable results. Within the MetS 
group, 8 samples were LLOQ. The MetS group had significantly increased TNFα in 
serum (P<0.0001) and seminal (P=0.0001) samples.  
 
Serum interleukin 1-beta (IL1β) had results for 32 samples from the CG, and 25 
samples from the MetS group analysed.  Within the CG, 10 samples were LLOQ, 
and 2 removed due to unreliable results. Within the MetS group, 8 samples were 
LLOQ, and 1 removed due to unreliable results. Seminal IL1β had 35 samples from 
the CG, and 27 samples from the MetS group.  Within the CG, 8 samples were 
LLOQ. Within the MetS group, 5 samples were LLOQ, and 2 removed due to 
unreliable results . The MetS group had significantly increased IL1β in serum 
(P<0.0001) and seminal (P=0.0008) samples. 
 
Serum interleukin 6 (IL6) had results for 31 samples from the CG, and 28 samples 
from the MetS group analysed.  Within the CG, 11 samples were LLOQ. Within the 
MetS group, 6 samples were LLOQ. Seminal IL6 had 32 samples from the CG, and 
33 samples from the MetS group.  Within the CG, 12 samples were LLOQ. Within 
the MetS group, 1 sample was LLOQ. The MetS group had significantly increased 
IL6 in serum (P<0.0001) and seminal (P<0.0001) samples. 
 
Serum interleukin 8 (IL8) had results for 34 samples from the CG, and 27 samples 
from the MetS group analysed.  Within the CG, 8 samples were LLOQ, and 2 
removed due to unreliable results. Within the MetS group, 7 samples were LLOQ. 
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Seminal IL1β had 33 samples from the CG, and 20 samples from the MetS group.  
All samples excluded from data analysis for seminal IL8 from both groups was due to 
results being above the upper level of quantification (ULOQ). The MetS group had 
significantly increased IL8 in serum (P=0.0001) and seminal (P=0.0007) samples. In 
addition, seminal IL-8 is highly concentrated compared to serum levels.  
 
Table 13: Serum and seminal  inflammatory cytokines compared between the 
control group and participants diagnosed with the metabolic syndrome. All statistical 
analysis using Mann-Whitney tests, and values expressed as median (interquartile 
range). 
Parameter Control MetS P-value 
Serum TNFα (pg/ml) 5.8 (5.6 – 8.0) 
19.7 
(15.9 – 23.5) <0.0001 
Seminal TNFα (pg/ml) 6.8 (6.1 – 11.6) 
16.2 
(11.7 – 21.1) 0.0001 
Serum IL-1β (pg/ml) 12.5 (8.7 – 16.4) 
28.5  
(17.9 – 32.9) <0.0001 
Seminal IL-1β (pg/ml) 22.3 (14.2 – 30.3) 
42.3 
(20.7 – 99.4) 0.0008 
Serum IL-6 (pg/ml) 5.8 (5.4 – 6.3) 
16.5 
(15.8 – 33.5) <0.0001 
Seminal IL-6 (pg/ml) 9.8 (5.6 – 21.9) 
30.0 
(18.9 – 59.1) <0.0001 
Serum IL-8 (pg/ml) 10.9 (7.4 – 14.8) 
21.6 
(14.9 – 29.5) 0.0001 
Seminal IL-8 (pg/ml) 1266.8  (836.0 – 2037.8) 
2324.9 
(1598.1 – 3658.7) 0.0007 
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3.7. Serum and seminal leptin results 
 
A total of 78 serum and semen samples were available for leptin assays. Of these, 
54 serum and 23 semen samples provided accurate data for statistical analysis. 
Within the serum samples, 30 were in the CG and 24 in the MetS group. Serum 
samples not included in data analysis was due to results either below the lowest 
level of quantification (LLOQ) (n=12 in the CG and n=3 in the MetS group) or above 
the upper level of quantification (ULOQ) (n=2 in the CG and n=7 in the MetS group). 
Within the semen samples, 10 were in the CG and 13 in the MetS group. Semen 
samples not included in data analysis was due results either below the lowest level 
of quantification (LLOQ) (n=2 in the CG and n=5 in the MetS group) or above the 
upper level of quantification (ULOQ) (n=2 in the CG and n=0 in the MetS group), or 
due to semen sample being too small (n=12 in the CG and n=16 in the MetS group). 
Both serum (P=0.0049) and seminal (P=0.0002) leptin was significantly increased in 
the MetS group compared to the CG group. Results are summarised in Table 14.  
 
Table 14: Serum and seminal  leptin compared between the control group (n=30 and 
n=10 respectively) and participants diagnosed with the metabolic syndrome (n=24 
and n=30 respectively). All statistical analysis using the Student‘s t-test, and values 
expressed as mean±SD (range). 
Parameter Control MetS P-value 
Serum Leptin (ng/ml) 1.23 (0.43 – 2.23) 
6.97 
(0.86 – 12.1) 0.0049 
Seminal Leptin (ng/ml) 6.8 (4.5 – 8.0) 
18.0  
(12.4 – 21.7) 0.0002 
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3.8. Correlations between variables in the case controlled study 
 
Correlations between variables were analysed in three components. The full cohort 
was assessed (combined CG and MetS groups), as was the CG and MetS groups 
separately. All correlation details (P-value and correlation coefficient) are tabulated. 
The abbreviations for the various parameters have not been included in the table 
legends. Statistically significant correlations (P<0.05) are included, with non-
significant correlations indicated with NS.  
 
3.8.1. Clinical and biochemical correlations 
 
Correlation details for the clinical and biochemical variables are summarised in 
Tables 15, 16 and 17. 
 
Age correlated positively with waist circumference (WC) in the cohort and CG (but 
not MetS group), fasting blood glucose (FBG) in the cohort and MetS group (but not 
the CG) and free testosterone (FT) in all three groups. Age correlated negatively with 
insulin resistance (IR) in the cohort, but not in the CG or MetS groups. Although 
there was no significant correlation with age and high density lipoprotein (HDL) 
cholesterol in the cohort and MetS groups, there was a significant positive correlation 
in CG. There were no significant correlations between age and body mass index 
(BMI), systolic blood pressure (sBP), diastolic blood pressure (dBP), triglycerides 
(TG), fasting blood insulin (FBI), C-Reactive protein (CRP) and free progesterone 
(FP) in all three groups.  
 
BMI correlated positively with WC in the cohort, CG and MetS groups, with sBP and 
dBP in the cohort only, with TG in the cohort and CG (but not the MetS group), with 
FBI in all three groups and CRP in the cohort only. BMI negatively correlated with 
HDL, FT and FP in the cohort only, and IR in all three groups. There was no 
correlation between BMI and FBG in all three groups.  
 
WC correlated positively with dBP, sBP, FBI and CRP, and negatively with HDL, IR, 
FT and FP in the cohort, but not the CG and MetS groups. There was no significant 
correlation of WC with TG or FBG in any of the three groups.   
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sBP and dBP significantly positively correlated in all three groups. Both of the 
variables correlated positively with TG, FBI and CRP, and negatively with IR in the 
cohort, but not CG and MetS groups. There was no significant correlation between 
sBP or dBP and HDL, FT and FP for all three groups. HDL correlated positively with 
IR and FP, and negatively with TG, FBI and CRP in the cohort, but not CG and MetS 
groups. There was no HDL correlation with FBG or FT in any of the groups. TG 
correlated positively with FBI and negatively with IR in the cohort and CG (but not 
the MetS group). TG further correlated positively with CRP and negatively with FT 
and FP in the cohort, but not the CG and MetS groups. There was no significant 
correlation with TG and FBG in any of the groups. FBG correlated positively with 
CRP in all three groups. Furthermore, FBG correlated positively with FBI and 
negatively with IR in the cohort and MetS groups (but not the CG). There was no 
significant FBG correlation with FT and FP in any of the groups.  
 
FBI correlated negatively with IR in all three groups. There was a positive correlation 
between FBI and CRP in the cohort and CG (but not the MetS group), and with FP in 
the control group (but not the cohort nor MetS groups).  There was no significant 
correlation between FBI and FT in any of the groups. However, IR correlated 
positively with FT in the cohort, but not the CG nor MetS groups. There was a 
negative correlation between IR and CRP in the cohort and CG (but not the MetS 
group), with no correlation between IR and FP in any of the groups. CRP correlated 
negatively with FT in the cohort, but not the CG or MetS groups, with no correlation 
between CRP and FP in any of the groups. FT and FP positively correlated in the 
cohort and CG, with no correlation in the MetS group.   
 
Legend for Table’s 15, 16 and 17:  NS = not significant.  BMI = body mass index; WC 
= waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
HDL = high density lipoprotein cholesterol; TG = triglycerides; FBG = fasting blood 
glucose; FBI = fasting blood insulin; IR = insulin resistance (based on QUICKI); CRP = 
highly sensitive C-reactive protein; FT = free testosterone; FP = free progesterone.  
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Table 15: Clinical and biochemical parameter correlations for the cohort.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Age 
r2= 
P= 
NS 
0.231 
0.0416 
NS NS NS NS 
0.385 
0.0005 
NS 
-0.229 
0.0435 
NS 
-0.444 
0.0001 
NS 
BMI 
r2= 
P= 
- 
0.912 
<0.0001 
0.241 
0.0335 
0.307 
0.0062 
-0.427 
0.0001 
0.234 
0.0396 
NS 
0.706 
<0.0001 
-0.692 
<0.0001 
0.562 
<0.0001 
-0.303 
0.0119 
-0.307 
0.0108 
WC 
r2= 
P= 
 - 
0.320 
0.0043 
0.400 
0.0003 
-0.403 
0.0003 
NS NS 
0.650 
<0.0001 
-0.661 
<0.0001 
0.608 
<0.0001 
-0.395 
0.0008 
-0.345 
0.0040 
SBP 
r2= 
P= 
  - 
0.846 
<0.0001 
NS 
0.308 
0.0061 
NS 
0.328 
0.0033 
-0.332 
0.0030 
0.386 
0.0005 
NS NS 
DBP 
r2= 
P= 
   - NS 
0.322 
0.0041 
NS 
0.400 
0.0003 
-0.427 
0.0001 
0.411 
0.0002 
NS NS 
HDL 
r2= 
P= 
    - 
-0.249 
0.0279 
NS 
-0.372 
0.0008 
0.413 
0.0002 
-0.326 
0.0036 
NS 
0.268 
0.0274 
TG 
r2= 
P= 
     - NS 
0.477 
<0.0001 
-0.436 
0.0001 
0.325 
0.0037 
-0.247 
0.0422 
-0.257 
0.0343 
FBG 
r2= 
P= 
      - 
0.218 
0.0493 
-0.422 
0.0001 
0.317 
0.0046 
NS NS 
FBI 
r2= 
P= 
       - 
-0.889 
<0.0001 
0.571 
<0.0001 
NS NS 
IR 
r2= 
P= 
        - 
-0.644 
<0.0001 
0.259 
0.0332 
NS 
CRP 
r2= 
P= 
         - 
-0.239 
0.0494 
NS 
FT 
r2= 
P= 
          - 
0.498 
<0.0001 
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Table 16: Clinical and biochemical parameter correlations for the control group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Age 
r2= 
P= 
NS 
0.391 
0.0086 
NS NS 
0.317 
0.0362 
NS NS NS NS NS 
-0.332 
0.0418 
NS 
BMI 
r2= 
P= 
- 
0.757 
<0.0001 
NS NS NS 
0.349 
0.0204 
NS 
0.412 
0.0055 
-0.478 
0.0010 
NS NS NS 
WC 
r2= 
P= 
 - NS NS NS NS NS NS NS NS NS NS 
SBP 
r2= 
P= 
  - 
0.780 
<0.0001 
NS NS NS NS NS NS NS NS 
DBP 
r2= 
P= 
   - NS NS NS NS NS NS NS NS 
HDL 
r2= 
P= 
    - NS NS NS NS NS NS NS 
TG 
r2= 
P= 
     - NS 
0.366 
0.0145 
0.366 
0.0144 
NS NS NS 
FBG 
r2= 
P= 
      - NS NS 
0.309 
0.0414 
NS NS 
FBI 
r2= 
P= 
       - 
-0.882 
<0.0001 
0.454 
0.0020 
NS 
0.336 
0.0392 
IR 
r2= 
P= 
        - 
-0.406 
0.0063 
NS NS 
CRP 
r2= 
P= 
         - NS 
0.462 
0.0035 
FT 
r2= 
P= 
          - 
0.427 
0.0076 
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Table 17: Clinical and biochemical parameter correlations for the MetS group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Age 
r2= 
P= 
NS NS NS NS NS NS 
0.470 
0.0050 
NS NS NS 
-0.610 
0.0003 
NS 
BMI 
r2= 
P= 
- 
0.858 
<0.0001 
NS NS NS NS NS 
0.463 
0.0058 
-0.362 
0.0351 
NS NS NS 
WC 
r2= 
P= 
 - NS NS NS NS NS NS NS NS NS NS 
SBP 
r2= 
P= 
  - 
0.843 
<0.0001 
NS NS NS NS NS NS NS NS 
DBP 
r2= 
P= 
   - NS NS NS NS NS NS NS NS 
HDL 
r2= 
P= 
    - NS NS NS NS NS NS NS 
TG 
r2= 
P= 
     - NS NS NS NS NS NS 
FBG 
r2= 
P= 
      - NS 
-0.403 
0.0182 
NS NS NS 
FBI 
r2= 
P= 
       - 
-0.849 
<0.0001 
NS NS NS 
IR 
r2= 
P= 
        - NS NS NS 
CRP 
r2= 
P= 
         - NS NS 
FT 
r2= 
P= 
          - 
0.458 
0.0032 
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3.8.2. Seminal analysis correlations 
 
Correlation details for the clinical and biochemical variables are summarised in 
Tables 18, 19 and 20. 
 
Age correlated negatively with ejaculation volume (EV) in the cohort and CG (but not 
the MetS group), progressively motility (PM), total motility (TM) and vitality in the 
cohort and MetS group (but not the CG). There was a positive correlation between 
age and DNA fragmentation (DF) in the cohort and MetS group (but not the CG). No 
correlation of age with sperm concentration (SC), total sperm count (TSC), 
morphology and mitochondrial membrane potential (MMP) in any of the groups was 
found.  
 
EV correlated positively with TSC in all three groups, and with PM, TM and vitality in 
the cohort (but not the CG or MetS group). There was a negative correlation 
between EV and MMP for the cohort and CG (but not the MetS group). No significant 
correlation of EV was found with SC, morphology and DF in any of the groups. SC 
correlated positively with TSC, PM, TM and vitality in all three groups, and 
morphology in the cohort (but not the CG or MetS group).  
 
SC correlated negatively with MMP in the cohort and MetS group (but not the CG) 
and with DF in the cohort (but not the CG or MetS group). TSC correlated positively 
with PM, TM and vitality in all three groups, and morphology in the cohort and MetS 
groups (but not the CG). There was a negative correlation between TSC and MMP in 
all three groups, and no correlation between TSC and DF in all three groups.  
 
PM and TM correlated positively in all three groups. Both PM and TM correlated 
positively with vitality, negatively with MMP and not at all with morphology in all three 
groups. There was no correlation between PM and DF in all three groups, however, 
TM correlated negatively with DF in the cohort only.  
 
Vitality correlated positively with morphology in the cohort only and negatively with 
MMP in all three groups. Vitality and DF correlated negatively with DF in the cohort 
and MetS groups (but not the CG). There was a negative correlated between 
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morphology and DF in the cohort (but not the CG or MetS group), with no significant 
correlation between morphology and MMP in any of the groups. MMP and DF did not 
correlate in any of the groups.  
 
Legend for Table’s 18, 19 and 20:  NS = not significant.  EV = ejaculation volume; SC 
= sperm concentration; TSC = total sperm count; PM = progressive motility; TM = total 
motility; Morph = normal morphology; MMP = abnormal mitochondrial membrane 
potential; DF = DNA fragmentation. 
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Table 18: Seminal correlations for the cohort.  
 
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Age 
r2= 
P= 
-0.256 
0.0253 
NS NS 
-0.443 
0.0001 
-0.321 
0.0060 
-0.341 
0.0033 
NS NS 
0.282 
0.0369 
EV 
r2= 
P= 
- NS 
0.629 
<0.0001 
0.342 
0.0033 
0.304 
0.0094 
0.306 
0.0089 
NS 
-0.420 
0.0005 
NS 
SC 
r2= 
P= 
 - 
0.769 
<0.0001 
0.341 
0.0034 
0.589 
<0.0001 
0.517 
<0.0001 
0.250 
0.0341 
-0.457 
0.0001 
-0.280 
0.0384 
TSC 
r2= 
P= 
  - 
0.391 
0.0007 
0.543 
<0.0001 
0.473 
<0.0001 
0.281 
0.0166 
-0.526 
<0.0001 
NS 
PM 
r2= 
P= 
   - 
0.801 
<0.0001 
0.686 
<0.0001 
NS 
-0.643 
<0.0001 
NS 
TM 
r2= 
P= 
    - 
0.825 
<0.0001 
NS 
-0.675 
<0.0001 
-0.367 
0.0059 
Vitality 
r2= 
P= 
     - 
0.229 
0.0495 
-0.556 
<0.0001 
-0.439 
0.0008 
Morph 
r2= 
P= 
      - NS 
-0.356 
0.0077 
MMP 
r2= 
P= 
       - NS 
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Table 19: Seminal correlations for the control group.  
 
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Age 
r2= 
P= 
-0.304 
0.0451 
NS NS NS NS NS NS NS NS 
EV 
r2= 
P= 
- NS 
0.494 
0.0009 
NS NS NS NS 
-0.562 
0.0004 
NS 
SC 
r2= 
P= 
 - 
0.770 
<0.0001 
0.373 
0.0149 
0.580 
0.0001 
0.437 
0.0038 
NS NS NS 
TSC 
r2= 
P= 
  - 
0.414 
0.0065 
0.569 
0.0001 
0.467 
0.0018 
NS 
-0.398 
0.0178 
NS 
PM 
r2= 
P= 
   - 
0.774 
<0.0001 
0.589 
<0.0001 
NS 
0.566 
0.0004 
NS 
TM 
r2= 
P= 
    - 
0.756 
<0.0001 
NS 
-0.525 
0.0012 
NS 
Vitality 
r2= 
P= 
     - NS 
-0.483 
0.0033 
NS 
Morph 
r2= 
P= 
      - NS NS 
MMP 
r2= 
P= 
       - NS 
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Table 20: Seminal correlations for the MetS group.  
 
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Age 
r2= 
P= 
NS NS NS 
-0.528 
0.0019 
-0.458 
0.0083 
-0.396 
0.0250 
NS NS 
0.369 
0.0485 
EV 
r2= 
P= 
- NS 
0.773 
<0.0001 
NS NS NS NS NS NS 
SC 
r2= 
P= 
 - 
0.637 
0.0001 
0.352 
0.0259 
0.451 
0.0096 
0.446 
0.0106 
NS 
-0.452 
0.0107 
NS 
TSC 
r2= 
P= 
  - NS NS NS NS 
-0.358 
0.0480 
NS 
PM 
r2= 
P= 
   - 
0.792 
<0.0001 
0.710 
<0.0001 
NS 
-0.483 
0.0059 
NS 
TM 
r2= 
P= 
    - 
0.852 
<0.0001 
NS 
-0.576 
0.0007 
NS 
Vitality 
r2= 
P= 
     - NS 
-0.452 
0.0107 
-0.394 
0.0423 
Morph 
r2= 
P= 
      - NS NS 
MMP 
r2= 
P= 
       - NS 
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3.8.3. Cytokine, leptin, seminal insulin and glucose correlations  
 
Correlation details for the clinical and biochemical variables are summarised in 
Tables 21, 22 and 23. 
  
Age did not correlate with any of the variables in any group. Serum TNFα strongly 
correlated positively with all serum and seminal cytokines, and negatively with serum 
glucose, in the cohort. A correlation between serum TNFα and seminal TNFα, serum 
and seminal IL6, and serum leptin was observed in both the CG and MetS groups in 
addition to the cohort. Serum TNFα also correlated with seminal IL8 in the MetS 
group. Seminal TNFα correlated positively with seminal IL1β, IL6 and IL8 in the 
cohort and MetS groups, and also with serum leptin in the CG.  
 
Serum IL1β correlated strongly with seminal IL1β, IL8, leptin and insulin, and serum 
IL6, IL8 and leptin in the cohort, with only the correlation with serum IL6 and seminal 
IL8 observed in the MetS group. These correlations were not observed in the CG. 
Seminal IL1β did not further correlate with other cytokines, leptin or insulin in any 
group.  
 
Serum IL6 correlated positively with serum IL8 and leptin, and with seminal IL6, IL8, 
leptin and insulin in the cohort, but not in the CG or MetS groups.  Seminal IL6 
further correlated with serum and seminal IL8 in the cohort, seminal IL8 and the CG 
and seminal leptin in the MetS group.  
 
Serum IL8 further correlated positively with seminal insulin in the cohort only, and the 
the CG or MetS groups. Seminal IL8 also correlated with seminal leptin in the cohort 
and MetS group, but not in the CG.  
 
Serum leptin strongly correlated with seminal leptin in the cohort, control and MetS 
groups. Seminal leptin further correlated with seminal insulin in the cohort, but not he 
CG or MetS groups.  
 
Legend for Table’s 21, 22 and 23:  NS = not significant.  TNFα = tumour necrosis 
factor-alpha; IL1β = Interleukin 1-beta; IL6 = interleukin 6; IL8=interleukin 8.
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Table 21: Seminal and serum cytokine and seminal insulin and glucose correlations for the cohort.  
 
 
 
Serum 
TNFα 
Seminal 
TNFα 
Serum 
IL1β 
Seminal 
IL1β 
Serum 
IL6 
Seminal 
IL6 
Serum 
IL8 
Seminal 
IL8 
Serum 
Leptin 
Seminal 
Leptin 
Seminal 
Insulin 
Seminal 
glucose 
Age 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum  
TNFα 
r2= 
P= 
- 
0.561 
<0.0001 
0.611 
<0.0001 
0.251 
0.0424 
0.671 
<0.0001 
0.450 
0.0004 
0.615 
<0.0001 
0.456 
0.0016 
0.427 
0.0020 
0.777 
<0.0001 
0.661 
<0.0001 
-0.310 
0.0252 
Seminal 
TNFα 
r2= 
P= 
 - NS 
0.460 
0.0004 
NS 
0.456 
0.0007 
NS 
0.382 
0.0137 
NS NS NS NS 
Serum 
IL1β 
r2= 
P= 
  - 
0.028 
0.8494 
0.676 
<0.0001 
NS 
0.290 
0.0482 
0.516 
0.0007 
0.283 
0.0464 
0.682 
0.0009 
0.571 
0.0012 
NS 
Seminal 
IL1β 
r2= 
P= 
   - NS NS NS NS NS NS NS NS 
Serum 
IL6 
r2= 
P= 
    - 
0.327 
0.0452 
0.374 
0.0416 
0.424 
0.0057 
0.360 
0.0406 
0.691 
0.0007 
0.563 
0.0012 
NS 
Seminal 
IL6 
r2= 
P= 
     - 
0.293 
0.0313 
0.503 
0.0003 
NS NS NS NS 
Serum 
IL8 
r2= 
P= 
      - NS NS NS 
0.463 
0.0034 
NS 
Seminal 
IL8 
r2= 
P= 
       - NS 
0.645 
0.0094 
NS NS 
Serum 
Leptin 
r2= 
P= 
        - 
0.7374 
0.0001 
NS NS 
Seminal 
Leptin 
r2= 
P= 
         - 
0.658 
0.0006 
NS 
Seminal 
Insulin 
r2= 
P= 
          - NS 
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Table 22: Seminal and serum cytokine and seminal insulin and glucose correlations for the control group.  
 
 
 
Serum 
TNFα 
Seminal 
TNFα 
Serum 
IL1β 
Seminal 
IL1β 
Serum 
IL6 
Seminal 
IL6 
Serum 
IL8 
Seminal 
IL8 
Serum 
Leptin 
Seminal 
Leptin 
Seminal 
Insulin 
Seminal 
glucose 
Age 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum  
TNFα 
r2= 
P= 
- 
0.567 
0.0016 
NS NS 
0.396 
0.0275 
0.522 
0.0036 
NS 
0.446 
0.0153 
0.480 
0.0113 
NS NS NS 
Seminal 
TNFα 
r2= 
P= 
 - NS NS NS NS NS 
0.427 
0.0296 
0.448 
0.0365 
NS NS NS 
Serum 
IL1β 
r2= 
P= 
  - NS NS NS NS NS NS NS NS NS 
Seminal 
IL1β 
r2= 
P= 
   - NS NS NS NS NS NS NS NS 
Serum 
IL6 
r2= 
P= 
    - NS NS NS NS NS NS NS 
Seminal 
IL6 
r2= 
P= 
     - NS 
0.485 
0.0103 
NS NS NS NS 
Serum 
IL8 
r2= 
P= 
      - NS NS NS NS NS 
Seminal 
IL8 
r2= 
P= 
       - NS NS NS NS 
Serum 
Leptin 
r2= 
P= 
        - 
0.775 
0.0143 
NS NS 
Seminal 
Leptin 
r2= 
P= 
         - NS NS 
Seminal 
Insulin 
r2= 
P= 
          - NS 
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Table 23: Seminal and serum cytokine and seminal insulin and glucose correlations for the MetS group.  
 
 
 
Serum 
TNFα 
Seminal 
TNFα 
Serum 
IL1β 
Seminal 
IL1β 
Serum 
IL6 
Seminal 
IL6 
Serum 
IL8 
Seminal 
IL8 
Serum 
Leptin 
Seminal 
Leptin 
Seminal 
Insulin 
Seminal 
glucose 
Age 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum  
TNFα 
r2= 
P= 
- 
0.443 
0.0300 
NS NS 
0.502 
0.0065 
0.418 
0.0269 
0.539 
0.0066 
NS 
0.559 
0.0056 
NS NS NS 
Seminal 
TNFα 
r2= 
P= 
 - NS 
0.445 
0.0256 
NS 
0.481 
0.0128 
NS 
0.427 
0.0268 
NS NS NS NS 
Serum 
IL1β 
r2= 
P= 
  - NS 
0.540 
0.0053 
NS NS 
0.599 
0.0183 
NS NS NS NS 
Seminal 
IL1β 
r2= 
P= 
   - NS NS NS NS NS NS NS NS 
Serum 
IL6 
r2= 
P= 
    - NS NS NS NS NS NS NS 
Seminal 
IL6 
r2= 
P= 
     - NS NS NS 
0.556 
0.0405 
NS NS 
Serum 
IL8 
r2= 
P= 
      - NS NS NS NS NS 
Seminal 
IL8 
r2= 
P= 
       - NS 
0.556 
0.0605 
NS NS 
Serum 
Leptin 
r2= 
P= 
        - 
0.443 
0.0244 
NS NS 
Seminal 
Leptin 
r2= 
P= 
         - NS NS 
Seminal 
Insulin 
r2= 
P= 
          - NS 
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3.8.4.  Clinical, biochemical and seminal parameters correlations 
 
There were no significant correlations between any of these parameters for the CG 
Table 25. This group will therefore not be further reported in under this sub-heading. 
Within the MetS group, there was a positive correlation between SC and HDL only. 
FBG negatively correlated with PM and TM within the MetS group. There were no 
other significant correlations within the MetS group (Table 26). This group will not 
further reported in under this sub-heading.  
 
Within the entire cohort, the following significant correlations were observed. These 
are tabulated in Table 24.  
 
BMI and WC correlated negatively with SC, TSC, TM and vitality, and positively with 
MMP and DF. There was no BMI correlation with EV, PM and morphology. There 
was no correlation with sBP and any seminal parameters. dBP correlated negatively 
with SC, TM and vitality only. HDL and TG did not correlate with any semen 
parameters (as reported above, HDL correlated positively with SC in the MetS group 
only). FBG correlated negatively with PM, TM (as well as in the MetS group) and 
vitality, and negatively with DF.  
 
FBI correlated negatively with EV, SC, TSC, PM, TM and vitality, and positively with 
MMP.  IR correlated positively with EV, SC, TSC, PM, TM and vitality, and negatively 
with MMP and DF. CRP correlated negatively with SC, TSC, PM, TM and vitality, 
and positively with MMP and DF. FT correlated positively with SC, TSC, PM, TM and 
vitality. FP did not correlate with any semen parameter assessed.    
 
Legend for Table’s 24, 25 and 26: NS = not significant.  BMI = body mass index; WC = 
waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
HDL = high density lipoprotein cholesterol; TG = triglycerides; FBG = fasting blood 
glucose; FBI = fasting blood insulin; IR = insulin resistance (based on QUICKI); CRP = 
highly sensitive C-reactive protein; FT = free testosterone; FP = free progesterone; EV = 
ejaculation volume; SC = sperm concentration; TSC = total sperm count; PM = 
progressive motility; TM = total motility; Morph = morphology; MMP = mitochondrial 
membrane potential; DF = DNA fragmentation. 
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Table 24: Clinical, biochemical and seminal parameters correlations for the cohort.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
EV 
r2= 
P= 
NS NS NS NS NS NS NS 
-0.239 
0.0372 
0.263 
0.0215 
NS NS NS 
SC 
r2= 
P= 
-0.385 
0.0008 
-0.372 
0.0013 
NS 
-0.295 
0.0120 
NS NS NS 
-0.368 
0.0015 
0.384 
0.0009 
-0.319 
0.0063 
0.310 
0.0142 
NS 
TSC 
r2= 
P= 
-0.352 
0.0024 
-0.367 
0.0015 
NS NS NS NS NS 
-0.362 
0.0018 
0.377 
0.0011 
-0.283 
0.0160 
0.317 
0.0120 
NS 
PM 
r2= 
P= 
NS NS NS NS NS NS 
-0.318 
0.0066 
-0.310 
0.0355 
0.234 
0.0484 
-0.240 
0.0420 
0.309 
0.0147 
NS 
TM 
r2= 
P= 
-0.275 
0.0195 
-0.344 
0.0031 
NS 
-0.267 
0.0232 
NS NS 
-0.330 
0.0047 
-0.390 
0.0392 
0.308 
0.0085 
-0.236 
0.0463 
0.288 
0.0231 
NS 
Vitality 
r2= 
P= 
-0.381 
0.0010 
-0.452 
0.0001 
NS 
-0.262 
0.0262 
NS NS 
-0.321 
0.0060 
-0.245 
0.0383 
0.385 
0.0009 
-0.299 
0.0106 
0.255 
0.0458 
NS 
Morph 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
MMP 
r2= 
P= 
0.336 
0.0063 
0.386 
0.0015 
NS NS NS NS NS 
0.290 
0.0190 
-0.340 
0.0057 
0.354 
0.0038 
NS NS 
DF 
r2= 
P= 
0.306 
0.0231 
0.368 
0.0057 
NS NS NS NS 
0.300 
0.0258 
NS 
-0.339 
0.0114 
0.262 
0.0432 
NS NS 
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Table 25: Clinical, biochemical and seminal parameters correlations for the control group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
EV 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
SC 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
TSC 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
PM 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
TM 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Vitality 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Morph 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
MMP 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
DF 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
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Table 26: Clinical, biochemical and seminal parameters correlations for the MetS group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
EV 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
SC 
r2= 
P= 
NS NS NS NS 
0.471 
0.0065 
NS NS NS NS NS NS NS 
TSC 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
PM 
r2= 
P= 
NS NS NS NS NS NS 
-0.359 
0.0464 
NS NS NS NS NS 
TM 
r2= 
P= 
NS NS NS NS NS NS 
-0.361 
0.0422 
NS NS NS NS NS 
Vitality 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Morph 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
MMP 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
DF 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
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3.8.5. Clinical, biochemical, cytokine, insulin and glucose correlations 
 
Correlation details for the clinical and biochemical variables are summarised in 
Table’s 27, 28 and 27. 
 
BMI and WC correlated with all serum and seminal cytokines except serum IL8, as 
well as serum and seminal leptin and serum insulin in the cohort. Only the correlation 
between BMI and WC was observed in the CG, and none of these correlations 
observed in the MetS group.  
 
Systolic and diastolic blood pressure correlated with serum TNFα, IL1β, IL6 and IL8, 
and seminal insulin, in the cohort only.  
 
HDL negatively correlated with serum TNFα, IL1β and IL6, and seminal TNFα and 
insulin in the cohort only.  
 
TG correlated positively with serum TNFα and IL1β, and seminal insulin in the cohort 
only. TG correlated negatively with seminal glucose in the cohort. 
 
Fasting blood glucose correlated negatively with seminal glucose in the cohort, but 
no in the CG or MetS groups. Blood glucose further correlated positively with serum 
and seminal TNFα in the cohort and MetS groups, and serum IL1β in the cohort only.  
 
Serum insulin (FBI) correlated very strongly with seminal insulin and negatively with 
QUICKI in the cohort, CG and MetS groups. Serum insulin and QUICKI further 
correlated with seminal glucose negatively and positively respectively in the cohort, 
but not the Cg and MetS group.  
 
Serum insulin and QUICKI correlated negatively with each other. Both these 
parameters further correlated positively and negatively respectively with serum 
TNFα, IL1β, IL6, IL8 and leptin, and seminal IL8 and leptin in the cohort, but not the 
CG or MetS groups.  
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hs-CRP correlated strongly and positively  with serum and seminal TNFα, IL1β, IL6, 
IL8 and leptin in the cohort, in addition to seminal insulin. There was a negatively 
correlation with hs-CRP and seminal glucose in the cohort. These correlations were 
not observed in the CG or MetS group.  
 
FT correlated with serum TNFα, IL1β and IL6 and seminal IL8 in the cohort. FT also 
correlated negatively with serum seminal IL8 in the MetS group. FP negatively 
correlated with serum and seminal TNFα in the cohort, serum and seminal IL1β in 
the CG, serum TNFα and seminal IL6 in the MetS group.  
 
Legend for Table’s 27, 8 and 29:  NS = not significant.  BMI = body mass index; WC = 
waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
HDL = high density lipoprotein cholesterol; TG = triglycerides; FBG = fasting blood 
glucose; FBI = fasting blood insulin; IR = insulin resistance (based on QUICKI); CRP = 
highly sensitive C-reactive protein; FT = free testosterone; FP = free progesterone; 
TNFα = tumour necrosis factor-alpha; IL1β = Interleukin 1-beta; IL6 = interleukin 6; 
IL8=interleukin 8.  
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Table 27: Clinical, biochemical, cytokine and seminal insulin and glucose correlations for the cohort.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Serum  
TNFα 
r2= 
P= 
0.579 
<0.0001 
0.619 
<0.0001 
0.317 
0.0102 
0.387 
0.0015 
-0.441 
0.0002 
0.302 
0.0144 
0.446 
0.0002 
0.539 
<0.0001 
-0.579 
<0.0001 
0.653 
<0.0001 
-0.284 
0.0264 
-0.330 
0.0095 
Seminal 
TNFα 
r2= 
P= 
0.371 
0.0042 
0.376 
0.0037 
NS NS 
-0.303 
0.0209 
NS 
0.385 
0.0028 
NS NS 
0.331 
0.0112 
NS 
-0.292 
0.0305 
Serum 
IL1β 
r2= 
P= 
0.411 
0.0015 
0.462 
0.0003 
0.297 
0.0249 
0.371 
0.0045 
-0.259 
0.0485 
0.270 
0.0426 
0.410 
0.0015 
0.327 
0.0131 
-0.377 
0.0038 
0.506 
0.0001 
-0.272 
0.0407 
NS 
Seminal 
IL1β 
r2= 
P= 
0.293 
0.0219 
0.303 
0.0177 
NS NS NS NS NS NS NS 
0.504 
<0.0001 
NS NS 
Serum 
IL6 
r2= 
P= 
0.378 
0.0031 
0.405 
0.0015 
0.264 
0.0437 
0.339 
0.0087 
-0.255 
0.0490 
NS NS 
0.315 
0.0150 
-0.304 
0.0191 
0.328 
0.0112 
-0.264 
0.0450 
NS 
Seminal 
IL6 
r2= 
P= 
0.269 
0.0314 
0.275 
0.0277 
NS NS NS NS NS NS NS 
0.406 
0.0025 
NS NS 
Serum 
IL8 
r2= 
P= 
NS NS 
0.375 
0.0032 
0.332 
0.0097 
NS NS NS 
0.253 
0.0490 
-0.290 
0.0247 
0.429 
0.0006 
NS NS 
Seminal 
IL8 
r2= 
P= 
0.358 
0.0086 
0.374 
0.0058 
NS NS NS NS NS 
0.283 
0.0401 
-0.287 
0.0372 
0.415 
0.0020 
-0.304 
0.0425 
NS 
Serum 
Leptin 
r2= 
P= 
0.362 
0.0357 
0.372 
0.0368 
NS NS NS NS NS 
0.423 
0.023 
-0.403 
0.0223 
0.523 
0.0053 
NS NS 
Seminal 
Leptin 
r2= 
P= 
0.581 
0.0036 
0.563 
0.0052 
NS NS NS NS NS 
0.525 
0.01 
-0.522 
0.0107 
0.723 
0.0001 
NS NS 
Seminal 
Insulin 
r2= 
P= 
0.651 
<0.0001 
0.564 
0.0001 
0.336 
0.0294 
0.334 
0.0306 
-0.436 
0.0039 
0.341 
0.0271 
NS 
0.832 
<0.0001 
-0.770 
<0.0001 
0.515 
0.0005 
NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS NS NS 
-0.279 
0.0297 
-0.271 
0.0344 
-0.265 
0.0394 
0.351 
0.0056 
-0.240 
0.0627 
NS NS 
 
 
 
 
119 
 
Table 28: Clinical, biochemical, cytokine and seminal insulin and glucose correlations for the control group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Serum  
TNFα 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
TNFα 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS 
0.405 
0.0217 
Seminal 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS 
0.332 
0.0438 
Serum 
IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum 
IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
Insulin 
r2= 
P= 
0.559 
0.0104 
0.364 
0.0403 
NS NS NS NS NS 
0.697 
0.0006 
-0.662 
0.0015 
NS NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
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Table 29: Clinical, biochemical, cytokine and seminal insulin and glucose correlations for the MetS group.  
 
 
 BMI WC SBP DBP HDL TG FBG FBI IR CRP FT FP 
Serum  
TNFα 
r2= 
P= 
NS NS NS NS NS NS 
0.414 
0.0254 
NS NS NS NS 
-0.386 
0.0426 
Seminal 
TNFα 
r2= 
P= 
NS NS NS NS NS NS 
0.402 
0.0419 
NS NS NS NS NS 
Serum 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Serum 
IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS 
-0.490 
0.0070 
Serum 
IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS 
-0.565 
0.0146 
NS 
Serum 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
Seminal 
Insulin 
r2= 
P= 
NS NS NS NS NS NS NS 
0.695 
0.0003 
-0.581 
0.0046 
NS NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS NS NS NS NS NS NS NS NS NS 
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3.8.6. Seminal, cytokine and seminal insulin and glucose correlations  
 
Correlation details for the clinical and biochemical variables are summarised in 
Table’s 30, 31 and 32. 
 
Serum and seminal TNFα correlated negatively with sperm concentration and total 
sperm count, but not ejaculation volume, in the cohort. These cytokines further 
negatively correlated with total motility (but not progressive motility), vitality and 
normal sperm morphology, and positively with DF, in the cohort. These correlations 
were not observed in the CG. In the MetS group, serum TNFα correlated negatively 
with total motility, and both serum and seminal TNFα correlated positively with DF in 
this group. Similarly, serum and seminal leptin correlated negatively with sperm 
concentration, total sperm count, progressive and total motility and abnormal sperm 
morphology, in addition to a positive correlation with DF in the cohort only.  
 
Serum IL1β correlated negatively with sperm concentration in the cohort only. Serum 
and seminal IL1β correlated negatively with normal sperm morphology in the MetS 
group only. Serum and seminal IL6 correlated negatively with normal sperm 
morpgology and positively with DF, and seminal IL6 correlated negatively with sperm 
concentration in the cohort. These correlations were not observed in the CG or MetS 
groups. Serum and seminal IL8 did not correlate with any sperm parameters in any 
group.  
 
Seminal insulin correlated negatively with sperm concentration in the cohort only, 
and progressive and total motility in the cohort, CG and MetS groups. Seminal 
glucose correlated negatively with progressive and total motility and positively with 
abnormal MMP in the MetS group only.  
 
Legend for Table’s 30, 31 and 32:  NS = not significant.  EV = ejaculation volume; 
SC = semen concentration; TSC = total sperm count; PM = progressive motility; TM 
= total motility; Morph = morphology; MMP = mitochondrial membrane potential; DF 
= DNA fragmentation; TNFα = tumour necrosis factor-alpha; IL1β = Interleukin 1-
beta; IL6 = interleukin 6; IL8=interleukin 8.  
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Table 30: Seminal, cytokine and seminal insulin and glucose correlations for the cohort.  
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Serum 
TNFα 
r2= 
P= 
NS 
-0.422 
0.0007 
-0.304 
0.0173 
NS 
-0.317 
0.0128 
-0.379 
0.0026 
-0.295 
0.0211 
NS 
0.603 
<0.0001 
Seminal 
TNFα 
r2= 
P= 
NS 
-0.402 
0.0163 
-0.302 
0.0263 
NS 
-0.378 
0.0048 
-0.374 
0.0054 
-0.333 
0.0399 
NS 
0.330 
0.0353 
Serum IL1β 
r2= 
P= 
NS 
-0.286 
0.0381 
NS NS NS NS NS NS NS 
Seminal 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum IL6 
r2= 
P= 
NS NS NS NS NS NS 
-0.281 
0.0376 
NS 
0.382 
0.0149 
Seminal IL6 
r2= 
P= 
NS 
-0.353 
0.0415 
NS NS NS NS 
-0.277 
0.0321 
NS 
0.336 
0.0209 
Serum IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum 
Leptin 
r2= 
P= 
NS 
-0.327 
0.0206 
-0.354 
0.0454 
-0.312 
0.0325 
-0.345 
0.0398 
NS 
-0.337 
0.0167 
NS 
0.333 
0.0470 
Seminal 
Leptin 
r2= 
P= 
NS 
-0.241 
0.0443 
-0.307 
0.0418 
-0.341 
0.0398 
-0.307 
0.0325 
NS 
-0.254 
0.0397 
NS 
0.368 
0.0488 
Seminal 
Insulin 
r2= 
P= 
NS 
-0.372 
0.0216 
NS 
-0.239 
0.0457 
-0.379 
0.0374 
NS NS NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
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Table 31: Seminal, cytokine and seminal insulin and glucose correlations for the control group.  
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Serum 
TNFα 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
TNFα 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
IL1β 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
Insulin 
r2= 
P= 
NS NS NS 
-0.430 
0.0352 
-0.393 
0.3479 
NS NS NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
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Table 32: Seminal, cytokine and seminal insulin and glucose correlations for the MetS group.  
 
 
 EV SC TSC PM TM Vitality Morph MMP DF 
Serum 
TNFα 
r2= 
P= 
NS NS NS NS 
-0.435 
0.0337 
NS NS NS 
0.677 
0.0005 
Seminal 
TNFα 
r2= 
P= 
NS NS NS NS NS NS NS NS 
0.291 
0.0491 
Serum IL1β 
r2= 
P= 
NS NS NS NS NS NS 
-0.400 
0.0483 
NS NS 
Seminal 
IL1β 
r2= 
P= 
NS NS NS NS NS NS 
-0.385 
0.0473 
NS NS 
Serum IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal IL6 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal IL8 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Serum 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
Leptin 
r2= 
P= 
NS NS NS NS NS NS NS NS NS 
Seminal 
Insulin 
r2= 
P= 
NS NS NS 
0.449 
0.0405 
0.335 
0.0490 
NS NS NS NS 
Seminal 
glucose 
r2= 
P= 
NS NS NS 
-0.329 
0.0464 
-0.361 
0.0422 
NS NS 
0.445 
0.0138 
NS 
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3.9. Cell culture experiments 
 
3.9.1. Insulin  
 
TM3 cell viability was significantly increased for the 0.01 (P=0.0016), 0.1 (P=0.0288) 
and 1 pg/ml (P=0.0466) concentrations. There was no significant impact with the 10 
pg/ml concentration. The ANOVA repeated measures analysis of variance was not 
significant (P=0.802). Nevertheless, the one-way analysis of variance did reach 
statistical significance (P=0.022). Results are shown in Figure 16. Protein 
concentrations were significantly increased for 0.1 (P=0.0003), 1 (P=0.0279) and 10 
(P<0.0001) pg/ml concentrations, but not 0.01 pg/ml concentrations. The ANOVA 
repeated measures analysis of variance was statistically significant (P=0.0033), as 
was the one-way analysis of variance (P<0.001).  Results are shown in Figure 17. 
Testosterone was significantly increased for 0.01 (P=0.0002), 0.1 (P<0.0001), 1 
(P=0.0104) and 10 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was statistically significant (P=0.0154), as was the 
one-way analysis of variance (P<0.001).  Results are shown in Figure 18. The 
testosterone-to-protein ratio was significantly increased for 0.01 (P=0.0005) pg/ml 
concentration, but not for 0.1 (P=0.111), 1 (P=0.0557) and 10 (P=0.2535) pg/ml 
concentrations. The ANOVA repeated measures analysis of variance was not 
significant (P=0.1925). The ANOVA one-way analysis of variance was significant 
(P<0.001).  Results are shown in Figure 19. Progesterone concentrations were 
significantly decreased for 0.01 (P<0.0001), 0.1 (P<0.0001), 1 (P<0.0001) and 10 
(P<0.0001) pg/ml concentrations. The ANOVA repeated measures analysis of 
variance was statistically significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).  Results are shown in Figure 20. The progesterone-to-protein 
ratio was significantly decreased for the 0.01 (P=0.0245), 0.1 (P<0.0001), 1 
(P=0.0006) and 10 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was statistically significant (P=0.0002). The ANOVA 
one-way analysis of variance was significant (P<0.001).  Results are shown in Figure 
21.  
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Figure 16: Cell viability results for TM3 cell exposure to various insulin 
concentrations. Cell viability was significantly increased for the 0.01, 0.1 and 1 pg/ml 
concentrations. ANOVA repeated measures analysis of variance was not significant 
(P=0.802). The one-way analysis of variance did reach significance (P=0.022).   
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Figure 17: Protein concentration results for TM3 cell exposure to various insulin 
concentrations. Protein concentrations were significantly increased for 0.1, 1 and 10 
pg/ml concentrations, but not 0.01 ng/ml concentrations. ANOVA repeated measures 
analysis of variance was significant (P=0.0033), as was the one-way analysis of 
variance (P<0.001).   
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Figure 18: Testosterone concentration results for TM3 cell exposure to various 
insulin concentrations. Testosterone concentrations were significantly increased for 
all concentrations. ANOVA repeated measures analysis of variance was significant 
(P=0.0154), as was the one-way analysis of variance (P<0.001).   
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Figure 19: Testosterone-to-protein ratio results for TM3 cell exposure to various 
insulin concentrations. The ratio was significantly increased for 0.01pg/ml 
concentration, but not for 0.1, 1 and 10 pg/ml concentrations. ANOVA repeated 
measures analysis of variance was not significant (P=0.1925). The ANOVA one-way 
analysis of variance was significant (P<0.001).   
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Figure 20: Progesterone concentration results for TM3 cell exposure to various 
insulin concentrations. Progesterone concentrations were significantly decreased for 
all concentrations. ANOVA repeated measures analysis of variance was statistically 
significant (P<0.0001), as was the one-way analysis of variance (P<0.001).   
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Figure 21: Progesterone-to-protein ratio results for TM3 cell exposure to various 
insulin concentrations. The ratio was significantly decreased for all concentrations. 
ANOVA repeated measures analysis of variance was significant (P=0.0002), as was 
the ANOVA one-way analysis of variance was significant (P<0.001).   
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3.9.2. Tumour necrosis factor-alpha 
 
TM3 cell viability was significantly decreased for the 0.1 (P=0.0359), 1 (P=0.0145), 
10 (P<0.0001) and 100 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was significant (P<0.0001), as was the one-way 
analysis of variance (P<0.001).  Results are shown in Figure 22. Protein 
concentrations were significantly decreased for all concentrations. The ANOVA 
repeated measures analysis of variance was statistically significant (P<0.0001), as 
was the one-way analysis of variance (P<0.001).  Protein concentrations were 
significantly decreased the 0.1 (P<0.0001), 1 (P<0.0001), 10 (P<0.0001) and 100 
(P<0.0001) pg/ml concentrations. The ANOVA repeated measures analysis of 
variance was statistically significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).  Results are shown in Figure 23. Testosterone concentrations 
were significantly decreased for the 0.1 (P<0.0001), 1 (P<0.0001), 10 (P<0.0001) 
and 100 (P<0.0001) pg/ml concentrations. The ANOVA repeated measures analysis 
of variance was statistically significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).  Results are shown in Figure 24. The testosterone-to-protein 
ratio was significantly increased for the 0.1 (P=0.0215) concentration, and 
significantly decreased for the 10 (P=0.0393) and 100 (P<0.0001) pg/ml 
concentrations. The 1 pg/ml concentration was decreased, but this did not reach 
statistical significance (P=0.0648). The ANOVA repeated measures analysis of 
variance was statistically significant (P<0.0001), as was the ANOVA one-way 
analysis of variance (P<0.001).  Results are shown in Figure 25. Progesterone 
concentrations were significantly decreased for the 0.1 (P<0.0001), 1 (P<0.0001), 10 
(P<0.0001) and 100 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was statistically significant (P<0.0001), as was the 
one-way analysis of variance (P<0.001).  Results are shown in Figure 26. The 
progesterone-to-protein ratio was significantly increased for 0.1 (P=0.0036) pg/ml 
concentration and significantly decreased for the 100 pg/ml concentration 
(P=0.0054).  There was no significant change for the 1 (P=0.3272) and 10 
(P=0.6593) pg/ml concentrations. The ANOVA repeated measures analysis of 
variance was not statistically significant (P=0.1797). The ANOVA one-way analysis 
of variance was significant (P<0.001).  Results are shown in Figure 27. 
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Figure 22: Cell viability results for TM3 cell exposure to various tumour necrosis 
factor-alpha (TNFα) concentrations. Cell viability was significantly decreased for all 
concentrations. ANOVA repeated measures analysis of variance was significant 
(P<0.0001), as was the one-way analysis of variance (P<0.001).   
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Figure 23: Protein concentration results for TM3 cell exposure to various tumour 
necrosis factor-alpha (TNFα) concentrations. Protein concentrations were 
significantly decreased for all concentrations. The ANOVA repeated measures 
analysis of variance was significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).   
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Figure 24: Testosterone concentration results for TM3 cell exposure to various 
tumour necrosis factor-alpha (TNFα) concentrations. Testosterone concentrations 
were significantly decreased for all concentrations. ANOVA repeated measures 
analysis of variance was significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).   
 
 
 
 
 
 
 
  
0
400
800
1200 
1600 
200
600
1000 
1400 
1800 
0 0.1 1 10 100 
TNFα (pg/ml) 
P<0.0001 
Te
st
o
st
e
ro
n
e
 
Co
n
ce
n
tra
tio
n
 
(pg
/m
l) 
P<0.0001
 
P<0.0001 
P<0.0001 
 
 
 
 
136 
 
 
 
 
 
 
Figure 25: Testosterone-to-protein ratio results for TM3 cell exposure to various 
tumour necrosis factor-alpha (TNFα) concentrations. The ratio was significantly 
increased for 0.1 concentrations, and significantly decreased for the 10 and 100 
pg/ml concentrations. The 1 pg/ml concentration was decreased, but this was not 
significant. ANOVA repeated measures analysis of variance was significant 
(P<0.0001), as was the ANOVA one-way analysis of variance (P<0.001).   
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Figure 26: Progesterone concentration results for TM3 cell exposure to various 
tumour necrosis factor-alpha (TNFα) concentrations. Progesterone concentrations 
were significantly decreased for all concentrations. ANOVA repeated measures 
analysis of variance was significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).   
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Figure 28: Progesterone-to-protein ratio results for TM3 cell exposure to various 
tumour necrosis factor-alpha (TNFα) concentrations. The ratio was significantly 
increased for 0.1 pg/ml concentration and significantly decreased for the 100 pg/ml 
concentration, but no significant change for the 1 and 10 pg/ml concentrations. 
ANOVA repeated measures analysis of variance was not significant (P=0.1797). 
However, ANOVA one-way analysis of variance was significant (P<0.001).   
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3.9.3. Interleukin 1-beta 
 
TM3 cell viability was significantly decreased for the 0.1 (P=0.0001), 1 (P<0.0001), 
10 (P<0.0001) and 100 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was significant (P<0.0001), as was the one-way 
analysis of variance (P<0.001).  Results are shown in Figure 29. Protein 
concentrations were significantly decreased for the 0.1 (P<0.0001), 1 (P<0.0001), 10 
(P<0.0001) and 100 (P<0.0001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was significant (P<0.0001), as was the one-way 
analysis of variance (P<0.001).  Results are shown in Figure 30. Testosterone 
concentrations were significantly decreased for the 0.1 (P=0.0001), 1 (P=0.0013), 10 
(P<0.0001) and 100 (P=0.001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was not statistically significant (P=0.1589), nor was 
the ANOVA one-way analysis of variance (P=0.256).  Results are shown in Figure 
31.The testosterone-to-protein ratio was not significantly different for the 0.1 
(P=0.6457) and 1 (P=0.1046) pg/ml concentrations, and significantly increased for 
the 10 (P<0.0001) and 100 (P=0.001) pg/ml concentrations. The ANOVA repeated 
measures analysis of variance was not statistically significant (P=0.093). The 
ANOVA one-way analysis of variance was statistically significant (P<0.001).  Results 
are shown in Figure 32. Progesterone concentrations were significantly decreased 
for the 0.1 (P<0.0001), 1 (P<0.0001), 10 (P<0.0001) and 100 (P<0.0001) pg/ml 
concentrations. The ANOVA repeated measures analysis of variance was significant 
(P<0.0001), as was the one-way analysis of variance (P<0.001).  Results are shown 
in Figure 33. The progesterone-to-protein ratio was significantly decreased for the 
0.1 (P=0.0001), 1 (P=0.0001), 10 (P=0.0039) and 100 (P=0.0003) pg/ml 
concentrations.  The ANOVA repeated measures analysis of variance was not 
statistically significant (P=0.0694). The ANOVA one-way analysis of variance was 
significant (P<0.001).  Results are shown in Figure 34. 
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Figure 29: Cell viability results for TM3 cell exposure to various interleukin 1-beta 
(IL1β) concentrations. Cell viability was significantly decreased for all concentrations. 
ANOVA repeated measures analysis of variance was significant (P<0.0001), as was 
the one-way analysis of variance (P<0.001).   
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Figure 30: Protein concentration results for TM3 cell exposure to various interleukin 
1-beta (IL1β) concentrations. Protein concentrations were significantly decreased for 
all concentrations. ANOVA repeated measures analysis of variance was significant 
(P<0.0001), as was the one-way analysis of variance (P<0.001).   
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Figure 31: Testosterone concentration results for TM3 cell exposure to various 
interleukin 1-beta (IL1β) concentrations. Testosterone concentrations were 
significantly decreased for all concentrations. ANOVA repeated measures analysis of 
variance was not significant (P=0.1589), nor was the ANOVA one-way analysis of 
variance (P=0.256).   
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Figure 32: Testosterone-to-protein ratio results for TM3 cell exposure to various 
interleukin 1-beta (IL1β) concentrations. The ratio not was significantly different for 
0.1 and 1 pg/ml concentrations, and significantly increased for the 10 and 100 pg/ml 
concentrations. ANOVA repeated measures analysis of variance was not significant 
(P=0.093). ANOVA one-way analysis of variance was significant (P<0.001).   
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Figure 33: Progesterone concentration results for TM3 cel exposure to various 
interleukin 1-beta (IL1β) concentrations. Progesterone concentrations were 
significantly decreased for all concentrations. ANOVA repeated measures analysis of 
variance was significant (P<0.0001), as was the one-way analysis of variance 
(P<0.001).   
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Figure 34: Progesterone-to-protein ratio results for TM3 cell exposure to various 
interleukin 8 (IL8) concentrations. The ratio was significantly decreased for all 
concentrations. ANOVA repeated measures analysis of variance was not significant 
(P=0.0694). ANOVA one-way analysis of variance was significant (P<0.001).   
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3.9.4. Interleukin 6 
 
TM3 cell viability was significantly decreased for the 0.1 (P=0.0001), 1 (P<0.0001), 
10 (P<0.0001) and 100 (P<0.0001) concentrations. The ANOVA repeated measures 
analysis of variance was significant (P<0.0001), as was the one-way analysis of 
variance (P<0.001).  Results are shown in Figure 35. Protein concentrations were 
not significantly different for the 0.1 (P=0.4284), 1 (P=0.9094) and 10 (P=0.6738) 
pg/ml concentrations, but were significantly decreased (P=0.0414) for the 100 pg/ml 
concentrations. The ANOVA repeated measures analysis of variance was not 
statistically significant (P=0.1039). The one-way analysis of variance was 
significantly different (P<0.001). Results are shown in Figure 36. Testosterone 
concentrations were significantly decreased for the 0.1 (P=0.0031), 1 (P=0.0025), 10 
(P=0.0134) and 100 (P=0.0003) concentrations. The ANOVA repeated measures 
analysis of variance was statistically significant (P<0.0001), as was the one-way 
analysis of variance (P=0.009).  Results are shown in Figure 37. The testosterone-
to-protein ratio not was significantly different for the 0.1 (P=0.8893), 1 (P=0.3134), 10 
(P=0.8799) and 100 (P=0.9587) concentrations. The ANOVA repeated measures 
analysis of variance was not statistically significant (P=0.7268). The ANOVA one-
way analysis of variance was statistically significant (P<0.001).  Results are shown in 
Figure 38. Progesterone concentrations were significantly decreased for the 0.1 
(P<0.0001), 1 (P<0.0001), 10 (P<0.0001) and 100 (P<0.0001) concentrations. The 
ANOVA repeated measures analysis of variance was significant (P<0.0001), as was 
the one-way analysis of variance (P<0.001).  Results are shown in Figure 39. The 
progesterone-to-protein ratio was significantly decreased for the 0.1 (P<0.0001), 1 
(P<0.0001), 10 (P<0.0001) and 100 (P<0.0001) concentrations. The ANOVA 
repeated measures analysis of variance was statistically significant (P=0.003), as 
was the ANOVA one-way analysis of variance was significant (P<0.001).  Results 
are shown in Figure 40. 
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Figure 35: Cell viability results for TM3 cell exposure to various interleukin 6 (IL6) 
concentrations. Cell viability was significantly decreased for all concentrations. 
ANOVA repeated measures analysis of variance was significant (P<0.0001), as was 
the one-way analysis of variance (P<0.001).   
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Figure 36: Protein concentration results for TM3 cell exposure to various interleukin 
6 (IL6) concentrations. Protein concentrations were not significantly different for 0.1, 
1 and 10 pg/ml concentrations, but were significantly decreased for the 100 pg/ml 
concentrations. ANOVA repeated measures analysis of variance was not significant 
(P=0.1039). ANOVA one-way analysis of variance was significantly different 
(P<0.001).   
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Figure 37: Testosterone concentration results for TM3 cell exposure to various 
interleukin 6 (IL6) concentrations. Testosterone concentrations were significantly 
decreased for all concentrations. ANOVA repeated measures analysis of variance 
was significant (P<0.0001), as was the one-way analysis of variance (P=0.009).   
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Figure 38: Testosterone-to-protein ratio results for TM3 cell exposure to various 
interleukin 6 (IL6) concentrations. The ratio not was significantly different for all 
concentrations. ANOVA repeated measures analysis of variance was not statistically 
significant (P=0.7268). ANOVA one-way analysis of variance was statistically 
significant (P<0.001).   
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Figure 39: Progesterone concentration results for TM3 cell exposure to various 
interleukin 6 (IL6) concentrations. Progesterone concentrations were significantly 
decreased for all concentrations. ANOVA repeated measures analysis of variance 
was significant (P<0.0001), as was the one-way analysis of variance (P<0.001).   
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Figure 40: Progesterone-to-protein ratio results for TM3 exposure to various 
interleukin 6 (IL6) concentrations. The ratio was significantly decreased for all 
concentrations. ANOVA repeated measures analysis of variance was significant 
(P=0.003), as was the ANOVA one-way analysis of variance was significant 
(P<0.001).   
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3.9.5. Interleukin 8 
 
TM3 cell viability was significantly increased for the 0.1 (P=0.0016), 1 (P=0.0359), 
10, (P<0.0001) and 100 (P<0.0001) concentrations. The ANOVA repeated measures 
analysis of variance was significant (P=0.0014), as did the one-way analysis of 
variance (P=0.004).  Results are shown in Figure 41. Protein concentrations were 
significantly (P=0.0037) decreased for 10 pg/ml and significantly (P=0.0037) 
increased for 100 pg/ml, with no significant difference for the 0.1 (P=0.1249) and 1 
(P=0.6556) pg/ml concentrations. The ANOVA repeated measures analysis of 
variance was not statistically significant (P=0.1048). The ANOVA one-way analysis 
of variance did reach statistical significance (P<0.001).  Results are shown in Figure 
42. Testosterone concentrations were not significantly affected for the 0.1 
(P=0.0958), 1 (P=0.6763), 10 (P=0.6314) and 100 (P=0.5334) concentrations The 
ANOVA repeated measures analysis of variance was not statistically significant 
(P=0.0524), nor was the ANOVA one-way analysis of variance (P=0.187).  Results 
are shown in Figure 43. The testosterone-to-protein ratio was significantly increased 
for the 0.1 (P<0.0001) and 10 (P=0.0099) pg/ml concentrations, but the 1 (P=0.3593) 
and 100 (P=0.2690) pg/ml concentrations did not reach significance. The ANOVA 
repeated measures analysis of variance was not statistically significant (P=0.1895). 
The ANOVA one-way analysis of variance was significant (P<0.001). Results are 
shown in Figure 44. Progesterone concentrations were significantly decreased for 
the 0.1 (P=0.0007), 1 (P=0.0074), 10, (P=0.0022) and 100 (P=0.0076) 
concentrations. The ANOVA repeated measures analysis of variance was 
statistically significant (P=0.0024), as was the one-way analysis of variance 
(P<0.001).  Results are shown in Figure 45.The progesterone-to-protein ratio was 
significantly decreased for 0.1 (P=0.0492), 1 (P=0.019) and 100 (P=0.0059) pg/ml 
concentrations, but not for 10 pg/ml concentration (P=0.1295). The ANOVA repeated 
measures analysis of variance was statistically significant (P=0.0032). The ANOVA 
one-way analysis of variance was significant (P=0.004).  Results are shown in Figure 
46. 
 
    
 
  
 
 
 
 
154 
 
 
 
 
 
 
Figure 41: Cell viability results for TM3 cell exposure to various interleukin 8 (IL8) 
concentrations. Cell viability was significantly increased for all concentrations.  
ANOVA repeated measures analysis of variance was significant (P=0.0014), as was 
the one-way analysis of variance (P=0.004).   
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Figure 42: Protein concentration results for TM3 cell exposure to various interleukin 
8 (IL8) concentrations. Protein concentrations were significantly decreased for 10 
pg/ml and significantly increased for 100 pg/ml, with no significant difference for 0.1 
and 1 pg/ml concentrations. ANOVA repeated measures analysis of variance was 
not statistically significant (P=0.1048). ANOVA one-way analysis of variance did 
reach statistical significance (P<0.001).   
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Figure 43: Testosterone concentration results for TM3 cell exposure to various 
interleukin 8 (IL8) concentrations. Testosterone concentrations were not significantly 
affected for all concentrations. ANOVA repeated measures analysis of variance was 
not statistically significant (P=0.0524), nor was the ANOVA one-way analysis of 
variance (P=0.187).   
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Figure 44: Testosterone-to-protein ratio results for TM3 cell exposure to various 
interleukin 8 (IL8) concentrations. The ratio was significantly increased for 0.1 and 10 
pg/ml concentrations, but 1 and 100 pg/ml concentrations did not reach significance. 
ANOVA repeated measures analysis of variance was not statistically significant 
(P=0.1895). ANOVA one-way analysis of variance was significant (P<0.001).   
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Figure 45: Progesterone concentration results for TM3 cell exposure to various 
interleukin 8 (IL8) concentrations. Progesterone concentrations were significantly 
decreased for all concentrations. ANOVA repeated measures analysis of variance 
was significant (P=0.0024), as was the one-way analysis of variance (P<0.001).   
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Figure 46: Progesterone-to-protein ratio results for TM3 cell exposure to various 
interleukin 8 (IL8) concentrations. The ratio was significantly decreased for 0.1, 1 
and 100 pg/ml concentrations, but not for 10 pg/ml concentration. ANOVA repeated 
measures analysis of variance was statistically significant (P=0.0032). ANOVA one-
way analysis of variance was significant (P=0.004).   
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CHAPTER 4 – DISCUSSION 
 
4.1. Introduction  
 
The metabolic syndrome (MetS) is a poorly understood pathophysiological 
phenomenon, associated with complex metabolic, hormonal and immune 
dysfunction, resulting in various deleterious effects on patients such as 
cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) (Alberti et al., 
2009). The syndrome is characterised by abdominal obesity, hypertension, 
dyslipidaemia and poor glucose regulation (Eckel et al., 2005; Kasturi et al., 2008; 
Huang, 2009; Taslim & Tai, 2009).  Further phenomena associated with MetS and 
pertinent to this study include hyperinsulinaemia and insulin resistance, 
hyperleptinaemia and leptin resistance, a low grade, chronic, systemic inflammation 
and in males, hypogonadism (Eckel et al., 2005; Kasturi et al., 2008; Huang, 2009; 
Taslim & Tai, 2009). The impact of MetS on male fertility has not been previously 
evaluated in a case controlled epidemiological based study, and therefore remains 
relatively unknown. This study aimed to assess the impact of MetS on male fertility 
parameters, free testosterone and progesterone concentrations, serum and seminal 
inflammatory cytokines, insulin and leptin concentrations. In addition, a cell culture 
model has been used to further investigate the effect of insulin and inflammatory 
cytokines on testosterone and progesterone synthesis in the TM3 Leydig cell line. 
 
The results of this study, consisting of a cohort of males of reproductive age, have 
reinforced the known clinical and biochemical features of MetS. As expected, highly 
significant differences between the control group (CG) and and metabolic syndrome 
(MetS) group was found for BMI, abdominal adiposity (waist circumference), systolic 
and diastolic blood pressure, serum HDL cholesterol, serum triglycerides and serum 
glucose. Phenomena closely related to the pathophysiology of MetS was also found 
to be significantly different between the groups, specifically serum insulin 
concentrations and fasting blood insulin, insulin resistance (based on the QUICKI), 
serum CRP and free testosterone. The individual components of MetS also generally 
correlated with each other in the cohort, except for fasting blood glucose which 
showed no correlation with the other components of MetS. These are all well defined 
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aspects of MetS in the scientific literature, with the results of this study correlating 
with the extensive literature defining the syndrome.   
 
4.2. The metabolic syndrome and male fertility potential and sperm function 
 
Results show statistically significant differences in various sperm parameters 
analysed in males in the CG and those clinically diagnosed with MetS. This was in 
the absence of reproductive tract inflammation and leukocytospermia. Mean 
ejaculation volume and sperm concentration was significantly reduced in males with 
MetS, as was the total sperm count. It should be noted, however, that the mean 
sperm concentration in the MetS group was 26.7±15.8 million/ml, which is above the 
15 million/ml threshold are therefore considered normal according to parameters 
defined by WHO (2010). This is also seen with the total sperm count in the MetS 
group (median = 48.1 million spermatozoa in the ejaculate), which is above the 40 
million threshold outlined by WHO (2010). Patients in the MetS group also showed 
significantly reduced spermatozoa vitality, progressive motility and total motility. The 
mean values for vitality (50.0±23.2%) and progressive motility (20.0±17.1%) are both 
below the threshold levels set by WHO (2010) (58% and 32%, respectively), with the 
mean value for total motility (42.9±19.9%) above the suggested cut-off value of 40% 
(WHO, 2010) in the MetS group. The MetS group showed a decrease in percentage 
of spermatozoa with normal morphology, however, this did not reach statistical 
significance. Interestingly, both groups had a mean value of normal morphological 
forms below the WHO (2010) recommended threshold of 4%, with 3.9±3.17% in the 
CG and 2.72±2.38% in the MetS group, with both groups showing a wide variation in 
percentages (indicated by the large standard deviations). In terms of classic semen 
analysis parameters, males with MetS in this study have a reduced fertility potential 
compared to the CG.  
 
In addition to the total number of spermatozoa introduced to the female reproductive 
tract, and the ability of a large percentage of these cells to swim in a progressive 
manner towards the fallopian tubes, numerous additional characteristics of 
spermatozoa and the quality of seminal fluid are required to ensure a successful 
fertilisation with an oocyte (Aitken, 2006). These parameters include seminal 
fructose concentration (Said et al., 2009), oxidant-antioxidant balance (Henkel, 2005; 
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Henkel, 2011a), normal sperm head morphology (Menkveld et al., 2001), 
capacitation and acrosome reaction (Aitken, 2006), normal sperm mitochondrial 
membrane potential (MMP) (Paoli et al., 2011; Marchetti et al., 2012) and DNA 
integrity (Henkel et al., 2010; Lewis and Simon, 2010). The results of this study 
strongly suggest that males with MetS have significantly increased damage to 
mitochondrial function and spermatozoa DNA.  
 
Damage to the mitochondria is suggested to negatively affect oxidative 
phosphorylation, reducing ATP synthesis and thus energy availability for motility 
(Paoli et al., 2011; Marchetti et al., 2012). Percentage of sperm with abnormal 
mitochondrial membrane potential (MMP) was negatively correlated with vitality and 
total and progressive motility in the entire cohort, as well as the CG and MetS 
groups, supporting this well defined relationship.  Cut-off values for MMP are not well 
defined. Xia et al. (2008) identified 31 fertile control males to have a mean MMP of 
24.1%, with 32 infertile counterparts having a mean of 46%. Hu et al. (2009) found a 
mean MMP in a healthy male cohort to be 23.8%, with increased means in males 
with grade 1 (43.7%), grade 2 (55%) and grade 3 (68.4%) varicoceles. La Vignera et 
al. (2012c) found normal weight men to have a mean MMP of 5%, with overweight 
and obese males having a mean of 27% and 44%, respectively. In two separate 
publications, males with varicocele (La Vignera et al., 2012c) and male accessory 
gland infection (MAGI) (La Vignera et al., 2011) had a mean MMP of 28%. However, 
it has been suggested by Marchetti et al. (2012) that the percentage of sperm with 
abnormal (compromised) MMP should be less than 36%. The mean values of MMP 
in both the CG and MetS groups in this study were above that of these studies, with 
42.1±25.8% and 63.1±22.2%, respectively. Reasons for the higher values in both 
groups are not clear based on the data. It may be related to genetics, may be 
geographical, or possibly due to the methodology used in the study (DePsipher 
staining kit), as JC-1 methods were used in the above mentioned studies.  
 
Percentage of sperm with DNA fragmentation (DF) was also significantly increased 
in the MetS group. As with MMP, DF cut off values for risks are not well defined. 
Literature reports for healthy fertile males range from 7.5% - 25.7%. Values 
associated with poor fertility outcomes and various male reproductive disorders 
range from 14.8% - 64.9% (Evenson & Wixon, 2005; Fernández et al,. 2005; Enciso 
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et al,. 2006; Kort et al., 2006; Chavarro et al., 2010; Rybar et al., 2011; Venkatesh et 
al., 2011; Zini & Dohle, 2011). Recently, Simon et al. (2013) has suggested that DF 
should be less than 25%. The MetS group showed a mean percentage of 
spermatozoa DF above this suggested threshold (26.9 ± 19.7%), but not the CG. 
However, results indicate that MetS is associated with an increase in percentage of 
spermatozoa with DF, and thus potentially decreasing fertility potential in males.  
 
There are few publications in the literature which support the results of this study. 
Lotti and colleagues (2013a) associated MetS with poor sperm morphology and 
testes ultrasound inhomogeneity, in addition to hypogonadism, erectile dysfunction 
(ED) and depression and a significant decline in sexual and overall health. This 
study found no significant relationship between other sperm parameters. This may 
be explained by the fact that the cohort recruited by Lotti et al. (2013a) involved 
males already attending a fertility clinic due to a history of couple infertility (there was 
a mean duration of infertility of 1.9 years in the entire cohort), and were then placed 
into a MetS group or group without MetS. Of a cohort of 351 participants, only 27 
(7.7%) were in the MetS group. Furthermore, within the entire cohort, there was a 
mean sperm concentration of 13 million/ml and total sperm count of 36 million per 
ejaculate (both below WHO threshold), 14% were diagnosed with azoospermia (only 
33% were normospermic), a mean progressive motility of 36.5%, a mean of 5% 
normal morphological forms and 8.7% participants had leukocytospermia. Therefore, 
generally, the entire cohort had reduced semen parameters from the outset. The 
results of this study are taken from the general population, and not necessarily males 
with already established couple infertility.  
 
An interesting study by Ozturk and colleagues (2012) aimed to investigate the impact 
of MetS on varicocele surgery success. Of patients that underwent surgical vein 
ligation, they were retrospectively divided into two groups, those with and without 
MetS. Preoperatively, those with MetS had a mean sperm concentration of 
17.03±7.6 million/ml, mean motile spermatozoa of 16.3±6.6% and mean normal 
sperm morphological forms of 5.04±7.05%. There was no significant difference 
between the non-MetS group, with 18.01±1.88 million/ml, mean motile spermatozoa 
of 17.9±6.6% and mean normal sperm morphological forms of 7.01±7.05%. The lack 
of significant difference at baseline between the groups may be due to the diagnosis 
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of varicocele within all patients. Both groups had a significant improvement in all 
three parameters assessed following surgery. Interestingly, 3 months post-surgical 
treatment, the MetS group had a significantly decreased sperm concentration and 
motility compared to the non-MetS group, but no difference for normal morphological 
forms. The post-surgical MetS group showed a mean sperm concentration of 
30.1±4.7 million/ml, mean motile spermatozoa of 20.6±5.5% and mean normal 
sperm morphological forms of 10.5±4.21%. These are similar means for sperm 
concentration (26.7±15.8 million/ml) and progressive motility (20.0±17.1%) found in 
the MetS group of this study. As part of the conclusion, the authors stated that MetS 
may be an independent predictor for poor sperm parameters, and that patients with 
MetS and varicocele improved sperm parameters after surgery, but not as well as 
those without MetS. The number of patients was not reported, but the authors 
mentioned it as ‘low’. Furthermore, detailed sperm analyses according to WHO 
(2010) guidelines, as well as the criteria used to define MetS, are not provided in this 
study.   
 
According to the Laboratory Manual for the Examination and Processing of Human 
Semen 5th Edition (WHO, 2010), the semen parameters are important markers for 
fertility. However, it is difficult to assess fertility potential based on the semen 
parameters, particularly as these were a once off semen sample that have not been 
repeated. Lewis (2007) has described that only 16% of infertile men and 5% of fertile 
men have a poor semen analysis. Therefore, these results do not accurately reflect 
the fertility potential of the males in the cohort. However, a decrease in sperm 
concentration and motility are closely associated with a decrease in male fertility 
potential (Hammoud et al., 2008b). It is therefore clear that this data indicates the 
MetS is associated with a general decrease in sperm quantity and quality, potentially 
decreasing the chances of achieving a successful fertilisation and live birth.  
 
Although not a central component of this thesis, and caution should be expressed in 
the interpretation of this data, it is interesting to note that there is a significant 
increase in a clinical history of males with recent couple infertility in the MetS group. 
However, this does not include any potential female factor infertility, only male 
partners of couples with infertility as defined by the WHO (2010), and thus caution is 
required in the interpretation of this significance. Similarly, the CG had a significant 
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increase in males with a live birth within the last two years of the consultation date. 
These interesting statistics may indicate a reduced fertility potential in males with 
MetS, and certainly warrant that studies related to fertility rates and live births in 
couples in which the male partner has MetS be undertaken.  
 
Many semen parameters correlated with each other as expected. However, there 
was little significant correlation within the cohort between clinical and biochemical 
parameters associated with MetS and semen parameters. This was partially evident 
in very few correlations in the CG and MetS groups. Within the entire cohort, age 
correlated negatively with ejaculation volume, progressive and total motility and 
vitality and positively with DNA fragmentation.  
 
4.2.1. Semen parameters and body weight 
 
The effect of BMI and sperm parameters has been investigated in numerous studies. 
In a systemic review of the literature, over 10 000 articles, including duplicates, are 
reportedly available (Sermendade et al., 2013). However, the effect of BMI on sperm 
characteristics remains controversial (Sermendade et al., 2013). Within the cohort, 
BMI and waist circumference (reflecting abdominal obesity) correlated negatively 
with sperm concentration, total sperm count, total motility and vitality, and positively 
with MMP and DF. These correlations were not seen in the CG or MetS groups. 
These correlations are not always supported in the scientific literature.  
 
Hofny and colleagues (2009) negatively correlated BMI with sperm concentration 
and motility, but also with abnormal morphological forms, in male partners of couples 
attending a fertility clinic. In a similar cohort of males seeking fertility treatment, 
Hammound and colleagues (2008b) found an increasing incidence of oligospermia 
and reduced motility correlated to increasing BMI. Investigating normal weight, 
overweight and obese individuals, Fejes and colleagues (2006) reported a negative 
correlation with BMI and sperm concentration. Prior to this publication, Fejes and 
colleagues (2005) found that an increasing waist circumference (and hip 
circumference) negatively correlated with sperm concentration and motility in a 
cohort of male patients presenting with infertility. In Danish men recruited for the 
military, Jensen and colleagues (2004) found a negative correlation between sperm 
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count and concentration with BMI. These studies generally agree with the 
correlations between BMI, waist circumference and semen parameters observed in 
this study, and further studies from various authors (Kort et al., 2006; Pauli et al., 
2008; Chavarro et al., 2010; Håkonsen et al., 2011).  
 
A meta-analysis by Sermondade et al. (2013) found that obesity is associated with 
an increased risk for oligozoospermia or azoospermia. However, many authors have 
found no relationship between BMI and sperm profiles in males (Aggerholm et al., 
2008; Chavarro et al., 2010; Rybar et al., 2011). Aggerholm and colleagues (2008) 
found interesting yet mixed results, with a marginally negative effect of BMI on sperm 
quality, despite a significant effect on sex hormones. A similar conclusion was 
published by MacDonald et al. (2010), reporting no negative association between 
increased body weight and reduced semen parameters alongside strong evidence 
for reduced testosterone with increased body mass index in a limited meta-analysis. 
Interestingly, there was no correlation between poor sperm morphology and BMI in 
this study, which is consistent with many studies (Fejes et al., 2005, Qin et al., 2007, 
Pauli et al., 2008; Chavarro et al., 2010; Rybar et al., 2011, Tunc et al., 2011, 
Fariello et al., 2013), but in contrast to other studies indicating a relationship (Jensen 
et al., 2004; Kort et al., 2006; Hammoud et al., 2008b; Hofny et al., 2009; Kriegel et 
al., 2009; Paasch et al., 2010). The inconsistency in results may be due to various 
potential confounders, such as lifestyle, nutrition and genetic backgrounds. Further 
factors that might have to be considered are the numerous metabolic, endocrine, 
immunological and physical factors associated with obesity and the MetS that have 
not been fully elicited.   
 
Although the molecular structure of spermatozoa is a well accepted parameter in 
order to achieve a successful pregnancy (Palmer et al., 2012a), a more limited 
number of studies have assessed correlations between obesity and DF and MMP. 
BMI and waist circumference (WC) were both positively correlated with MMP and DF 
in the cohort, but not the CG and MetS groups. The negative impact of BMI on DF 
and MMP reported in this study has been observed in previous studies (Kort et al., 
2006; Agbaje et al. 2007; Kriegel et al., 2009; Bakos et al., 2010; Chavarro et al., 
2010; Fabriello et al., 2012; La Vignera et al., 2012b). Although it can be 
hypothesised that MetS related phenomena, such as inflammation and oxidative 
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stress may mediate damage to spermatozoa mitochondria and DNA integrity, the 
mechanisms of these relationships require further information, however.  
 
4.2.2. Semen parameters and metabolic syndrome components 
 
Relationships found between WC, a component of MetS, and sperm parameters 
have been discussed above. Correlations between the additional components of 
MetS, namely hypertension, dyslipidaemia and glucose intolerance are further 
discussed here. The scientific literature has very limited studies investigating these 
relationships independently, reviewed in detail by Kasturi et al. (2008). Within this 
study, correlations between MetS components and sperm parameters indicated few 
relationships within the cohort.  
 
Hypertension is a pertinent feature of MetS, and closely related to an increased risk 
of CVD. Hypertension has also been established as an independent risk factor for 
erectile dysfunction. However, there are no conclusive studies linking hypertension 
with reduced fertility potential in males (Kasturi et al., 2008). Results of a study by 
Ramírez-Torres and colleagues (2000) reported no correlation between sperm 
abnormalities and hypertension. More recently, hypertension has been strongly 
associated with increased DF in a small pilot study (Muciaccia et al., 2012). This 
study found no correlation between blood pressure and DF, and most other sperm 
parameters assessed. Limited and relatively weak negative correlations were found 
for diastolic blood pressure and sperm concentration, total motility and vitality within 
the entire cohort only.  
 
Although Ramírez-Torres et al. (2000) reported no correlation between sperm 
abnormalities and hypertension, they did report a relationship between dyslipidaemia 
and sperm abnormalities. Non-obstructive azoospermia has also been associated 
with dyslipidameia in human males (Bobjer et al., 2012). Shalaby et al. (2004) 
reported a potential role for dyslipidaemia in the development of infertility in male rats 
fed a high cholesterol diet, with improvements in fertility parameters on simvastatin 
and α-tocopherol treatment. Hypercholsterolaemia induced by diet in rabbits was 
associated with reduced semen volume, motility and normal morphology (Saez 
Lancellotti et al., 2012). In a Japanese population, increased triglycerides have also 
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been associated with poor semen quality and androgen levels (Haqiuda et al., 2012). 
The data in this study found no direct correlation between HDL cholesterol or 
triglycerides with any semen parameter. However, the association with hypertension 
and dyslipidaemia in various studies may not be an independent factor, but rather 
associated features with common underlying pathophysiological features associated 
with MetS, such as insulin resistance, inflammation and oxidative stress. This is 
further indicated by Shalaby et al. (2004), where a small but significant improvement 
in semen characteristics was observed with cholesterol lowering medications 
(simvastatin), but highly remarkable improvements were seen in a subgroup of 
animals given both simvastatin and α-tocopherol (a potent antioxidant), implying a 
role of oxidation in the setting of dyslipidaemia as an important mechanism of 
decreased fertility potential.  
 
Correlations with fasting blood glucose and semen parameters were more prominent 
in this study, showing negative correlations with progressive motility, total motility 
and vitality and a positive correlation with DF within the entire cohort, and a negative 
correlation with progressive and total motility in the MetS group. However, Ramírez-
Torres et al. (2000) found no correlation between glucose and sperm abnormalities. 
The correlation between blood sugar on DF does agree with a recent publication by 
Palmer et al. (2012a), which reported a positive correlation between glycaemia and 
sperm DF regardless of adiposity, in mice fed a high fat diet. This study found a 
negative correlation for dysglycaemia to normal morphological sperm, which was not 
observed in this study, which is contrary to Palmer et al. (2012a).  
 
Mallidis and colleagues (2011) induced MetS characteristics in male rabbits fed a 
high fat diet for 12 weeks, although this study did not assess the impact of the 
syndrome itself on reproductive function. Within the context of induced 
hypogonadotropic hypogonadism, experimental rabbits did not find increased DF in 
spermatozoa, with no histological changes in the testes or epididymal histology. 
They concluded that there are minimal effects on spermatogenesis and sperm 
quality, and attributed these effects to increased blood glucose rather than 
hypogonadism. This conclusion would agree with the correlations found in this study 
pertaining to blood glucose and hypertension on sperm parameters. T2DM, a known 
consequence of MetS characterised by high blood glucose, has increasingly been 
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associated with male factor infertility in recent years (La Vignera et al., 2012a). Poor 
semen quality, such as reduced sperm concentration and motility, abnormal 
morphology, mitochondrial DNA damage, nuclear DNA damage and increased 
seminal plasma abnormalities have been reported (Amaral et al., 2008; La Vignera 
et al., 2012a).  However, if this is directly related to glucose intolerance or the 
complex underlying metabolic dysfunction associated with MetS is not well described 
nor investigated.  
 
Neither the scientific literature nor the data in this study support any cause and effect 
hypothesis. Any relationship between individual components of MetS and semen 
parameters may be due to common underlying mechanisms. However, there is the 
potential that components of the MetS expressed in patients may further negatively 
impact reproductive potential in males, and hence may provide a compouding 
detrimental effect on male fertility. These associations require further clarification 
from further research.   
 
4.2.3. Relationships between semen parameters, blood insulin and systemic 
inflammation 
 
Fasting blood insulin and insulin resistance (IR), as established by the Quantitative 
Insulin Check Index (QUICKI) (Katz et al., 2000; Hrebicek et al., 2002; Rabasa-
Lhoret et al., 2003), strongly correlated with each other as expected in the cohort, as 
well as the CG and MetS groups. Both serum insulin and IR further strongly 
correlated as expected with BMI, WC, systolic blood pressure, diastolic blood 
pressure, HDL, triglycerides and fasting glucose in the cohort. Serum hs-CRP, as a 
reflection of inflammation (Brooks et al., 2010), was also correlated as expected with 
BMI, WC, systolic blood pressure, diastolic blood pressure, HDL, triglycerides and 
fasting glucose in the cohort. These are expected correlations within the context of 
MetS.  
 
Fasting blood insulin correlated negatively with ejaculation volume, semen 
concentration, total sperm count, motility and vitality in the cohort, with a positive 
correlation with abnormal MMP. Similarly, IR correlated positively with ejaculation 
volume, semen concentration, total sperm count and vitality, in addition to 
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progressive and total motility, in the cohort, with a negative correlation with abnormal 
spermatozoa MMP and DF. There was no correlation with morphology. On reviewing 
the literature, there are no studies indicating correlations between serum insulin and 
IR with sperm parameters. hs-CRP correlated negatively with semen concentration, 
total sperm count, total motility, progressive motility, and vitality in the cohort, with a 
positive correlation with abnormal MMP and DF. Similarly, there are no reports 
identified in the literature in which to contrast these findings.  
 
These correlations, although week, suggest an important influence between insulin 
and systemic inflammation and spermatogenesis. As insulin directly and indirectly 
modules reproductive function (Pasquali et al., 1995; Pasquali  et al., 1997; Andò & 
Aquila, 2005; Lampiao et al., 2009), this is a plausible consideration discussed in 
further detail below. These serum markers could also be considered as potential 
markers for reduced male fertility if these possible correlations can be further 
researched and confirmed by additional studies.  
 
4.3. Metabolic syndrome and salivary steroid hormones in males 
 
Hypogonadism has been well established in adult males with MetS (Pasquali 2006; 
Kasturi et al., 2008; Guay 2009; Saad & Gooren, 2009). In addition, it is emerging 
that reduced serum testosterone in non-obese men, including those with 
asymptomatic androgen deficiency, increases the risk of developing obesity and 
MetS, as well as developing T2DM and CVD (Boyanov et al., 2003; Kupelian et al., 
2006; Traish et al., 2009), with further lines of evidence suggesting that the clinical 
administration of testosterone can improve many of the characteristics associated 
with the syndrome (Saad & Gooren, 2009). Therefore, in males, testosterone 
appears to be a significant hormone involved in the aetiology and pathogenesis of 
MetS.  
 
The results of this study indicate that free testosterone, determined via saliva 
samples of the male participants, is significantly decreased in the MetS group 
compared to the controls. Although there are no reports identified in the literature 
investigating the effect of MetS on free testosterone measured in saliva, this study 
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agrees with the well described literature of male hypogonadism associated with 
MetS (Pasquali 2006; Kasturi et al., 2008; Guay 2009; Saad & Gooren, 2009).  
 
Changes in free progesterone concentrations associated with MetS in males have 
not been previously investigated. A significant reduction in progesterone alongside 
reduced testosterone in the MetS group when compared to the CG is a novel finding. 
As progesterone is a well defined precursor hormone in testosterone synthesis 
(Sherbet et al., 2003), this finding suggests that steroidogenesis cascades may be 
compromised in males with MetS. 
 
Progesterone, as a well defined ‘female’ and pregnancy hormone has been 
traditionally ignored in male physiology and pathology. This is highlighted by very 
few detailed and comprehensive studies assessing progesterone in the male 
available on searching the scientific literature. This is particularly interesting, as adult 
men and woman generally have similar concentrations of serum progesterone 
except during the luteal phase of the menstrual cycle and during pregnancy (Oetell & 
Mukhopadhyay, 2004; Andersen & Tufik, 2006). The majority of research in this field 
has focused on male contraception (McLachlan et al., 2004; Wang et al., 2010), the 
treatment of male hypersexuality (Andersen & Tufik, 2006) and the role of 
progesterone in fertilisation (Thomas & Meizel, 1991; Foresta et al., 1992; Emilioza 
et al., 1996; Meizel & Turner, 1996; Baldi et al., 2002; De Amicis et al., 2011). The 
general view of progesterone in males is therefore limited to an essential precursor 
for testosterone synthesis via its immediate metabolite, 17α-hydroxprogesterone 
(17α-OH-P), which is further hydrolysed into androstenedione, which is itself 
hydrolysed into testosterone following the ∆5-steroid pathway (as opposed to the ∆4-
steroid pathway via dehydroepiandosterone) (Sherbet et al., 2003; Oettel & 
Mukhopadhyay, 2004; Midzak et al., 2009; Ye et al., 2011).  
 
Progesterone has not been completely studied in men who are overweight or obese, 
been diagnosed with MetS or T2DM. The results of this study indicate that saliva 
concentrations of free progesterone are significantly reduced in MetS positive males. 
Considered with the reduced testosterone concentrations in saliva, it would be 
logical, albeit premature, to suggest that testosterone production is reduced due to a 
restriction in the progesterone precursor supply based on the ∆4-steroid pathway. 
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This would agree with Isidori et al. (1999), who found that serum 17α-OH-P is 
reduced in obese patients compared to controls, and moderately obese (BMI 30 – 
40) patients compared to those who were described as massively obese (BMI > 40). 
However, testosterone may be sourced via the ∆5-steroid pathway, bypassing the 
need for progesterone and 17α-OH-P.  
 
In rats fed a high fat diet, both progesterone and testosterone decreased in both 
serum and testes, which would agree with the results found in this male cohort (Ahn 
et al., 2013). This would imply that cholesterol conversion into pregnenolone may be 
affected by MetS, although the molecular mechanisms associated with these results 
are unlikely to be this simplistic.  
 
These previous studies, in conjunction with results in this study, indicate that 
steroidogenesis cascades may be compromised, especially via the ∆4-steroid 
pathway for testosterone synthesis. FT and FP strongly correlated with each other 
within the cohort, as well as the CG and MetS groups, providing some evidence that 
the steroidogenic pathways may be compromised in patients with MetS. However, 
testosterone can be synthesised via the ∆5-steroid pathway, which would then 
bypass progesterone (Sherbet et al., 2003). Future research would need to 
investigate the effect of dehydroepiandosterone (DHEA) to further explore a potential 
impact on this alternative pathway. 
 
The mechanisms of these relationships require further investigation. Obesity and 
MetS in males is associated with both a decrease in testosterone and an increase in 
oestrogen (Kasturi et al., 2008; Guay, 2009). This is due to an increase cytochrome 
P450 aromatase activity, particularly in white adipose tissues, with increased 
expression in increasing obesity and MetS (Cabler et al., 2010). The activity of 
aromatase would increase oestrogen while drawing on the pool of testosterone.   
Another metabolite of testosterone, dihydrotestosterone (DHT), is converted from 
testosterone via the enzyme 5α-reductase. DHT in obesity and MetS has not been 
fully investigated, but appear to be decreased in obesity (Blanchette et al., 2006). It 
is therefore well accepted that peripheral testosterone metabolism into 17β-
oestradiol via an upregulation on aromatase in adipose tissues is a well-defined 
mechanism for hypogonadism associated with MetS (Kasturi et al., 2008; Guay, 
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2009). This would not necessarily explain why testosterone levels are not maintained 
by upregulating steroidogenesis via negative feedback mechanisms, nor would this 
explain the decreased progesteorne observed in the male cohort with MetS (and 
obesity as described by Blanchette et al. (2006). Levels of LH appear to be low or 
normal in males with obesity and/or MetS, with a better defined decrease in LH-pulse 
amplitude. There is also an associated decrease in gonadotropin secretion from the 
hypothalamus and a breakdown of the hypothalamus-pituitary-testis (HPT) axis 
(Kasturi et al., 2008; Guay, 2009). A decline in gonadotropin stimulation of the 
pituitary, and/or a decrease in LH stimulation of Leydig cell steroidogenesis would 
explain a decrease in both progesterone and testosterone observed in this study.  
 
Insulin (Lampiao et al., 2009), leptin (Lampiao et al., 2009), inflammatory cytokines 
(Hales et al., 1999; Bornstein et al., 2004) and oxidative stress (Diemer et al., 2003) 
are all proposed to directly modulate Leydig cell steroidogenesis, with all of these 
phenomena associated with an increase in serum in males with MetS (Kasturi et al., 
2008). It can be hypothesised that these phenomena may provide a novel 
explanation for reduced steroidogenesis (progesterone and testosterone), in addition 
to effects on semen parameters. However, the mechanisms for this relationship will 
require further investigation.  
 
As the decrease in progesterone and testosterone indicates a collapse of 
steroidogensis in the ∆4-steroid pathway, testosterone could still be synthesised via 
the ∆5-steroid pathway. Firstly, insulin, leptin, cytokine or oxidative stress induced 
decreased in LH mediated signalling, StAR activation and/or P450scc regulation 
would collapse both pathways. However, this is not clear in the data obtained in this 
study, with 17α-pregnenolone and DHEA as important hormones in the ∆5-steroid 
pathway. DHEA is a known modulator of endothelial function, inflammation, insulin 
sensitivity, blood flow, cellular immunity, body composition, bone metabolism, sexual 
function, and physical strength in frailty and provides neuroprotection, improves 
cognitive function, and memory enhancement (Traish et al., 2011). DHEA-sulphate is 
negatively correlated with body weight in males, and progesterone and DHEA-
sulphate are closely correlated with each other, and both negatively correlated with 
BMI, waist circumference and subcutaneous adipose diameter (hip circumference) 
(Blanchette et al., 2006). However, DHEA-sulphate is a derivative of DHEA, and any 
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decline may not be associated with a decrease in DHEA itself. This is, however, 
biologically plausible, and the impact of decreased DHEA on male reproduction, as 
well as within MetS and its consequences, requires further study by scientists.  
 
4.3.1. Relationship between steroid hormones clinical and biochemical 
parameters 
 
Age was negatively correlated with FT in the cohort, as well as the CG and MetS 
groups. Androgen decline is well established in ageing males (Dohle et al., 2003). 
FP, however, was not significantly associated with age in either group. This is in 
contrast to the study by Pirke et al. (1980), in which progesterone may be increased 
in ageing males, possibly inhibiting testosterone synthesis and Leydig cell function 
(Gruenewald et al., 1992). FT and FP was negatively correlated with BMI and WC in 
the cohort, but not in the CG or MetS groups. Androgens are well accepted to be 
decreased in obese males, as well as MetS (Kasturi et al., 2008). A decline in FP 
with obesity has been suggested by Blanchette and colleagues (2006), alongside 17-
OH-P, DHEA-sulphate, testosterone and dihydrotestosterone (DHT), futher 
indicating steroidogenesis collapse associated with obesity.   
 
Several studies have found an inverse relationship between blood pressure and total 
serum testosterone concentrations, which may result in impaired reproductive 
potential (Kusturi et al., 2008).  Results of this study found no relationship between 
blood pressure and FT within the entire cohort, or either group. No relationship was 
found between FP and blood pressure either. Interestingly, HDL cholesterol was 
correlated with FP in the cohort, but not FT. Both FT and FP negatively correlated 
with triglycerides. There are no studies identified investigating relationships between 
lipids and FP in males. However, numerous studies assessing obesity and MetS in 
males correlate dyslipidaemia with hypogonadism (Kasturi et al., 2008). Neither FT 
nor FP correlated with fasting blood glucose.  
 
Several studies inversely correlate testosterone with BMI and insulin, and 
hyperinsulinaemia may be a common aetiological factor for both hypogonadism and 
onset of T2DM (as reviewed by Kasturi et al., 2008). Increasing insulin administration 
has also been associated with decreased Leydig cell testosterone secretion 
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independent of changes at the hypothalamus or pituitary (Pitteloud et al., 2005). 
Within the cohort, QUICKI (but not fasting blood insulin) was negatively correlated 
with FT in the cohort, indicating that testosterone declines with increasing IR. This 
was not observed in with FP. Similarly, systemic inflammation and hypogonadism 
are well correlated in males with MetS (Kasturi et al., 2008). Within the cohort, FT 
correlated negatively with CRP.  
 
However, in this study there was no correlation between FP and hs-CRP (although a 
weak negative correlation between serum and seminal TNFα was found). The 
correlations between testosterone, insulin and CRP were not as strong as would be 
expected. Furthermore, these correlations were absent within the MetS group. A 
relatively small cohort may be a reason for this. However, as this is the first study 
assessing FT in saliva samples, these correlations may not be as strong as serum 
samples possibly are.  
 
4.3.2. Relationship between steroid hormones and semen parameters 
 
FT correlated with semen concentration, total sperm count, progressive and total 
motility and vitality in the cohort. These correlations were not observed in the CG or 
MetS groups. There was no correlation in any group for FT and ejaculation volume, 
normal morphology, MMP or DF. FP did not correlate with any semen parameter 
assessed in any group. As testosterone is an essential hormone in the maintenance 
of spermatogenesis, it has a well established close association with sperm 
concentration and sperm count, as observed in the cohort. However, this 
testosterone in within the reproductive tract, where it is generally concentrated 25-
125 times compared to that of serum levels (Dohle et al., 2003; Walker, 2011). There 
is no data in this study to suggest a decrease in androgens, or progesterone, within 
the reproductive tract.  
 
It is also known that progesterone influences spermatogenesis within the testes 
(Oettel & Mukhopadhyay, 2004). Similarly, there is no data to indicate that this is 
negatively influenced in this study. However, a decrease in both testosterone and 
progesterone in the reproductive tract is certainly plausible. Furthermore, considering 
the essential actions of progesterone on sperm function after ejaculation, as well as 
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fertilisation (Thomas & Meizel, 1991; Foresta et al., 1992; Emilioza et al., 1996; 
Meizel & Turner, 1996; Baldi et al., 2002; De Amicis et al., 2011), it will be of 
importance to establish if there is a related change in progesterone within seminal 
fluid. Some studies have indicated that sperm obtained from oligospermic males 
have decreased sensitivity to progesterone stimulation, suggesting that progesterone 
has a key role in sperm development (Falsetti et al., 1993; Oehninger et al., 1994). It 
could be hypothesised that decreased progesterone within the male reproductive 
tract may negatively influence spermiogenesis, in addition to reduced androgen 
stimulation, in males with MetS opening a novel avenue for molecular study. Some 
studies have suggested that a reduced or absent action of progesterone on 
ejaculated sperm can be a sole reason for infertility, especially in idiopathic cases 
(Tesarik & Mendoza, 1992). The confirmation and establishment of these plausible 
biological mechanisms requires further investigation.  
 
4.4. The effect of metabolic syndrome on glucose and insulin concentrations 
 
As discussed above, serum insulin and glucose was significantly increased in the 
MetS group, as was expected. However, changes in seminal plasma concentrations 
of glucose or insulin in patients with MetS has not previously been investigated. As 
glucose (Truta et al., 2010) and insulin (Lampiao et al., 2009) are found in human 
semen, and utilised in sperm function and/or fertilisation, any alterations in 
concentrations or function of these molecules may influence reproduction in males.  
 
4.4.1. Serum and seminal glucose in metabolic syndrome 
 
Glucose has been identified in human semen (Truta et al., 2010), with more than half 
the sugar consumed by ejaculated spermatozoa being in the form of glucose 
(Diamandis et al., 1999). In addition, although various sugars are used by 
spermatozoa post ejaculation, glucose is generally used more as time progresses 
(Diamandis et al., 1999). Although there have been glucose assessments in human 
semen for over 100 years, reports on normal concentrations vary widely, from 183 
µg/ml – 1020 µg/ml (Truta et al., 2010). The study carried out by Truta et al. (2010) 
identified a mean concentration of 471.7 µg/ml glucose in seminal fluid from 30 
normozoospermic males. However, Diamandis et al. (1999) reported a mean 
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concentration of 1180 µg/ml, with ranges as low as 36 µg/ml and as high as 2700 
µg/ml, in 202 semen samples from healthy donors (there was no difference between 
normozoospermic, oligozoospermic and azoospermic males). Seminal glucose 
concentrations in this study showed a mean of 472.1 µg/ml in the CG and 357.1 
µg/ml in the MetS group. There was a range across the entire cohort of 48.1 – 990.0 
µg/ml, with both the lowest and highest concentration in the CG. Although there was 
a lower mean in the CG compared to the MetS group, this did not reach statistical 
significance (P=0.0531). The mean values and range of seminal glucose 
concentrations was found to be similar to previous reports outlined by Truta et al. 
(2010), but lower than that reported by Diamandis et al. (1999).  
 
Mean serum glucose in the CG was 5.03 mmol/L, which is equivalent to 905.4 µg/ml, 
with seminal glucose mean at 472.1 µg/ml. This indicates a general lower 
concentration of seminal glucose compared to serum concentrations (a seminal to 
serum ratio of 0.52 based on the means). Similarly in the MetS group, mean serum 
glucose was 5.79 mmol/L, which is equivalent to 1042.2 µg/ml, and seminal glucose 
was 357.1 µg/ml (a seminal to serum ratio of 0.34 based on the means). This 
decreased seminal glucose compared to serum may be due to a tight control 
mechanism for glucose to pass from the peripheral circulation into the reproductive 
tract through the blood testis barrier (BTB), reducing glucose concentrations in order 
to optimally support and maintain spermatogensis.  Testicular cells have glucose 
sensing machinary which enable them to react and adapt to hormonal fluctuations 
and counteract hyper- or hypoglycaemic events, as reviewed in a recent publication 
by Alves and colleagues (2013).  
 
Spermatogenesis maintainance in vivo is dependent on  adequate glucose 
metabolism. The BTB tightly controls transport of glucose to germ cells and Sertoli 
cells, which  are relevant cells for the functions of the BTB. Glucose transport across 
the BTB is mediated by various glucose transport molecules (GLUT’s), such as 
GLUT1, GLUT3 and GLUT8, and are sensitive to various hormones (including 
insulin), inflammatory cytokines and growth factors (Alves et al., 2013). With 
changes in glucose or insulin, glucose transport machinary adapts in order to 
maintain lactate production (Alves et al., 2013). Insulin deprived Sertoli cells in 
culture show decreased glucose uptake via the BTB barrier (Alves et al., 2013). 
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Therefore, it may be biologically pausible that insulin resistance in the setting of 
MetS may be associated with a decrease in glucose uptake across the BTB. This is 
however hypothetical, and further research in the physiology and pathophysiology of 
the BTB in relation to glucose, insulin sensitivity and inflammation is required.  
 
Seminal glucose correlated negatively to serum concentrations of triglycerides, 
glucose, insulin and hs-CRP, and positively with insulin sensitivity in the cohort. 
These correlations were not observed in either the CG or MetS groups. These 
seemingly counter intuitive results are likely due to a non-significant decrease in 
seminal glucose observed in the MetS group compared to CG. Based on a 
biologically plausible hypothesis that glucose transport across the BTB may be 
comprised in the setting if insulin resistance, larger studies may find seminal glucose 
to be significantly decreased in males with MetS. Although the data does not support 
this speculation, if potentially true, this would likely be associated with negative 
correlations to MetS parameters such as triglycerides, serum glucose, insulin and 
hs-CRP observed in this study.  
 
There is a positive correlation suggested in the literature between seminal glucose 
and sperm motility (Truta et al., 2010). However, other studies did not find such a 
correlation (Diamandis et al., 1999). Seminal glucose was negatively correlated with 
progressive and total motility, and positively correlated with sperm MMP in the MetS 
group, but not in the CG, nor in the cohort. These correlations support data 
published by Truta and colleagues (2010). ATP levels in sperm are maintained by 
several substrates, and both glycolysis and mitochondrial respiration are active in 
human sperm (Alves et al., 2013). Sperm capacitation is known to be stimulated by 
glucose, and also via oxidative stress possibly mediated via oxidative 
phosphorylation of glucose (Alves et al., 2013). A potential decrease in seminal 
glucose in MetS and T2DM may be a novel mechanism by which a decrease in 
motility and mitochrondial function is mediated, especially as glucose is an essential 
fuel for sperm activity and motility (Diamandis et al., 1999). Ejaculated sperm cell 
function may therefore be negatively influenced by a decrease in optimal 
concentrations of glucose, a hypothesis that would require further investigation, 
especially in the setting of MetS and T2DM.  
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4.4.2. Serum and seminal insulin in metabolic syndrome 
 
Insulin is well described as the key hormone involved in the regulation of glucose 
and free fatty acid uptake by tissue cells, with roles in the promotion and regulation 
of growth, differentiation and metabolism (Kim et al., 2006a; Karnieli & Armoni, 
2008). The concept of insulin resistance is used to describe the process whereby 
target tissues develop impaired sensitivity to the action of the hormone, particularly 
in adipose tissue, liver and skeletal muscle (Eckel et al., 2005; Huang, 2009; 
Gallagher et al., 2010). Obesity and increased WC is a predominant risk factor for 
the development of insulin resistance, and appears to play a central role in the 
pathogenesis of atherosclerosis and type 2 diabetes mellitus (Liao et al., 2005; 
Zeyda & Stulnig 2009; Gallagher et al., 2010). The Quantitative Insulin Sensitivity 
Check Index (QUICKI) is calculated from fasting blood glucose and insulin 
concentrations, with a decreased score indicative of decreased insulin sensitivity 
(increased insulin resistance) (Hrebicek et al., 2002; Yokoyama et al., 2004). As 
discussed, the MetS group had significantly increased serum insulin as compared to 
the CG, with a significantly decreased QUICKI (indicating increased insulin 
resistance).  
 
Insulin has been reported as an important regulator of male reproduction via actions 
on the HPT axis, with modulating actions on gonadotropin releasing hormone 
(GnRH), LH and FSH centrally, and Leydig and Sertoli cell function locally (Lampiao 
et al., 2009). Furthermore, Pitteloud et al. (2005) published in vivo evidence that 
insulin resistance is associated with decreased testosterone secretion from Leydig 
cells in males. Furthermore, insulin is present in human semen, and insulin receptors 
are expressed on spermatozoa cell membranes, having important regulatory roles 
for sperm function and in fertilisation (Aquila et al., 2005; Lampiao et al., 2009).  
Interestingly, leptin as well as insulin, appears to be synthesised and secreted by 
ejaculated spermatozoa (Aquila et al., 2005b; Andò & Aquila, 2005). Insulin 
produced in uncapacitated sperm is found in granules predominantly on the 
midpiece and tail. This is associated with a massive intracellular decline and 
extracellular increase at capacitation, indicating a role in capacitation (Andò & 
Aquila, 2005). However, the role of insulin in male (in)fertility has not been well 
elicited and remains poorly understood.  
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The results of this study indicated a significantly increased insulin concentration in 
the semen in the MetS group compared to the CG. Serum and seminal insulin 
strongly correlated with each other, and seminal insulin inversely correlated with 
QUICKI (as did serum insulin). These correlations were found in the cohort, CG and 
MetS group. This suggests that insulin in the semen gains access to the reproductive 
tract via the BTB, seminal vesicles or prostate. Insulin and insulin-like peptides in 
human semen have previously been suggested to be secreted by the seminal 
vesicles (Paz et al., 1977; Stahler et al., 1987). García-Díez and colleagues (1991) 
concluded that insulin appears to freely cross the BTB into the reproductive tract, 
and thereby supports findings of concentrated seminal insulin in this study.  
 
Insulin was found to be highly concentrated in human semen as compared to serum. 
Based on the mean serum and seminal insulin concentrations, insulin is 28.7 times 
more concentrated in seminal fluid than in serum in the CG, and 42.7 times more 
concentrated in the MetS group. There are a few studies in the literature which 
compare the seminal insulin concentrations too. Hicks et al. (1973) found that insulin 
was more than twice as concentrated in human semen as compared to serum in 
non-diabetic men (19±3 µU/ml and 7.5±1.5, µU/ml respectively). In a Portuguese 
publication, Povoa Junior et al. (1973) observed higher seminal concentrations of 
45.8±15.1 µU/ml in human semen of normozoospermic men. García-Díez and 
colleagues (1991) reported insulin to be concentrated in human semen compared to 
serum in human males with type 1 diabetes mellitus. This was across numerous 
groups, including fertile and infertile normoglycaemic subjects, carbohydrate 
intolerant subjects and excretory and secretory azoospermic subjects.  
 
Seminal insulin, alongside serum insulin and insulin resistance, correlated with BMI, 
WC, blood pressure, triglycerides HDL (negative correlation) and hs-CRP in the 
cohort. Seminal insulin correlated with BMI and WC in the CG, but not the MetS 
group. Numerous metabolic and immunological features of MetS are therefore 
associated with increased seminal insulin, and it can be postulated that this has a 
negative influence of sperm function and fertilisation capability in males with MetS.   
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Seminal insulin correlated negatively with sperm concentration in the cohort, but not 
CG and MetS groups, and motility (progressive and total) in the cohort, CG and 
MetS groups.  
 
Although García-Díez and colleagues (1991) reported no correlation between 
seminal or serum insulin and sperm parameters in males with type 1 diabetes 
mellitus, Lampiao & du Plessis (2008a) showed that ejaculated healthy sperm 
exposed to 10 µIU insulin significantly increased total and progressive motility, 
acrosome reaction and nitric oxide production in vitro after 1, 2 and 3 hours of 
incubation. Further lines of evidence (Pasquali et al., 1995; Andò & Aquila, 2005; 
Pitteloud et al., 2005) support the notion that insulin concentrations in serum and 
semen can directly and indirectly modulate the HPT axis, spermatogenesis and 
sperm function.  
 
The data available from this study indicates an important role for seminal insulin in 
the sperm function. Although acute increase in insulin exposure may increase 
motility and acrosome reaction in the spermatozoa (Andò & Aquila, 2005; Lampiao & 
du Plessis, 2008a), this study found a negative correlation with seminal insulin and 
motility. As the increased seminal insulin is in the setting of insulin resistance and 
MetS, increased insulin exposure during spermatogenesis may develop insulin 
resistance in the spermatozoa themselves. Evidence to support this hypothesis may 
be found in the intracellular molecular cascades associated with insulin receptor 
stimulation in these cells. Insulin exert its effect on spermatozoa via the PI3K/Akt 
intracelleular signalling pathway, leading to protein kinase B (PKB) phosphorylation 
(Aiston & Agius, 1999; Andò & Aquila, 2005), which may mediate beneficial effects 
on ejaculated spermatozoa (Lampiao et al., 2009). This pathway ultimately increases 
cellular nitric oxide production (Aiston & Agius, 1999; Andò & Aquila, 2005; Lampiao 
et al., 2009). In human tissues, particularly hepatocytes, adipocytes and skeletal 
muscle cells, this intracellular pathway is negatively influenced in insulin resistance 
(Huang, 2009). Therefore, over the spermatogenic cycle, it is conceivable that 
spermatozoa may induce insulin resistance in a manner similar to other tissue cell. 
This hypothesis would provide an explanation as to the potential negative 
association between increased seminal insulin and reduced motility of ejaculated 
sperm. This requires further detailed investigation.  
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Insulin-dependent (type 1) diabetic males have severe structural and motility 
abnormalities with sperm, indicating the important role in morphology and function of 
insulin (Baccetti et al., 2002). Although this occurs in patients with low insulin, insulin 
resistance could results in a similar end point. As this data indicates that serum and 
seminal insulin is negatively associated with sperm motility, this may provide some 
evidence that spermatogenesis is subjective to negative effect of insulin resistance. 
However, there was no correlation with normal morphology and insulin in this study.  
 
4.5. The effect of metabolic syndrome on serum and seminal leptin 
 
Leptin, a predominantly adipocyte-derived polypeptide, has a significant role in the 
regulation of body weight, appetite and energy expenditure, mediating many of these 
actions via the hypothalamus (Bastard et al., 2006; Kwon & Pessin, 2009; Wozniac 
et al., 2009; Galic et al., 2010). Furthermore, leptin exerts numerous effects on the 
immune, endocrine, metabolic and reproductive systems, playing a key and complex 
psycho-neuro-immuno-endocrine function (Casabiell et al., 2001). Leptin therefore 
has a direct and independent effect on the HPT axis, influencing spermatogenesis 
and steroidogenesis at the very least (Casabiell et al., 2001). Leptin has been 
strongly associated with a role in the pathophysiology of MetS, although this role has 
not been well understood or described (Bastard et al., 2006; Esteghamati et al., 
2009).  
 
The results of this study agree with the literature in general, with the MetS group 
showing significantly increased serum leptin. Previously unreported in the literature, 
seminal leptin concentrations were also significantly increased in the MetS group. 
Serum leptin strongly correlated with seminal leptin in the cohort, as well as the CG 
and MetS group. These correlations suggest that leptin may freely cross into seminal 
plasma, either across the blood-testes barrier, or alternatively via the seminal 
vesicles or prostate directly. However, results should be interpreted carefully, due to 
the generally lower number of samples analysed.  
 
Various studies have assessed leptin concentrations in male serum, although an 
adequate reference range appears elusive. Hanafy et al. (2007) reported serum 
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leptin mean of 6.8 ng/ml in fertile male control patients, and a significantly increased 
concentration of 16.3 ng/ml in oligozoospermic infertile males. These serum ranges 
agree with concentrations found in the male cohort of this study. Niskanen et al. 
(1997) found mean serum leptin concentrations of 19.8 ng/ml in obese males. 
Zitzmann et al. (2005) reported mean serum leptin concentrations of 3.0 ng/ml in 27 
healthy males. Zorn et al. (2007) reported serum concentrations of 12.4 – 18.2 ng/ml 
in a male cohort with fertility complaints. Serum leptin concentrations in the cohort of 
this study therefore generally agree with concentrations found in the literature.  
 
Based on the results of this study, seminal leptin appears to be concentrated 
compared to serum levels. However, Thomas and colleagues (2013), comparing 
serum and seminal leptin in normal weight to overweight men, found serum levels to 
be higher than seminal levels. In 41 normal weight males, a median of 2.36 ng/ml 
was found in serum, and 0.91 ng/ml in semen. In 55 overweight or obese males, a 
median of 8.69 ng/ml was found in serum, and 0.83 ng/ml in semen (Thomas et al., 
2013). These are comparable to serum concentrations in this study as indicated 
above, but seminal concentrations are much lower in comparison. Camiña et al. 
(2002) reported a mean seminal leptin concentration of 0.95 ng/ml in 40 healthy 
male donars, also much lower than the concentrations found in the CG of this study.  
Glander et al. (2002) found seminal leptin concentrations of 1.5 ng/ml in 
normozoospermic infertile men, and 3.2 ng/ml in pathozoospermic infertile men. 
These previous studies all reported lower seminal concentrations of leptin than 
reported in the cohort of this study.  
 
4.5.1. Correlations of seminal and serum leptin with clinical and biochemical 
parameters 
 
Age did not correlate with serum or seminal leptin in the cohort, or either group. Both 
serum and seminal leptin positively correlated with BMI, WC, serum insulin and hs-
CRP, with a negative correlation with QUICKI (insulin sensitivity). These correlations 
were not found in the CG or MetS groups.  
 
These results agree with the literature suggesting that serum leptin is associated 
with abdominal obesity (BMI and WC) and serum insulin and insulin resistance 
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(Isidori et al., 1999; Esteghamati et al., 2009). Although it appears that leptin has a 
role in MetS independent of BMI, it exerts detrimental effects through the setting of 
obesity (Esteghamati et al., 2009). In fact, the five MetS participants with a BMI < 30 
(normal weight or overweight, not obese) and with a recorded serum leptin result, 
had a mean leptin concentration of 21.3 ng/ml. Thus, this is more comparable to the 
CG than MetS group. This subset sample is too small for statistical analysis, but 
would indicate that increased leptin in MetS may be related to the abdominal obesity 
component specifically, agreeing with Esteghamati et al. (2009). In a study of normal 
weight compared to overweight males (Thomas et al., 2013), leptin was significantly 
increased in serum of the overweight males as would be expected. However, 
seminal concentrations of leptin were not significantly different, with no correlation 
between serum and seminal concentrations (Thomas et al., 2013). These authors 
would disagree with results in this study, correlated seminal and serum leptin with 
BMI and WC.  
 
The close association between insulin and insulin resistance is reportedly 
independent of BMI, indicating that leptin exerts independent detrimental 
consequences within the aetiology and or pathophysiology of MetS (Esteghamati et 
al., 2009). Leptin is known to be associated with inflammation. The correlation with 
hs-CRP within the cohort of this study agrees with previous research (Meyers et al., 
2005). Leptin is considered an acute phase protein, and is further correlated in the 
literature to cytokines such as TNFα, IL6 and IL1 in acute and chronic inflammatory 
states (Meyers et al., 2005). Therefore, leptin, insulin and inflammation are closely 
associated with each other within the cohort of this study.  
 
Serum leptin is generally associated with male hypogonadism, particularly in obesity, 
in the scientific literature (Isidori et al., 1999). Interestingly, the results in this study 
did not show a correlation between serum or seminal leptin and either testosterone 
or progesterone as expected. This may be due to the low numbers used in the 
correlation analyses. However, increased concentrations of leptin have been closely 
associated with a decrease in testosterone production at the level of the testes 
(Tena-Sempere et al., 2001; Tena-Sempere et al., 2002). 
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4.5.2. Impact of seminal and serum leptin on sperm parameters 
 
Leptin is found in human seminal fluid, and leptin receptors are expressed on 
spermatozoa in addition to soluble receptors in seminal fluid (Jope et al., 2003). 
Interestingly, leptin (as well as insulin) appears to be synthesised and secreted by 
ejaculated spermatozoa, particularly mediating motility (Aquila et al., 2005b; Andò & 
Aquila, 2005). In uncapacitated samples, leptin is found within intracellular granules 
in the midpiece predominantly, and decreases significantly at capacitation, indicating 
a role alongside insulin in capacitation (Andò & Aquila, 2005). However, the source 
of seminal leptin is not known based on the data.   
 
Both serum and seminal leptin negatively correlated with semen concentration, total 
sperm count, total motility, progressive motility and morphology, with a positive 
correlation with DF. These correlations were not found in the CG or MetS groups. 
Glander and colleagues (2002) reported an association between increased seminal 
leptin and a reduced sperm function, particularly a negative correlation with motility. 
These findings agree with the correlations in this study, where motility correlated 
negatively with seminal (and serum) leptin. However, Zorn et al. (2007) found no 
correlation between serum leptin and any sperm parameters investigating males with 
infertility problems (including azoospermia).  
 
Injecting 8 – 10 week old rats with increasing dosages (5, 10 and 30 µg/Kg) of leptin 
over 42 days, Abbasihormozi and colleagues (2013) recently reported a  dose and 
time dependent negative effect on progressive motility, as well as an increase in 
seminal reactive oxygen species (ROS) and DF using the TUNEL method. This 
would agree with results obtained in this study, with DF showing a positive 
correlation and progressive motility showing a negative correlation with both serum 
and seminal leptin and DF in the male cohort. Abbasihormozi et al. (2013) allude to 
an inflammatory activity of leptin based on an increase in seminal ROS. In addition, 
leptin injections induced a dose- and time-dependent decrease in testosterone (with 
increases in LH and FSH) (Abbasihormozi et al., 2013). There was no correlation 
between testosterone and leptin in this study.  In the study by Thomas et al. (2013), 
serum leptin correlated negatively with sperm count and poor sperm morphology, 
which agrees with observations in this study. However, seminal leptin correlated 
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negatively with sperm volume, but positively with sperm motility (which would 
disagree with results in this study).  
 
Alongside an investigation into the effects of insulin on human sperm function, 
Lampiao & du Plessis (2008a) published a study in which washed human 
spermatozoa from normozoospermic doners where exposed to 10 nmol leptin. Leptin 
was shown to significantly increase total and progressive motility, acrosome reaction 
and nitric oxide production in vitro at 1, 2 and 3 hours after incubation. This study 
indicates an important role for seminal leptin in the fertilisation process. Leptin 
appears to exert its effect via the PI3K/Akt intracellular signalling pathway, leading to 
protein kinase B (PKB) phosphorylation (Andò & Aquila, 2005). This is similar to that 
seen for insulin and leptin in other cell types, particularly hepatocytes, skeletal 
muscle and adipocytes, and leptin may mimic insulin action on glycogen synthase 
(Aiston & Agius, 1999). Ultimately, a key end point in this pathway is the mediation of 
nitric oxide, and hence a positive effect on motility in spermatozoa (Lampiao et al., 
2009). Interestingly, this is the same intracellular pathway that is negatively affected 
with insulin resistance, associated with decreased nitric oxide production (Huang, 
2009). These hypotheses would provide an explanation as to the potential negative 
association between increased seminal leptin, induction of leptin resistance in 
developing spermatozoa, and reduced motility of ejaculated sperm. Although 
Lampiao & du Plessis (2008a) found an increase in motility of ejaculated 
spermatozoa exposed to leptin, this was not found by Li et al. (2008), nor was there 
an effect on capcitated or acrosome reacted cells. The effect of leptin on various 
sperm parameters and fertilisation in physiology therefore needs further 
investigation, as does the potential detrimental effects of increased seminal leptin 
associated with MetS.  
 
As leptin is akin in structure to the inflammatory cytokine IL6, it is biologically 
plausible that it may exert similar detrimental effects as previously reported by IL6 
(discussed below). This may therefore directly implicate increase leptin in decreased 
Leydig cell steroidogenesis, impaired spermatogenesis, and impaired sperm 
morphology and increased DF. Alternatively, as leptin is closely correlated to IL6, 
these correlations may be due to increased levels of IL6, and not as direct influence 
of leptin itself. However, as Leydig cells, Sertoli cells and spermatozoa express 
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receptors for leptin (Aquila et al., 2005b; Lampiao & du Plessis, 2008a), it is likely 
that increased leptin concentrations in serum and semen directly influence sperm 
production and function, as well as steroidogenesis. This would require further 
research to elicit these associations and pathways (Ahima & Flier, 2000).   
 
Seminal insulin and seminal leptin strongly correlated in the cohort. With an 
associated increase in serum, as well as potential overlaps on function in both of 
these hormones on function of ejaculated sperm (Andò & Aquila, 2005; Lampiao et 
al., 2009), these seminal increases offer novel and potentially critical areas of 
research for the impact of MetS, as well as obesity, on male reproduction, sperm 
function and fertilisation ability.  
 
4.6. The effect of metabolic syndrome on serum and seminal inflammatory 
cytokines 
 
MetS is associated with a low grade, systemic and chronic inflammatory state, 
demonstrated by a subtle and detrimental increase in serum CRP (Haffner, 2003; 
Tamakoshi et al., 2003; Brooks et al., 2010). This is associated with increased serum 
inflammatory cytokines, particularly tumour necrosis factor-alpha (TNFα), interleukin 
1-beta (IL1β), interleukin-6 (IL6) and interleukin 8 (IL8) (Haffner 2003; Tamakoshi et 
al., 2003; Khaodhiar et al., 2004; Kim et al., 2006b; Brooks et al., 2010; Tack et al., 
2012).  
 
As expected, the results of this study agree with the well defined literature (Haffner 
2003; Tamakoshi et al., 2003; Khaodhiar et al., 2004; Kim et al., 2006b; Brooks et 
al., 2010; Tack et al., 2012), indicating that serum TNFα, IL1β, IL6 and IL8 are all 
significantly increased in MetS males compared to the control group. Furthermore, 
within the cohort, the serum cytokines correlated strongly and positively with each 
other, as well as serum leptin (with the exception of serum IL8 and leptin). These 
correlations were not always preserved when analysing the CG and MetS 
correlations. This may be due to the smaller numbers within the correlation 
equations not providing a strong enough correlation for significance. Nevertheless, 
this data indicates a strong pro-inflammatory relationship between the serum 
cytokines and leptin within the cohort.  
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Within the cohort, BMI and WC (abdominal obesity) were strongly correlated with 
serum TNFα, IL1β and IL6, but not IL8, in addition to serum leptin and insulin as 
discussed elsewhere. Furthermore, hs-CRP was strongly correlated to all cytokines 
in addition to leptin in the cohort. These correlations again agree with the well-
defined literature, which suggests that apipocytes and immune activity within white 
adipose tissue are a major source of cytokines and inflammation in obesity 
(Nawrocki et al., 2004; Juge-Aubry et al., 2005; Kintscher et al., 2008; Nishimura et 
al., 2009; Fuentes et al., 2013).   
 
Further features of MetS as serum cytokines showed correlations, such as blood 
pressure positively correlating with all serum cytokines, HDL correlating negatively 
with serum TNFα, IL1β and IL6, triglycerides correlating positively with serum TNFα 
and IL1β, suggesting common underlying metabolic features associated with the 
MetS. Serum insulin and insulin resistance, based on the QUICKI, was also strongly 
correlated with all serum cytokines in the cohort, in addition to serum leptin and 
seminal insulin as discussed elsewhere. Again, it is well defined that inflammation, 
hyperinsulinaemia/insulin resistance and hyperleptinaemioa are common 
phenomenon that underlies the poorly understood pathophysiology of MetS 
(Nawrocki et al., 2004; Kasturi et al., 2008, Kintscher et al., 2008; Phillips & Prins, 
2008), and these correlations were expected.  
 
4.6.1. Serum cytokine concentrations 
 
A range of 3.8 – 12.5 pg/ml was found for serum TNFα in the CG, with 8 samples 
undetectable. The MetS group had a range of 5.7 – 45.7 pg/ml, with 5 samples 
undetectable. Although previous studies assessing serum TNFα in health and 
disease has shown a variation in concentrations, the medians (reported) and means 
(unreported) in addition to the ranges, generally agree with previous studies 
assessing serum TNFα concentrations. González et al. (2001) found 15 healthy 
subjects to have a concentration of 3.14 pg/ml. In 24 lean (BMI < 25) subjects, 
Straczkowski et al. (2002) found a concentration of 5.34 pg/ml, in contrast to 5.76 
pg/ml in 30 obese (BMI > 30) subjects. Khaodhiar et al. (2004) published a 
concentration of 0.3 pg/ml in 9 non-obese (BMI < 30) patients and 3.2 pg/ml in 41 
obese subjects. Bahceci et al. (2007) found a concentration of 6.8 pg/ml in 30 lean 
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patients, 12.6 pg/ml in 30 non-diabetic obese patients, 19.6 pg/ml in 20 diabetic 
obese patients and 11.2 pg/ml non-obese diabetic patients. Healthy normal weight 
control participants (n=23) in a psoriasis study were found to have a concentration of 
11.2 pg/ml with a range of 0 – 32.5 pg/ml (Arican et al., 2005). Maes et al. (2011) 
reported a concentration of 7.41 pg/ml in a group of 20 healthy control participants in 
a study assessing inflammatory correlates with chronic fatigue syndrome. 
Interestingly, Naz & Kaplan (1994) reported TNFα to be undetected in 20 healthy 
male participants.  
 
Within the CG, a range of 7.6 – 24.7 pg/ml was found for serum IL1β, with 10 
samples undetectable. The MetS group had a range of 16.2 – 80.2 pg/ml, with 8 
samples undetectable. Although previous studies assessing serum IL1β in health 
and disease has shown a variation in concentrations, the medians (reported) and 
means (unreported) in addition to the ranges, generally agree with previous studies 
assessing serum IL1β concentrations. Naz & Kaplan (1994) found a concentration of 
20.1 pg/ml (range: 11 – 42 pg/ml) in 10 fertile (not defined) males, and 38.3 pg/ml 
(range: 0 – 111 pg/ml) in 10 males with infertility due to antisperm antibodies. 
González et al. (2001) found 15 healthy subjects to have a concentration of 0.67 
pg/ml. Maes et al. (2011) reported a concentration of 3.6 pg/ml in a group of 20 
healthy control participants in a study assessing inflammatory correlates with chronic 
fatigue syndrome.  
 
A range of 4.5 – 14.0 pg/ml was found for serum IL6 in the CG, with 11 samples 
undetectable. The MetS group had a range of 6.1 – 100.6 pg/ml, with 6 samples 
undetectable. Although previous studies assessing serum IL6 in health and disease 
has shown a variation in concentrations, the medians (reported) and means 
(unreported) in addition to the ranges, generally agree with previous studies 
assessing serum IL6 concentrations. Naz & Kaplan (1994) found a concentration of 
6.9 pg/ml (range: 0 – 18 pg/ml) in 10 fertile (not defined) males, and 28.8 pg/ml 
(range: 0 – 105 pg/ml) in 10 males with infertility due to antisperm antibodies. 
Fernandez-Real et al. (2001) found a concentration of 6.4 pg/ml in 132 normal 
weight males and 5.8 pg/ml in 96 normal weight females, and correlated IL6 
concentrations with blood pressure, serum insulin and insulin resistance. Khaodhiar 
et al. (2004) published a concentration of 0.1 pg/ml in 9 non-obese subject (BMI < 
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30) and 1 pg/ml in 41 obese (BMI > 30) subjects. Bahceci et al. (2007) found a 
concentration of 6.6 pg/ml in 30 lean (BMI < 25) patients, 11.7 pg/ml in 30 non-
diabetic obese patients, 15.9 pg/ml in 20 diabetic obese patients and 10.4 pg/ml non-
obese diabetic patients, with IL6 correlating positively with hs-CRP and TNFα. 
Healthy normal weight control participants (n=23) in a psoriasis study were found to 
have a concentration of 4.2 pg/ml, with a range of 0 – 12.7 pg/ml (Arican et al., 
2005). 
 
Within the CG, a range of 4.3 – 20.9 pg/ml was found for serum IL8, with 2 samples 
undetectable. The MetS group had a range of 3.5 – 12.7 pg/ml, with 7 samples 
undetectable. Although previous studies assessing serum IL8 in health and disease 
has shown a variation in concentrations, the medians (reported) and means 
(unreported) in addition to the ranges, generally agree with previous studies 
assessing serum IL8 concentrations. González et al. (2001) found 15 healthy 
subjects to have a concentration of 3.68 pg/ml. In 24 lean (BMI < 25) subjects, 
Straczkowski et al. (2002) found a concentration of 3.24 pg/ml, in contrast to a 
concentration of 4.31 pg/ml in 24 obese (BMI > 30) subjects. This was positively 
correlated to TNFα. Healthy normal weight control participants (n=23) in a psoriasis 
study were found to have a concentration of 12.9 pg/ml, with a range of 0 – 50.4 
pg/ml (Arican et al., 2005).  
 
With serum cytokine concentrations supported by previous studies, in the setting of a 
significant increase in inflammatory markers in the MetS group as compared to the 
CG, a further discussion and investigation of cytokines in seminal fluid of males with 
MetS is warranted.  
 
4.6.2. Seminal cytokines and metabolic syndrome 
 
Human seminal plasma contains significant levels of various cytokines normally 
present in the male genital tract (Huleihel et al., 1996; Dousset et al., 1997; Martinez 
et al., 2007; Politch et al., 2007). They are secreted by different parts of the male 
genital tract and may exert effects on steroidogenesis, spermatogenesis and sperm 
functions (Huleihel et al., 1996; Dousset et al., 1997; Martinez et al., 2007; Politch et 
al., 2007). In addition to beneficial roles within the HPT axis, inflammatory cytokines 
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in physiological concentrations in ejaculated semen are considered to be beneficial 
for fertility, and may promote sperm membrane lipid perioxidation beneficial for 
fertilisation (Basu et al., 2004; Martinez et al., 2007).  
 
As peripheral inflammatory cytokines, associated with inflammatory disease, as well 
as local inflammatory cytokines associated with reproductive tract infections, are 
associated with a negative impact on male reproductive health and fertility, it is 
conceivable that low grade chronic inflammation associated with MetS may also 
have a negative influence on male reproduction. It is plausible that increased serum 
cytokines may be associated with increased seminal cytokines. In order to further 
investigate any relationship between MetS, serum and seminal inflammatory 
cytokines (i.e. inflammation), inflammatory cytokines in seminal fluid were assessed 
alongside serum cytokine concentrations in the male cohort.  
 
All cytokines were found to be significantly increased in seminal fluid of the MetS 
groups as compared to the CG. This is a novel and important finding that has not 
been previously reported. This reflects a local reproductive tract inflammatory state 
in the absence of leukocytospermia or other clinical or biochemical causes of local 
inflammation.  This increase is associated with an increase in serum cytokines 
concentrations, as well as increased serum and seminal insulin.  
 
There was some correlation between seminal cytokines and other seminal fluid 
parameters. Seminal TNFα strongly correlated with seminal IL1β, IL6 and IL8, but 
not seminal leptin or glucose, in the cohort and MetS groups. IL6 further correlated 
with seminal IL8 and insulin in the cohort and CG, and with seminal leptin in the 
MetS group only. However, seminal IL1β did not correlate with any IL6, IL8, leptin 
nor glucose in the semen of any group. 
 
There were strong correlations between most serum and seminal cytokines. Serum 
and seminal TNFα correlated strongly in all groups. Serum and seminal IL1β 
correlated strongly in the cohort, but this was not observed in the CG or MetS 
groups. Similarly, serum and seminal IL6 correlated in the cohort, but not in the CG 
or MetS group. However, there was no correlation between serum and seminal IL8 in 
any group. This may be due to IL8 being highly concentrated in seminal fluid as 
 
 
 
 
192 
 
 
compared to serum, with a wide variation in concentrations. However, seminal IL8 
concentrated strongly with seminal leptin  in the cohort and MetS group, but not the 
CG. This strongly supports the concept that cytokines do not act in isolation, but 
rather in a network with other cytokines (Eggert-Kruse et al., 2001).  
  
Furthermore, serum and seminal cytokines correlated generally with other cytokines 
in serum and seminal fluid. TNFα correlated with seminal IL1β, IL6, IL8, leptin and 
insulin, as well as negatively with seminal glucose in the cohort only. Serum IL1β 
correlated with seminal IL8, leptin and insulin in the cohort, with the correlation 
between serum IL1β and seminal IL8 also observed in the MetS group. Serum IL6 
further correlated with seminal IL8, leptin and insulin in the cohort, serum IL8 
correlated with seminal insulin. Alongside correlations between hs-CRP and serum 
cytokines, all seminal cytokines strongly correlated with hs-CRP in the cohort, as did 
serum and seminal leptin and insulin. This suggests that hs-CRP may be a useful 
marker of reproductive tract inflammation in males with obesity and MetS, and may 
be of benefit in fertility assessments in these patients.  
 
The source of these cytokines in the reproductive tract is not clear based on the 
scientific literature. Cytokines in seminal plasma have been suggested to originate 
from Leydig cells, Sertoli cells, the epididymis and the prostate, with expressions 
modulated during the seminiferous epithelium cycle (Huleihel et al., 1999; Martinez 
et al., 2007). Leydig cells function optimally in close proximity and in conjunction with 
unique macrophages which produce cytokines, amongst other communication 
proteins (Hales, 2002). An additional and previously unexplored consideration would 
be the role of epididymal adipose tissue itself, which, similarly to abdominal adipose 
tissue, may up-regulate expression of cytokines in MetS. The correlations reported in 
this study suggest that the inflammation associated with MetS is dependent on 
multiple inflammatory cytokines acting together, as well as leptin and insulin being 
associated with this inflammatory response. It is conceivable that the increase in 
reproductive tract inflammation may be, at least in part, due to serum cytokines 
crossing into the reproductive tract from an increase in serum concentrations. 
However, as Sertoli cells, Leydig cells and testicular macrophages are able to 
synthesis and secrete these cytokines, a change in cellular function within these 
cells may also account for the reproductive tract inflammation. However, high TNFα 
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concentrations in males with obstructive azoospermia (Seshadri et al., 2009) 
suggests that the testis may not be the only source of seminal TNFα, at least. An 
interesting consideration is the potential physiological and pathological role of 
epididymal fat in cytokine secretion, as change is these adipocyte structure and or 
function may be akin to that of abdominal adipocytes in MetS, with detrimental 
consequences on sperm and testosterone. This hypothesis would require further 
investigation, as there is no evidence in the literature to support this notion currently.  
However, regardless of the source, it is likely that an increase in seminal cytokines 
provide a novel mechanism for infertility related to not only MetS, but obesity in 
general, as there is a strong correlation between all seminal cytokines and BMI and 
waist circumference (alongside similar correlations between serum cytokines and 
BMI/WC).  
 
Much of the published literature related to cytokines in the male reproductive tract 
has been in the setting of genital tract infections (GTI), as GTI are associated with 
leukocytospermia and increased inflammatory cytokines (Koçak et al., 2002; Basu et 
al.,2004; Eggert-Kruse et al., 2007; Martinez et al., 2007; Politch et al., 2007; 
Gallegos et al., 2008; La Vignera et al., 2011a). This is associated with infertility in 
males (Politch et al., 2007). Numerous lines of evidence have indicated a reduction 
in sperm count, motility and reduced male fertility potential as a result of increased 
inflammation and cytokine activity (Gruschwitz et al.,1996; Dousset et al.,1997; 
Koçak et al., 2002; Basu et al.,2004; Lampiao & du Plessis, 2008b; Tronchon et al., 
2008). Increased cytokines in the male reproductive tract are therefore considered to 
have detrimental consequences on spermatogenesis and the function of ejaculated 
spermatozoa, and elevated seminal plasma cytokine concentrations have been 
closely associated with fertility problems (Koçak et al., 2002; Basu et al.,2004; 
Eggert-Kruse et al., 2007; Martinez et al., 2007; Gallegos et al., 2008; Seshadri et 
al., 2009; La Vignera et al., 2011a).  
 
In addition to local effects of reproductive tract inflammation on sperm production 
and function, peripheral inflammation and increased serum cytokines have also been 
suggested to negatively influence male reproduction. Changes in serum cytokines 
may have direct detrimental effects on the HPT axis affecting steroidogenesis, as 
well as the Sertoli cells affecting spermatogenesis (Hales, 2002). Both local 
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(reproductive tract) or systemic inflammation and inflammatory cytokine expression 
during injury, illness, infection or chronic inflammatory disease may contribute to the 
disruption of testicular function and fertility that frequently accompanies these 
conditions (Hales et al., 1999; Hedger & Meinhardt, 2003). Acute systemic 
inflammatory disease is associated with a transient decrease in spermatogensis and 
the HPT axis, and chronic inflammatory disease is associated with impaired HPT 
function and sperm concentration (Hales et al., 1999; Hales, 2002; Hedger & 
Meinhardt, 2003). As MetS is considered a systemic inflammatory disease, albeit low 
grade inflammation (Haffner, 2003; Tamakoshi et al., 2003; Brooks et al., 2010), this 
warrants investigation of the effect of this inflammation on male reproductive health.  
 
The data of this study does not support any argument on the source of the cytokines. 
Although the source, physiological roles and pathophysiological mechanisms are still 
a matter of contention and debate, mechanisms associated with increased 
inflammatory cytokines in serum and semen of males with MetS requires further 
investigation. However, this study appears to be the first to report an association 
between non-infectious, asymptomatic and chronic reproductive tract inflammation in 
males and the MetS. Although the cytokines are further discussed individually, it is 
important to note that these cytokines rarely act in isolation, but as a complex 
interacting network with other cytokines and proteins that may positively or 
negatively influence sperm function (Seshadri et al., 2009).  
 
4.6.3. Tumour necrosis factor-alpha and male reproduction 
 
TNFα is a key and critical mediator of inflammation, with increased levels in serum, 
tissues or semen associated with increased inflammation (Alexander et al., 1998; 
Eggert-Kruse et al., 2007). Furthermore, based on receptors for TNFα  in almost all 
cells, increased serum or seminal concentration may negatively influence 
reproduction in males (Eggert-Kruse et al., 2007). A single nucleotide polymorphism 
(SNP) in the gene encoding TNFα (-308 polymorphism), which is associated with 
obesity and MetS risks, has also been associated with infertile males (based on 
altered sperm parameters or motility) (Tronchon et al., 2008). Patients with this SNP 
have higher basal serum TNFα compared to those without this SNP (Tronchon et al., 
2008). This study further indicates an important role of this cytokine in male fertility. 
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Increased TNFα associated with chronic pelvic pain syndrome, irrespective of 
leukocytes (Alexander et al., 1998). 
 
Within the CG, a range of 5.3 – 24 pg/ml was found for serum TNFα, with 5 samples 
undetectable. A range of 5.3 – 106.1 pg/ml was found for serum TNFα in the MetS 
group, with 8 samples undetectable. Although previous studies assessing serum 
TNFα in health and disease has shown a variation in concentrations, the medians 
(reported) and means (unreported) in addition to the ranges, generally agree with 
previous studies assessing serum TNFα concentrations. Gruschwitz et al. (1996) 
reported a concentration of 2.4 pg/ml in 8 normospermic males, 62.5 pg/ml in 8 
subfertilite males with positive sperm culture and 4.0 pg/ml in 9 subfertile males with 
negative sperm culture. Koçak et al. (2002) reported a concentration of 4.4 pg/ml 
(range: 1.2 – 14.3 pg/ml) in 24 fertile males, 5.1 pg/ml (range: 1.4 – 13.7 pg/ml) in 23 
infertile males diagnosed with varicocele and 11 pg/ml (range: 2.3 – 61.3 pg/ml) in 
10 Infertile males with male accessory gland infection. Eggert-Kruse et al. (2005) 
reported a concentration of 18.7 pg/ml (range: 0.1 – 144.4 pg/ml) in 148 
asymptomatic men from subfertile couples. In a cohort of 59 healthy and fertile men, 
Politch et al. (2007) reported a generally lower concentration of 1.5 pg/ml (range: 0 – 
40.3 pg/ml). Penna et al. (2007), however,  reported higher concentrations (33 pg/ml; 
interquartile range: 22 – 65 pg/ml) in 20 healthy males, with 68 pg/ml (interquartile 
range: 34 – 200 pg/ml) in 23 men with symptomatic benign prostatic hyperplasia, 58 
pg/ml (interquartile range: 37 – 95 pg/ml) in 9 males with chronic prostatitis without 
leukocytospermia, and 48 pg/ml (interquartile range: 34 – 90 pg/ml)  in 31 males with 
chronic prostatitis with leukocytospermia. Investigating at a cohort of infertile males, 
Ulcova-Gallova et al. (2009) reported a concentration of 2.6 pg/ml (range: 0.1 – 24.7 
pg/ml) in 20 males with normospermia, 1.7 pg/ml (range: 0.1 – 26.7 pg/ml) in 17 
males with asthenospermia and 3.4 pg/ml (range: 0.1 – 19.2 pg/ml) in 103 males 
with oligoasthenospermia. Interestingly, in a cohort of males from subfertile couples, 
divided into normospermic (n=14), asthenospermic (n=8), oligospermic (n=13), 
oligoasthenospermic (n=19), obstructive azoospermic (n=10) and non-obstructive 
azoospermic groups (n=9), Seshadri et al. (2009) reported undetectable levels in 
most samples, although a range across all groups was 0 – 73 pg/ml. Similarly, Naz & 
Kaplan (1994) did not detect TNFα in 20 semen samples.  
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Both serum and seminal TNFα negatively correlated with sperm concentration and 
total sperm count, but not ejaculation volume, in the cohort. There was also negative 
correlation with total motility, vitality and morphology for both serum and seminal 
TNFα. This is somewhat supported in the literature. Koçak et al. (2002) reported that 
seminal TNFα was negatively correlated with sperm motility in fertile and infertile 
males. Other authors have also reported negative correlations between seminal 
TNFα and sperm concentration and motility (Gruschwitz et al., 1996; Ulcova-Gallova 
et al., 2009). However, others have reported no such correlation in different male 
cohorts (Eggert-Kruse et al., 2007; Seshadri et al., 2009). There was no association 
between serum TNFα and any sperm parameter, except leukocytes, in seminal 
samples of asymptomatic males from subfertile couples as reported by Eggert-Kruse 
and colleagues (2007), and also in a report published by Camejo et al. (2001). 
Although Gruschwitz et al. (1996) found a correlation with sperm concentration and 
sperm motility, this study did not find a correlation with total sperm counts, viability, 
morphological alterations or testosterone in a very small cohort. Within this study, 
both serum and seminal TNFα correlated negatively with sperm DF. This was also 
observed in the MetS group, but not the CG. This may suggest that the cytokine may 
mediate damage to the DNA of spermatozoa, negatively influencing fertility.  
 
As with other cytokines, TNFα associated with increased oxidative stress and 
pathological processes in semen (Sanocka et al., 2003). Martinez and colleagues 
(2007) showed that TNFα may negatively influence sperm perioxidation in ejaculated 
spermatozoa, concluding that higher concentrations in semen may negatively 
influence fertilisation.  
 
4.6.4. Interleukin 1-beta and male reproduction 
 
The interleukin 1 family, and particularly IL1β, are classic proinflammatory 
polypeptides synthesised by a range of immunological and non-immunological cells, 
and known to promote the inflammatory response, typically inducing production of 
other proinflammatory cytokines (Tanaka et al., 1999; Jager et al., 2007). Leydig 
cells (Wang et al., 1991) and testicular macrophages (Kern et al., 1995) have been 
found to synthesis and secrete IL1β. Human ejaculated spermatozoa have also been 
shown to synthesis and secrete an IL1-like molecule under in vitro conditions 
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(Huleihel et al., 1997). Increased IL1 has also been associated with chronic pelvic 
pain syndrome, irrespective of leukocytes (Alexander et al., 1998) 
 
Within the CG, a range of 8.0 – 164.0 pg/ml was found for serum IL1β, with 10 
samples undetectable. A range of 15.6 – 181.0 pg/ml was found for serum IL1β in 
the MetS group, with 8 samples undetectable. Although previous studies assessing 
serum IL1β in health and disease has shown a variation in concentrations, the 
medians (reported) and means (unreported) in addition to the ranges appear to be 
generally lower than those reported in with previous studies assessing serum IL1β 
concentrations. Gruschwitz et al. (1996) reported a concentration of 4.9 pg/ml in 8 
normospermic males, 59.3 pg/ml in 8 subfertilite males with positive sperm culture 
and 7.0 pg/ml in 9 subfertile males with negative sperm culture. Dousset et al. (1997) 
reported a mean of 5.0 pg/ml in 21 fertile males compared to 11.9 pg/ml in 119 
males with androgenic disease undergoing routine infertility assessments. In 11 
males with normal speriograms, a concentration of 3.0 pg/ml was reported by 
Papadimas et al. (2002), in contrast to a concentration of 9.0 pg/ml in 42 males 
diagnosed with mild oligoasthenoteratospermia, 7.0 pg/ml in 10 males diagnosed 
with severe oligoasthenoteratospermia and 6.0 in 8 males diagnosed with 
azoospermia. These results are substantially lower than those reported in this study. 
In a cohort of 83 healthy and fertile men, Politch et al. (2007) reported a mean 
concentration of 2.3 pg/ml (range: 0 – 118 pg/ml). Ulcova-Gallova et al. (2009) 
reported a mean of 0.4 pg/ml (range: 0.1 - 3.2 pg/ml) in 20 males with 
normospermia, 0.8 pg/ml (range: 0.1 - 45.4 pg/ml) in 17 males with asthenospermia 
and 0.4 pg/ml (range: 0.1 - 2.1 pg/ml) in 103 males with oligoasthenospermia. Naz & 
Kaplan (1994) did not detect ILβ in 20 semen samples. In contrast, Eggert-Kruse et 
al. (2005) reported a concentration of 37.8 pg/ml (range: 3 - 361.7 pg/ml) in 139 
asymptomatic men from subfertile couples, generally a higher concentration than 
previous studies. Penna et al. (2007) reported similar concentrations as found in the 
in study,  with a concentration of 17 pg/ml (interquartile range: 10 – 41 pg/ml) in 20 
healthy males, 20 pg/ml (interquartile range: 10 – 32 pg/ml) in 23 men with 
symptomatic benign prostatic hyperplasia, 13 pg/ml (interquartile range: 9 – 19 
pg/ml) in 9 males with chronic prostatitis without leukocytospermia, and 61 pg/ml 
(interquartile range: 22 – 108 pg/ml)  in 31 males with chronic prostatitis with 
leukocytospermia.  
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Within the cohort of this study, seminal IL1β did not correlate with any semen. Serum 
IL1β did correlate negatively, yet weakly, with sperm concentration however. As with 
the other cytokines, the literature has offered inconclusive evidence of the role of 
IL1β in sperm function. Gruschwitz et al. (1996) reported IL1β to negatively correlate 
with sperm motility, but not with total sperm counts, viability, morphological 
alterations or testosterone. However, this study had low numbers (8 healthy and 14 
infertile). IL1β has also been associated with increased oxidative stress and 
pathological processes in semen (Sanocka et al., 2003).  
 
4.6.5. Interleukin 6 and male reproduction 
 
IL6 is produced by many cell types, including monocytes and macrophages, 
fibroblasts and endothelial cells (Bastard et al., 2006), with much of it estimated to be 
derived from adipose tissue in the absence of inflammation (Mohamed-Ali et al., 
1997). This cytokine appears to play a very prominent role in the link between 
obesity, MetS and coronary heart disease (Yudkin et al., 2000). TNFα is also a 
strong inducer of IL6 from adipocytes themselves (Rotter et al., 2003). IL6 is a 
multifunctional cytokine involved in numerous processes in human spermatozoa, as 
well as autocrine and paracrine activity (Matalliotakis et al., 1998). The prostate 
appears to be a major source of IL6 in seminal plasma (Naz & Kaplan, 1994), with 
additional IL6 possibly originating from Sertoli cells or seminal vesicles (Seshadri et 
al., 2009). However, the role of IL6 in reproduction requires further investigation 
(Seshadri et al., 2009).  
 
Within the CG, a range of 4.2 – 203.1 pg/ml was found for serum IL6, with 12 
samples undetectable. A range of 5.3 – 255.0 pg/ml was found for serum IL6 in the 
MetS group, with 1 sample undetectable. Although previous studies assessing 
serum IL6 in health and disease has shown a variation in concentrations, the 
medians (reported) and means (unreported) in addition to the ranges, appear to be 
generally lower than those reported in with previous studies assessing serum IL1β 
concentrations. Naz & Kaplan (1994) found a concentration of 23.6 pg/ml (range: 15 
– 41 pg/ml) in 10 fertile (not defined) males, and 46.0 pg/ml (range: 15 - 62 pg/ml) in 
10 males with infertility due to antisperm antibodies. Gruschwitz et al. (1996) 
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reported a concentration of 21.5 pg/ml in 8 normospermic males, 272 pg/ml in 8 
subfertilite males with positive sperm culture and 63.3 pg/ml in 9 subfertile males 
with negative sperm culture. Dousset et al. (1997) reported a concentration of 19 
pg/ml in 21 fertile males compared to 22.9 pg/ml in 119 males with androgenic 
disease undergoing routine infertility assessments. In 29 males with normal 
spermiograms, Matalliotakis et al. (1998) reported a concentration of 19.1 pg/ml 
(range: 3 – 92 pg/ml), with a concentration of 24.4 pg/ml (range: 5 – 75 pg/ml) in 45 
males with sterile but abnormal spermiogram and 39.0 pg/ml (range: 7 – 102 pg/ml) 
in 18 males with male accessory gland infections. Eggert-Kruse et al. (2001) 
reported a concentration of 15.0 pg/ml (range: 3.3 - 520 pg/ml) in 137 subfertile 
males. Koçak et al. (2002) reported a concentration of 18.8 pg/ml (range: 5 - 51.8 
pg/ml) in 24 fertile males, 21.8 pg/ml (range: 7.4-51 pg/ml) in 23 infertile males 
diagnosed with varicocele and 42.8 pg/ml (range: 10 - 152.7 pg/ml) in 10 infertile 
males with male accessory gland infection. In a cohort of 79 healthy and fertile men, 
Politch et al. (2007) reported a concentration of 6.4 pg/ml (range: 0 – 110 pg/ml). 
Penna et al. (2007) reported a concentration of 16 pg/ml (interquartile range: 10 – 26 
pg/ml) in 20 healthy males, 74 pg/ml (interquartile range: 21 – 132 pg/ml) in 23 men 
with symptomatic benign prostatic hyperplasia, 20 pg/ml (interquartile range: 13 – 39 
pg/ml) in 9 males with chronic prostatitis without leukocytospermia, and 99 pg/ml 
(interquartile range: 31 – 130 pg/ml)  in 31 males with chronic prostatitis with 
leukocytospermia. Kokab et al. (2010) reported a concentration of 16.3 pg/ml (range: 
1 – 150 pg/ml) in 239 males uninfected with Chlamydia trachomatis, and 22.8 
(range: 1 – 120 pg/ml) in 16 males infected with Chlamydia trachomatis. In a cohort 
of males from subfertile couples, divided into normozoospermic (n=14), 
asthenozoospermic (n=8), oligozoospermic (n=13), oligoasthenozoospermic (n=19), 
obstructive azoospermic (n=10) and non-obstructive azoospermic groups (n=9), 
Seshadri et al. (2009) reported concentrations of 18 pg/ml, 69.5 pg/ml, 38 pg/ml, 31 
pg/ml 42 pg/ml and 37 pg/ml respectively.  A range across all groups was 4 – 1006 
pg/ml. Investigating a cohort of infertile males, Ulcova-Gallova et al. (2009) reported 
a concentration of 29.6 pg/ml (range: 3.1 – 98.3 pg/ml) in 20 males with 
normozoospermia, 35.2 pg/ml (range: 1.9 – 492.6 pg/ml) in 17 males with 
asthenozoospermia and 40.1 pg/ml (range: 6.1 – 158.2 pg/ml) in 103 males with 
oligoasthenozoospermia.  
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Camejo et al. (2001) found no correlation between seminal IL6 and sperm 
parameters in males of infertile couples. This is supported by numerous additional 
studies (Dousset et al., 1997; Matalliotakis et al., 1998; Eggert-Kruse et al., 2001; 
Friebe et al., 2003). However, seminal IL6 correlated negatively with sperm 
concentration and morphology, and positively with DF, in the cohort, with some 
support from the literature. In a small study, IL6 has been associated previously with 
poor sperm motility, but not sperm concentration nor motility (Gruschwitz et al., 
1996). IL6 has been negatively correlated with sperm concentrations in ejaculated 
semen, with increased IL6 associated with oligozoospermic and asthenozoospermic 
men (Seshadri et al., 2009). Further lines of evidence negatively correlate seminal 
IL6 with motility and oocyte penetration rates (Naz & Kaplan, 1994; Seshadri et al., 
2009) Seminal IL6 has also been associated with increased oxidative stress and 
pathological processes in semen (Sanocka et al., 2003). Camejo et al., (2001) also 
reported that Increasing IL6 levels in semen of infertile men associated with 
detrimental effects on sperm lipid perioxidation.   
 
4.6.6. Interleukin 8 and male reproduction 
 
IL8, a well established proinflammatory and chemotactic cytokine, is an active 
component in acute inflammation as well as angiogenesis and endothelial cell 
proliferation (Baggiolini & Clark-Lewis, 1992). It is produced by immune cells (such 
as macrophages, neutrophils and T-lymphocytes) and non-immune cells (such as 
endothelial cells, fibroblasts and adipocytes) (Baggiolini & Clark-Lewis, 1992; Kim et 
al., 2006b). IL8 generally exerts its function in association with other cytokines and 
chemokines, and is crucially involved in numerous inflammatory conditions, including 
atherosclerosis (Lotti & Maggi, 2013b). Being classed as part of the chemokine 
family, it is suggested that IL8 has these functions within the reproductive tract 
(Politch et al., 2007).   
 
Increased serum IL8 associated with increased waist-to-hip ratio and fat mass 
(Straczkowski et al., 2002; Lotti et al., 2011). Furthermore, IL8 correlates positively 
with other proinflammatory cytokines, such as TNFα, IL1β and IL6 (Straczkowski et 
al., 2002; Lotti & Maggi, 2013b). Origins of seminal IL8 has not been fully elicited, but 
IL8 appears to be significantly associated with male accessory gland infections 
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suggesting a seminal vesicle and/or prostate origin (Seshadri et al., 2009). Seminal 
IL8 is considered an important and reliable predicting marker in the diagnostics of 
prostate inflammatory diseases, such as chronic pelvic pain syndrome and benign 
prostatic hyperplasia (Penna et al., 2007; Lotti et al., 2011; Lotti et al., 2013b).  
 
Within the CG, a range of 10.3 – 4503 pg/ml was found for serum IL8, with 11 
samples undetectable (ULOQ). A range of 420.9 – 4290.3 pg/ml was found for 
serum IL8 in the MetS group, with 14 samples undetectable (ULOQ). Seminal IL8 
appears to be highly concentrated in human semen as compared to serum. As 
discussed below, this is in agreement with other studies. Based on medians obtained 
in this study, the CG had IL8 concentrated 116.1 times in semen, and the MetS 
group had IL8 concentrated 107.6 times in semen. However, there does not appear 
to be a physiological explanation for this cytokine to be concentrated. 
 
Koumantakis et al. (1998) found a concentration of 5948.4 pg/ml (range: 2000 – 
13500 pg/ml) in 29 males with a normal spermiogram, and 5670.4 pg/ml (range: 
1550 – 17000 pg/ml) in 48 males with abnormal spermiograms. Eggert-Kruse et al. 
(2001) reported a concentration of 1257.0 pg/ml (range: 251 – 7854 pg/ml) in 137 
subfertile males. In a cohort of 82 healthy and fertile men, Politch et al. (2007) 
reported a concentration of 1583.3 pg/ml (range: 384 – 14712 pg/ml). Penna et al. 
(2007) reported a concentration of 1984 pg/ml (interquartile range: 1164 – 2444 
pg/ml) in 20 healthy males, 5044 pg/ml (interquartile range: 3063 – 11795 pg/ml) in 
23 men with symptomatic benign prostatic hyperplasia, 2983 pg/ml (interquartile 
range: 2033 – 5287 pg/ml) in 9 males with chronic prostatitis without 
leukocytospermia, and 15240 pg/ml (interquartile range: 10630 – 19501 pg/ml)  in 31 
males with chronic prostatitis with leukocytospermia. Kokab et al. (2010) reported a 
concentration of 727.1 pg/ml (range: 100 – 7000 pg/ml) in 239 males uninfected with 
Chlamydia trachomatis, and 1457.8 (range: 70 – 12000 pg/ml) in 16 males infected 
with Chlamydia trachomatis. In a cohort of males from subfertile couples, divided into 
normozoospermic (n=14), asthenozoospermic (n=8), oligozoospermic (n=13), 
oligoasthenozoospermic (n=19), obstructive azoospermic (n=10) and non-obstructive 
azoospermic groups (n=9), Seshadri et al. (2009) reported concentrations of 1300 
pg/ml, 2850 pg/ml, 1450 pg/ml, 1750 pg/ml 2050 pg/ml and 2100 pg/ml respectively.  
A range across all groups was 70 – 49500 pg/ml. Investigating a cohort of infertile 
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males, Ulcova-Gallova et al. (2009) reported a concentration of 693.5 pg/ml (range: 
128.9 – 1532.3 pg/ml) in 20 males with normozoospermia, 836.8 pg/ml (range: 149.7 
– 2000 pg/ml) in 17 males with asthenozoospermia and 919.2 pg/ml (range: 235.6 – 
1925.7 pg/ml) in 103 males with oligoasthenozoospermia.  
 
Within the cohort, CG and MetS groups, IL8 did not correlate with any sperm 
parameter. However, Seshadri et al. (2009) reported that serum IL8 has been 
associated with decreased sperm concentrations, as did Eggert-Kruse et al. (2001). 
Martinez and colleagues (2007) showed that IL8 may negatively influence sperm 
lipid perioxidation in ejaculated spermatozoa at physiological (50 pg/ml) and 
pathological (100 pg/ml) concentrations over 2 hours, concluding that higher 
concentrations in semen may negatively influence fertilisation.  
 
4.6.7. Possible contribution from reactive oxygen species  
 
In addition to a systemic low grade inflammatory state, there is an increase in 
systemic oxidative stress (OS) in patients with MetS (Furukawa et al., 2004; Holvoet, 
2008). OS is the result of an imbalance between the production of reactive oxygen 
species (ROS) and total antioxidant concentrations (TAC), and has been implicated 
in the pathogenesis of numerous conditions, including MetS and related 
complications such as CVD, T2DM and cancer (Furukawa et al., 2004; Amaral et al., 
2008; Holvoet, 2008; Makker et al., 2009; La Vignera et al., 2012a). Although ROS 
was initially thought to be exclusively toxic to human spermatozoa, recent studies 
have highlighted the physiological importance of these unstable molecules on 
fertilisation (Agarwal et al., 2009; Henkel, 2011a).  
 
Low ROS concentrations play a fundamental role in triggering capacitation, 
hyperactivation, acrosome reaction, sperm zona binding and oocyte fusion (Henkel, 
2005; Agarwal et al., 2009; Henkel, 2011a). Conversely, increased ROS 
concentrations (ROS-TAC mismatch) in seminal fluid have numerous detrimental 
effects on various parameters of sperm function (Henkel 2005; Henkel 2011a). Thus, 
the state between ROS and antioxidants (AO) needs to be finely balanced and 
maintained by various enzymatic and non-enzymatic processes (Henkel, 2005; 
Henkel, 2011a).  
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ROS are generated as a byproduct of spermatozoan oxidative phosphorylation, and 
are therefore intrinsic to the reproductive tract (Henkel, 2005; Henkel, 2011a). 
Furthermore, ROS in the male reproductive tract and ejaculate are also derived from 
seminal leukocytes, and play significant defensive and destructive roles in infections, 
inflammation and cellular defence (Henkel, 2005; Henkel, 2011a). Proinflammatory 
cytokines, particularly TNFα, IL1β, IL6 and IL8, are known to modulate both OS and 
antioxidant status, with increased concentrations correlating positively with ROS and 
OS in seminal fluid (Sonocka et al., 2003). Additional ROS are derived from lifestyle 
and other exogenous sources, such a smoking, alcohol consumption, heavy metals 
and pesticides, and pathological states such as varicocele and spinal cord injuries, 
and all these factors have been linked to impairment of fertility status via OS 
(Henkel, 2005; Henkel, 2011a).  
 
High levels of OS in the male reproductive tract and seminal fluid, associated with 
sperm lipid perioxidation of the polyunsaturated fatty acids in the spermatozoa 
membrane and DNA damage, has been extensively implicated in male factor 
infertility (Henkel, 2005; Pasqualotto et al., 2008; Agarwal et al., 2009). Excessive 
OS has been correlated with reduced sperm concentration and  motility, 
morphological derangements and damage to both cellular and mitochondrial DNA 
(Henkel, 2005; Aitken et al., 2006; Amaral et al., 2008; Pasqualotto et al., 2008; 
Agarwal et al., 2009; Desai et al., 2009; Kefer et al., 2009; Makker et al., 2009; 
Henkel, 2011a; La Vignera et al., 2012a).    
 
4.6.8. Inflammation and steroid hormones  
 
Interestingly, free testosterone in saliva was negatively correlated with serum TNFα, 
IL1β, IL6 in the cohort (as well as seminal IL8). This illustrates a relationship 
between MetS, inflammation and hypogonadism in males (Kasturi et al., 2008). 
Testosterone is associated with a down-regulation of cytokine-mediated 
inflammation in males (Cutolo et al., 2004; Malkin et al., 2004). It therefore appears 
that a decrease in testosterone may in part promote inflammation in MetS, and 
conversely, inflammation may in part down-regulate testosterone synthesis, as 
discussed below.  
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Furthermore, free progesterone negatively correlated with serum and seminal TNFα 
in the cohort, but not with any other cytokines. Progestins can stimulate monocyte 
production of inflammatory cytokines in woman (Jain et al., 2004). In woman, 
however, progesterone suppresses immune function during pregnancy (Oettel & 
Mukhopadhyay, 2004).  
 
Positive correlations have been suggested between endogenous progesterone and 
CRP, IL6, and leptin in healthy, non-smoking males. In addition, a significant 
increase in IL6 and decrease in IL10 (inflammatory regulatory role) was found in 
males receiving testosterone and progestin treatment for hypogonadism as 
compared to males receiving testosterone plus placebo (Zitzmann et al., 2005).   In a 
study of Chinese men and woman, progesterone concentration in males was found 
to be independently associated with atherosclerosis via assessment of carotid artery 
thickness (with no such correlation found in males) (Ma et al., 2009). As 
inflammation is closely associated with CVD and atherosclerosis, changes in 
progesterone may be an important mediator. However, with scanty information 
related to the impact of progesterone on immune function in males, this requires 
further exploration. Evidence indicates that endogenous progesterone beneficially 
regulates coronary artery reactivity in humans (Ma et al., 2009). Therefore, 
decreased progesterone in MetS may independently contribute to atherosclerosis 
and CVD in males. However, if this is mediated via the immune system remains to 
be studies. This is further discussed in the effect of cytokines on progesterone in 
TM3 Leydig cells below.  
 
4.7. Steroid hormone synthesis in TM3 Leydig cells in the setting of insulin 
and inflammation 
 
MetS is closely associated with the poorly understood phenomenon of 
hyperinsulinaemia (insulin resistance) and a low grade chronic and asymptomatic 
inflammatory state (Eckel et al., 2005; Kasturi et al., 2008; Huang, 2009; Monteiro & 
Azevedo, 2010). The results in the case-controlled arm of the study, as expected, 
have agreed with the extensive literature describing these associations. A novel 
finding is the increase in insulin, TNFα, IL1β, IL6 and IL8 within the seminal fluid of 
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males diagnosed with MetS. In addition, hypogonadism (Pasquali, 2006; Guay, 
2009; Saad & Gooren, 2009) is a feature of MetS in males.  
 
The results of this study found both free testosterone and free progesterone to be 
decreased in the saliva of males with MetS compared to the control counterparts. 
Insulin (Lampiao et al., 2009) and inflammatory cytokines (Hales et al., 1999; 
Bornstein et al., 2004) are thought to directly and indirectly modulate the HPT axis. 
This is achieved by actions centrally, via the hypothalamus (modulating GnRH) and 
anterior pituitary gland (modulating LH), and peripherally (via action on Leydig cells 
and Sertoli cells) (Hales et al., 1999; Bornstein et al., 2004; Lampiao et al., 2009). 
However, the role of insulin and cytokines on modulation of male reproduction has 
not been fully elicited and requires further extensive research. Furthermore, this 
relationship has not been studied in light of known underlying phenomenon 
associated with MetS in males.  
 
In order to further investigate the impact of insulin and inflammatory cytokines on 
steroidogenesis, a TM3 mouse Leydig cell line was used. Leydig cells stimulated 
with hCG were exposed to various concentrations of insulin, TNFα, IL1β, IL6 and 
IL8. Cell viability, protein concentration, testosterone and progesterone 
concentrations were assayed.  
 
4.7.1. Insulin 
 
Results showed TM3 cell viability to be increased for all concentrations of insulin. 
This was most marked at 0.001 pg/ml concentrations, and generally less marked 
with increasing concentrations. At 10 pg/ml, the maximum concentration the cells 
were exposed to, this was no longer significant. At relatively lower concentrations of 
insulin, the increase in cell viability may indicate cellular stress. Higher 
concentrations of insulin (≥ 10 pg/ml) may indicate cellular death in a dose-
dependent manner. Protein concentrations generally increased in a dose-dependant 
manner, with significant increases at 0.1, 1 and 10 pg/ml. Testosterone synthesis 
increased for all concentrations compared to the controls. This was most 
pronounced at the 0.01 and 0.1 pg/ml concentrations, and then appeared to be less 
pronounced at the higher concentrations, although still being a dose-dependent 
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increase. Similarly, testosterone-to-protein ratio was markedly and significantly 
increased at 0.01 pg/ml, further indicating cellular stress. There was a dose-
dependant decline in this ratio for the higher concentrations, each one not 
statistically different from the control group.  In stark contrast to testosterone 
concentrations, progesterone was significantly decreased for all concentrations 
assessed, in a dose-dependent manner. As a result, the progesterone-to-protein 
ratios were also significantly decreased in a dose-dependent manner.  
 
The results of these experiments indicate that insulin appears to induce some 
cellular stress at the lower concentrations used. However, as testosterone and 
protein both increases, and testosterone-to-protein ratio, this may indicate a 
stimulation of metabolic activity.   
 
Insulin resistance is closely associated with low testosterone in males. However, the 
mechanisms for this relationship remain unclear (Kasturi et al., 2008).  There is a 
close relationship between insulin sensitivity and testosterone concentrations in men 
across a wide range of glucose intolerance, including those with T2DM, and 
independent of SHBG concentrations (Pitteloud et al., 2005b). This indicates a direct 
relationship between insulin and testosterone in males. Furthermore, males with 
hypogonadism are twice as insulin-resistant as eugonadal counterparts (Pitteloud et 
al., 2005b). Pitteloud and colleagues also published a paper (2005a) indicating that 
insulin resistance is associated with decreased secretion of testosterone from Leydig 
cells in a small male cohort using a novel model to systematically assess every level 
of the HPT axis. The results of the cell culture experiments in this study indicate that 
insulin increases testosterone secretion within the Leydig cells. This would agree 
with Pitteloud et al. (2005a) conclusions that insulin sensitivity is directly related to 
testosterone synthesis.  
 
Insulin independently stimulates testosterone production and simultaneously inhibits 
SHBG in normal weight and obese males, and that this can be suppressed with 
diazoxide (inhibits secretion of insulin from the pancreas) treatments (Pasquali et al., 
1995). Further experiments on insulin resistance in normal weight and obese males 
have been consistent with this hypothesis (Pasquali et al., 1997). Exposure of a 
crude preparation of primary mouse Leydig cell culture to insulin showed that 
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exposing the cells to 1 µg/ml  insulin (equivalent to 103 pg/ml, therefore higher 
concentrations than this study) for one hour prior to addition of LH for 3 hours 
increased testosterone production compared to no insulin pre-treatment (Bebakar et 
al., 1990). Lin et al. (1986) also demonstrated insulin stimulation of testosterone 
synthesis in a primary rat Leydig cell culture model, as well as potentiating hCG-
induced cAMP formation, and this was blocked with administration of a protein 
synthesis inhibitor, cycloheximide.  
 
In contrast, Benitez and Perez Diaz (1985) showed that destruction of pancreatic β-
cells using streptozotocin, thus inducing type 1 diabetes mellitus, caused a dramatic 
decrease in serum testosterone in male rats. This was reversed with insulin 
treatments. More recently, 24-hour exposure of primary catfish Leydig cells to 1 
ng/ml insulin stimulated testosterone synthesis (Dubey & Lal, 2009). Interestingly, 
these authors found a direct influence of testicular macrophages on Leydig cell 
steroidogeneis mediated by nitric oxide in catfish, which augmented insulin 
stimulation of testosterone synthesis (Dubey & Lal, 2009).  
 
These series of publications indicate that both hypoinsulinaemia and 
hyperinsulinaemia (associated with insulin resistance) result in decreased 
testosterone synthesis. At optimal concentrations, insulin appears to therefore 
directly stimulate Leydig cells steroidogenesis, as indicated by the TM3 cell 
exposures to insulin concentrations.  However, there are no studies identified that 
investigate the effect of insulin on progesterone synthesis. In the experiments with 
TM3 cells, results indicate that progesterone concentrations are significantly 
reduced, in the setting of an increasing testosterone synthesis. As progesterone is 
an essential precursor of testosterone, these results suggest enzymatic activity 
downstream of progesterone may be upregulated, and not those upstream. This 
hypothetical scenario would draw from the pool of progesterone for testosterone 
synthesis, without replacing the metabolised progesterone.  
 
Hypothetically, insulin may upregulate one or more of the enzymes associated with 
progesterone metabolism into testosterone via the ∆4-steroid pathway, particularly 
cytochrome P450 17α-hydroxylase (CYP17), cytochrome P450 17,20-lyase 
(CYP17,20) or 17β-hydroxysteroid dehydrogenase (17β-HSD) (Sherbet et al., 2003). 
 
 
 
 
208 
 
 
Insulin may therefore stimulate an upregulation of testosterone synthesis via the ∆5-
steroid pathway, acting on one or more of these enzymes such as CYP17, 
CYP17,20, 3β-hydroxysteroid dehydrogenase (3β-HSD) or 17β-HSD. Of these, 
CYP17, CYP17,20 and 17β-HSD are downstream of progesterone on the ∆4-steroid 
pathway and are used in the ∆5-steroid pathway (Sherbet et al., 2003), and therefore 
more likely to explain these results. 3β-HSD, on the other hand, also metabolises 
pregnenolone into progesterone as the gateway to the ∆4-steroid pathway (Sherbet 
et al., 2003), and an up-regulation of this enzyme should be associated with an 
increase in progesterone. Alternatively, insulin may down-regulate 3β-HSD, leading 
to a decrease in the ∆4-steroid pathway, in the setting of an up-regulation of one or 
more of CYP17, CYP17,20 and 17β-HSD.  
 
This evidence in this study and the literature indicates that insulin, at least acutely, 
increases testosterone synthesis in males, and may decrease progesterone 
synthesis. However, in animals and humans, increasing insulin medium- and long-
term, such as hyperinsulinaemia and insulin resistance, is closely associated with 
decreased testosterone. This may imply that insulin resistance affects the Leydig 
cells insulin receptors and/or intracellular mediators to negatively affect steroidogenic 
cascades. This would explain both a decrease in progesterone and testosterone in 
the MetS group of this study. It was demonstrated by Pasquali et al. (1997) that 
increasing insulin resistance induced in obese males, as well as a subset of normal 
weight males, was associated with decreasing testosterone synthesis. However, 
acute hyperinsulinaemia stimulated testosterone synthesis.  
 
A very recent study published in April 2013, Ahn and colleagues studied the potential 
effect of insulin on steroidogenesis in light of insulin resistance (Ahn et al., 2013). 
Insulin (20 & 40 nM) treated MA-10 Leydig cells demonstrated a dose-dependent 
decrease in cAMP mediated steroidogenesis, via the induction of DAX-1. This 
appears to disagree with most other cell culture, animal- and human-based studies, 
including the results in this study, in which insulin increases testosterone synthesis in 
the absence of insulin resistance (Benetiz & Perez Diaz, 1985; Lin et al., 1986; 
Bebakar et al., 1990; Benetiz & Perez Diaz, 1985; Pasquali et al., 1995; Pasquali et 
al., 1997; Pitteloud et al., 2005).  
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Furthermore, the Ahn et al. (2013) study found that injecting 1 unit insulin per Kg 
body weight into rats fed a high fat diet decreased testosterone synthesis (which also 
appears to disagree with results found by Pasquali et al. (1997) in human obese 
males). This was mediated by upregulation of intratesticular DAX-1. In addition, 
steroidogenic acute regulatory protein (StAR), cytochrome P450 cholesterol side 
chain cleavage (P450scc) and 3β-hydroxysteroid dehydrogenase (3β-HSD) were all 
decreased in the rats (Ahn et al. 2013). If correct, this would explain a decrease in 
both progesterone and testosterone in the MetS group of this study.   
 
Ahn and colleagues (2013) further reported that insulin activates the insulin 
signalling pathway in Leydig cells via the Akt kinase pathway. It is known that this 
intracellular pathway breaks down with insulin resistance (Huang, 2009). A down-
regulation of this pathway is also associated with decreased nitric oxide (NO) 
production in endothelial cells. Interestingly, NO release from testicular macrophages 
has been suggested to up-regulate testosterone synthesis in Leydig cells in 
experiments on catfish (Dubey & Lal, 2009). If translated into mammals and humans, 
this may be another interesting potential pathway of IR induced steroidogenesis 
collapse in Leydig cells.  
 
The impact of insulin on steroidogensis is complex in insulin sensitivity, and appears 
to be augmented when insulin resistance is present. As MetS is associated with 
hyperinsulinaemia and hypogonadism in males, the fact that insulin exposure to 
Leydig cells resulting in increased testosterone indicated that insulin resistance is a 
key phenomenon in any downregulation of steroidogenesis in MetS. This can be 
mediated by downregulating StAR, P450scc and 3β-HSD transcriptions. However, the 
cell culture arm of this study indicated that in insulin sensitive TM3 Leydig cells, 
progesterone is decreased with increased testosterone. This may be due to up-
regulation of CYP17, CYP17,20 and 17β-HSD on both steroid pathways as an 
important mediator in insulin induced testosterone synthesis. These too would likely 
be compromised in the setting of insulin resistance. Further studies investigating 
these potential effects are required in order to fully elicit the effect of insulin (and 
insulin resistance), and the associated mechanisms, on steroidogenesis and hence 
testosterone synthesis.  
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4.7.2. Tumour necrosis factor-alpha 
 
TNFα exerted a highly significant and detrimental dose-dependent effect on cell 
viability, protein concentration, testosterone and progesterone concentrations. The 
testosterone-to-protein ratio was initially increased compared to controls, before 
decreasing, as was the progesterone-to-protein ratio. These results indicate that at 
all TNFα exerts a significant toxic effect on the Leydig cells in ascending 
concentrations, and leads to a collapse of the steroidogenesis cascade, reflected in 
dose-dependent declines in all variables.  
 
TNFα has been suggested to negatively affect the HPT axis. In animal and human 
experiments, administration of TNFα is associated with a decrease in serum 
testosterone (van der Poll et al., 1993; Bornstein et al., 2004). These results agree 
with previous publications that have assessed the impact of TNFα on Leydig cell 
function in vitro and in vivo. TNFα at a dose of 10 ng/ml reduced testosterone 
production in cAMP-stimulated primary mouse cultures of Leydig cells, but not basal 
stimulation. There was also a decrease in P450scc and CYP17 mRNA by 1.5% 
compared to stimulated controls (Xiong & Hales, 1993). The same authors further 
reported a negative effect of TNFα at similar concentrations on 3β-HSD in addition to 
P450scc, CYP17 in cAMP both cAMP stimulated and basal primary cultures of mouse 
Leydig cells.  TNFα was therefore shown to inhibit testosterone production in both 
stimulated and basal cultures (Xiong & Hales, 1997). Li and colleagues (1995) also 
showed that TNFα decreased testosterone production in cAMP stimulated MA-10 
mouse Leydig cells in a dose-dependent manner from 0.1 – 10 ng/ml, with no more 
negative effect at 100 ng/ml. This was associated with a decrease in CYP17 mRNA.  
 
In a primary culture of Leydig cells produced from immature porcine testes (2-3 
weeks old), 0.02 pg/ml TNFα decreased hCG induced testosterone concentrations 
(but not basal testosterone concentrations) in a time dependent manner. Between 
0.5 and 6 hours, no effect on testosterone was observed. A decrease was only 
observed after 24 hours, and peaked at 48 hours. This was associated with a 
decrease in StAR mRNA (Mauduit et al., 1998). Intratesticular delivery of TNFα has 
been shown to reduce StAR and testosterone secretion in both a basal and hCG 
stimulated rat model (Morales et al., 2003).  
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R2C Leydig cells exposed to 10 ng/ml TNFα (basal) decreased testosterone 
synthesis compared to control after 2 hours, with a corresponding decrease in StAR, 
P450scc, CPY17 and 3βHSD. Interestingly, after 12 hours, testosterone had 
recovered to approximately 50% to that of controls, and enzyme levels completely 
recovered, before decreasing at longer intervals (Hong et al., 2004). In the same 
study, 10 week-old male mice were injected intraperitoneally with TNFα at 50 µg/Kg 
body weight. Both testosterone and progesterone levels reduced by 10 – 25% after 6 
hours with a decrease in CYP17 in the testis (Hong et al., 2004). Wu and colleagues 
(2012) reported a significant decrease in cell viability in TM3 Leydig cells exposed to 
0.01 pg/ml TNFα, which was prevented by co-stimulation of Sirt1 (associated with 
cellular protection from inflammatory stress) activation via resveratrol.  
 
These results indicate that enzymes mediating cholesterol uptake into the 
mitochondria (regulated by StAR), conversion to pregnenolone (mediated by 
P450scc), pregnenolone conversion to progesterone (mediated by 3βHSD) and 
progesterone conversion to 17-OH-P (mediated by CYP17) are all negatively 
impacted by increasing TNFα concentrations. There are few previous studies 
measuring progesterone concentrations in the cell culture models, with Hong et al. 
(2004) reporting a decrease in progesterone in a mouse model. In the mouse tumour 
cell line mLTC-1, basal exposure of TNFα at 50 ng/ml was associated with an 
increase in StAR after 6 hours. Phosphorylation of StAR (p-StAR), an important 
requirement for steroid synthesis, was not seen in either the control or TNFα 
exposed cells, but only with exposure to hCG (50 ng/ml). No significant effect was 
found for any of these factors for P450scc or 3β-HSD. TNFα exposure was 
associated with a decrease in progesterone levels, whereas hCG increased 
progesterone levels (Manna et al., 2006). The increase in StAR found in this study, 
with generally no effect on P450scc or 3β-HSD does not generally agree with other 
studies reported.  
 
The results of this study agree with much of the literature, as TNFα is associated 
with a decrease in progesterone and testosterone concentrations and collapse of 
steroidogenesis at concentrations similar to those associated with human serum 
concentrations. A down-regulation of StAR, P450scc and 3β-HSD would translate into 
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a decrease in progesterone synthesis, agreeing with the decrease in FP observed in 
the MetS group. Hypothetically, a decrease in these enzyme transcriptions would 
also be associated with a decline in 17-hydroxy-pregnenolone, DHEA and 
androstenedione via the ∆5-steroid pathway. The negative impact on cell viability and 
protein synthesis further indicates that TNFα is cytotoxic to Leydig cells. This may 
indicate that a down-regulation of steroidogenic enzymes may be related to a 
downregulation of cellular function. TNFα appears to cause a collapse in 
steroidogenesis in concentrations as low as 0.01 pg/ml (Wu et al., 2012). Increasing 
serum concentrations of TNFα associated with MetS is an important mechanism 
associated with male hypogonadism that required detailed investigations.  
 
4.7.3. Interleukin 1-beta 
 
IL1β showed a more subtle decline in cell viability, but this was dose-dependent 
across all concentrations, as was protein and testosterone. However, the 
testosterone-to-protein ratio actually increased in a dose-dependent manner, with 
significant increases only at the 10 and 100 pg/ml concentrations. This reflects a 
more prominent negative effect on protein concentrations as compared to the 
testosterone decline, causing the ratio to increase.  The effect on progesterone was 
marked, with a very large impact at all concentrations, as therefore the 
progesterone-to-protein ratio declined. These results suggest that IL1β is associated 
with increased Leydig cell damage, with a decline in metabolic activity. A negative 
effect on progesterone is more marked than testosterone decline, suggesting direct 
effects on enzymes associated with cholesterol metabolism to progesterone, and 
less direct effect on progesterone metabolism to testosterone.  
 
Previous studies on the effect of IL1 on Leydig cell steroid regulation have provided 
conflicting results. This appears to be due to a variety of different stages of puberty 
in which primary Leydig cells were obtained from animals. Also, both IL1α and IL1β 
have been reported to have a role in Leydig cell function, and results from 
experiments depend on which isoform is used (Svechnikov et al., 2001). Calkins et 
al. (1988) showed a decrease in hCG-stimulated testosterone synthesis by 1 U/ml 
IL1β in a primary culture of immature rat Leydig cells after 8 hours of exposure. This 
was associated with a decrease in hCG stimulated cAMP production. Lin et al., 
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(1991) indicated that IL1β decreases testosterone and P450scc mRNA in an hCG 
stimulated culture of highly purified Leydig cells prepared from adult male rats (55-65 
days old). Concentrations of 1 – 100 ng/ml IL1β were cultured over 24 hours, and a 
dose-dependent effect was observed, and these inhibitory effects could be reversed 
by the concomitant addition of IL1 receptor antagonist.  
 
In contrast, IL1β (0.5 – 10 U/ml) did not significantly alter basal or LH stimulated 
Leydig cell testosterone synthesis at 24, 48 or 72 hours of culture, neither did IL1α 
(0.5 – 10 U/ml) significantly alter testosterone synthesis over the same exposure 
times (Sun et al., 1993).  IL1β (1 U/ml) markedly increased basal and low 
concentrations of LH stimulated C19 (testosterone and androstenedione) and C21 
(progesterone, 17α-OH-P and 20α-hydroxypregnenolone) steroid hormone 
production in a primary culture of immature rat Leydig cells.  Higher concentrations 
of LH, IL1β inhibits C19 steroid production after 6 hours of exposure at 1 U/ml 
concentrations (Verhoeven et al., 1998). Leydig cell culture from 80 day old rats 
showed a dose-dependent decrease in hCG stimulated testosterone synthesis when 
exposed to 0.1 – 10 ng/ml (100 – 10000 pg/ml) IL1β. Interestingly, IL1β stimulated 
testosterone synthesis in cells obtained from 40 day old rats.  
 
This study showed that this inhibitory effect was abolished by addition of 
androstenedione, suggesting that IL1 (both alpha and beta) suppresses CYP17 
(Svechnikov et al., 2001). In the mouse tumour cell line mLTC-1, basal exposure of 
IL1 (unknown which isoform) at 20 ng/ml (20 000 pg/ml) was associated with an 
increase in StAR after 6 hours. Phosphorylation of StAR (p-StAR), an important 
requirement for steroid synthesis, was not seen in either the control or IL1 exposed 
cells, but only with exposure to hCG (50 ng/ml). No significant effect was found for 
any of these factors for P450scc or 3β-HSD. IL1 exposure was associated with a 
decrease in progesterone levels (which agrees with the results from this study), 
whereas hCG increased progesterone levels (Manna et al., 2006).  
 
In 21 day old hemicastrated rats, a local bilateral injection or unilateral testicular 
administration of IL1β (0.1 µg/testis) resulted in a significant increase in basal 
testosterone secretion in vitro and serum testosterone concentration after 24 hours. 
Six days after treatment, the cytokine induced opposite effect in animals with two 
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testes in situ, i.e., it suppressed steroidogenesis. No effect was seen on LH or FSH. 
In adult animals subjected to bilateral treatment or to unilateral injection followed by 
hemicastration, IL1β (1.5 & 15 µg/testis) did not influence steroidogenesis and serum 
testosterone concentration. No change in serum LH and FSH concentration could be 
observed in any experimental group (Gerendai et al., 2005).  
 
In a similar study design, intratesticular administration of IL1β in immature 
hemicastrated rats induced a significant rise in testosterone secretion after 24 hours 
that could be prevented by vasectomy (that also means transection of the inferior 
spermatic nerve) in a study indicating an interaction between testicular nerves, IL1β 
action and testicular seratonin (5-HT2) receptors and local effect of IL1β on 
testosterone secretion (Gerendai et al., 2007). In human NCI-H295R adrenocortical 
cells, IL1β showed an increase in cortisol, androstenedione and DHEA synthesis in a 
dose-dependent relationship from 0.001 – 10 ng/ml (1 – 10000 pg/ml) at intervals of 
24 and 48 hours. This was associated with increased mRNA’s for StAR, CYP17 and 
3β-HSD (Tkachenko et al., 2011).  More recently, Wu and colleagues (2012) 
reported that a significant decrease in cell viability in TM3 Leydig cells exposed to 
0.02 pg/ml IL1β. Interestingly, thiswas prevented by co-stimulation of Sirt1 
(associated with cellular protection from inflammatory stress) activation via 
resveratrol (Wu et al., 2012).   
 
4.7.4. Interleukin 6 
 
Similarly to IL1β, IL6 showed a more subtle decline in cell viability as opposed to that 
observed in TNFα. A dose-dependent decline in cell viability was observed. Protein 
was significantly decreased only at 100 pg/ml IL6 concentration. Again, very similar 
results to IL1β for both testosterone and progesterone were found. Testosterone 
decline was observed in a dose-dependent manner for all concentrations. A more 
marked effect was observed for progesterone, with a very dramatic decline in 
progesterone concentrations at all IL6 concentrations. This more marked effect also 
indicates some specific action on the cholesterol conversions to progesterone 
pathways. As there was a generally small negative effect on testosterone and protein 
at all concentrations, the testosterone-to-protein ratio was not significantly different 
compared to the control at all concentrations. In contrast, there was a significant and 
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dose-dependent decline in progesterone-to-protein ratio at all IL6 concentrations, 
reflecting the specific negative action on progesterone synthesis.  
 
Although the effects of TNFα and IL1 (to a lesser degree IL1β) on Leydig cell 
steroidogensis have been investigated, but not fully elicited, the effect of IL6 has 
been less studies in controlled experiments (Hales et al., 1999). It is indicated that 
IL6 comprimised cAMP induced expression of CYP17 and, interestingly, 17β-HSD, 
at concentrations of 100 ng/ml in primary mouse Leydig cells (Hales et al., 1999). 
Tsigos and colleagues (1999) injected increasing single doses of IL6 (0.1, 0.3, 1.0, 
3.0, and 10.0 µg/kg body weight) subcutaneously into 15 healthy male volunteers. 
The three higher IL6 doses caused significant decreases in testosterone levels at 24 
and 48 hours, returning to baseline by 7 days, with maximal effect at 3 µg/kg. This 
was associated with a small but significant increase in LH at these doses, but no 
change for FSH and SHBG.   
 
IL6 may induce resistance to LH mediated steroidogenesis in Leydig cells (Tsigos et 
al., 1999). Hales (2002) has reported that IL6 decreases CYP17 and 3βHSD. Wu 
and colleagues (2012) reported a significant decrease in cell viability in TM3 Leydig 
cells exposed to 0.02 pg/ml IL6 was prevented by co-stimulation of Sirt1 (associated 
with cellular protection from inflammatory stress) activation via resveratrol. IL6 is 
suggested to increase mineralocorticoids (aldosterone), glucocorticoids (cortisol) and 
androgens (DHEA) synthesis in a dose- and time- dependant manner. At 
concentrations of 10-8 – 10-12 mol/L, IL6 stimulation of adrenal hormones reached a 
peak after 48 hours in adrenal cells obtained from male patients 50 - 61 years of age 
following nephrectomy with unilateral adrenalectomy (Päth et al., 1997). IL6 appears 
to up-regulate adrenal steroidogenesis. However, this appears to be focused on 
glucocorticoids predominantly (Bornstein et al., 2004). Yet, it is not certain if the 
effects on androgens in testes would be similar however.   
 
4.7.5. Interleukin 8 
 
IL8 was associated with a dose-dependent and significant increase in cell viability. 
This would reflect either cellular stress or cellular stimulation, which is unclear with 
this data. Protein concentrations were not significantly different from the control at 
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0.1 or 1 pg/ml concentrations. There was a significant decrease in protein at 10 
pg/ml. In contrast, there was a significant increase in protein at 100 pg/ml. The 
ANOVA repeated measures analysis of variance was not statistically significant, 
however, the ANOVA one-way analysis of variance did reach statistical significance.   
 
There was no specific or significant effect on testosterone concentration, with no 
difference between the various IL8 concentrations and testosterone. The 
testosterone-to-protein ratio showed various results at the 0.1 and 10 pg/ml 
concentrations, with no significant change at the 1 and 100 pg/ml concentrations. At 
0.1 pg/ml, this was significantly (P<0.0001) increased, owing to a non-significant 
decline in protein and increase in testosterone at this concentration. As both protein 
concentration and testosterone changes at 0.1 pg/ml IL8 were not significant, the 
significance of the testosterone-to-protein ratio is questionable. In contrast, at a 
concentration of 100 pg/ml concentration, there was a significant decline in this ratio. 
This was mostly due to a significant increase in the protein concentration at  
100 pg/ml IL8 (testosterone had a non-significant decrease at 100 pg/ml). This is 
associated with an increase in cell viability, indicating increased metabolic activity. 
Progesterone was decreased at all concentrations. Although this decrease was not 
as marked as the negative association with IL1β and IL6, it indicates a more specific 
action on progesterone synthesis from cholesterol as opposed to testosterone 
synthesis from the progesterone pool. Based on the decline in progesterone, the 
progesterone-to-protein ratio showed a significant and dose-dependent decline at all 
concentrations of IL8.   
 
Unlike TNFα, IL1β and IL6, there appear to be no published investigations into the 
possible effects of IL8 on steroidogenesis in Leydig cells. In this study, testosterone 
is maintained, but progesterone decreased. It therefore appears that IL8 may 
influence progesterone via CYP17 or P450scc or StAR. As testosterone is not 
different from controls over 48 hours, this would imply that the ∆5-steroid pathway is 
at least maintained, for which CYP17 or P450scc and StAR are required. 
Progesterone is also a precursor hormone for mineralocorticoids and glucocorticoids. 
Therefore, it may be plausible that production of these hormones typically associated 
with adrenal glands is up-regulated by IL8, further drawing from the progesterone 
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pool, but leaving pregnenolone and the ∆5-steroid pathway intact for normal 
testosterone synthesis.  
 
4.7.6. Potential mechanisms of Leydig cell dysfunction in metabolic syndrome 
 
Adequate Leydig cell function with the central purpose of testosterone production via 
steroidogenesis cascades is critical not only for male reproduction, but in general for 
male health and well being (Walker et al., 2001; Midzak et al., 2009; Saad & Gooren, 
2011). MetS is closely associated with hypogonadism in males, and a decline in 
testosterone is a significant risk and aetiological factor in the pathogenesis of MetS 
(Kasturi et al., 2008; Saad & Gooren, 2011).  
 
It has been demonstrated that Leydig cell MMP, ATP synthesis and mitochondrial 
calcium concentrations are all required for steroidogenesis, and that this is a key 
control point for steroidogenesis (Hales et al., 2005). These mechanisms may be 
disrupted by oxidative stress (OS), and reactive oxygen species (ROS) are known to 
inhibit both ovarian and testicular steroidogenesis, most notably the initial step of 
cholesterol transfer into Leydig cell mitochondria (Diemer et al., 2003; Hales et al., 
2005; Midzak et al., 2009; Midzak et al., 2011).  
 
Typically, inflammation and OS occur in a close relationship together (in both 
infectious and non-infectious inflammation), and both of these phenomenoa have 
been well established in MetS patients (excessive OS in the setting of chronic 
inflammation) (Kasturi et al., 2008). As indicated by the results of the cell culture 
experiments and previous studies, inflammatory cytokines are able to down-regulate 
steroidogenesis at various stages. Furthermore, ROS disrupts various stages of 
steroidogenesis, including mitochondrial function and MMP, ATP synthesis by the 
mitochondria and StAR transcription (Diemer et al., 2003; Hales et al., 2005). 
Therefore, in the setting of chronic inflammation and OS associated with MetS, these 
mechanisms provide an important role in both the aetiology and propagation of MetS 
in males, negatively influencing reproductive potential and overall health and well 
being.  
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Ageing is associated with a significant decline in Leydig cell ability to produce 
testosterone in response to LH stimulation, with various mechanisms proposed 
(Midzak et al., 2009). For example, there is a reduction on cAMP production, StAR 
mRNA and the activity of P450scc, as are the activities of CYP17 and 3βHSD (Zirkin 
and Chen, 2000; Midzak et al., 2009). This is associated with a gradual decline in 
testosterone in ageing males (Midzak et al., 2009). Age is also a significant risk 
factor closely associated with the prevalence of MetS (Cameron et al., 2004; Pais et 
al., 2009; Potenza & Meckanick, 2009; Razzouk & Muntner, 2009). There is likely a 
close relationship between these phenomena that requires further understanding, 
both in terms of age related non-communicable chronic disease (e.g. MetS, T2DM, 
CVD, cancer) and male reproductive health.  
 
It is proposed that mitochondrial dysfunction has a key role in the development of 
insulin resistance (Kim et al., 2008). Furthermore, based on results from this study 
and previous studies (Lin et al., 1986; Bebakar et al., 1990; Pasquali  et al., 1995; 
Pasquali et al., 1997; Pitteloud et al., 2005a; Pitteloud et al., 2005b), insulin appears 
to have an independent role in steroidogenesis. Inflammatory and ROS-induced 
damage on mitochondria may create insulin resistance in the Leydig cells, further 
negatively impacting testosterone synthesis. The relationship between the role of the 
mitochondrial, ROS, cytokines, insulin and testosterone require further research. 
Detailed understanding of these pathways may open the possibility of novel 
treatments to improve steroidogensis in males with MetS, thereby potentially 
reversing the consequences of MetS and improving reproductive potential and 
sexual function. 
 
A further point of consideration is the potential change in role of testicular 
macrophages in MetS. A detailed review by Hales (2002) outlines the key regulatory 
roles macrophages have in Leydig cell function (and hence steroidogenesis) and 
Sertoli cell function (and hence spermatogenesis). These macrophages are distinct 
from macrophages elsewhere in the body, and secrete a variety of proteins, 
including cytokines, in a distinct manner. It is plausible that there may be a change in 
testicular macrophage function with MetS, negatively influencing steroidogenesis in 
the Leydig cells. This potentially critical relationship will require further investigation.  
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4.8. Conclusions 
 
The results of this study suggest that males diagnosed with MetS have reduced 
fertility potential as defined by standard fertility testing, MMP and DF. This has been 
observed in the absence of leukocytospermia and clinical detection of varicocele. 
Reduced peripheral free testosterone associated with males with MetS patients has 
been further confirmed. In addition, free peripheral progesterone concentrations 
have also been found to be lower in MetS patients compared to control, indicating a 
collapse in steroidogenesis. Closely associated with hyperinsulinaemia/insulin 
resistance, hyperleptinaemia and a proinflammatory state, seminal fluid analysis 
indicated an increase in seminal TNFα, IL1β, IL6, IL8, leptin and insulin in males with 
MetS, which can have detrimental consequences on ejaculated sperm function. The 
association of MetS with decreased male fertility parameters and reproductive tract 
inflammation in the absence of leukocytospermia is a novel, and warrant further 
investigations into these mechanisms. Furthermore, insulin and IL8 are highly 
concentrated in human semen in both healthy and MetS males, for unknown 
reasons. This requires further investigation. Numerous correlations between 
parameters have been identified, however, these results do not investigate causation 
of pathological changes associated with MetS and male reproductive health, and 
many are likely indirectly associated via the poorly understood MetS 
pathophysiology.  
 
TM3 cell culture data directly implicated the inflammatory cytokines TNFα, IL1β and 
IL6 in a dose dependent decline in steroidogenesis, and IL8 may stimulate TM3 
Leydig cell growth. Insulin is associated with a dose-dependent increase in 
testosterone synthesis, with a significant decline in progesterone synthesis. Insulin 
resistance may be associated with an impaired ability for insulin to stimulate 
testosterone synthesis. Although indications of these mechanisms have been 
previously published, the importance of inflammation and insulin resistance in male 
reproduction, spermatogeneis and steroidogensis in the setting of MetS has not 
been previously reported, and is a novel and exciting area for further research in the 
fields of andrology, immunology and endocinrology.  
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Taken together, important underlying metabolic, immune and endocrine 
phenomenon associated with MetS likely negatively influence steroidogensis and 
Leydig cell function, resulting in impaired reproductive potential and overall health 
and well being in males.  
 
This study provides novel insights into the impact and potential mechanisms 
between metabolic syndrome and male reproductive health. These areas may have 
important implications not only in the field of andrology and, but also for other 
disciples such as immunology and endocrinology.  
 
 
  
 
 
 
 
221 
 
 
REFERENCES 
 
Abbasihormozi S, Shahverdi A, Kouhkan A, Cheraghi J, Akhlaghi AA, Kheimeh A. 
2013. Relationship of leptin administration with production of reactive oxygen 
species, sperm DNA fragmentation, sperm parameters and hormone profile in the 
adult rat. Arch Gynecol Obstet 287(6):1241-9. 
 
Acosta-Martínez M. 2012. PI3K: An attractive candidate for the central integration of 
metabolism and reproduction. Front Endocrinol (Lausanne) 24;2:110. 
 
Acton BM, Juriscova A, Jurisica I, Casper RF. 2004. Alterations in mitochondrial 
membrane potential during preimplantation stages of mouse and human embryo 
development. Molecular Human Reproduction 10(1): 23-33. 
 
Agarwal A, Desai NR, Ruffoli R, Carpi A. 2008. Lifestyle and testicular dysfunction: a 
brief update. Biomed Pharmacother 62(8):550-3. 
 
Aggerholm AS, Thulstrup AM, Toft G, Ramlau-Hansen CH, Bonde JP. 2008. Is 
overweight a risk factor for reduced semen quality and altered serum sex hormone 
profile? Fertil Steril 90(3):619–26. 
 
Ahima RS, Flier JS. 2000. Leptin. Annu Rev Physiol 62:413. 
 
Ahn SW, Gang GT, Kim YD, Ahn RS, Harris RA, Lee CH, Choi HS. 2013. Insulin 
directly regulates steroidogenesis via induction of the orphan nuclear receptor DAX-1 
in testicular Leydig cells. J Biol Chem 288(22):15937-46. 
 
Aiston S, Agius L. 1999. Leptin enhances glycogen storage in hepatocytes by 
inhibition of phosphorylase and exerts an additive effect with insulin. Diabetes 
48:15–20. 
 
Aitken RJ. 2006. Sperm function tests and fertility. Int J Androl 29(1):69-75. 
 
 
 
 
 
222 
 
 
Alberti KG, Zimmet PZ. 1998. Definition, diagnosis, and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes 
mellitus provisional report of a WHO consultation. Diabet Med 15(7):539-553. 
 
Alberti KG, Zimmet P, Shaw J. 2005. The metabolic syndrome-a new worldwide 
definition. Lancet 366(9491):1059–1062. 
 
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, 
James WP, Loria CM, Smith SC Jr. 2009. Harmonizing the metabolic syndrome: a 
joint interim statement of the International Diabetes Federation Task Force on 
Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American 
Heart Association; World Heart Federation; International Atherosclerosis Society; 
and International Association for the Study of Obesity. Circulation 120(16):1640-5. 
 
Alexander RB, Ponniah S, Hasday J, Hebel JR. 1998. Elevated levels of 
proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic 
pelvic pain syndrome. Urology 52(5):744-9. 
 
Alves MG, Martins AD, Rato L, Moreira PI, Socorro S, Oliveira PF. 2013. Molecular 
mechanisms beyond glucose transport in diabetes-related male infertility. Biochim 
Biophys Acta. 1832(5):626-35. 
 
Amaral S, Oliveira PJ, Ramalho-Santos J. 2008. Diabetes and the impairment of 
reproductive function: possible role of mitochondria and reactive oxygen species. 
Curr Diabetes Rev 4(1):46-54. 
 
Andersen ML, Tufik S. 2006. Does male sexual behavior require progesterone? 
Brain Res Rev 51(1):136-43. 
 
Andò S, Aquila S. 2005. Arguments raised by the recent discovery that insulin and 
leptin are expressed in and secreted by human ejaculated spermatozoa. Mol Cell 
Endocrinol 245(1-2):1-6. 
 
 
 
 
 
223 
 
 
Aquila S, Gentile M, Middea E, Catalano S, Andò S. 2005a. Autocrine regulation of 
insulin secretion in human ejaculated spermatozoa. Endocrinology 146(2):552-7. 
 
Aquila S, Gentile M, Middea E, Catalano S, Morelli C, Pezzi V, Andò S. 2005b. 
Leptin secretion by human ejaculated spermatozoa. J Clin Endocrinol Metab 
90(8):4753-61. 
 
Araneta MR, Barrett-Connor E. 2005. Ethnic differences in visceral adipose tissue 
and type 2 diabetes: Filipino, African-American, and white women. Obes Res 
13(8):1458-65. 
 
Arican O, Aral M, Sasmaz S, Ciragil P. 2005. Serum levels of TNF-α, IFN-γ, IL-6, IL-
8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with 
disease severity. Mediators Inflamm 5:273–279.  
 
Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. 2003. Weak 
and non-independent association between plasma TAFI antigen levels and the 
insulin resistance syndrome. J Thromb Haemost 1(4):791–97. 
 
Avicenna. 1593. The disadvantages of excessive weight. In: Avicenna. The canon of 
medicine, book IV: diseases involving more than one member; the Cosmetic art. 
Rome: Medical Press: 173–174. 
 
Baccetti B, La Marca A, Piomboni P, Capitani S, Bruni E, Petraglia F, De Leo V. 
2002. Insulin-dependent diabetes in men is associated with hypothalamo-pituitary 
derangement and with impairment in semen quality. Hum Reprod 17(10):2673–2677. 
 
Baggiolini M, Clark-Lewis I. 1992. Interleukin-8, a chemotactic and inflammatory 
cytokine. FEBS Lett 307(1):97-101. 
 
Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. 2007. The 
correlation between adiposity and adiponectin, tumor necrosis factor alpha, 
interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size 
associated with inflammation in adults? J Endocrinol Invest 30(3):210-4. 
 
 
 
 
224 
 
 
Bakos HW, Henshaw RC, Mitchell M, Lane M. 2011. Paternal body mass index is 
associated with decreased blastocyst development and reduced live birth rates 
following assisted reproductive technology. Fertil Steril 95(5):1700-4.  
 
Baldi E, Luconi M, Bonaccorsi L, Forti G. 2002. Signal transduction pathways in 
human spermatozoa. J Reprod Immunol 53(1-2):121-31. 
 
Balkau B, Charles MA. 1999. Comment on the provisional report from the WHO 
consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet 
Med 16(5):442-443 
 
Banks WA. 2004. The source of cerebral insulin. Eur J Pharm 490(1-3):5–12. 
 
Barratt CL, Mansell S, Beaton C, Tardif S, Oxenham SK. 2011. Diagnostic tools in 
male infertility-the question of sperm dysfunction. Asian J Androl 13(1):53-8. 
 
Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. 
2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous 
adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 
85(9):3338-42. 
 
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. 
2006. Recent advances in the relationship between obesity, inflammation, and 
insulin resistance. Eur Cytokine Netw 17(1):4-12. 
 
Basu S, Aballa TC, Ferrell SM, Lynne CM, Brackett NL. 2004. Inflammatory cytokine 
concentrations are elevated in seminal plasma of men with spinal cord injuries. J 
Androl 25(2):250-254. 
 
Bebakar WM, Honour JW, Foster D, Liu YL, Jacobs HS. 1990. Regulation of 
testicular function by insulin and transforming growth factor-beta. Steroids 55(6):266-
70. 
 
 
 
 
 
225 
 
 
Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. 2004. 
Intranasal insulin improves memory in humans. Psychoneuroendocrinology 
29(10):1326–34.  
 
Benitez A, Perez Diaz J. 1985. Effect of streptozotocin-diabetes and insulin 
treatment on regulation of Leydig cell function in the rat. Horm Metab Res 17(1):5-7. 
 
Behre HM, Nieschlag E. 2000. Testosterone substitution in the aging man. Urologe A 
39(5):421-4. 
 
Białas M, Fiszer D, Rozwadowska N, Kosicki W, Jedrzejczak P, Kurpisz M. 2009. 
The role of IL-6, IL-10, TNF-alpha and its receptors TNFR1 and TNFR2 in the local 
regulatory system of normal and impaired human spermatogenesis. Am J Reprod 
Immunol 62(1):51–9. 
 
Björntorp P. 2001. Do stress reactions cause abdominal obesity and comorbidities? 
Obes Rev 2(2):73-86. 
 
Blanchette S, Marceau P, Biron S, Brochu G, Tchernof A. 2006. Circulating 
progesterone and obesity in men. Horm Metab Res 38(5):330-5. 
 
Bobjer J, Naumovska M, Giwercman YL, Giwercman A. 2012. High prevalence of 
androgen deficiency and abnormal lipid profile in infertile men with non-obstructive 
azoospermia. Int J Androl 35(5):688-94. 
 
Boden G, Chen X, Ruiz J, et al. 1994. Mechanisms of fatty acid-induced inhibition of 
glucose uptake. J Clin Invest 93(6):2438–2446. 
 
Bornstein SR, Rutkowski H, Vrezas I. 2004. Cytokines and steroidogenesis. Mol Cell 
Endocrinol 215(1-2):135-41. 
 
Boyanov MA, Boneva Z, Christov VG. 2003. Testosterone supplementation in men 
with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 
6(1):1–7. 
 
 
 
 
226 
 
 
Brange J, Langkjoer L. 1993. Insulin structure and stability. Pharm Biotechnol 5:315-
50. 
 
Braun S, Bitton-Worms K, LeRoith D. 2011. The link between the metabolic 
syndrome and cancer. Int J Biol Sci 7(7):1003-15. 
 
Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. 
2001. What are the physical characteristics associated with a normal metabolic 
profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol 
Metab 86(3):1020-5. 
 
Brooks GC, Blaha MJ, Blumenthal RS. 2010. Relation of C-reactive protein to 
abdominal adiposity. Am J Cardiol 106(1):56-61. 
 
Brown GL, McGarvey EL, Shirtcliff EA, Keller A, Granger DA, Flavin K. 2008. 
Salivary cortisol, dehydroepiandrosterone, and testosterone interrelationships in 
healthy young males: a pilot study with implications for studies of aggressive 
behavior. Psychiatry Res 159(1-2):67-76. 
 
Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, 
Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A,  Lowe 
GDO, Stansfeld SA, Marmot MG. 2002. Adrenocortical, autonomic, and inflammatory 
causes of the metabolic syndrome. Circulation 106(21):2659-2665. 
 
Bruun JM, Pedersen SB, Richelsen B. 2001. Regulation of interleukin 8 production 
and gene expression in human adipose tissue in vitro. The Journal of Clinical 
Endocrinology and Metabolism 86(3):1267–1273. 
 
Brzozowski AM, Weiss MA, Ward CW, Lawrence MC. 2013. How insulin engages its 
primary binding site on the insulin receptor. Nature 10;493(7431):241-5.  
 
Cabler S, Agarwal A, Flint M, du Plessis SS. 2010. Obesity: modern man's fertility 
nemesis. Asian J Androl 12(4):480-9. 
 
 
 
 
 
227 
 
 
Camera A, Hopps E, Caimi G. 2008. Metabolic syndrome: from insulin resistance to 
adipose tissue dysfunction. Minerva Med 99(3):307-21. 
 
Cameron AJ, Shaw JE, Zimmet PZ. 2004. The metabolic syndrome: prevalence in 
worldwide populations. Endocrinol Metab Clin North Am 33(2):351–375. 
 
Camiña JP, Lage M, Menendez C, Graña M, García-Devesa J, Dieguez C, 
Casanueva FF. 2002. Evidence of free leptin in human seminal plasma. Endocrine 
17(3):169-174.  
 
Caprio M, Isidori AM, Carta AR, Moretti C, Dufau ML, Fabbri A. 1999. Expression of 
functional leptin receptors in rodent Leydig cells. Endocrinology 140(11):4939-47. 
 
Calkins JH, Sigel MM, Nankin HR, Lin T. 1988. Interleukin-1 inhibits Leydig cell 
steroidogenesis in primary culture.Endocrinology 123(3):1605-10. 
 
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, 
and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J 
Med 348(17):1625-38. 
 
Camejo MI, Segnini A, Proverbio F. 2001. Interleukin-6 (IL-6) in seminal plasma of 
infertile men, and lipid perioxidation of their sperm. Arch Androl 47(2):97-101. 
 
Casabiell X, Piñeiro V, Vega F, De La Cruz LF, Diéguez C, Casanueva FF. 2001. 
Leptin, reproduction and sex steroids. Pituitary 4(1-2):93-9. 
 
Chadwick J, Mann WN. 1950. Medical works of Hippocrates. Boston, MA: Blackwell 
Scientific Publications: p154. 
 
Chandola T, Brunner E, Marmot M. 2006. Chronic stress at work and the metabolic 
syndrome: prospective study. BMJ 4;332(7540):521-5. 
 
 
 
 
 
228 
 
 
Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R. 2010. Body mass index in 
relation to semen quality, sperm DNA integrity, and serum reproductive hormone 
levels among men attending an infertility clinic. Fertil Steril 93(7):2222-31. 
 
Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. 2004. 
Relationship to insulin resistance of the Adult Treatment Panel III Diagnostic Criteria 
for identification of the syndrome. Diabetes 53(5):1195–1200. 
 
Chemes HE, Rawe YV. 2003. Sperm pathology: a step beyond descriptive 
morphology. Origin, characterization and fertility potential of abnormal sperm 
phenotypes in infertile men. Hum Reprod Update 9(5):405-428. 
 
Chen JJ, Berlin FS, Margolis S. 1986. Effect of large-dose progesterone on plasma 
levels of lipids, lipoproteins and apolipoproteins in males. J Endocrinol Invest 
9(4):281-5. 
 
Cheng JY, Mg EM. 2007. Body mass index, physical activity and erectile 
dysfunction: an u-shaped relationship from population based study. Int J Obes 
31(10):1571-1578. 
 
Coetzee K, Kruge TF, Lombard CJ. 1998. Predictive value of normal sperm 
morphology: a structured literature review. Hum Reprod Update 4(1):73-82. 
 
Correa-Pérez JR, Fernández-Pelegrina R, Aslanis P, Zavos PM. 2004. Clinical 
management of men producing ejaculates characterized by high levels of dead 
sperm and altered seminal plasma factors consistent with epididymal necrospermia. 
Fertil Steril 81(4):1148-1150. 
 
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH. 2004. 
Sex hormones influence on the immune system: basic and clinical aspects in 
autoimmunity. Lupus 13(9):635–638. 
 
Dada R, Thilagavathi J, Venkatesh S, Esteves SC, Agarwal A. 2011. Genetic testing 
in male infertility. The Open Reproductive Science Journal 3:42-56. 
 
 
 
 
229 
 
 
Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A. 2003. The Gly16-
Arg16 and Gln27-Glu27 polymorphisms of beta2-adrenergic receptor are associated 
with metabolic syndrome in men. J Clin Endocrinol Metab 88(10):4862–66. 
 
Das UN. 2006. Biological significance of essential fatty acids. J Assoc Physicians 
India 54:309–319. 
 
De Amicis F, Guido C, Perrotta I, Avena P, Panza S, Andò S, Aquila S. 2011. 
Conventional progesterone receptors (PR) B and PRA are expressed in human 
spermatozoa and may be involved in the pathophysiology of varicocoele: a role for 
progesterone in metabolism. Int J Androl 34(5 Pt 1):430-45. 
 
De Felice FG. 2013. Alzheimer's disease and insulin resistance: translating basic 
science into clinical applications. J Clin Invest 123(2):531-9. 
 
DeFronzo RA, Ferrannini E. 1991. Insulin resistance. A multifaceted syndrome 
responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic 
cardiovascular disease. Diabetes Care 14(3):173-94. 
 
Deurenberg P, Deurenberg-Yap M, Guricci S. 2002. Asians are different from 
Caucasians and from each other in their body mass index/body fat per cent 
relationship. Obes Rev 3(3):141-6. 
 
Diamandis EP, Arnett WP, Foussias G, Pappas H, Ghandi S, Melegos DN, Mullen B, 
Yu H, Srigley J, Jarvi K. 1999. Seminal plasma biochemical markers and their 
association with semen analysis findings. Urology 53(3):596-603. 
 
Diemer T, Allen JA, Hales KH, Hales DB. 2003. Reactive oxygen disrupts 
mitochondria in MA-10 tumor Leydig cells and inhibits steroidogenic acute regulatory 
(StAR) protein and steroidogenesis. Endocrinology 144(7):2882-91. 
 
Dohle GR, Smit M, Weber RF. 2003. Androgens and male fertility. World J Urol 
21(5):341-5. 
 
 
 
 
 
230 
 
 
Dohle GR, Colpi GM, Hargreave TB, Papp GK, Jungwirth A, Weidner W; EAU 
Working Group on Male Infertility. 2005. EAU guidelines on male infertility. Eur Urol 
48(5):703-11. 
 
Domínguez-Fandos D, Camejo MI,  Ballescà JL, Oliva R. 2007. Human sperm DNA 
fragmentation: correlation of TUNEL results as assessed by flow cytometry and 
optical microscopy. Cytometry A 71(12):1011-8. 
 
Donato J Jr, Frazão R, Elias CF. 2010. The PI3K signaling pathway mediates the 
biological effects of leptin. Arq Bras Endocrinol Metabol 54(7):591-602. 
 
Dousset B, Hussenet F, Daudin M, Bujan L, Foliguet B, Nabet P. 1997. Seminal 
cytokine concentrations (IL-1b, IL-2, IL-6, sR IL-2, sR IL-6), semen parameters and 
blood hormonal status in male infertility. Hum Reprod 12(7):1476–1479. 
 
Dubey N, Lal B. 2009. Paracrine role of macrophage produced-nitric oxide (NO) in 
Leydig cell steroidogenesis in a teleost, Clarias batrachus: Impact of gonadotropin, 
growth hormone and insulin on NO production by testicular macrophages. Gen 
Comp Endocrinol 160(1):12-8. 
 
Du Plessis SS, Cabler S, McAlister DA, Sabanegh E, Agarwal A. 2010. The Effect of 
Obesity on Sperm Disorders and Male Infertility. Nat Rev Urol 7(3):153-61. 
 
Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet 
365(9468):1415-28. 
 
Eggert-Kruse W, Reimann-Andersen J, Rohr G, Pohl S, Tilgen W, Runnebaum B. 
1995. Clinical relevance of sperm morphology assessment using strict criteria and 
relationship with sperm-mucus interaction in vivo and in vitro. Fertil Steril 63(3):612-
24. 
 
Eggert-Kruse W, Boit R, Rohr G, Aufenanger J, Hund M, Strowitzki T. 2001. 
Relationship of seminal plasma interleukin (IL) -8 and IL-6 with semen quality. Hum 
Reprod 16(3):517-528. 
 
 
 
 
231 
 
 
Eggert-Kruse W, Kiefer I, Beck C, Demirakca T, Strowitzki T. 2007. Role for tumor 
necrosis factor alpha (TNF-alpha) and interleukin 1-beta (IL-1beta) determination in 
seminal plasma during infertility investigation. Fertil Steril 87(4):810-823. 
 
Emiliozi C, Cordonier H, Guerin JF, Ciapa B, Benchaib M, Fenichel P. 1996. Effects 
of progesterone on human spermatozoa prepared for in-vitro fertilization. Int J Androl 
19(1):39–47. 
 
Endtz AW. 1974. A rapid staining method for differentiating granulocytes from 
‘germinal cells’ in Papanicolaou-stained semen. Acta Cytol 18(1):2-7. 
 
Enciso M, Muriel L, Fernández JL, Goyanes V, Segrelles E, Marcos M, Montejo JM, 
Ardoy M, Pacheco A, Gosálvez J. 2006. Infertile men with varicocele show a high 
relative proportion of sperm cells with intense nuclear damage level, evidenced by 
the sperm chromatin dispersion test. J Androl 27(1):106-11. 
 
Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. 2003. Historical perspective: 
visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De sedibus 
et causis morborum per anatomen indagata'. Int J Obes Relat Metab Disord 
27(4):534-5. 
 
Erkelens DW, deBruin TW, Cabezas MC. 1993. Tulp syndrome. Lancet 342:1536–
1537. 
 
Ervin RB. 2009. Prevalence of metabolic syndrome among adults 20 years of age 
and over, by sex, age, race and ethnicity, and body mass index: United States, 
2003–2006. Natl Health Stat Report 13:1–7. 
 
Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, 
Giugliano D. 2013a. Metabolic syndrome and postmenopausal breast cancer: 
systematic review and meta-analysis. Menopause [Epub ahead of print] 
 
 
 
 
 
 
232 
 
 
Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, 
Panagiotakos DB, Giugliano D. 2013b. Colorectal cancer association with metabolic 
syndrome and its components: a systematic review with meta-analysis. Endocrine 
[Epub ahead of print] 
 
Esposito K, Giugliano D. 2004. The metabolic syndrome and inflammation: 
association or causation? Nutr Metab Cardivasc Dis 14(5):228-232.  
 
Esteghamati A, Khalilzadeh O, Anvari M, Rashidi A, Mokhtari M, Nakhjavani M. 
2009. Association of serum leptin levels with homeostasis model assessment-
estimated insulin resistance and metabolic syndrome: the key role of central obesity. 
Metab Syndr Relat Disord 7(5):447-52. 
 
Esteves SC, Hamada A, Kondray V, Pitchika A, Agarwal A. 2012. What every 
gynecologist should know about male infertility: an update. Arch Gynecol Obstet 
286(1):217-29. 
 
Evenson DP, Wixon R. 2005. Environmental toxicants cause sperm DNA 
fragmentation as detected by the Sperm Chromatin Structure Assay (SCSA). Toxicol 
Appl Pharmacol 207(2 Suppl):532-7. 
 
Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. 2004. Comparison of the 
release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from 
visceral and subcutaneous abdominal adipose tissues of obese humans. 
Endocrinology 145(5):2273. 
 
Falsetti C, Baldi E, Krausz C, Casano R, Failli P, Forti G. 1993. Decreased 
responsiveness to progesterone of spermatozoa in oligozoospermic patients. J 
Androl 14(1):17–22. 
 
Fariello RM, Pariz JR, Spaine DM, Cedenho AP, Bertolla RP, Fraietta R. 2012. 
Association between obesity and alteration of sperm DNA integrity and mitochondrial 
activity. BJU Int 110(6):863-7. 
 
 
 
 
 
233 
 
 
Fejis I, Koloszar S, Szollosi J, Zavaczki Z, Pal A. 2005. Is Semen Quality Affected by 
Male Body Fat Distribution? Andrologia 37(5):155-159. 
 
Fejes I, Koloszár S, Závaczki Z, Daru J, Szöllösi J, Pál A. 2006. Effect of body 
weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 
52(2):97-102. 
 
Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart 
W. 2001. Circulating interleukin 6 levels, blood pressure and insulin sensitivity in 
apparently healthy men and women. J Clin Endocrinol Metab 86(3):1154-1159. 
 
Fernandez-Real JM, Ricart W. 2003. Insulin resistance and chronic cardiovascular 
inflammatory syndrome. Endocrine Reviews 24(3):278–301. 
 
Fernández JL, Muriel L, Goyanes V, Segrelles E, Gosálvez J, Enciso M, 
LaFromboise M, De Jonge C. 2005. Simple determination of human sperm DNA 
fragmentation with an improved sperm chromatin dispersion test. Fertil Steril 
84(4):833-42. 
 
Flier JS. 2004. Obesity Wars: Molecular Progress Confronts an Expanding Epidemic. 
Cell 116(2):337-350.  
 
Ford ES. 2005. Risks for all-cause mortality, cardiovascular disease, and diabetes 
associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 
28(7):1769–1778. 
 
Foresta C, Rossato M, Mioni R, Zorzi M. 1992. Progesterone induces capacitation in 
human spermatozoa. Andrologia 24(1):33–5. 
 
Fraczek M, Kurpisz M. 2007. Inflammatory mediators exert toxic effects of oxidative 
stress on human spermatozoa. J Androl 28(2):325–33. 
 
 
 
 
 
234 
 
 
Friebe K, Bohring C, Skrzypek J, Krause W. 2003. Levels of Interleukin-6 and 
Interleukin-8 in Seminal Fluid of Men Attending an Andrological Clinic. Andrologia 
35(2):126-129. 
 
Fried SK, Bunkin DA, Greenberg AS. 1998. Omental and subcutaneous adipose 
tissues of obese subjects release interleukin-6: depot difference and regulation by 
glucocorticoid. J Clin Endocrinol Metab 83(3):847-850. 
 
Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I. 2013. Mechanisms of 
chronic state of inflammation as mediators that link obese adipose tissue and 
metabolic syndrome. Mediators Inflamm 2013:136584. 
 
Fumeron F, Aubert R, Siddiq A, Betoulle D, Péan F, Hadjadj S, Tichet J, Wilpart E, 
Chesnier MC, Balkau B, Froguel P, Marre M; Epidemiologic Data on the Insulin 
Resistance Syndrome (DESIR) Study Group. 2004. Adiponectin gene 
polymorphisms and adiponectin levels are independently associated with the 
development of hyperglycemia during a 3-year period: the epidemiologic data on the 
insulin resistance syndrome prospective study. Diabetes 53(4):1150-7. 
 
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama 
O, Makishima M, Matsuda M, Shimomura I. 2004. Increased oxidative stress in 
obesity and its impact on metabolic syndrome. J Clin Invest 114(12):1752-61. 
 
Gale E. 2008. Should we dump the metabolic syndrome? Yes. BMJ 336(7645):640. 
 
Galic S, Oakhill JS, Steinberg GR. 2010. Adipose tissue as an endocrine organ. Mol 
Cell Endocrinol 316(2):129-39. 
 
Gallagher EJ, Leroith D, Karnieli E. 2010. Insulin resistance in obesity as the 
underlying cause for the metabolic syndrome. Mt Sinai J Med 77(5):511-23. 
 
Gallagher EJ NR, Yakar S. 2010. The Increased Risk of Cancer in Obesity and Type 
2 Diabetes: Potential Mechanisms. Principles of Diabetes Mellitus, 2nd ed. New 
York, USA: Springer 2010:579-99 
 
 
 
 
235 
 
 
 
Gallegos G, Ramos B, Santiso R, Goyanes V, Gosálvez J, Fernández JL. 2008. 
Sperm DNA fragmentation in infertile men with genitourinary infection by Chlamydia 
trachomatis and Mycoplasma. Fertil Steril 90(2): 328-34. 
 
Gallon F, Marchetti C, Jouy N, Marchetti P. 2006. The functionality of mitochondria 
differentiates human spermatozoa with high and low fertilizing capability. Fertil Steril 
86(5):1526–1530. 
 
García-Díez LC, Corrales Hernandez JJ, Hernandez-Diaz J, Pedraz MJ, Miralles JM. 
1991. Semen characteristics and diabetes mellitus: significance of insulin in male 
infertility. Arch Androl 26(2):119-28.  
 
George JA, Norris SA, van Deventer HE, Crowther NJ. 2013. The association of 25 
hydroxyvitamin D and parathyroid hormone with metabolic syndrome in two ethnic 
groups in South Africa. PLoS One 8(4):e61282. 
 
Gerendai I, Banczerowski P, Csernus V. 2005. Interleukin 1-beta injected into the 
testis acutely stimulates and later attenuates testicular steroidogenesis of the 
immature rat. Endocrine 28(2):165-70. 
 
Gerendai I, Banczerowski P, Csernus V, Halász B. 2007. Innervation and 
serotoninergic receptors of the testis interact with local action of interleukin-1beta on 
steroidogenesis. Auton Neurosci 30;131(1-2):21-7. 
 
Giagulli VA, Kaufman JM, Vermeulen A. 1994. Pathogenesis of the decreased 
androgen levels in obese men. J Clin Endocrinol Metab 79(4):997-1000. 
 
Giovambattista A, Suescun MO, Nessralla CC, França LR, Spinedi E, Calandra RS. 
2003. Modulatory effects of leptin on leydig cell function of normal and 
hyperleptinemic rats. Neuroendocrinology.  78(5):270-9. 
 
Glander HJ, Lammert A, Paasch U, Glasow A, Kratzsch J. 2002. Leptin exists in 
tubuli seminiferi and in seminal plasma. Andrologia 34(4):227-33. 
 
 
 
 
236 
 
 
 
Goncharov N, Katsya G, Dobracheva A, Nizhnik A, Kolesnikova G, Todua T, 
Lunenfeld B. 2005. Serum testosterone measurement in men: evaluation of modern 
immunoassay technologies. The Aging Male 8(3-4):194–202. 
 
Goncharov N, Katsya G, Dobracheva A, Nizhnik A, Kolesnikova G, Herbst V, 
Westermann J. 2006. Diagnostic significance of free salivary testosterone 
measurement using a direct luminescence immunoassay in healthy men and in 
patients with disorders of androgenic status. Aging Male 9(2):111-22. 
 
González C, Cava F, Ayllón A, Guevara P, Navajo JA, González-Buitrago JM. 2001. 
Biological variation of interleukin-1beta, interleukin-8 and tumor necrosis factor-alpha 
in serum of healthy individuals. Clin Chem Lab Med 39(9):836-41. 
 
Groop L. 2000. Genetics of the metabolic syndrome. Br J Nutr 83 Suppl 1:S39-48. 
 
Gruenewald DA, Hess DL, Wilkinson CW, Matsumoto AM. 1992. Excessive 
testicular progesterone secretion in aged male Fischer 344 rats: a potential cause of 
age-related gonadotropin suppression and confounding variable in aging studies. J 
Gerontol Biol Sci 47(5):B164–70. 
 
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart 
Association; National Heart, Lung, and Blood Institute. 2004. Definition of metabolic 
syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart 
Association conference on scientific issues related to definition. Circulation 
27;109(3):433-8. 
 
Grundy SM. 2006. Does the metabolic syndrome exist? Diabetes Care 29(7):1689–
1692. 
 
Gruschwitz MS, Brezinschek R, Brezenschek HP. 1996. Cytokine levels in seminal 
plasma of infertile males. J Androl 17(2):158-163. 
 
 
 
 
 
237 
 
 
Guay AT. 2009. The emerging link between hypogonadism and metabolic syndrome. 
J Androl 30(4):370–376. 
 
Guilherme A, Virbasius JV, Puri V, Czach MP. 2008. Adipocyte dysfunctions linking 
obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol  9(5):367–
377. 
 
Haffner SM. 2003. Insulin resistance, inflammation and the prediabetic shape. Am J 
Cardiol 92(suppl):18J-26J 
 
Haffner SM. 2006. The metabolic syndrome: inflammation, diabetes mellitus, and 
cardiovascular disease. Am J Cardiol 97(2A):3A-11A. 
 
Hagiuda J, Ishikawa H, Furuuchi T, Hanawa Y, Marumo K. 2012. Relationship 
between dyslipidaemia and semen quality and serum sex hormone levels: an 
infertility study of 167 Japanese patients. Andrologia doi: 10.1111/and.12057. [Epub 
ahead of print] 
 
Håkonsen LB, Thulstrup AM, Aggerholm AS, Olsen J, Bonde JP, Andersen CY, 
Bungum M, Ernst EH, Hansen ML, Ernst EH, Ramlau-Hansen CH. 2011. Does 
weight loss improve semen quality and reproductive hormones? Results from a 
cohort of severely obese men. Reprod Health 8:24. 
 
Hales DB, Diemer T, Hales KH. 1999. Role of cytokines in testicular function. 
Endocrine 10(3):201-17. 
 
Hales DB. 2002. Testicular macrophage modulation of Leydig cell steroidogenesis. J 
Reprod Immunol 57(1-2):3-18. 
Hales DB, Allen JA, Shankara T, Janus P, Buck S, Diemer T, Hales KH. 2005. 
Mitochondrial function in Leydig cell steroidogenesis. Ann N Y Acad Sci 1061:120-
34. 
 
Haller H. 1977. Epidemiology and associated risk factors of hyperlipoproteinemia. Z 
Gesamte Inn Med 32:124–128. 
 
 
 
 
238 
 
 
Hallschmid M, Benedict C, Schultes B, et al. 2008. Obese men respond to cognitive 
but not to catabolic brain insulin signaling. Int J Obes 32(2):275–282. 
 
Hamada A, Esteves SC, Agarwal A. 2011. The role of contemporary andrology in 
unraveling the mystery of unexplained male infertility. The Open Reproductive 
Science Journal 3: 27-41. 
 
Hamada A, Esteves SC, Nizza M, Agarwal A. 2012a. Unexplained male infertility: 
diagnosis and management. Int Braz J Urol 38(5):576-94.  
 
Hamada AJ, Montgomery B, Agarwal A. 2012b. Male infertility: a critical review of 
pharmacologic management. Expert Opin Pharmacother 13(17):2511-31. 
 
Hammoud AO, Gibson M, Peterson CM, Meikle W, Carrell DT. 2008(a). Impact of 
male obesity on infertility: a critical review of the current literature. Fert Steril, 
90(4):897-904 
 
Hammoud AO, Wilde N, Gibson M, Parks A, Carrell DT, Meikle AW. 2008(b). Male 
obesity and alteration in sperm parameters. Fertil Steril 90(6):2222–5. 
 
Hanafy S, Halawa FA, Mostafa T, Mikhael NW, Khalil KT. 2007. Serum leptin 
correlates in infertile oligozoospermic males. Andrologia 39(5):177-80. 
 
Hedger MP, Meinhardt A. 2003. Cytokines and the Immune-Testicular Axis. J 
Reprod Immunol 58(1):1-26. 
 
Hegele RA. 2003. Monogenic forms of insulin resistance: apertures that expose the 
common metabolic syndrome. Trends Endocrinol Metab 14(8):371–77. 
 
Henkel R, Schill WB. 1998. Sperm separation in patients with urogenital infections. 
Andrologia 30(Suppl 1):91–7. 
 
 
 
 
 
239 
 
 
Henkel R, Hajimohammad M, Stalf T, Hoogendijk C, Mehnert C, Menkveld R, Gips 
H, Schill W-B, Kruger TF. 2004. Influence of deoxyribonucleic acid damage on 
fertilization and pregnancy. Fertil Steril 81(4):965-972. 
 
Henkel R. 2005. The impact of oxidants on sperm function. Andrologia 37(6):205-6. 
 
Henkel R, Maaβ G, Jung A, Haidl G, Schill WB, Schuppe HC. 2007. Age-related 
changes in seminal polymorphonuclear elastase in men with asymptomatic 
inflammation of the genital tract. Asian J Androl 9(3): 299-304. 
 
Henkel R, Hoogendijk CF, Bouic PJ, Kruger TF. 2010. TUNEL assay and SCSA 
determine different aspects of sperm DNA damage. Andrologia 42(5):305-13. 
 
Henkel RR. 2011a. Leukocytes and oxidative stress: dilemma for sperm function and 
male fertility. Asian J Androl 13(1):43-52. 
 
Henkel R, Fransman WO, Hipler UC, Wiegand C, Schreiber G, Menkveld R, Weitz F, 
Fisher D. 2011b. Typha capensis (Rohrb.) N.E.Br. (bulrush) extract scavenges free 
radicals, inhibits collagenase activity and affects human sperm motility and 
mitochondrial membrane potential in vitro – a pilot study. Andrologia 44 (Suppl. 
1):287-294 
 
Hicks JJ, Rojas L, Rosado A. 1973. Insulin regulation of spermatozoa metabolism. 
Endocrinology 92(3):833-9. 
 
Hjollund NH, Bonde JP, Jensen TK, Olsen J. 2000. Diurnal scrotal skin temperature 
and semen quality. The Danish First Pregnancy Planner Team. Int J Androl 
23(5):309-318. 
 
Hodson L, Skeaff CM, Chisholm WA. 2001. The effect of replacing dietary saturated 
fat with polyunsaturated or monounsaturated fat on plasma lipids in free living young 
adults. European Journal of Clinical Nutrition 55(10):908-915.  
 
 
 
 
 
240 
 
 
Hofny ERM, Ali ME, Abdel-Hafez HZ, Kamal EED, Mohamed EE, El-Azeem HGA, 
Mostafa T. 2010. Semen parameters and hormonal profile in obese fertile and 
infertile males. Fertil Steril 94(2):581-4. 
 
Holvoet P. 2008. Relations between metabolic syndrome, oxidative stress and 
inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 70(3):193-
219. 
 
Hong CY, Park JH, Ahn RS, Im SY, Choi HS, Soh J, et al. 2004. Molecular 
mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine 
tumor necrosis factor alpha. Mol Cell Biol 24(7):2593–604. 
 
Hrebicek J, Janout V, Malinclikova J, Horakova D, Cizec L. 2002. Detection of insulin 
resistance by simple Quantitative Insulin Sensitivity Check Index (QUICKI) for 
epidemiological assessment and prevention. J Clin Endocrinol Metab 87(1):144-147. 
 
Hsing AW, Sakoda LC, Chua S Jr. 2007. Obesity, metabolic syndrome, and prostate 
cancer. Am J Clin Nutr 86(3):s843-57. 
 
Huang PL. 2009. A comprehensive definition for metabolic syndrome. DMM 2:231-
237. 
 
Huleihel M, Lunenfeld E, Levy A, Potashnik G, Glezerman M. 1996. Distinct 
expression levels of cytokines and soluble cytokine receptors in seminal plasma of 
fertile and infertile men. Fertil Steril 66(1):135. 
 
Huleihel M, Levy A, Lunenfeld E, Horowitz S, Potashnik G, Glezerman M. 1997. 
Distinct expression of cytokines and mitogenic inhibitory factors in semen of fertile 
and infertile men. Am J Reprod Immunol 37(4):304-9. 
 
Huleihel M, Lunenfeld E, Horowitz S, Levy A, Potashnik G, Mazor M, Glezerman M. 
1999. Expression of IL-12, IL-10, PGE2, sIL-2R and sIL-6R in seminal plasma of 
fertile and infertile men. Andrologia 31(5):283. 
 
 
 
 
 
241 
 
 
Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. 1999. Leptin 
and androgens in male obesity: evidence for leptin contribution to reduced androgen 
levels. J Clin Endocrinol Metab 84(10):3673–3680. 
 
Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. 2007. 
Interleukin-1beta-induced insulin resistance in adipocytes through downregulation of 
insulin receptor substrate-1 expression. Endocrinology 148(1):241–251. 
 
Jain SK, Kannan K, Prouty L, Jain SK. 2004. Progesterone, but not 17β-estradiol, 
increases TNF-α secretion in U937 monocytes. Cytokine 26(3):102–105. 
 
Jensen TK, Andersson AM, Jørgensen N, Andersen AG, Carlsen E, Petersen JH, 
Skakkebaek NE. 2004. Body mass index in relation to semen quality and 
reproductive hormones among 1,558 Danish men. Fertil Steril 82(4):863-70. 
 
Jochum M, Pabst W, Schill WB. 1986. Granulocyte Elastase as a Sensitive 
Diagnostic Parameter of Silent Male Genital Tract Inflammation. Andrologia 
18(4):413–9. 
 
Johanisson E, Campana A, Luthi R, de Agostini A. 2000. Evaluation of 'round cells' 
in semen analysis: a comparative study. Hum Reprod Update 6(4):404-12. 
 
Jope T, Lammert A, Kratzsch J, Paasch U. 2003. Leptin and Leptin Receptor in 
Human Seminal Plasma and Human Spermatozoa. Int J Androl 26(6):335–41. 
 
Juge-Aubry CE, Henrichot E, Meier CA. 2005. Adipose tissue: a regulator of 
inflammation. J Clin Endocrinol Met 19(4):547–566. 
 
Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, Krausz C; 
European Association of Urology Working Group on Male Infertility. 2012. European 
Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol 
62(2):324-32. 
 
 
 
 
 
242 
 
 
Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, El-Saed 
A, Miyamatsu N, Edmundowicz D, Kita Y, Sutton-Tyrrell K, Kuller LH, Ueshima H. 
2006. Japanese men have larger areas of visceral adipose tissue than Caucasian 
men in the same levels of waist circumference in a population-based study. Int J 
Obes (Lond) 30(7):1163-5. 
 
Kahn R. 2006. The metabolic syndrome (Emperor) wears no clothes. Diabetes Care 
29:1693–1696. 
 
Kalk WJ, Joffe BI. 2008. The metabolic syndrome, insulin resistance, and its 
surrogates in African and white subjects with type 2 diabetes in South Africa. Metab 
Syndr Relat Disord 6(4):247-55. 
 
Kaplan NM. 1989. The deadly quartet. Upper-body obesity, glucose intolerance, 
hypertriglyceridemia, and hypertension. Arch Intern Med 149(7):1514-20. 
 
Karnieli E, Armoni M. 2008. Transcriptional regulation of the insulin-responsive 
glucose transporter GLUT4 gene: from physiology to pathology. Am J Physiol 
Endocrinol Metab 295:E38–E45. 
 
Kasturi SS, Tannir J, Brannigan R. 2008. The metabolic syndrome and male 
infertility. J Androl 29:251–259. 
 
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. 2000. 
Quantitative insulin sensitivity check index: a simple, accurate method for assessing 
insulin sensitivity in humans. J Clin Endocrinol Metab 85(7):2402–2410. 
 
Kaukua J, Pekkarinen T, Sane T, Mustajoki P. 2003. Sex hormones and sexual 
function in obese men losing weight. Obes Res 11(6):689–94. 
 
Kefer JC, Agarwal A, Sabanegh E. 2009. Role of antioxidants in the treatment of 
male infertility. Int J Urol 16(5):449-57. 
 
 
 
 
 
243 
 
 
Ker J, Rheeder P, Van Tonder R. 2007. Frequency of the metabolic syndrome in 
screened South African corporate executives. Cardiovasc J S Afr 18(1):30-3. 
 
Kern S, Robertson SA, Mau VJ, Maddocks S. 1995. Cytokine secretion by 
macrophages in the rat testis. Biol Reprod 53(6):1407–1416. 
 
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. 2001. Adipose tissue 
tumor necrosis factor and interleukin 6 expression in human obesity and insulin 
resistance. Am J Physio 1280:E745-E751.  
 
Kern W, Benedict C, Schultes B, Plohr F, Moser A, Born J, Fehm HL, Hallschmid M. 
2006. Low cerebrospinal fluid insulin levels in obese humans. Diabetologia 
49(11):2790–2792. 
 
Khaodhiar L, Ling PR, Blackburn GL, Bistrian BR. 2004. Serum levels of interleukin-
6 and C-reactive protein correlate with body mass index across the broad range of 
obesity. JPEN J Parenter Enteral Nutr 28(6):410-5. 
 
Kim JA, Montagnani M, Koh KK, Quon MJ. 2006a. Reciprocal relationships between 
insulin resistance and endothelial dysfunction: molecular and pathophysiological 
mechanisms. Circulation 113(15):1888-1904. 
 
Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, 
Yu R. 2006b. Circulating levels of MCP-1 and IL-8 are elevated in human obese 
subjects and associated with obesity-related parameters. Int J Obes (Lond) 
30(9):1347-55. 
 
Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-
Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Blüher M, Unger T, Wolf AM, 
Knippschild U, Hombach V, Marx N. 2008. T-lymphocyte infiltration in visceral 
adipose tissue: a primary event in adipose tissue inflammation and the development 
of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 28(7):1304–
1310. 
 
 
 
 
 
244 
 
 
Koçak I, Yenisey C, Dündar M, Okyay P, Serter M. 2002. Relationship between 
seminal plasma interleukin-6 and tumor necrosis factor alpha levels with semen 
parameters in fertile and infertile men. Urol Res 30(4):263-7. 
 
Koch L, Wunderlich FT, Seibler J, Könner AC, Hampel B, Irlenbusch S, Brabant G, 
Kahn CR, Schwenk F, Brüning JC. 2008. Central insulin action regulates peripheral 
glucose and fat metabolism in mice. J Clin Invest 118(6):2132–2147. 
 
Kohn FM, Erdmann I, Oeda T, el Mulla KF, Schiefer HG, Schill WB. 1998. Influence 
of urogenital infections on sperm functions. Andrologia 30(Suppl 1):73–80. 
 
Kokab A,  Akhondi MM, Sadeghi MR, Modarresi MH, Aarabi M, Jennings R, Pacey 
AA, Eley A. 2010. Raised inflammatory markers in semen from men with 
asymptomatic chlamydial infection: Interleukin-8 in men with chlamydia. J Androl 
31(2):114-20. 
 
Kopa Z, Wenzel J, Papp GK, Haidl G. 2005. Role of granulocyte elastase and 
interleukin-6 in the diagnosis of male genital tract inflammation. Andrologia. 
37(5):188-94. 
 
Kort HI, Massey JB, Elsner CW, Mitchell-Leef D, Shapiro DB, Witt MA, Roudebush 
WE. 2006. Impact of body mass index values on sperm quantity and quality. J Androl 
27(3):450-2. 
 
Koumantakis E, Matalliotakis I, Kyriakou D, Fragouli Y, Relakis K.1998. Increased 
levels of interleukin-8 in human seminal plasma. Andrologia 30(6):339-43. 
 
Kriegel TM, Heidenreich F, Kettner K, Pursche T, Hoflack B, Grunewald S, Poenicke 
K, Glander HJ, Paasch U. 2009. Identification of diabetes- and obesity-associated 
proteomic changes in human spermatozoa by difference gel electrophoresis. Reprod 
Biomed Online 19(5):660-70. 
 
 
 
 
 
245 
 
 
Kruger TF, Menkveld R, Stander FS, Lombard CJ, Van der Merwe JP, van Zyl JA, 
Smith K. 1986. Sperm morphologic features as a prognostic factor in in vitro 
fertilization. Fertil Steril 46(6):1118-23. 
 
Kruger TF. 1993. The self teaching programme for strict sperm morphology. Bellville, 
South Africa, MQ Medical. 
 
Kuk JL, Ardern CI. 2009. Are metabolically normal but obese individuals at lower risk 
for all-cause mortality? Diabetes Care 32(12):2297-9. 
 
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. 2006. 
Low sex hormone-binding globulin, total testosterone, and symptomatic androgen 
deficiency are associated with development of the metabolic syndrome in nonobese 
men. J Clin Endocrinol Metab 91(3):843–850. 
 
Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. 
Front Endocrinol (Lausanne) 12;4:71. 
 
Lampiao F, du Plessis SS. 2008(a). Insulin and leptin enhance human sperm 
motility, acrosome reaction and nitric oxide production. Asian J Androl 10(5):799–
807. 
 
Lampiao F, du Plessis SS. 2008(b). TNF-alpha and IL-6 affect human sperm function 
by elevating nitric oxide production. Reprod Biomed Online 17(5):628-31. 
 
Lampiao F, Agarwal A, du Plessis SS. 2009. The role of insulin and leptin in male 
reproduction. Arch Med Sci 5(1A):S48-S54. 
 
La Vignera S, Condorelli RA, Vicari E, Calogero AE. 2011. Semen alterations and 
flow-citometry evaluation in patients with male accessory gland infections (MAGI). J 
Androl 35(2):219-23. 
 
 
 
 
 
246 
 
 
La Vignera S, Condorelli R, Vicari E, D'Agata R, Calogero AE. 2012a. Diabetes 
mellitus and sperm parameters. J Androl 33(2):145-53.  
 
La Vignera S, Condorelli RA, Vicari E, Calogero AE. 2012b. Negative effect of 
increased body weight on sperm conventional and nonconventional flow 
cytometric spermparameters. J Androl 33(1):53-8.  
 
La Vignera S, Condorelli R, Vicari E, D'Agata R, Calogero AE. 2012c. Effects of 
varicocelectomy on sperm DNA fragmentation, mitochondrial function, chromatin 
condensation, and apoptosis. J Androl 33(3):389-96. 
 
Lear SA, Humphries KH, Kohli S, Birmingham CL. 2007. The use of BMI and waist 
circumference as surrogates of body fat differs by ethnicity. Obesity (Silver Spring) 
15(11):2817-24. 
 
Lewis SE. 2007. Is sperm evaluation useful in predicting human fertility? 
Reproduction 134(1):31-40. 
 
Lewis SE, Simon L. 2010. Clinical implications of sperm DNA damage. Hum Fertil 
(Camb) 13(4):201-7. 
 
Li HW, Chiu PC, Cheung MP, Yeung WS, O WS. 2009. Effect of leptin on motility, 
capacitation and acrosome reaction of human spermatozoa. Int J Androl 32(6):687-
94. 
 
Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey 
WT. 2004. Critical evaluation of Adult Treatment Panel III criteria in identifying insulin 
resistance with dyslipidaemia. Diabetes Care 27(4):978-983. 
 
Lin T, Haskell J, Vinson N, Terracio L. 1986. Characterization of insulin and insulin-
like growth factor I receptors of purified Leydig cells and their role in steroidogenesis 
in primary culture: a comparative study. Endocrinology 119(4):1641-7. 
 
 
 
 
 
247 
 
 
Lin T, Wang TL, Nagpal ML, Calkins JH, Chang WW, Chi R. 1991. Interleukin-1 
inhibits cholesterol side-chain cleavage cytochrome P450 expression in primary 
cultures of Leydig cells. Endocrinology 129(3):1305-11. 
 
Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML,Wang DJ, Klein AS, Bulkley 
GB, Bao C, Noble PW, Lane MD, Diehl AM. 1998. Leptin regulates proinflammatory 
immune responses. FASEB J 12(1):57-65. 
 
Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI.1998. Leptin 
Modulates the T-Cell Immune Response and Reverses Starvation-Induced 
Immunosuppression. Nature 394(6696):897- 901. 
 
Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci 
I, Forti G, Adorini L, Maggi M. 2011. Elevated body mass index correlates with higher 
seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the 
prostate in men attending an andrology clinic for infertility. J Endocrinol Invest 
34(10):e336-42. 
 
Lotti F, Corona G, Degli Innocenti S, Filimberti E, Scognamiglio V, Vignozzi L, Forti 
G, Maggi M. 2013a. Seminal, ultrasound and psychobiological parameters correlate 
with metabolic syndrome in male members of infertile couples. Andrology 1(2):229-
39. 
 
Lotti F, Maggi M. 2013b. Interleukin 8 and the male genital tract. J Reprod Immunol 
pii: S0165-0378(13)00046-6. doi: 10.1016/j.jri.2013.02.004. [Epub ahead of print] 
 
Luboshitzky R, Lavie L, Shen-Orr Z, Herer P. 2005. Altered luteinizing hormone and 
testosterone secretion in middle-aged obese men with obstructive sleep apnea. 
Obes Res 13(4):780-786. 
 
Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. 2007. Increased inflammatory 
properties of adipose tissue macrophages recruited during diet-induced obesity. 
Diabetes 56(1):16–23. 
 
 
 
 
 
248 
 
 
Ma Q, Sun X, Chen Y, Chen X, Zhi G, Tan G. 2009. Progesterone levels and carotid 
intima-media thickness: a negative association in older northern Chinese men. Tex 
Heart Inst J 36(4):303-8. 
 
MacDonald AA, Herbison GP, Showell M, Farquhar CM. 2010. The impact of body 
mass index on semen parameters and reproductive hormones in human males: a 
systematic review with meta-analysis. Hum Reprod Update 16(3):293-311. 
 
Maes M, Twisk FNM, Kubera M, Ringel K. 2011. Evidence for inflammation and 
activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-α, PMN-
elastase, lysozyme and neopterin. J Affect Disord 136(3):933-9. 
 
Makker K, Varghese A, Desai NR, Mouradi R, Agarwal A. 2009. Cell phones: 
modern man's nemesis? Reprod Biomed Online 18(1):148-57. 
 
Malendowicz W, Rucinski M, Macchi C, Spinazzi R, Ziolkowska A, Nussdorfer GG, 
Kwias Z. 2006. Leptin and leptin receptors in the prostate and seminal vesicles of the 
adult rat. Int. J. Mol. Med. 18(4):615–8. 
 
Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. 2005. Cardiovascular 
Disease in U.S. Patients with Metabolic Syndrome, Diabetes and Elevated C-
Reactive Protein. Diabetes Care 28(3):690-693. 
 
Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. 2004. The effect 
of testosterone replacement on endogenous inflammatory cytokines and lipid profiles 
in hypogonadal men. J Clin Endocrinol Metab 89(7):3313–3318. 
 
Mallidis C, Czerwiec A, Filippi S, O'Neill J, Maggi M, McClure N. 2011. 
Spermatogenic and sperm quality differences in an experimental model of metabolic 
syndrome and hypogonadal hypogonadism. Reproduction 142(1):63-71. 
 
 
 
 
 
249 
 
 
Manna PR, Chandrala SP, Jo Y, Stocco DM. 2006. cAMP-independent signaling 
regulates steroidogenesis in mouse Leydig cells in the absence of StAR 
phosphorylation. J Mol Endocrinol 37(1):81-95. 
 
Marchetti P, Ballot C, Jouy N, Thomas P, Marchetti C. 2012. Influence of 
mitochondrial membrane potential of spermatozoa on in vitro fertilisation outcome. 
Andrologia. 44(2):136-41. 
 
Martinez R, Proverbio F, Camejo MI. 2007. Sperm lipid perioxidation and pro-
inflammatory cytokines. Asian J Androl 9(1):102-107. 
 
Martínez-Prado E, Camejo Bermúdez MI. 2010. Expression of IL-6, IL-8, TNF-alpha, 
IL-10, HSP-60, anti-HSP-60 antibodies, and anti-sperm antibodies, in semen of men 
with leukocytes and/or bacteria. Am J Reprod Immunol 63(3):233-43. 
 
Matalliotakis I, Kiriakou D, Fragouli I, Sifakis S, Eliopoulos G, Koumantakis E. 1998.  
Interleukin-6 in seminal plasma of fertile and infertile men. Arch Androl 41(1):43–50. 
 
Matarese G, et al. 2002. Balancing susceptibility to infection and autoimmunity: a 
role for leptin? Trends Immunol 23(4): 182 -7. 
 
Matsha T, Hassan S, Bhata A, Yako Y, Fanampe B, Somers A, Hoffmann M, 
Mohammed Z, Erasmus RT. 2009. Metabolic syndrome in 10-16-year-old learners 
from the Western Cape, South Africa: Comparison of the NCEP ATP III and IDF 
criteria. Atherosclerosis 205(2):363-6. 
 
Mauduit C, Gasnier F, Rey C, Chauvin MA, Stocco DM, Louisot P, et al. 1998. 
Tumor necrosis factor-alpha inhibits Leydig cell steroidogenesis through a decrease 
in steroidogenic acute regulatory protein expression. Endocrinology 139(6):2863–8. 
 
McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH, Roche 
HM. 2011. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-
induced adipose tissue inflammation coincident with improved glucose homeostasis. 
Diabetes 60(6):1688-98. 
 
 
 
 
250 
 
 
McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, 
Bremner WJ, Meriggiola C. 2004. Relationship between serum gonadotropins and 
spermatogenic suppression in men undergoing steroidal contraceptive treatment. J 
Clin Endocrinol Metab 89(1):142-9. 
 
Meigs JB. 2004. Metabolic Syndrome: In Search of a Clinical Role. Diabetes Care 
27(1):2761-2763. 
 
Meizel S, Turner KO. 1991. Progesterone acts at the plasma membrane of human 
sperm. Mol Cell Endocrinol 77:R1–5. 
 
Mendiola J, Torres-Cantero AM, Agarwal A. 2009. Lifestyle factors and male 
infertility: an evidenace based review. Arch Med Sci 5,1A:S3-S12. 
 
Menkveld R, Stander FS, Kotze TJ, Kruger TF, van Zyl JA. 1990. The evaluation of 
morphological characteristics of human spermatozoa according to stricter criteria. 
Hum Reprod 5(5):586-92. 
 
Menkveld R, Wong WY, Lombard CJ, Wetzels AM, Thomas CM, Merkus HM, 
Steegers-Theunissen RP. 2001. Semen parameters, including WHO and strict 
criteria morphology, in a fertile and subfertile population: an effort towards 
standardization of in-vivo thresholds. Hum Reprod 16(6):1165-1171. 
 
Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GK, Smith BJ, Watson 
CJ, Záková L, Kletvíková E, Jiráček J, Chan SJ, Steiner DF, Dodson GG, 
Brzozowski AM, Weiss MA, Ward CW, Lawrence MC. 2013. How insulin engages its 
primary binding site on the insulin receptor. Nature 10;493(7431):241-5. 
 
Midzak AS, Chen H, Papadopoulos V, Zirkin BR. 2009. Leydig cell aging and the 
mechanisms of reduced testosterone synthesis. Mol Cell Endocrinol 5;299(1):23-31. 
 
Midzak AS, Chen H, Aon MA, Papadopoulos V, Zirkin BR. 2011. ATP synthesis, 
mitochondrial function, and steroid biosynthesis in rodent primary and tumor Leydig 
cells. Biol Reprod 84(5):976-85. 
 
 
 
 
251 
 
 
 
Miller WL, Auchus RJ. 2011. The Molecular Biology, Biochemistry, and Physiology of 
Human Steroidogenesis and Its Disorders.  Endocr Rev. 32(1):81-151. 
 
Mills KH, Dunne A. 2009. Immune modulation: IL-1, master mediator or initiator of 
inflammation. Nat Med 15(12):1363–1364. 
 
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, 
Coppack  W. 1997. Subcutaneous adipose tissue releases interleukin-6, but not 
tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82(12):4196-4200. 
 
Monteiro R, Azevedo I. 2010. Chronic inflammation in obesity and the metabolic 
syndrome. Mediators Inflamm pii: 289645.  
 
Moore C, Moger WH. 1991. Interleukin-1 alpha-induced changes in androgen and 
cyclic adenosine 3',5'-monophosphate release in adult rat Leydig cells in culture. J 
Endocrinol 129(3):381-90. 
 
Morales V, Santana P, Diaz R, Tabraue C, Gallardo G, Lopez Blanco F, Hernandez 
I, Fanjul LF, Ruiz de Galarreta CM. 2003. Intratesticular delivery of tumor necrosis 
factor-_ and ceramide directly abrogates steroidogenic acute regulatory protein 
expression and Leydig cell steroidogenesis in adult rats. Endocrinology 
144(11):4763–4772. 
 
Mortimer D, Menkveld R. 2001. Sperm morphology assessment—historical 
perspectives and current opinions. Journal of Andrology 22(2):192-205. 
 
Muciaccia B, Pensini S, Culasso F, Padula F, Paoli D, Gandini L, Di Veroli C, 
Bianchini G, Stefanini M, D'Agostino A. 2012. Higher clusterin immunolabeling and 
sperm DNA damage levels in hypertensive men compared with controls. Hum 
Reprod 27(8):2267-76. 
 
Najjar SM, Yang Y, Fernstrom MA, et al. 2005. Insulin acutely decreases hepatic 
fatty acid synthase activity. Cell Metab 2(1):43–53. 
 
 
 
 
252 
 
 
 
Nakano S, Kuboki K, Matsumoto T, Nishimura C, Yoshino G. 2010. Small Dense 
LDL and High-Sensitive C-Reactive Protein (hs-CRP) in Metabolic Syndrome with 
Type 2 Diabetes Mellitus. J Athero and Thromb 17(4):410-5. 
 
National Cholesterol Education Program (NCEP): Expert Panel on Detection and 
Treatment of High Blood Cholesterol in Adults (2002). Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 106(25):3143-3421. 
 
Nawrocki AR, Scherer PE. 2004. The delicate balance between fat and muscle: 
adipokines in metabolic disease and musculoskeletal inflammation. Current Opinion 
in Pharmacology 4(3):281–289. 
 
Naz RK, Kaplan P. 1994. Increased Levels of Interleukin-6 in Seminal Plasma of 
Infertile Men. J Androl 15(3):220-227. 
 
Neel V. 1962. Diabetes mellitus: a ‘‘thrifty’’ genotype rendered detrimental by 
progress? Am J Hum Genet 14:352–362. 
 
Nilsson S. 2001. Research contributions of Eskil Kylin. Sven Med Tidskr 5(1):15-28. 
 
Ng KK, Donat R, Chan L, Lalak A, Di Pierro I, Handelsman DJ. 2004. Sperm output 
of older men. Hum Reprod 19(8):1811-5. 
 
Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara 
K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R. 2009. CD8+ effector T 
cells contribute to macrophage recruitment and adipose tissue inflammation in 
obesity. Nat Med 15(8):914-20. 
 
Niskanen LK , Haffner S, Karhunen1 LJ, Turpeinen AK, Miettinen H, Uusitupa MIJ. 
1997. Serum leptin in obesity is related to gender and body fat topography but does 
not predict successful weight loss. Euro J Endocrinol 137(1):61–67. 
 
 
 
 
253 
 
 
 
Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. 2004. 
Changes in sex hormone-binding globulin and testosterone during weight loss and 
weight maintenance in abdominally obese men with the metabolic syndrome. 
Diabetes Obes Metab 6(3):208–15. 
 
Obara H, Shibahara H, Tsunoda H, Taneichi A, Fujiwara H, Takamizawa S, Idei S, 
Sato I. 2001. Prediction of unexpectedly poor fertilization and pregnancy outcome 
using the strict criteria for sperm morphology before and after sperm separation in 
IVF-ET. Int J Androl 24(2):102-8. 
 
Oda E. 2008. The metabolic syndrome as a concept of adipose tissue disease. 
Hypertens Res 31(7):1283-91. 
 
Oehninger S, Blackmore P, Morshedi M, Sueldo C, Acosta AA, Alexander NJ. 1994. 
Defective calcium influx and acrosome reaction (spontaneous and progesterone-
induced) in spermatozoa of infertile men with severe teratozoospermia. Fertil Steril 
61(2):349–54. 
 
Oettel M, Mukhopadhyay AK. 2004. Progesterone: the forgotten hormone in men? 
Aging Male 7(3):236-57. 
 
Ozturk U, Sener NC, Nalbant I, Karabacak OR, Ulusoy MG, Imamoglu MA. 2012. 
The effect of metabolic syndrome upon the success of varicocelectomy. 
ScientificWorldJournal 2012:985201. 
 
Paasch U, Grunewald S, Kratzsch J, Glander HJ. 2010. Obesity and age affect male 
fertility potential. Fertil Steril 94(7):2898-901.  
 
Pagotto U. 2009. Where does insulin resistance start? The brain. Diabetes Care 
32(suppl 2):S174–S177. 
 
Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. 2009. Metabolic syndrome 
and risk of subsequent colorectal cancer. World J Gastroenterol 15(41):5141-8. 
 
 
 
 
254 
 
 
 
Palmer NO, Bakos HW, Fullston T, Lane M. 2012a. Impact of obesity on male 
fertility, sperm function and molecular composition. Spermatogenesis 1;2(4):253-
263. 
 
Palmer NO, Bakos HW, Owens JA, Setchell BP, Lane M. 2012b. Diet and exercise 
in an obese mouse fed a high fat diet improves metabolic health and reverses 
perturbed sperm function. Am J Physiol Endocrinol Metab 1;302(7):E768-80. 
 
Paoli D, Gallo M, Rizzo F, Baldi E, Francavilla S, Lenzi A, Lombardo F, Gandini L. 
2011. Mitochondrial membrane potential profile and its correlation with increasing 
sperm motility. Fertil Steril 95(7):2315-9. 
 
Papadimas J, Goulis DG, Sotiriades A, Daniilidis M, Fleva A, Bontis JN, 
Tourkantonis A. 2002. Interleukin-1 beta and tumor necrosis factor-alpha in 
normal/infertile men. Arch Androl 48(2):107-13. 
 
Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti 
M, Vicennati V. 1995. Insulin regulates testosterone and sex hormone-binding 
globulin concentrations in adult normal weight and obese men. J Clin Endocrinol 
Metab 80(2):654-8. 
 
Pasquali R, Macor C, Vicennati V, Novo F, De lasio R, Mesini P, Boschi S, Casimirri 
F, Vettor R. 1997. Effects of acute hyperinsulinemia on testosterone serum 
concentrations in adult obese and normal-weight men. Metabolism 46(5):526-9. 
 
Pasquali R. 2006. Obesity and androgens: facts and perspectives. Fertil Steril 
85(5):1319–40. 
 
Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA.1997. Interleukin-6 and 
the interleukin-6 receptor in the human adrenal gland: expression and effects on 
steroidogenesis. J Clin Endocrinol Metab 82(7):2343-9. 
 
 
 
 
 
255 
 
 
Pauli EM, Legro RS, Demers LM. 2008. Diminished Paternity and Gonadal Function 
with Increasing Obesity in Men. Fertil Steril 90(2):346-351. 
 
Payne AH, Youngblood GL. 1995. Regulation of expression of steroidogenic 
enzymes in Leydig cells. Biol Reprod 52(2):217-25. 
 
Paz G, Homonnai ZT, Ayalon D, Cordova T, Kraicer PF. 1977. Immunoreactive 
insulin in serum and seminal plasma of diabetic and nondiabetic men and its role in 
the regulation of spermatozoal activity. Fertil Steril 28(8):836-40. 
 
Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi 
B, Colli E, Maggi M, Adorini L. 2007. Seminal plasma cytokines and chemokines in 
prostate inflammation: interleukin 8 as a predictive biomarker in chronic 
prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 
51(2):524-33. 
 
Phillips LK, Prins JB. 2008. The link between abdominal obesity and the metabolic 
syndrome. Curr Hypertens Rep 10(2):156-64. 
 
Pirke KM, Sintermann R, Vogt HJ. 1980. Testosterone and testosterone precursors 
in the spermatic vein and in the testicular tissue of old men. Reduced oxygen supply 
may explain the relative increase of testicular progesterone and 17 
alphahydroxyprogesterone content and production in old age. Gerontology 26:2.21–
30. 
 
Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. 2005a. 
Increasing insulin resistance is associated with a decrease in Leydig cell 
testosterone secretion in men. J Clin Endocrinol Metab 90(5):2636-41. 
 
Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, 
Yialamas M, Groop L, Elahi D, Hayes FJ. 2005b. Relationship between testosterone 
levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 
28(7):1636-42. 
 
 
 
 
 
256 
 
 
Pluchino N, Luisi M, Lenzi E, Centofanti M, Begliuomini S, Freschi L, Ninni F, 
Genazzani AR. 2006. Progesterone and progestins: effects on brain, 
allopregnanolone and beta-endorphin. J Steroid Biochem Mol Biol 102(1-5):205-13. 
 
Pocai A, Lam TK, Gutierrez-Juarez R, et al. 2005. Hypothalamic K(ATP) channels 
control hepatic glucose production. Nature 434(7036):1026–1031. 
 
Politch JA, Wolff H, Hill JA, Anderson DJ. 1993. Comparison of methods to 
enumerate white blood cells in semen. Fertil Steril 60(2):372–375. 
 
Politch JA, Tucker L, Bowman FP, Anderson DJ. 2007. Concentrations and 
significance of cytokines and other immunologic factors in semen of healthy fertile 
men. Human Reproduction 22(11):2928–2935. 
 
Potenza MV, Mechanick JI. 2009. The metabolic syndrome: definition, global impact, 
and pathophysiology. Nutr Clin Pract 24(5):560-77. 
 
Povoa Junior H, Rezende MTL, Souza AC. 1973. Insulina imunoreativa em líquidos 
biológicos. Memórias do Instituto Oswaldo Cruz, v.71, n.4, p.425-438. 
 
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. 2001. C-reactive protein, 
interleukin-6, and risk developing type 2 diabetes mellitus. J Am Med Assoc 
286(3):327-334. 
 
Procaccini C, Jirillo E, Matarese G. 2012. Leptin as an immunomodulator. Mol 
Aspects Med 33(1):35-45. 
 
Qin DD, Yuan W, Zhou WJ, Cui YQ, Wu JQ, Gao ES. 2007. Do reproductive 
hormones explain the association between body mass index and semen quality? 
Asian J Androl 9(6):827-34.  
 
Quinn P, Kerin JF, Warnes GM. 1985. Improved pregnancy rate in human in vitro 
fertilization with the use of a medium based on the composition of human tubal fluid. 
Fertil Steril 44(4):493-498.  
 
 
 
 
257 
 
 
 
Rabasa-Lhoret R, Bastard JP, Jan V, Ducluzeau PH, Andreelli F, Guebre F, Bruzeau 
J, Louche-Pellissier C, MaItrepierre C, Peyrat J, Chagné J, Vidal H, Laville M. 2003. 
Modified quantitative insulin sensitivity check index is better correlated to 
hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity 
in different insulin-resistant states. J Clin Endocrinol Metab 88(10):4917-23. 
 
Ramírez-Torres MA, Carrera A, Zambrana M. 2000. High incidence of 
hyperestrogenemia and dyslipidemia in a group of infertile men. Ginecol Obstet Mex 
68:224-9.  
 
Rask-Madsen C, Kahn CR. 2012. Tissue-specific insulin signaling, metabolic 
syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 32(9):2052-9. 
 
Razzouk L, Muntner P. 2009. Ethnic, gender, and age-related differences in patients 
with the metabolic syndrome. Curr Hypertens Rep 11(2):127-32. 
 
Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in human 
disease. Diabetes 37(12):1595-607. 
 
Riccardi G, Giacco R, Rivellese AA. 2004. Dietary fat, insulin sensitivity and the 
metabolic syndrome. Clinical Nutrition 23(4):447-456. 
 
Roth MY, Amory JK, Page ST. 2008. Treatment of male infertility secondary to 
morbid obesity. Nat Clin Pract Endocrinol Metab 4(7):415–9. 
 
Rotter V, Nagaev I, Smith U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 
3t3-l1 adipocytes and is, like il-8 and tumor necrosis factor-alpha, overexpressed in 
human fat cells from insulin-resistant subjects. J Biol Chem 278(46):45777-45784. 
 
Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. 1998. The metabolically 
obese, normal-weight individual revisited. Diabetes  47(5):699–713.  
 
 
 
 
 
258 
 
 
Rybar R, Kopecka V, Prinosilova P, Markova P, Rubes J. 2011. Male obesity and 
age in relationship to semen parameters and sperm chromatin integrity. Andrologia 
43(4):286-91. 
 
Saad F, Gooren L. 2009. The role of testosterone in the metabolic syndrome: A 
review. J Steroid Biochem Mol Bio 114(1-2):40-3. 
 
Saad F, Gooren LJ. 2011. The role of testosterone in the etiology and treatment of 
obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes pii: 471584. 
 
Saez Lancellotti TE, Boarelli PV, Monclus MA, Cabrillana ME, Clementi MA, 
Espínola LS, Cid Barría JL, Vincenti AE, Santi AG, Fornés MW. 2010. 
Hypercholesterolemia impaired sperm functionality in rabbits. PLoS One 
18;5(10):e13457. 
 
Said L, Galeraud-Denis I, Carreau S, Saâd A. 2009. Relationship between semen 
quality and seminal plasma components: alpha-glucosidase, fructose and citrate in 
infertile men compared with a normospermic population of Tunisian men.Andrologia 
41(3):150-6. 
 
Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman 
GI.2004. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver 
disease.J Biol Chem 279(31):32345–32353. 
 
Sanocka D, Jedrzejczak P, Szumała-Kaekol A, Fraczek M, Kurpisz M. 2003. Male 
Genital Tract Inflammation: The role of selected interleukins in regulation of pro-
oxidant and antioxidant enzymatic substances in seminal plasma. J Androl 
24(3):448-55. 
 
Sanocka-Maciejewska D, Ciupinska M, Kurpisz M. 2005. Bacterial infection and 
semen quality. J Reprod Immunol 67(1-2):51–6. 
 
 
 
 
 
259 
 
 
Sawiński P, Lukaszyk A. 2002. The influence of interleukin-1 and interleukin-6 on 
expression of proteins involved in steroidogenesis in Leydig cells and on their 
apoptosis or necrosis in vitro. Folia Histochem Cytobiol 40(2):159-60. 
 
Schulte RT, Ohl DA, Sigman M, Smith GD. 2010. Sperm DNA damage in male 
infertility: etiologies, assays, and outcomes. J Assist Reprod Genet 27(1):3-12. 
 
Schweiger C, Cirrincione V, Ignone G. 2008. Metabolic syndrome: a true syndrome 
or only a cluster of risk factors? G Ital Cardiol (Rome) 9(4 Suppl 1): 67S-73S. 
 
Sergerie M, Bleau G, Teulé R, Daudin M, Bujan L. 2005. Sperm DNA integrity as 
diagnosis and prognosis element of male fertility. Gynecol Obstet Fertil 33(3):89-101. 
 
Sermondade N, Faure C, Fezeu L, Shayeb AG, Bonde JP, Jensen TK, Van Wely M, 
Cao J, Martini AC, Eskandar M, Chavarro JE, Koloszar S, Twigt JM, Ramlau-Hansen 
CH, Borges E Jr, Lotti F, Steegers-Theunissen RP, Zorn B, Polotsky AJ, La Vignera 
S, Eskenazi B, Tremellen K, Magnusdottir EV, Fejes I, Hercberg S, Lévy R, 
Czernichow S. 2013. BMI in relation to sperm count: an updated systematic review 
and collaborative meta-analysis. Hum Reprod Update 19(3):221-31. 
 
Seshadri S, Bates M, Vince G, Lewis Jones DI. 2009. The role of cytokine 
expression in different subgroups of subfertile men. Am J Reprod Immunol 
62(5):275–282. 
 
Shalaby MA, el-Zorba HY, Kamel GM. 2004. Effect of alpha-tocopherol and 
simvastatin on male fertility in hypercholesterolemic rats. Pharmacol Res 50(2):137-
42. 
 
Sharma RK, Sabanegh E, Mahfouz R, Gupta S, Thiyagarajan A, Agarwal A. 2010. 
TUNEL as a test for sperm DNA damage in the evaluation of male infertility. Urology 
76(6):1380-6. 
 
 
 
 
 
260 
 
 
Sharma R, Masaki J, Agarwal A. 2013. Sperm DNA fragmentation analysis using 
the TUNEL assay. Methods Mol Biol 927:121-36. 
 
Sharman MJ, Volek JS. 2004. Weight loss leads to reductions in inflammatory 
biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. 
Clin Sci (Lond) 107:365–9. 
 
Sherbet DP, Tiosano D, Kwist KM, Hochberg Z, Auchus RJ. 2003. CYP17 mutation 
E305G causes isolated 17,20-lyase deficiency by selectively altering substrate 
binding. J Biol Chem 5;278(49):48563-9. 
 
Simon L, Proutski I,  Stevenson M, Jennings D,  McManus J, Lutton D, Lewis SE. 
2013. Sperm DNA damage has a negative association with live-birth rates after IVF. 
Reprod Biomed Online 26(1):68-78.  
 
Singh J, O’Neill C, Handelsman DJ. 1995. Induction of spermatogenesis by 
androgens in gonadotropin-deficient (hpg) mice. Endocrinology 136(12):5311–5321. 
 
Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger 
V, Taksali S, Barbetta G, Sherwin RS, Caprio S. 2002. Prevalence of impaired 
glucose tolerance among children and adolescents with marked obesity. N Engl J 
Med 346(11):802–10. 
 
Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. 2011 Antioxidants for 
male subfertility. Cochrane Database Syst Rev (1):CD007411. 
 
Sonocka D, Jedrzejczak P, Szumala-Kakol A, Fraczek M, Kurpisz M. 2003. Male 
Genital Tract Inflammation: The role of selected interleukins in regulation of pro-
oxidant and antioxidant enzymatic substances in seminal plasma. J Androl 
24(3):448-455. 
 
Stahler MS, Budd GC, Pansky B. 1987. Evidence for insulin synthesis in normal 
mouse seminal vesicle based on in situ RNA-DNA hybridization. Biol Reprod 
36(4):999-1006. 
 
 
 
 
261 
 
 
Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, 
Machicao F, Fritsche A, Häring HU. 2008a. Identification and characterization of 
metabolically benign obesity in humans. Arch Intern Med 168(15):1609–1616. 
 
Stefan N, Kantartzis K, Haring HU. 2008b. Causes and metabolic consequences of 
fatty liver. Endocr Rev 29(7):939–960. 
 
Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, 
Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Müller M, van den Berg 
WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack 
CJ, Netea MG. 2010. The inflammasome-mediated caspase-1 activation controls 
adipocyte differentiation and insulin sensitivity. Cell Metab 12(6):593–605. 
 
Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, Kowalska I, Szelachowska M, 
Kinalska I. 2002. Plasma interleukin-8 concentrations are increased in obese 
subjects and related to fat mass and tumor necrosis factor-alpha system. The 
Journal of Clinical Endocrinology and Metabolism 87(10):4602–4606. 
 
Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. 1998. A leptin missence 
mutation associated with hypogonadism and morbid obesity. Nat Genet 18(3):213-5. 
 
Sun XR, Hedger MP, Risbridger GP. 1993. The effect of testicular macrophages and 
interleukin-1 on testosterone production by purified adult rat Leydig cells cultured 
under in vitro maintenance conditions. Endocrinology 132(1):186-92. 
 
Svechnikov KV, Sultana T, Söder O. 2001. Age-dependent stimulation of Leydig cell 
steroidogenesis by interleukin-1 isoforms. Mol Cell Endocrinol 182(2):193-201. 
 
Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. 2003. 
New Markers of Inflammation and Endothelial Cell Activation. Circulation 
108(16):1917-1923. 
 
Tack CJ, Stienstra R, Joosten LA, Netea MG. 2012. Inflammation links excess fat to 
insulin resistance: the role of the interleukin-1 family. Immunol Rev 249(1):239-52. 
 
 
 
 
262 
 
 
Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka 
R, Zhu S, Toyoshima H. 2003. The metabolic syndrome is associated with elevated 
circulating C-reactive protein in healthy reference range, a systemic low-grade 
inflammatory state. Int J Obes Relat Metab Disord 27(4):443-9. 
 
Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M, Yamashita J, Chun TH, 
Inoue M, Masatsugu K, Sawada N, Saito T, Inoue G, Nishimura H, Yoshimasa Y, 
Nakao K. 1999. Down regulation of peroxisome proliferatoractivated receptorgamma 
expression by inflammatory cytokines and its reversal by thiazolidinediones. 
Diabetologia 42(6):702–710. 
 
Taniguchi CM, Emanuelli B, Kahn CR. 2006. Critical nodes in signalling pathways: 
insights into insulin action. Nat Rev Mol Cell Biol 7(2):85–96. 
 
Taslim S, Tai ES. 2009. The relevance of the metabolic syndrome. Ann Acad Med 
Singapore 38:29-33. 
 
Tena-Sempere M, Manna PR, Zhang FP, Pinilla L, González LC, Diéguez C, 
Huhtaniemi I, Aguilar E. 2001. Molecular mechanisms of leptin action in adult rat 
testis: potential targets for leptin-induced inhibition of steroidogenesis and pattern of 
leptin receptor messenger ribonucleic acid expression. J Endocrinol 170(2):413-23. 
 
Tena-Sempere M, Barreiro ML. 2002. Leptin in male reproduction: the testis 
paradigm. Mol Cell Endocrinol 188(1-2):9-13. 
Tentorlouris N, Liatis S, Katsilambros N. 2006. Sympathetic system activity in 
obesityand metabolic syndrome. Ann N Y Acad Sci 1083:129-52. 
 
Tesarik J, Mendoza C. 1992. Defective function of a nongenomic progesterone 
receptor as a sole sperm anomaly in infertile patients. Fertil Steril 58(4):793–7. 
 
Thomas P, Meizel S. 1989. Phosphatidylinositol-4,5-bisphosphate hydrolysis in 
human sperm stimulated with follicular fluid or progesterone is dependent upon Ca2+ 
influx. Biochem J 264:539–46. 
 
 
 
 
 
263 
 
 
Thomas S, Kratzsch D, Schaab M, Scholz M, Grunewald S, Thiery J, Paasch U, 
Kratzsch J. 2013. Seminal plasma adipokine levels are correlated with functional 
characteristics of spermatozoa. Fertil Steril 99(5):1256-1263.e3. 
 
Tilg H, Moschen AR. 2008. Inflammatory mechanisms in the regulation of insulin 
resistance. Mol Med 14(3-4):222-231. 
 
Tkachenko IV, Jääskeläinen T, Jääskeläinen J, Palvimo JJ, Voutilainen R. 2011. 
Interleukins 1α and 1β as regulators of steroidogenesis in human NCI-H295R 
adrenocortical cells. Steroids 76(10-11):1103-15. 
 
Traish AM, Kang HP, Saad F, Guay AT. 2011. Dehydroepiandrosterone (DHEA)--a 
precursor steroid or an active hormone in human physiology. J Sex Med 8(11):2960-
82. 
 
Trayhurn P, Beattie JH. 2001. Physiological Role of Adipose Tissue: White Adipose 
Tissue as an Endocrine and Secretory Organ. Proc Nutr Soc 60(3):329-339. 
 
Trayhurn P, Wood IS. 2004. Adipokines: inflammation and the pleiotropic role of 
white adipose tissue. Br J Nutr 92(3):347. 
 
Tronchon V, Vialard F, El Sirkasi M, Dechaud H, Rollet J, Albert M, Bailly M, Roy P, 
Mauduit C, Fenichel P, Selva J, Benahmed M. 2008. Tumor necrosis factor-alpha -
308 polymorphism in infertile men with altered sperm production or motility.Hum 
Reprod 23(12):2858-66. 
 
Truta Z, Garlovanu M, Lerintiu S, Micu R. 2010. A new method for human semen 
glucose concentration evaluation. Rom Biotech Lett 15:5764–5772. 
 
Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP. 1999. Dose-
dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis. 
J Interferon Cytokine Res 19(11):1271-6. 
 
 
 
 
 
264 
 
 
Tsigos C, Chrousos GP. 2002. Hypothalamic-pituitary-adrenal axis, neuroendocrine 
factors and stress. J Psychosom Res 53(4):865-71. 
 
Tunc O, Bakos HW, Tremellen K. 2011. Impact of body mass index on seminal 
oxidative stress. Andrologia 43(2):121-8. 
 
Ulcova-Gallova Z, Gruberova J, Vrzalova J, Bibkova K, Peknicova J, Micanova Z, 
Topolcan O. 2009. Sperm antibodies, intra-acrosomal sperm proteins, and cytokines 
in semen in men from infertile couples. Am J Reprod Immunol 61(3):236-45. 
 
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. 1997. Protection from 
obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 
389(6651):610–614. 
 
Vague J. 1947. La differenciation sexuelle, facteur determinant des formes de 
l’obesite. Presse Med 55(30):339–40. 
 
Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, 
Ravussin E, Stephens JM, Dixit VD. 2011. The NLRP3 inflammasome instigates 
obesity-induced inflammation and insulin resistance. Nat Med 17(2):179–188. 
 
van der Poll T, Romijn JA, Endert E, Sauerwein HP. 1993. Effects of tumor necrosis 
factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 
42(3):303–7. 
 
van der Steeg JW, Steures P, Eijkemans MJ, F Habbema JD, Hompes PG, Kremer 
JA, van der Leeuw-Harmsen L, Bossuyt PM, Repping S, Silber SJ, Mol BW, van der 
Veen F; Collaborative Effort for Clinical Evaluation in Reproductive Medicine Study 
Group. 2010. Role of semen analysis in subfertile couples. Fertil Steril 95(3):1013-9. 
 
van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. 
2001.  Increased leptin concentrations correlate with increased concentrations of 
inflammatory markers in morbidly obese individuals. Int J Obes 25(12):1759. 
 
 
 
 
 
265 
 
 
Vartanian V, Lowell B, Minko IG, Wood TG, Ceci JD, George S, Ballinger SW, 
Corless CL, McCullough AK, Lloyd RS. 2006. The metabolic syndrome resulting 
from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci USA  
7;103(6):1864-9. 
 
Verhoeven G, Cailleau J, Van Damme J, Billiau A. 1988. Interleukin-1 stimulates 
steroidogenesis in cultured rat Leydig cells. Mol Cell Endocrinol 57(1-2):51-60. 
Venkatesh S, Singh A, Shamsi MB, Thilagavathi J, Kumar R, Mitra DK, Dada R. 
2011. Clinical significance of sperm DNA damage threshold value in the assessment 
of male infertility. Reprod Sci 18(10):1005-13. 
 
Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, Siegler IC. 2002. A path 
model of chronic stress, the metabolic syndrome, and coronary heart disease. 
Psychosom Med 64(3):418-35. 
 
Walker WH. 2011. Testosterone signaling and the regulation of spermatogenesis. 
Spermatogenesis 1(2):116-120. 
 
Wang DL, Nagpal ML, Calkins JH, Chang WW, Sigel MM, Lin T. 1991. Interleukin-
1beta induces interleukin-1alpha messenger RNA expression in primary cultures of 
Leydig cells. Endocrinology 129(6):2862–2866. 
 
Wang MY, Zhou YT, Newgard CB, Unger RH. 1996. A novel leptin receptor isoform 
in rat. FEBS Lett. 392(2):87–90. 
 
Wang P, Mariman E, Renes J, Keijer J. 2008. The secretory function of adipocytes in 
the physiology of white adipose tissue. J Cell Physiol 216(1):3-13. 
 
Wauters M, Considine RV, van Gaal LF. 2000. Human leptin: from an adipocyte 
hormone to an endocrine mediator. Euro J Endocrinol 143(3):293-311. 
 
Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. 2003. National 
surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 290(10):1345–
50. 
 
 
 
 
266 
 
 
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, 
Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. 2004. Obesity and the 
metabolic syndrome in children and adolescents. N Engl J Med 350(23):2362–74. 
 
Wolff H. 1995. The biologic significance of white blood cells in semen. Fertil Steril 
63(6): 1143-57. 
 
Wozniac SE, Gee LL, Wachtel M, Frezza EE. 2009. Adipose Tissue: The New 
Endocrine Organ? Dig DisSci 54(9):1847-1856.  
 
World Health Organisation. 2010. WHO Laboratory Manual for the Examination and 
Processing of Human Semen. 5th edn. Department of Reproductive Health and 
Reearch.  
 
Wu L, Zhang A, Sun Y, Zhu X, Fan W, Lu X, Yang Q, Feng Y. 2012. Sirt1 exerts 
anti-inflammatory effects and promotes steroidogenesis in Leydig cells. Fertil Steril 
98(1):194-9. 
 
Wylie-Rosett J. 2002. Fat substitutes and health – an advisory from the nutrition 
committee of the American Heart Association. Circulation 105(23):2800-2804. 
 
Xiong Y, Hales DB. 1993. The role of tumor necrosis factor-alpha in the regulation of 
mouse Leydig cell steroidogenesis. Endocrinology 132:2568-73. 
 
Xiong Y, Hales DB. 1997. Differential effects of tumor necrosis factor-alpha and 
interleukin 1 on 3 beta-hydroxysteroid dehydrogenase/delta 5-->delta4 isomerase 
expression in mouse Leydig cells. Endocrine 7(3):295-301. 
 
Ye L, Su ZJ, Ge RS. 2011. Inhibitors of testosterone biosynthetic and metabolic 
activation enzymes. Molecules 16(12):9983-10001. 
 
 
 
 
 
 
 
267 
 
 
Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, 
Koyama H, Shoji T, Inaba M, Nishizawa Y. 2004. Quantitative insulin sensitivity 
check index and the reciprocal index of homeostasis model assessment are useful 
indexes of insulin resistance in type 2 diabetic patients with wide range of fasting 
plasma glucose. J Clin Endocrinol Metab 89(3):1481-4. 
 
Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, Hong J, Gu Y, Li X, Ning G, Chen M. 
2006. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes 
and impaired glucose tolerance and related to adiponectin levels and insulin 
sensitivity. Diabetes Res Clin Pract. 72(3):244-50. 
 
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. 2000. Inflammation, obesity, 
stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 
148(2):209-14. 
 
Zaloga G, Marik P. 2001. Lipid modulation and systemic inflammation. Crit Care Clin 
17:201–218. 
 
Zammit VA. 2002. Insulin stimulation of hepatic triacylglycerol secretion in the 
insulin-replete state: implications for the etiology of peripheral insulin resistance. Ann 
N Y Acad Sci 967:52–65. 
 
Zeelie A, Moss SJ, Kruger HS. 2010. The relationship between body composition 
and selected metabolic syndrome markers in black adolescents in South Africa: the 
PLAY study. Nutrition 26(11-12):1059-64. 
 
 Zeyda M, Stulnig TM. 2009. Obesity, inflammation, and insulin resistance--a mini-
review. Gerontology 55(4):379-86. 
 
Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, 
Molinari AM, Giugliano D. 2002. Reduction of inflammatory cytokine concentrations 
and improvement of endothelial functions in obese women after weight loss over one 
year. Circulation 19;105(7):804-9. 
 
 
 
 
 
268 
 
 
Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implications of the diabetes 
epidemic. Nature 414(6865):782–87. 
 
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. 2005. The metabolic 
syndrome: a global public health problem and a new definition. J Atheroscler Thromb 
12(6):295-300. 
 
Zini A, Dohle G. 2011. Are varicoceles associated with increased deoxyribonucleic 
acid fragmentation? Fertil Steril 96(6):1283-7. 
 
Zitzmann M, Erren M, Kamischke A, Simoni M, Nieschlag E. 2005. Endogenous 
progesterone and the exogenous progestin norethisterone enanthate are associated 
with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 90(12):6603-
8. 
 
Zirkin BR, Chen H. 2000. Regulation of Leydig cell steroidogenic function during 
aging. Biol Reprod 63(4):977-81. 
 
Zorn B, Osredkar J, Meden-Vrtovec H, Majdic G. 2007. Leptin levels in infertile male 
patients are correlated with inhibin B, testosterone and SHBG but not with sperm 
characteristics. Int J Androl 30(5):439-44. 
 
 
 
 
 
